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                                                                                                                                          Abstract                         
Abstract 
 
Parkinson’s disease (PD) is a neurodegenerative disease which causes tremor, muscular 
rigidity and bradykinesia (slowness of initiation of voluntary movement with progressive 
reduction in speed and amplitude of repetitive actions). Although the underlying causes 
remain unknown, there is evidence that genetic factors play an important role in the disease 
process. In this thesis I investigated the role of a recently identified hereditary PD gene leucine 
rich repeat kinase 2 (LRRK2) in PD in the United Kingdom (UK). 
In this thesis I have confirmed the importance of pathogenic LRRK2 mutations in UK familial 
PD (fPD). In addition I identified three novel frameshift mutations. I investigated the 
functional effects of two of these mutations and provide evidence that nonsense mediated 
decay (NMD) is occurring in LRRK2-PD. 
In this thesis I also present data from an extensive screen of LRRK2 in UK subjects with 
sporadic PD (sPD). This confirms the importance of pathogenic LRRK2 mutations in UK sPD.  
In addition I report a novel missense mutation in the GTP cyclohydrolase I gene (GCH1) in a 
kindred with phenotypes ranging from PD to Dopa-responsive dystonia. The association of 
this novel GCH1 mutation with late onset parkinsonism suggests a potential role for GCH1 in 
PD. 
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1 General Introduction 
 
Parkinson’s disease (PD) is the second most common neurodegenerative disease after 
Alzheimer’s disease, with a cumulative life-time incidence estimated at 2% [1]. The economic 
burden in the UK alone is said to be approximately £6 billion per annum [2]. There has been 
much progress over the last few decades in devising more accurate diagnostic criteria for PD 
and in development of treatments for the condition. However despite this progress, the 
aetiology of PD remains poorly understood, with the vast majority of cases considered to be 
idiopathic. It has been proposed that a complex interplay between genetic and environmental 
factors contributes to an individual’s risk of developing PD.  
In the introduction to this thesis I will cover a number of topics related to PD, including some 
historical aspects of the condition, the clinical features and differential diagnosis of the 
condition, and our current understanding of the aetiology of the condition, with particular 
emphasis on the genetic hypothesis.  
 
1.1 Historical aspects of Parkinson’s disease 
The year 2005 marked the 250th anniversary of the birth of James Parkinson (1755-1824). His 
publication in 1817 An essay on the shaking palsy [3] gave a clear description of the condition 
that would eventually bear his name. The first few sentences of the essay evoke the main 
clinical features of PD, or paralysis agitans, perhaps better than any of the modern 
descriptions of the condition: ‘muscular power, in parts not in action and even when 
supported; with a propensity to bend the trunk forwards, and to pass from a walking to a 
running pace: the senses and intellects being uninjured.’ 
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This leaves an unanswered question, as to whether PD existed prior to the 19th century [28]. If 
it did not, then PD may be due to exposure to ubiquitous toxin or toxins which coincided with 
increasing industrialisation [29], [30]. Although their authors may not have been able to put 
together all aspects of the phenotype of the disease as Parkinson did, there do however appear 
to be several descriptions of PD in earlier literature. These include a description by Galen 
(Anno Domini 138-201) of a disorder compatible with the festinant gait of PD [28], and the 
description by Leonardo da Vinci (1452-1519) compatible with the involuntary rest tremor of 
PD [31]. This suggests that the disease entity is in fact much more ancient. 
The term ‘Parkinson’s disease’ was first used by Charcot in Paris [32] and Meynert was the 
first to suggest that PD was due to defective functioning of the basal ganglia [33]. Then in 
1913 Lewy reported spherical inclusions in the nucleus substantiae innominatae and the dorsal 
nucleus of the vagus [34], although he did not examine the substantia nigra. These so called 
‘Lewy bodies’ are a highly sensitive, but not entirely specific marker for PD [35]. However, it 
was another five years before the full importance of the substantia nigra became apparent after 
the work of Trétiakoff [36]. 
The biochemical abnormalities in PD only became apparent several decades later, when in 
1960 PD was shown to be associated with depleted dopamine production in the caudate 
nucleus and putamen [37]. Indeed these findings led to the successful use of levo-dopa (L-
Dopa) as a dopamine replacement therapy in PD [38]. From this time L-Dopa became the 
‘gold standard’ by which other anti-parkinsonian drugs would be compared. 
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1.2 Clinical features of PD 
Clinically PD is characterized by slowing of emotional and voluntary movement, muscular 
rigidity and tremor. Using the UK Parkinson’s Disease Society Brain Bank clinical diagnostic 
criteria for PD [14] the diagnosis can be further refined as consisting of bradykinesia (i.e. 
slowness of initiation of voluntary movement with progressive reduction in speed and 
amplitude of repetitive actions) along with at least one of the following: (i) muscular rigidity, 
(ii) 4-6Hz rest tremor, and (iii) postural instability that is not due to any other neurological 
cause. The full diagnostic criteria with exclusion criteria can be found below in table 1.1. PD 
is a progressive condition which will tend to evolve from mild unilateral symptoms through to 
end-stage nonambulatory state. The milestones in the illness are accurately outlined in the 
Hoehn and Yahr staging system [13] (see table 1.2). 
 
Inclusion Criteria Exclusion Criteria Supportive Criteria 
Bradykinesia 
And at least one of: 
Muscular rigidity 
4-6 Hz rest tremor 
Postural instability 
History of repeated strokes with stepwise 
progression of parkinsonian features 
History of repeated head injury 
History of definite encephalitis 
Oculogyric crises 
Neuroleptic treatment at onset of symptoms 
More than 1 affected relative 
Sustained remission 
Strictly unilateral features after 3 yrs 
Supranuclear gaze palsy 
Cerebellar signs 
Early severe autonomic involvement 
Early severe dementia with disturbances of 
memory, language and praxis 
Babinski sign 
Presence of cerebral tumour or 
communicating hydrocephalus on CT scan 
Negative response to large doses of 
levodopa (if malabsorption excluded) 
MPTP exposure  
Three or more required for 
diagnosis of definite PD 
Unilateral onset 
Rest tremor present 
Progressive disorder 
Persistent asymmetry affecting 
side of onset most 
Excellent response (70-100%) to 
levodopa 
Severe levodopa-induced chorea 
Levodopa response for 5 yr or 
more 
Clinical course of 10 yr or more  
 
 
Table 1.1 UK Parkinson’s Disease Society Brain Bank clinical diagnostic criteria for PD. 
Adapted from Gibb and Lees 1988 [14] 
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Stage Criteria  
Stage 0 No signs of disease 
Stage I Unilateral disease 
Stage I.5 Unilateral disease plus axial involvement 
Stage II Bilateral disease, without impairment of balance 
Stage II.5 Mild bilateral disease, with recovery on pull test 
Stage III Mild to moderate bilateral disease; some postural instability; 
physically independent 
Stage IV Severe disability; still able to walk or stand unassisted 
Stage V Wheel chair bound or bedridden unless aided 
 Table 1.2 Hoehn and Yahr staging of PD. Adapted from Hoehn and Yahr 1967 [13]. 
 
 
There are a number of studies which have looked at the initial clinical features in PD, and 
there is now preliminary evidence that some clinical features may in fact influence disease 
progression [39], [40]. A recent study found that the most common initial motor symptom in 
PD was tremor (49%). In 21% of subjects bradykinesia was the initial motor symptom, 
followed by gait difficulty (10%), micrographia (8%), rigidity (5%) and other (7%) [17]. 
Indeed tremor (59%) and bradykinesia (16%) were also the most common initial motor 
symptoms reported in the DATATOP series [41]. The upper extremities were the most 
common location for initial symptoms (70%) [17]. Overall a slower rate of progression for 
tremor as compared to gait difficulties has been found in several studies [17], [42], [13], [43]. 
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1.2.1 Nonmotor features of PD 
Almost all patients with PD have nonmotor symptoms, which contribute prominently to 
reduced quality of life [5]. Autonomic symptoms include reduced gastrointestinal transit time, 
urinary frequency and orthostatic hypotension. Anxiety and mood disorders are each found in 
up to 40% of PD patients [44]. Sleep disturbance and fatigue are also almost universal in PD 
[5]. 
Cognitive changes are also common in Parkinson’s disease and cause substantial disability 
[45], [5]. They can occur early in the disease and tend to involve impairments in executive 
functioning (ability to plan, organise, and regulate goal-directed behaviour). Over time PD 
with mild cognitive impairment can develop into a subcortical dementia, called PD with 
dementia (PDD).  Furthermore, cognitive symptoms in PD patients are associated with more 
rapid disease progression [46].  
The diagnosis of dementia in PD can be complicated by another disease entity called dementia 
with Lewy bodies (DLB). Indeed, debate still exists whether PDD and DLB are distinct 
disease entities or represent a spectrum of motor, cognitive and behavioural impairment [47], 
[20], [48].  The current clinical guidelines are that a diagnosis of DLB is made when cognitive 
symptoms appear within 1 year of the onset of motor symptoms, whereas a diagnosis of PDD 
is made when cognitive symptoms begin more than 1 year after onset of motor symptoms [49], 
[50]. The cognitive and psychiatric symptoms of DLB and PDD are essentially the same, with 
both having fluctuating abnormalities of cognition (confusion, disorientation, delusions) and 
well formed visual illusions and hallucinations [20], [49], [51]. The clinical profiles of PDD 
and DLB can be found below in table 1.3. 
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Neuropsychological performance almost identical 
 
Psychiatric symptoms the same 
 
Both have REM behavior disorder 
 
Parkinsonism more symmetrical and tremor less in DLB 
 
Neuroleptic sensitivity less in PDD 
 
Levodopa response not as robust in DLB 
 
                               Similar response to cholinergic treatment 
 
 
Table 1.3 Clinical features of PDD and DLB. Adapted from Lippa et 
al. (2007) [20].  
 
Depending on the population and criteria applied, reported rates of dementia in PD have been 
variable, ranging from 3 to 80% [52], [53], [54], [55], [56], [57]. It seems clear that the 
prevalence of PDD increases as PD progresses, for example one study showed a 26% 
prevalence at baseline, increasing to 51% at 4 years and to 78% at 8 years [58]. DLB is the 
second most common type of neurodegenerative dementia in older people, after Alzheimer’s 
disease. Estimates of prevalence of DLB vary between 3% [59], [60] and 26.3% [61] of all 
demented cases over the age of 65. Autopsy series reveal similar estimates ranging between 15 
and 25% [60], [62]. 
 
1.2.2 Heterogeneity of the PD phenotype 
It is now well recognised that PD can present in a variety of ways and perhaps as such is best 
regarded as syndrome rather than a single disease. There are also conditions which can mimic 
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PD, including the parkinsonian plus syndromes multiple system atrophy (MSA) and 
progressive supranuclear palsy (PSP), drug induced parkinsonism, and vascular parkinsonism. 
However, the reported difficulties in clinical diagnosis of PD could also be explained by this 
heterogeneity in disease phenotype. Some series have shown a diagnostic accuracy of less than 
80% [63]. However, a clinicopathological study has shown that strict implementation of 
diagnostic criteria, such as the UK Parkinson’s Disease Society Brain Bank clinical diagnostic 
criteria for PD [14], can improve diagnostic accuracy to over 95%, in the hands of movement 
disorders specilaists [64]. 
Many attempts have been made to investigate and define this heterogeneity in PD. Most have 
used classifications based on pre-determined patient attributes such as age of disease onset 
[65]; cognitive performance [66], [67]; motor phenotype [13]; presence of depression [68], 
[69]; disease severity [13], [70]; or motor symptom laterality, [71], [72].  
Some more recent studies have used cluster analysis to allow variables to be assessed in 
conjunction, rather than independently. Four cohorts of patients were identified: younger 
onset, tremor dominant, non-tremor dominant (with cognitive impairment and mild 
depression), and rapid disease progression (without cognitive impairment) [73], [74], [75].  
These findings do require careful consideration as cluster analysis is dependent on the 
variables that are entered into it. However, the finding of a group of patients with young onset 
disease has been consistent amongst many studies [76], [77], [78]. Generally patients in this 
subgroup show a slower rate of disease progression [65], [43], [79], [41]; less cognitive 
impairment [43], [41], [80]; and a greater potential to develop motor fluctuations [63], [81]. 
Further clinicopathological study of these subgroups is required, but it does seem likely that 
patients with different clinical phenotypes may have different pathological processes and foci 
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[82], [83]. Therefore, further investigation of these subgroups, including genetic analyses, may 
prove to be important for our understanding of the aetiology of PD. 
 
1.2.3 Differential diagnosis of PD 
There are a wide range of conditions which can mimic PD clinically, as listed below in table 
1.4.  
 
Multiple system atrophies 
Striatonigral degeneration 
Olivopontocerebellar atrophy 
Shy-Drager syndrome 
Infectious disorders 
Postencephalitis lethargica 
Postviral encephalitis 
Hereditary disorders 
Wilson’s disease 
Huntington’s disease (rigid variant) 
Hakkervorden-Spatz disease 
Dopa responsive dystonia 
Other CNS disorders 
Hydrocephalus 
Intracranial neoplasms 
Cerebral anoxia 
Repetitive head trauma 
Multiple cerebral infarcts 
Calcification of the basal ganglia 
Drug- induced parkinsonism 
Other degenerative diseases 
Progressive supranuclear palsy 
Corticobasal degeneration 
Diffuse Lewy body disease 
Parkinsonism-dementia complex of Guam 
Toxins 
N-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) 
 
 
Table 1.4 Causes of an akinetic-rigid syndrome. Adapted from  Koller 1992 
and Harding 1993 [4], [10]. 
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With modern diagnostic criteria it is usually possible to differentiate between these conditions, 
although this is not always the case. The commonest causes of mis-diagnosis by non-
specialists are probably essential tremor, artheriosclerotic pseudoparkinsonism  [84] and drug-
induced parkinsonism. However the commonest causes of misdiagnosis in prospective brain 
bank series are MSA and PSP [63], [64], [85]. These conditions are much rarer and largely 
escaped recognition as clinico-pathological entities until the 1960s.  
There are a number of ‘red flags’ in the clinical features that may suggest alternative 
diagnoses (see table 1.5). Cognitive impairment within the first year should raise the 
possibility of DLB, corticobasal degeneration (CBD) or PSP. Symmetrical or prominent 
midline or bulbar signs, early gait disorder with falls, dependence on a wheelchair within 5 
years of diagnosis, orthostatic hypotension, or urinary incontinence all suggest a ‘parkinsonian 
plus’ syndrome (MSA or PSP). An early gait disorder can also suggest vascular parkinsonism, 
whilst apraxia, alien limb, or cortical sensory loss suggest CBD.    
Early or prominent dementia 
Symmetrical signs 
Bulbar dysfunction 
Early gait disorder 
Falls within the first year 
Wheelchair dependence within 5 years 
Early autonomic failure 
Sleep apnoea 
Gasping respirations 
Apraxia 
Alien limb 
Cortical sensory loss 
 
Table 1.5 Red flags in the diagnosis of PD. Taken from Shannon 2004 [5]. 
 
 
 - 9 -
Chapter 1                                                                                                     General Introduction                         
1.3 Pathology of PD 
1.3.1 Functional anatomy of the basal ganglia   
The structure of the basal ganglia is well understood, and it is known to be made up of the 
striatum (caudate nucleus and putamen), globus pallidus (medial and lateral segments), nuclei 
of the diencephalon (thalamus and subthalamic nucleus) and the mesencephalon (substantia 
nigra and pedunculopontine nucleus). 
The striatum is regarded as the input area of the basal ganglia because it receives afferents 
from the cerebral cortex, thalamus and substantia nigra pars compacta (SNc). The medial 
globus pallidus (GPm) and substantia nigra pars reticulata (SNr) are the output area of the 
basal ganglia, with projections to a number of areas such as the thalamus and 
pedunculopontine nucleus (PPN).  The GPm is known to give rise to inhibitory GABAergic 
output [86], [5], [11]. These structures are represented in figure 1.1. 
The striatum gives rise to two inhibitory projections to the globus pallidus, the ‘direct’ 
pathway which projects to the GPm, and the ‘indirect’ pathway projects to the lateral globus 
pallidus (GPl). The direct pathway allows direct inhibitory control of the GPm whilst the 
indirect pathway controls the GPm via the subthalamic nucleus (STN). The STN also receives 
inhibitory projections from the GPl and projects excitatory fibres to the pallidum. Activation 
of the direct pathway therefore inhibits basal ganglia output, whilst activation of the indirect 
pathway will result in activation of the output neurons. These two pathways are known to be 
under differential dopaminergic control from the nigrostriatal pathway, with the direct 
pathway stimulated by D1 dopamine receptor activation, whilst the indirect pathway is 
inhibited by D2 dopamine receptor activation. There is in addition a GABAergic connection 
from the GPl to the basal ganglia output regions [86], [11]. 
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 Figure 1.1 Schematic representation of the functional anatomy of the
basal ganglia in health. The basal ganglia are made up of the
striatum (caudate nucleus and putamen), globus pallidus (medial and 
lateral segments), nuclei of the diencephalon (thalamus and 
subthalamic nucleus) and the mesencephalon (substantia nigra and 
pedunculopontine nucleus). The striatum receives dopaminergic
afferent input from the SNc and gives rise to two inhibitory
(GABergic) projections to the globus pallidus. The ‘direct’ pathway 
(1) which projects to the GPm, and the ‘indirect’ pathway (2) which 
projects to the GPl. The direct pathway allows direct inhibitory 
control of the GPm whilst the indirect pathway controls the GPm via 
the STN. The STN also receives inhibitory projections from the GPl 
and projects excitatory (glutamatergic) fibres to the pallidum
Activation of the direct pathway therefore inhibits basal ganglia 
output, whilst activation of the indirect pathway will result in 
activation of the output neurons. There is in addition a GABAergic 
connection from the GPl to the basal ganglia output regions. 
Abbreviations: GPl= Globus pallidus lateral; GPm= Globus pallidus 
medial; SNc= Substantia nigra pars compacta; SNr= Substantia nigra 
pars reticulata; GABA= Gamma-aminobutyric acid. Taken from 
Crossman 2004 [11]. 
1 
2 2 
 
 
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
In subjects with PD there is known to be a loss of dopaminergic neurons in the SNc, which 
leads to dopamine loss in the striatum. This will lead to an under-activity of the direct pathway 
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and an over-activity of the indirect pathway from the striatum to the GPl. This over-activity 
will in turn inhibit the pallidostriatal neurons, causing a disinhibition of the STN. The resulting 
overactivity of the STN, and hence of the GPm, results in inhibition of the motor thalamus, 
cerebral cortical mechanisms, and brain stem locomotor region (including pedunculopontine 
nucleus) [87], [88], [11]. This disease state is represented in figure 1.2 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Schematic representation of the pathophysiology of 
parkinsonism in the basal ganglia. In subjects with PD there is known to be 
a loss of dopaminergic neurons in the SNc, which leads to dopamine loss in 
the striatum. This will lead to an under-activity of the direct pathway (1) and 
an over-activity of the indirect pathway (2) from the striatum to the GPl. This 
over-activity will inhibit the pallidostriatal neurons, causing a disinhibition of 
the STN. The resulting overactivity of the STN, and hence of the GPm, results 
in inhibition of the motor thalamus, cerebral cortical mechanisms, and brain 
stem locomotor region (including pedunculopontine nucleus). Abbreaviations: 
GPI= Globus pallidus lateral; GPm= Globus pallidus medial. Taken from 
Crossman 2004 [11].  
GABA 
 
glutamate 
2 
2 
1 
2 
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Dyskinesias and dystonia are features that can be seen in PD, in the case of dyskinesias as side 
effects of medication. These symptoms appear to be mediated by the opposite changes to those 
seen in PD, with an overactivity of the direct pathway and an underactivity of the STN and 
GPm [11]. 
 
1.3.2 Cellular pathology of PD 
The neuropathological hallmark of PD is depigmentation of the substantia nigra pars compacta 
(SNc), representing loss of neuromelanin containing dopaminergic neurons. Up to 80% of 
dopaminergic neurons are lost before clinical signs and symptoms of PD develop [89], [90], 
[91]. There is also an associated neuronal loss in the ventral tegmental area and locus 
coeruleus [91], [92]. 
A prerequisite for the postmortem diagnosis of PD is evidence of abnormal proteinaceous 
cytoplasmic inclusions in nigrostriatal neurons, which develop as spindle or thread-like Lewy 
neurites (LNs) in dendrites and axons, and in the form of globular Lewy bodies (LBs) in the 
somata of involved nerve cells [93], [94], [95], [96] (see figure 1.3). LBs are intracellular 
aggregations of proteins and lipids that were first identified by eosin staining. They are now 
known to be enriched in α-synuclein and other proteins that are often highly ubiquitinated 
[97], [98], [99].  
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Whilst the LB is a sensitive marker for PD, it is not disease-specific and can be found in a 
number of other conditions such as Lewy body dementia, MSA and Hallervorden-Spatz 
Disease [100], [101], [102], [103]. Indeed LBs have also been detected in up to 10% of 
subjects over the age of 60 without clinical evidence of PD and it has been proposed that this 
may represent a pre-clinical phase of the disease [14], [104], [105], [106].  
Whilst neuronal loss in the SNc is pronounced in PD, there is also widespread 
neurodegeneration in other areas of the central nervous system (CNS) and it is thought that the 
Figure 1.3 Immunolabelling for alpha-synuclein in human brain tissue from a subject with 
dementia demonstrating Lewy body pathology. Panel A= High-magnification 
photomicrograph of a Lewy body (arrowhead) in a pyramidal neuron of the orbital frontal 
cortex. Toluidine blue counterstaining allows the visualization of Alzheimer-type plaques 
(centre, labelled with asterisk), into which Lewy neurites have developed. Panel B= A Lewy 
neurite in horizontal section. It is notable that Lewy neurites can extend for long distances. The 
neurite visible in B is from a region of the anterior olfactory nucleus and is approximately 220 
μm in length. Scale bar = 25 μm. The primary antibody used for the detection of alpha-
synuclein was rabbit anti-alpha-synuclein antibody (Sigma). Taken from Hubbard et al. 2007 
[24]. 
B 
A
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SNc becomes involved in the middle stages of the disease [98], [107]. A pathological staging 
system for PD based upon the topographical extent of lesions has been proposed [107]. 
Braak et al. suggest that rather than evolving simultaneously at all the nigral and extra-nigral 
sites the pathological process may follow a pre-determined sequence [107]. It appears to target 
specific induction sites, with lesions initially occurring in the dorsal motor nucleus of the 
glossopharyngeal and vagal nerves and anterior olfactory nucleus, progressing to involve the 
substantia nigra and eventually cortical areas become affected. The disease process in the 
brain stem progresses in an ascending course with little variation observed between 
individuals. Cortical involvement begins with the anteromedial temporal mesocortex, the 
neocortex then becomes involved, starting with the high order sensory association and 
prefrontal areas, followed by the first order sensory association/premotor areas and primary 
sensory/motor fields [107].  
The sequential pathological process in PD proposed by Braak et al. may give important 
insights into which areas to focus on when we consider the aetiology of PD, and be important 
as we attempt to develop pre-symptomatic markers of the condition.        
 
1.4 Investigation and treatment of PD 
PD remains a clinical diagnosis and routine laboratory investigations are unhelpful in 
diagnosing PD. Furthermore, computed tomography (CT) and magnetic resonance imaging 
(MRI) are also not helpful in making a diagnosis of PD, although they may suggest alternative 
diagnoses such as PSP or MSA. 
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Olfactory testing and functional neuro-imaging in PD can be helpful for diagnosis, and even 
for pre-symptomatic screening, and are discussed below. The treatment of PD is also covered 
in section 1.4.3.  
 
1.4.1 Olfaction and PD 
Olfactory dysfunction (hyposmia) is found in 70-100% of PD patients, rendering it as common 
a clinical sign as pill rolling tremor [108], [109], [110], [111]. It is associated with neuronal 
loss and Lewy body deposition in the olfactory pathway [112]. Olfactory dysfunction is 
markedly reduced early on in the course of PD, as assessed by the University of Pennsylvania 
smell identification test (UPSIT) a well validated method of quantification of olfactory 
dysfunction [113], [108], [114], [115] [116], [117]. Marked olfactory dysfunction is also 
common in DLB, but it is not found in vascular parkinsonism, PSP and CBD, and only 
relatively mild olfactory dysfunction has been found in MSA.  
The early or 'pre-clinical' detection of Parkinson's disease is an area in which olfactory testing 
may be of value in the future [118], [110], [117], [119], [120], [121], [122]. 
  
1.4.2 Functional imaging of the dopaminergic system 
The pathological changes in the basal ganglia discussed above can now be detected by 
functional imaging. The radiopharmaceutical 6-[18 F]-fluorodopa (F-dopa) is taken up by 
dopaminergic neurons in the SN and metabolised to 6-[18F]-fluorodopamine. Positron 
emission tomography (PET) scans using this radiopharmaceutical agent show reduced F-dopa 
uptake in dopaminergic nerve terminals in the putamen and caudate proportional to the 
severity of degeneration in the ipsilateral SN and symptoms in the contralateral hemibody [5].  
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Dopamine Transporter (DAT) imaging with single-photon emission CT (SPECT) enables in 
vivo demonstration of striatal dopamine activity, and yields results in keeping with other 
measures of the dopamine system such as autopsy studies [123], [124], [125]. DAT imaging is 
increasingly used in clinical practice. Although it is abnormal in PD, MSA and PSP it helps to 
distinguish theses conditions from essential tremor, vascular parkinsonism (unless there is 
focal basal ganglia infarction), drug-induced parkinsonism, or psychogenic parkinsonism in 
which DAT scanning is normal [126]. 
DAT is a sodium chloride-dependent protein on the pre-synaptic dopaminergic nerve terminal 
which controls dopamine levels by active re-uptake of dopamine after its interaction with the 
postsynaptic receptor [127]. The DAT ligands for SPECT, including [123I]FP-CIT 
(DaTSCAN) [128] all show significantly reduced striatal uptake in PD [129], even in early 
cases [130]. The abnormal uptake progresses from the putamen to caudate, and matches 
contralaterally to the side of the body more affected clinically. DAT imaging is reproducible 
with test/retest variability in healthy controls and PD of 7% for DaTSCAN [131]. However, as 
discussed further in section 4.1.2, in some large studies of PD 11-15% of subjects have been 
found to have normal nigrostriatal uptake of presynaptic ligands [132], [133], [134], [135], 
[136]. The diagnosis in these patients remained unclear, and they have since been referred to 
as SWEDDs (Scans Without Evidence of Dopaminergic Deficit) [137].  
 
1.4.3 Treatment of PD 
The treatment of PD is a complex and ever developing topic. However, as this is not a major 
focus of the work in this thesis, only a brief summary is given here.  
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There have been two main strategies for the treatment of PD: (i) a disease modifying approach 
to slow or delay the progression of disease, and (ii) symptomatic treatment for the motor and 
non-motor features of the disease. The prolonged preclinical phase in PD makes it an excellent 
candidate for neuro-protective agents. However perhaps mainly because of our poor 
understanding of the aetiology of PD, there is to date no agent which has been proven in 
clinical trials to be neuroprotective [5], and the treatment of PD remains symptomatic. 
The available symptomatic treatments for PD currently include both medical and surgical 
modalities. Since its discovery in the 1960s as a dopamine replacement therapy, L-Dopa has 
remained the ‘gold standard’ symptomatic medical therapy [38], [5]. Other medications which 
are available include anticholinergics, Amantadine, monoamine oxidase inhibitors (MAOIs), 
catechol-O-methyltransferase (COMT) inhibitors and dopamine agonists. The question as to 
which medication to use in an individual patient remains unanswered [5], although the 
ongoing ‘PD MED’ trial (www.pdmed.bham.ac.uk) aims to answer this question. 
As the patient’s symptoms progress the medical management of their PD becomes more 
complex as the medications become less effective, with patients often experiencing 
increasingly prolonged wearing off periods and dyskinesias [5]. In some patients, particularly 
with advanced disease, or where medical therapy has failed, surgical therapies are considered. 
Surgical techniques currently used include stereotactic destruction of physiologically defined 
overactive brain nuclei (e.g. pallidotomy) or more commonly deep brain stimulation (DBS) of 
the STN using implanted pulse generators [5].        
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1.5 Aetiology of PD 
Despite much research over the last few decades, the aetiology of PD remains poorly 
understood. Without a better understanding of what causes PD it may prove difficult to 
develop more effective symptomatic and neuro-protective treatments for the condition, thus 
there is a strong and continuing stimulus for further research into this area. 
Although it has been proposed for many years that PD may develop due to interplay between 
genetic and environmental factors, over the last 10 years the emphasis has shifted towards the 
genetic hypothesis of the aetiology of PD, mainly through the identification of a number of 
‘PD genes’. In the following sections I will summarise the evidence in support of the 
environmental and genetic hypotheses as well as outlining some of the current models for the 
aetiopathogenesis of PD.      
 
1.5.1 Environmental hypothesis 
A number of environmental risk factors have been proposed on the basis of presumed 
pathogenic mechanisms [138], [139]. The important discovery that 1-methyl-4-phenyl 
tetrahydropyridine (MPTP), a contaminant of a synthetic opiate, can cause parkinsonism, 
through its toxic metabolite 1-methyl-4-phenylpyridinium (MPP+), stimulated intense interest 
in environmental chemical exposures as risk factors for PD [140], [141]. This form of 
parkinsonism was similar in its phenotype to idiopathic PD, apart from the young age of onset 
and the associated pathology showed evidence of nigral cell loss without Lewy bodies [142], 
[143]. A similar parkinsonian syndrome can also be induced in MPTP-treated primates and 
rodents, with nigral inclusion bodies similar to Lewy bodies seen in some aged primate 
models [144], [145], but not rodent models [146]. MPP+ irreversibly inhibits NADH CoQ1 
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reductase (complex I) activity of the mitochondrial respiratory chain, thus leading to increased 
free radical formation and subsequently cell death [147]. MAO-B and various members of the 
cytochrome P-450 family are important in the activation of MPTP and similar compounds, for 
example by CYP2D6, CYP1A2 [148], [149], [150] and CYP1A1 [151]. 
There have been numerous subsequent epidemiological studies designed to investigate 
environmental risk factors and putative MPTP-like compounds. However, many of the studies 
have been retrospective, and thus prone to recall bias, and have had other methodological 
flaws, such as small sample size and use of inappropriate controls. Furthermore ‘reverse 
causality’ needs to be considered. For example dopamine shortage can affect food preferences 
[152], and thus result in altered intake of certain nutrients in PD patients, rather than the 
nutrients themselves having any aetiological role. 
Only over the last 5-10 years have larger prospective studies been performed. However even 
in these studies reversed causality can play a part, as can bias in exposure assessment before 
onset of PD and apparently asymptomatic participants may already have pre-symptomatic 
dopaminergic degeneration. Furthermore, the time period in which patients are at risk of 
developing PD is unknown and therefore it is not clear whether early, late, cumulative, or 
lifetime exposures should be studied [138], [153]. 
 
1.5.1.1 Toxin exposure and PD 
The discovery of MPTP stimulated interest in finding environmental toxins in PD, and in 
particular finding a more common neurotoxin that might be implicated in the pathogenesis of 
PD. The association between PD and pesticide exposure was extensively investigated, given 
the similarity between paraquat and MPTP [154]. There has also been interest in associations 
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between rural living, farming and well water consumption (all of which may be surrogate 
markers for pesticide exposure) and PD (see section 3.1.5.4). 
There have been a number of epidemiological studies into the relationship between pesticide 
exposure and incidence of PD. Most studies have used ‘pesticide’ or ‘pesticide and herbicide’ 
as contamination categories, and as in most environmental studies, have been retrospective 
case-control in design. A statistically significant link between pesticide exposure and PD has 
been found in approximately half of the studies. A meta-analysis of 19 of these studies 
calculated a pooled odds ratio of 1.94 (95% CI 1.49-2.53) [155], which fits with some of the 
more recent case-control studies [156], [157]. One large recent prospective study, with a 30 
year follow-up, found a significantly increased risk of PD for men working for more than ten 
years on a plantation and a non-significant association for men exposed to pesticides [158].  
The mechanism of pesticide toxicity in PD remains unknown. Pesticides are known to induce 
mitochondrial dysfunction through inhibition of complex I [159], [160], [161], [162], [163], 
[164], [165] and also modulate the xenobiotic metabolizing enzymes such as cytochrome P 
450, CYP2D6 and glutathione transferase [166], [167], [168], [169], [170]. Two in vivo 
animal studies have shown dopamine depletion after infusion with the pesticide rotenone 
[165], [171]. The relevance of this is highlighted by the finding of complex I defects in the 
substantia nigra of patients with sporadic PD [172].  
In addition to pesticides, much work has been done to investigate whether there may be links 
between other toxins, for example heavy metals, and the risk of developing PD. It has been 
proposed that these metals may accumulate in the substantia nigra and increase oxidative 
stress [173]. Case reports and case-control studies have linked long-term exposure to some 
specific metals such as manganese, copper, mercury, lead, iron, zinic, aluminium, amalgam, 
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and indeed combinations of these substances, with PD. However, the epidemiological 
evidence in support of a definite link remains inconclusive, as reviewed in Lai et al. 2002 and 
Jankovic et al. 2005 [173], [174]. 
The high incidence of a neurodegenerative disorder characterized by motor neuron disease, 
parkinsonism or dementia (‘Lytico-Bodig’) on the island of Guam in the western Pacific 
provides further supportive evidence of an environmental neurotoxin causing parkinsonism. 
Although there are inconsistencies between either a purely genetic or environmental 
hypothesis, the condition is thought to be related to the use of cycad seeds in the indigenous 
diet [175], [176].  
There have also been a number of studies into potential associations between dietary factors 
and risk of developing PD. Some studies have shown a positive association between fat 
consumption and PD [177], [173]. Other studies show a negative association between dietary 
items such as niacin, nuts and vegetables and PD [178], [179], [180], [181], [173]. Overall a 
link between dietary factors and risk of PD remains unproven [182], [173]. The results for 
antioxidants are even more complex to interpret, with numerous studies into the effects of 
vitamins A, C and E on risk of PD, as reviewed in Lai et al. 2002. Overall there is as yet no 
consistent evidence to show that antioxidant vitamins have a protective role in the aetiology of 
PD [178], [179], [180], [182], [173]. 
It remains unclear if there is a definite link between environmental toxins and risk of PD. 
Given the prevalence of PD, a common low-level exposure to a putative neurotoxin, such as 
pesticides, experienced by the majority of the population, will be difficult to detect and will 
require much larger sample sizes [183]. How environmental toxins may interact with genetic 
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variations found in certain populations, or indeed individuals, is also an area of research which 
could prove to be crucially important for understanding the pathogenesis of PD. 
 
1.5.1.2 Infections and PD 
A link between cerebral infection and parkinsonism was first considered during the influenza 
pandemic of the late 1910s when it was observed that encephalitis lethargica often preceded 
parkinsonism, suggesting a possible infectious cause [184]. There is strong evidence to 
support the link between the pandemics of influenza and encephalitis lethargica, namely their 
close time link, global distribution  and single aetiological agent (swine influenza virus) [185]. 
Furthermore the average age of onset of PD based on data from three London hospitals during 
the period of 1921-1930 was 36.8 years, compared to 54.7 years during the first 20 years of 
the 1900s, while the average age of diagnosis of postencephalitic parkinsonism from 1921 to 
1942 was 27.4 compared to 55.6 for paralysis agitans from 1900 to 1942 [186]. 
Further evidence suggesting an infectious cause for Parkinsonism comes from reports 
suggesting that other infections such as AIDS [187], and Japanese B encephalitis [188], [189], 
[190] and encephalitis induced by cocksakie B [191], influenza A [192], herpes simplex [193], 
measles [194], or mumps [195] can be associated with temporary parkinsonism, either acutely, 
or as long term complications. These findings are also supported by in vivo work on mice 
inoculated with neurovirulent influenza A viruses, showing that the substantia nigra is a major 
target for these viruses [196]. There have also been some reports suggesting a link between 
intra-uterine and childhood infections and risk of PD [173]. 
There is, however, no evidence from serological analysis to support any specific infection 
being more common in PD [197], [198], and indeed pathological examination has also failed 
 - 23 -
Chapter 1                                                                                                     General Introduction                         
to detect specific viral particles, inclusions or antigens in PD brain autopsy material [199], 
[173]. 
In summary, whilst there is enough evidence in support of a post-infective cause for 
parkinsonism to justify this being considered a potential mechanism, the infective hypothesis 
of PD remains far from proven.    
 
1.5.1.3 Smoking and PD 
Smoking is one of the most studied risk factors for PD, with a reduced risk of PD in smokers 
consistently found. Many of the earlier studies were retrospective case-control designs, but 
more recent cohort studies have also confirmed these results [200], [201], [202]. A large meta-
analysis of case control (44) and cohort (4) studies reports a relative risk of PD, compared 
with never smokers, of 0.59 for ever smokers, 0.80 for past smokers, and 0.39 for current 
smokers [203]. The relative risk per 10 additional pack-years was 0.84 in case-control studies 
and 0.78 in cohort studies [203].  
The reason for this association remains unclear. It may be due to bias from selective mortality 
of smokers among people without PD, or other unknown confounding variables. However, 
theories for true biological protection as a result of smoking have been proposed, along with 
laboratory evidence to back them up. The most likely proposed mechanisms involve nicotine’s 
actions to inhibit MAO-B, and stimulate nicotinic acetylcholine receptors leading to dopamine 
release and neuroprotection of dopaminergic neurons in the nigrostriatal tract [204], [205], 
[206], [207]. Another explanation involves the role of dopaminergic pathways in reward 
mechanisms. Patients with PD might be less prone to addictive behaviours because of 
dopamine depletion or a pre-morbid personality characterised by a lower frequency of 
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behaviours associated with novelty seeking [208], [209]. A final theory is that genetic 
polymorphisms that reduce tolerance to tobacco smoke may also increase the risk of PD and 
account for this association [138]. 
 
1.5.2 Genetic hypothesis 
The last decade has seen a revival of the genetic hypothesis of PD, mainly through the 
identification of a number of ‘PD genes’. It is important to emphasise that after increasing age 
[210], [211] a family history of PD remains the strongest risk factor for PD. Genetic influence 
on PD has been recognized as far back as the nineteenth century, when Gowers noted that 
15% of his patients had affected relatives [212].  
There have been many recent studies of genetic influence on PD, for example the DATATOP 
study in which 19% of patients reported a positive family history of PD [41]. In a separate 
population-based study, the reported frequency of a positive family history of PD was 10.3% 
in subjects with PD and 3.5% in age and sex-matched controls [213]. Furthermore, Bonifati et 
al. had previously reported that a family history of PD was positive in 24% of 100 consecutive 
PD cases and 6% of spouse controls (p<0.001) [214]. The risk of developing PD does vary 
significantly according to the population examined, with the relative risk to first-degree 
relatives 2.7 in the United States [215], 2.9 in Finland [216], 6.7 in Iceland [217] and 7.7 in 
France [218]. This suggests the influence of different genetic polymorphisms, or indeed 
environmental exposures within these various populations. 
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1.5.2.1 Twin studies 
Assessing the difference in concordance rates between identical and non-identical twins ‘twin 
studies’ has been the classic method of establishing whether a disease has a significant genetic 
aetiology. The initial twin studies in PD from the 1980s demonstrated similar concordance 
rates for monozygotic and dizygotic twins [219], [220]. However the results from more recent 
studies have been less clear cut. For example, in the largest PD twin study to date no 
difference in the concordance rate between monozygotic & dizygotic (MZ and DZ) twins was 
identified, for typical late onset PD. However,  in the group of subjects whose age of disease 
onset was less than 50 years, genetic factors were demonstrated to be important [221].  
One potential explanation for these findings is related to a fundamental problem associated 
with most studies of PD, that although the diagnosis of PD is entirely clinical there is a well 
recognised presymptomatic phase [14]. Thus those twin studies which have relied purely on 
clinical diagnosis alone will miss those subjects in the presymptomatic phase of disease. An 
attempt to counter this problem was made in a prospective study using fluorodopa PET to 
identify presymptomatic individuals. In this study the concordance rate for dopaminergic 
dysfunction and/or PD was 75% for the MZ twins compared with 12% in the DZ twins. Thus 
using this more sophisticated twin study design an important role for genetic factors in PD was 
demonstrated [222]. 
 
1.5.2.2 Familial studies 
Another approach to establishing the genetic aetiology of PD has been familial studies. 
Although large kindreds with classical Mendelian inheritance of PD are rare, in the last decade 
family-based linkage approaches and positional cloning have identified a number of 
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monogenic forms of PD, which I will discuss below. The process of linkage analysis considers 
co-segregation of genetic markers (alleles) with a defined phenotype (disease state) within 
pedigrees with multiple affected family members in several generations. The likelihood of 
linkage is described as the logarithim of the odds (LOD) score (ratio of the chance of the 
marker locus and disease being linked versus the chance that they are not linked), with a score 
greater than 3.0 representing significant evidence for linkage, for autosomal loci [223], [224].  
The findings from familial studies have generated a lot of interest, mainly because the study of 
these rare inherited forms of PD may enable us to obtain important pointers towards the 
pathogenesis of idiopathic PD.  
 
1.5.2.3 Nomenclature 
In this thesis I have used a nomenclature system for the description of changes (mutations and 
polymorphisms) in DNA and protein sequences based on that recommended by Antonarakis 
and the Nomenclature Working Group (http://www.dmd.nl/mutnomen.html) [225], [226]. 
I have used sequence variation or variant to describe sequence changes of unknown or 
unconfirmed functionality. This includes the term polymorphism, also referred to as single 
nucleotide polymorphism (SNP), which specifically refers to changes found at a frequency of 
1% or higher in the population. I have used the term mutation to describe sequence changes 
with known medical significance or phenotypic consequence. I have used the term pathogenic 
mutation when there is strong evidence in support of a pathogenic role for a mutation, such as 
evidence of segregation with disease in large pedigrees, and/or laboratory evidence in support 
of a functional effect on the protein.   
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1.5.2.4 Autosomal Dominant and Recessive PD 
Over the last 10 years through various population analyses a number of monogenic forms of 
PD, both dominant and recessive, have been identified. There is now robust evidence for five 
hereditary PD genes: alpha-synuclein, DJ-1, LRRK2, Parkin and PINK1 (see table 1.6). There 
is less conclusive evidence implicating other possible PD genes, including: NURR1, synphilin-
1 and UCH-L1 [227], [228], [229], [230], [25], [27], [231], [232]. 
Generally autosomal dominant PD (AD PD) is thought to present with a clinical and 
pathological phenotype similar to that of idiopathic PD (IPD) [233]. The AD loci identified to 
date are PARK1, PARK3, PARK8 and PARK11. Autosomal recessive forms of PD (AR PD) 
resemble IPD, but tend to present with an earlier age of onset and often demonstrate more 
slowly progressive disease [234], [235], [236]. The AR loci identified to date are PARK2, 
PARK6, PARK7 and PARK9. Importantly for our understanding of IPD, whilst both AD and 
AR PD resemble IPD clinically, they often lack specific pathological features. LBs, in 
particular, are an essential brain bank diagnostic criterion, but are inconsistently found in most 
forms of genetically mediated parkinsonism [237]. 
 
1.5.2.5 Dominant loci 
1.5.2.5.1 Alpha-synuclein (PARK1) 
The study of a large Italian pedigree of at least 60 members first led to the linkage of their 
form of AD PD to chromosome 4q. Subsequently an A53T (G209A) mutation in the α-
synuclein gene (SNCA) was identified in this family, and five unrelated Greek families [238], 
[228]. Apart from a relative paucity of tremor, young onset, and long disease course, there 
were no clinical features to differentiate between PD families with the A53T mutation and 
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subjects with sporadic disease [239]. Subsequently other SNCA mutations in unrelated German 
(A30P) and Spanish (E46K) families have been identified [240], [241]. However, extensive 
studies have now conclusively demonstrated that SNCA mutations are a rare cause of fPD 
[242], [243], [244].  
Additional mechanisms by which α-synuclein function can be altered have subsequently been 
identified. The level of protein expression may be altered by polymorphisms in the promoter 
or upstream regulatory regions, or by duplication or triplication of the gene. This latter 
phenomenon was initially erroneously allocated to the PARK4 locus [245], [246], [247], 
[248], [249], [250], [251], [252]. The most recent, and largest, analysis of SNCA promoter 
variability has indicated that allele length variability in the dinucleotide repeat sequence is 
associated with an increased risk of PD [253]. 
The importance of the genetic studies in SNCA was reinforced by the identification of α-
synuclein as the major component of LB [97]. This finding created a new field of research 
focusing on diseases associated with the pathological aggregation and deposition of the α-
synuclein protein, the so called ‘alpha-synucleinopathies’, which in addition to PD also 
includes diffuse LB disease, and MSA. Numerous histological studies have shown that α-
synuclein forms an important component of LB and the oligodendroglial inclusions 
characteristic of MSA [103]. Furhermore, transgenic animal models expressing human α-
synuclein, mutant A53T or A30P α-synuclein, or knock-out phenotypes have been developed 
showing a variety of phenotypic and pathological features with some similarities to IPD [254]. 
α-synuclein is now known to have lipid-binding properties [255], leading to speculation that 
the protein plays a role in stabilising lipid bilayers. Other studies suggest that the protein has a 
cellular housekeeping function, linking up with other synaptic vesicle proteins such as the 
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soluble N-ethylmaleimide-sensitive-factor attachment protein receptor ‘SNARE’ complex 
[256], altering proteasomal structure to modify protein synthesis and degradation, resulting in 
altered vulnerability to cellular stressors [257]. Despite this extensive and ongoing 
investigation, the normal physiological function of α-synuclein remains to be determined. 
 
1.5.2.5.2 PARK3 
The PARK3 locus was identified in 1998 in a genome-wide genetic linkage study using a 
group of families of European ancestry [258], with linkage to chromosome 2p13 found. 
Further linkage studies have subsequently confirmed linkage to the PARK3 locus in other 
families [259], [260], [261]. However, to date no relevant pathogenic mutations have been 
found in coding sequences of 14 candidate genes [262]. The associated clinical and 
pathological phenotype appears to be similar to IPD, with late-onset PD (average age of onset 
of 59 years) and associated LB pathology [259], [260], [261], [262]. A recent study showed 
linkage to the sepiapterin reductase (SPR) gene region, which is located in the PARK3 
linkage region, in 122 families of European ancestry [263]. Interestingly SPR is implicated in 
dopamine synthesis, but this linkage needs to be confirmed. 
 
1.5.2.5.3 UCH-L1 (PARK5) 
In 1998 as part of a candidate gene approach, the study of two German siblings with 
apparently AD PD identified a missense mutation (I93M) in the ubiquitin carboxy-terminal 
hydrolyase L1 (UCH-L1) gene located at chromosome 4p14 [264]. The significance of this 
finding remains controversial, with no mutations identified in any other kindreds to date and a 
lack of pathological reports. A subsequent study suggested that another UCH-L1 variant 
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(S18Y) reduces PD susceptibility [265], and this finding was confirmed in a pooled analysis 
from 11 studies involving 1,970 patients [266]. 
Intriguingly the UCH-L1 gene codes for a neuron-specific protein that catalyses the hydrolysis 
of ubiquitin from the C-terminal end of substrates, and is a component of the ubiquitin-
proteasome system [267], [268]. Although the functional relevance of mutations in this protein 
in PD are still being investigated, the findings to date suggest another potentially important 
link between protein processing, breakdown and fPD. 
 
1.5.2.5.4 LRRK2/dardarin (PARK8) 
This PD locus is the focus of the majority of the work presented in this thesis. In this section I 
will summarise in detail what was known about the PARK8 locus up until April 2005, when I 
started work on my project. More recent developments are covered in chapters 5, 6 and 7, in 
which I present my data. 
The PARK8 locus for AD PD was first identified in 2002 in a large Japanese pedigree named 
‘the Sagamihara’ kindred, after the region of origin in Japan, and was linked to chromosome 
12p11.2-q13.1 (see figure 1.4) [269]. These findings were subsequently confirmed in non-
Japanese families [270]. The clinical features of affected individuals were noted to be typical 
for idiopathic late-onset PD, including a good levodopa response  [269], [270]. Pathological 
examination of patients found the expected nigral dopaminergic neuron degeneration, but a 
variable range of other features, including alpha-synuclein positive Lewy bodies (LBs) in 
some, but not all,  cortical LB pathology, tau-positive axonal inclusions, or other 
uncharacterised neuronal cytoplasmic inclusions [271], [27]. 
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In 2004 the gene linked to the PARK8 locus was identified simultaneously by two groups as 
leucine rich repeat kinase 2 (LRRK2) [25], [27]. This large 51 exon gene encodes for a protein 
of 2527 amino acids (286kDa) called LRRK2, or dardarin, derived from the Basque word 
dardara, meaning tremor [25], [27].  
LRRK2 is known to be part of the Roco protein family. Members of the Roco protein family 
are characterized by having a conserved supradomain that contains as Ras-like GTPase 
domain, called Roc, and a characteristic COR (Carboxy-terminal of Roc) domain. In addition, 
a kinase domain and diverse regulatory and protein-protein interaction domains are also often 
found in these proteins [272]. Sequence analysis indicates that the protein contains several 
discrete regions: an ankyrin repeat domain, a LRR (leucine rich repeat) domain consisting of 
12 strands of a 22–28 amino acid motif, present in a tandem array; a Rho/Ras-like GTPase 
domain; a COR domain; a protein kinase domain related to the MLK (mixed lineage kinase) 
family; and a WD40-repeat domain consisting of approximately 40-60 amino acids which 
terminate in a Trp-Asp (W-D) dipeptide (see figure 1.4).  
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Figure 1.4 Schematic representation of the LRRK2 region of chromosome 12, the LRRK2 protein 
domain structure and three pathogenic LRRK2 mutations. Panel A= Ideogram of chromosome 12, 
LRRK2 spans a genomic region of 144 kb. Panel B= Schematic representation of LRRK2 exons 1-51 
with three pathogenic amino acid variants. Corresponding exon numbers are shown in black. Panel C= 
Schematic representation of LRRK2 protein structure from residue 1-2527. Abbreviations: 
ANK=ankyrin repeat region; COR=C terminal of Ras; Ex=exon; LRR=leucine-rich repeat domain; 
Roc=Ras of complex (GTPase); WD40= domain of 40-60 amino acids which terminate in a Trp-Asp 
(W-D) dipeptide; kb= kilobase pairs. Adapted from Mata et al. 2006, Paisán-Ruız et al. 2004 and 
Zimprich et al. 2004 [25], [27], [18]. 
 
 
 
 
 
 
 
 
 
 
Through what was already known about the types of functional domains identified in LRRK2, 
it was possible early on to speculate about what process the protein may be involved in. 
Ankyrin domains are known to be involved in protein-protein interactions [273]. The group of 
proteins which contain LRRs have been implicated in diverse cellular functions, ranging from 
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hormone receptor interactions, enzyme inhibition, cell adhesion, cellular trafficking, splicing, 
to substrate binding for ubiquitination. However an important and common property of these 
proteins again involves protein-protein interaction [274]. The Ras/GTPase domains are known 
to play a part in reorganisation of the actin cytoskeleton in response to external stimuli, with 
additional roles in cell transformation by Ras, cytokinesis, focal adhesion formation, and the 
stimulation of stress-activated kinases [275]. Enzymes which contain tyrosine kinase domains 
belong to a large family of proteins that share a conserved catalytic core common to both 
serine/threonine and tyrosine protein kinases. They are known to function by catalysing the 
transfer of the γ-phosphate of ATP to tyrosine residues on protein substrates [276]. Finally, 
WD40 domains have previously been found to be involved in signal transduction, pre-mRNA 
processing, and cytoskeleton assembly [277]. 
Following the original descriptions of mutations in LRRK2, a number of other putative 
pathological mutations were rapidly identified, including: R1441C, R1441G, and G2019S 
[18], [278], (see figure 1.3). These mutations were noted to be clustered around the kinase and 
GTPase domains. It soon became clear that LRRK2 mutations appear to account for up to 10% 
of familial PD cases with AD inheritance [279], [280]. Of the mutations identified, the 
G2019S mutation, (c.6055G>A) in exon 41, appeared to be particularly important, as it alone 
seems to be responsible for up to 5%-6% of hereditary and, importantly, 1%-2% of apparently 
sporadic PD cases [281], [282], [283], [284], [285]. Indeed the G2019S common mutation was 
found at even higher frequencies in certain populations, including Portugese (6%) [286], and 
North African Arab patients (41%) [287]. 
The clinical phenotype of most LRRK2 positive PD patients appears indistinguishable from 
that of typical IPD, including good response to Levodopa [27], [288], [283], [289], [290], 
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[285]. However, the age at onset is variable, ranging from 28 to 86 years in subjects with the 
G2019S mutation [285], [282], [284], [291]. 
One of the criticisms of the early work performed on LRRK2-PD was the relative dearth of 
studies in which a comprehensive analysis of the whole coding region of the gene had been 
performed on a large cohort of subjects with familial PD. By the end of 2005 there were only 
five such studies [27], [292], [279], [293], [294], compared to over 20 studies in which only a 
limited number of known LRRK2 mutations were investigated. The major reason for this is 
likely to be the large size of the gene, such that comprehensive analysis of the entire gene is 
time-consuming and expensive. The majority of studies in sporadic disease had focused on 
screening for previously identified mutations in different populations. I recognised the main 
drawbacks of such a piecemeal screening approach, namely important pathogenic LRRK2 
mutations may not be identified and potentially important insights into the pathogenesis of PD 
missed, and also that estimates of mutation frequency may be inaccurate. This is discussed 
further in chapters 5 and 6.     
When I commenced my study of LRRK2-PD in 2005 the putative functional domains of the 
protein had been proposed and various mutations identified. As the most common G2019S 
mutation is found in the kinase domain of the protein there was speculation that the pathogenic 
mechanism of this mutation may be via kinase over-activity. However, the physiological 
function of LRRK2 was unknown, as were the effects of the presumed pathogenic mutations. 
This is discussed further in chapter 7.  
In summary, when I started this thesis the evidence suggested that LRRK2-associated PD was 
quite common, had an age of onset and phenotype that is closer to sporadic PD than most 
other forms of familial PD, and it demonstrated a wide range of pathology. In addition, for the 
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first time, a specific PD gene mutation (G2019S), identified in familial cases, had been 
implicated in apparently sporadic disease. Overall these findings represented a potentially 
major breakthrough in our understanding of the aetiology of PD. Further comprehensive 
analyses of the LRRK2 gene were still required both in familial and sporadic PD, as well as a 
better understanding of the function of the protein and its potential role in the disease 
pathogenesis. 
 
1.5.2.5.5 PARK11 
In 2003 the PARK11 locus was identified with AD linkage to chromosome 2q36-37 in a 
sample of sibling-affected PD pairs, and subsequently expanded using 65 pedigrees to obtain a 
LOD score of 5.1 [295]. The significance of these findings remained controversial for some 
time as replication was not achieved in several other linkage studies [296], [297], [298]. 
More recently Lautier et al. investigated the GIGYF2 gene encoding GRB10-interacting GYF 
Protein 2, which had been found to contains the PARK11 microsatellite marker (D2S206) with 
the highest LOD score (5.14) [299]. On sequencing all 27 coding exons of GIGYF2 gene in 
over 200 patients and controls, they identified seven different missense mutations (single 
amino acid substitutions) in 12 unrelated index patients (4.8%) with none in controls. In 
addition three amino acid insertions or deletions were identified in four other index patients 
and none in controls. In four families with multiple affected family members amino acid 
substitutions (Asn56Ser, Thr112Ala, and Asp606Glu) were found to segregate with disease. In 
one family two unaffected mutation carriers were identified, which suggests age-dependent or 
incomplete penetrance for this mutation [299]. Whilst still to be replicated, this data does 
appear to support GIGYF2 as the PARK11 gene with a causal role in fPD. 
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Intriguingly the investigators also identified one index case with early onset PD, age 33, who 
had inherited a GIGYF2 mutation (Ile278Val) from her affected father (disease onset age 66) 
and a LRRK2 mutation (Ile1371Val) from her affected mother (disease onset age 61). They 
speculated that the earlier onset and more severe clinical course of disease in the index patient 
may suggest an additive effect of the these two mutations [299].  
 
1.5.2.6 Recessive loci 
1.5.2.6.1 Parkin (PARK2) 
Following the original descriptions of early onset AR PD in a series of Japanese families, the 
PARK2 locus was mapped to the long arm of chromosome 6, eventually leading to the cloning 
of the Parkin gene [229]. The associated clinical phenotype showed early onset of disease 
(typically with onset before age of 45), with slow progression, good levodopa response, and 
levodopa-induced dyskinesias. Whilst these cases can be difficult to distinguish clinically from 
Parkin-negative disease, they appear pathologically distinct, with nigral neuronal loss and 
deposition of extraneuronal melanin, but crucially LBs are absent in all but one of the reported 
cases [234], [235], [236], [300], [301], [302], [303]. 
It has now been demonstrated that homozygous parkin mutations are found in approximately 
10-20% of patients with early onset PD (before age 45), depending on series, with this 
frequency increasing to 50% in AR early onset fPD cases [304], making Parkin mutations the 
most common cause of ARPD. Over 100 Parkin mutations have now been identified in many 
different populations [305], [234], and mutation analysis remains technically demanding, 
particularly because of possible rearrangements in exons 3, 4 or both [306], [307]. 
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Parkin consists of 12 exons, which span over 1 megabase (Mb), and encode for a 465 amino 
acid protein widely expressed in both neuronal and glial cells as well in several extracerebral 
tissues. The protein contains an N-terminal ubiquitin-like sequence and a C-terminal RING 
‘really interesting new gene’ domain composed of two RING finger motifs (see figure 1.5).  
 
 
 
Figure 1.5 Schematic representation of human Parkin, 
showing its functional domains. This is a 465 amino acid 
protein, estimated domain boundaries are indicated by residue 
numbers above. Parkin contains a UBL= ubiquitin-like domain; a 
UPD= unique Parkin domain; and a RING= really interesting new 
gene box domain which consists of two RING finger motifs R1 
and R2 separated by an IBR= in-between RING motif. Taken 
from Hampe et al. 2006 [22]. 
 
 
 
 
 
As with other RING finger proteins, parkin has E2-dependent E3 ubiquitin-ligase (E3) activity 
(E2 is the ubiquitin-conjugating enzyme UBCH7) [308]. Importantly E3 acts as a substrate-
recognition molecule during ubiquitination by conjugation via a lysine residue to ubiquitin to 
form polyubiquitin chains, targeting proteins for degradation via the 26S proteasome. Thus 
Parkin would appear to provide a crucial link to proteasomal degradation [309]. 
However the true function of Parkin may be much more complex, with neuroprotective 
properties demonstrated in a variety of model systems [310]. For example in a Drosophila 
model of neuronal overexpression of mutant α-synuclein, Parkin was demonstrated to reduce 
dopaminergic neuronal loss [311]. In addition other reports have suggested that Parkin 
interacts with other proteins implicated in fPD, including PINK1, LRRK2 [312] and DJ-1 
[313]. The pathogenesis of Parkin-related PD may involve several cellular processes, 
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including protein quality control, mitochondrial dysfunction, oxidative stress, and apoptosis. 
The extensive potential interactions of the Parkin protein may also suggest it has a role in the 
pathogenesis of other forms of fPD.     
 
1.5.2.6.2 PINK1 (PARK6) 
In 2001 the PARK6 locus was identified in a large consanguineous family from Sicily, with 
linkage to chromosome 1p35-p36 [314], and subsequently these findings were replicated in 
other European families [315]. After further mapping and candidate gene analysis, two 
homozygous mutations affecting the PTEN (phosphatase and tensin homologue deleted on 
chromosome 10)-induced kinase-1 (PINK1) gene on chromosome 1, in three consanguineous 
PARK6 families, were identified: a truncating nonsense mutation (W437X) and a missense 
mutation (G309D) [227]. Subsequently a variety of point mutations, splice mutations and large 
deletions of PINK1 have been identified. Estimates of prevalence from European and Asian 
populations, suggest that PINK1 mutations are the second most frequent cause of AR PD, after 
Parkin mutations, with reported frequencies ranging from 1% to 7% [316], [317], [318], [319]. 
The clinical phenotype associated with PINK1 mutations demonstrates a wider age spectrum 
than Parkin related ARPD. The age of onset is usually in the third or fourth decade with 
similar features to Parkin-related disease, including slow progression, good response to L-
dopa and frequent treatment-induced dyskinesias. Rare associated features also include rest 
dystonia, sleep benefit and psychiatric disturbances [227], [320], [321]. 
More recently several reports have suggested that heterozygous PINK1 mutations may 
represent a susceptibility factor for PD, due to the increased frequency of PINK1 heterozygous 
mutations in apparently sPD populations, as compared to matched controls [316], [322], [323], 
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[324]. Supportive data for this theory comes from a small study of three subjects using 18F-
dopa PET imaging, in which a 20 to 30% mean reduction in the 18F-dopa uptake levels in the 
caudate and putamen was found in the heterozygote state [325]. 
PINK1 contains eight exons spanning 1.8 kb and encodes a 581 amino-acid, 63kDa, protein 
predicted to be a serine/threonine kinase of the Ca2+/calmodulin family with a 8kDa amino-
terminal, mitochondrial targeting sequence [227]. PINK1 is ubiquitously expressed throughout 
the human brain, and is found in  both neurons and glial cells [326]. The complete protein is 
thought to be transcribed in the nucleus, translated in the cytoplasm and imported intact into 
the mitochondria, with subsequent processing and intra-mitochondrial sorting. There is also 
now evidence that PINK1 is localised to the inner mitochondrial membrane [327], [328].  
Several in vitro and in vivo studies have provided evidence that loss of PINK1 function leads 
to a complex cellular phenotype including defects in mitochondrial morphology, increased 
sensitivity to cellular stressors and reduction in subsets of dopaminergic neurons [329], [330], 
[331], [332], [333], [334], [335], [336]. PINK1 inhibition has also been shown to lead to 
reduced Parkin expression, with an overexpression of Parkin rescuing some of the cellular 
defects in PINK1 mutants. This data suggests that the PINK1 and Parkin pathways interact, 
with Parkin appearing to function downstream of PINK1 [337], [338], [339].  
 
1.5.2.6.3 DJ-1 (PARK7) 
In 2001 the PARK7 locus was identified, following the study of a large Dutch consanguineous 
pedigree displaying AR PD, with linkage to chromosome 1p36 [340]. This linkage was 
subsequently confirmed in an Italian consanguineous pedigree [341]. Mutations in the DJ-1 
gene were eventually identified in these two families, a deletion in the Dutch family and a 
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missense mutation (L166P) in the Italian family [230]. Subsequently missense, truncating, and 
splice site mutations, as well as deletions have been described in several ethnic groups [342], 
[343], [344]. Much like for Parkin-related PD, the clinical phenotype associated with DJ-1 
mutations is of early-onset PD, with slow progression and good levodopa response. However, 
the frequency of DJ-1 mutations in early onset PD appears lower than that for Parkin 
mutations, ranging from 1-2% [342],  [344], [235], [345]. 
DJ-1 contains 8 exons, is 24 kb in length and encodes a 189 amino acid protein DJ-1, which 
belongs to the ThiJ/PfpI superfamily. DJ-1 is ubiquitously expressed throughout the brain and 
peripheral tissues, and is largely cytoplasmic with some localization to the mitochondria [230], 
[346], [347]. Whilst the exact role of DJ-1 in PD is not known, the protein appears to have 
several neural and non-neural functions, including cellular transformation, RNA binding, 
androgen-receptor signaling, spermatogenesis, and fertilization. [348]. In vivo and in vitro 
studies, including Drosophila and mouse knock-out experiments, indicate that DJ-1 may play 
a role in protecting dopaminergic neurons from oxidative stress [349], [350], [351], [352], 
[353], [354], [355]. DJ-1 is itself inactivated by extensive oxidation [352], and the observation 
that DJ-1 is oxidatively  damaged in the brains of subjects with IPD, suggests that protein 
aggregation may be mediated by high levels of oxidative stress [353], [356]. Interestingly, DJ-
1 has also been shown to associate with Parkin during oxidative stress [313].  
 
1.5.2.6.4 PARK9 (Kufor-Rakeb disease) 
This AR form of parkinsonism was described in a single consanguineous family from Kufor-
Rakeb in the north of Jordan, with linkage to chromosome 1p36, and allocated as the PARK9 
locus [357], [358].  The condition is known as Kufor-Rakeb disease (KRD), and is quite 
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distinct from other forms of fPD, with the additional features of pyramidal degeneration, 
cognitive dysfunction, supranuclear gaze palsy, oculogyric dystonic spasms, facial- faucial-
finger mini-myoclonus and visual hallucinations described [359]. No other families with a 
similar disease phenotype have been described.  
A recent study has determined that KRD is caused by loss-of-function mutations in a 
predominantly neuronal P-type ATPase gene, ATP13A2, leading to protein retention in the 
endoplasmic reticulum and subsequent enhanced proteasomal degradation [360]. Given its 
rarity, and distinct phenotype, the relevance of these findings to other forms of fPD remains 
unclear.  
 
1.5.2.7 Loci of uncertain inheritance- PARK10, PARK12 & PARK13 
The PARK10 locus was identified in 2002, following a genome-wide linkage analysis in 
Icelandic families, in which a susceptibility locus for late onset PD was discovered on 
chromosome 1p32 [361]. Subsequent studies have suggested that the PARK10 locus may 
control age of PD onset, and candidate genes including the gamma subunit of the translation 
initiation factor EIF2B gene (EIF2B3) and the ubiquitin-specific protease 24 gene (USP24) 
have been identified [362], [363]. However, to date the gene has not been identified, and there 
has been no reported confirmation of linkage in other population groups.  
Also in 2002 linkage analysis in 160 families without Parkin mutations identified an 
additional locus, PARK12, on the X chromosome [364]. Again no PD genes have been 
identified to date. 
The targeted disruption of the serine protease Omi/HtrA2 has previously been found to cause 
neurodegeneration and a parkinsonian phenotype in mice [365]. Therefore in 2005 a candidate 
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gene approach was used to screen a group of German PD patients for mutations in the HtrA2 
gene found on chromosome 2p13 (PARK13 locus). A novel heterozygous mutation (G399S) 
was found in four patients, and in addition a polymorphism (A141S) associated with disease. 
The associated patient phenotypes were typical for IPD [366]. Omi/HtrA2 is a nuclear 
encoded protein, with a mitochondrial targeting sequence and is proteolytically active during 
apoptosis. Intriguingly the G399S mutation led to mitochondrial dysfunction associated with 
altered mitochondrial morphology, and cells over-expressing the GS399S mutant protein were 
more susceptible to stress-induced cell death [366]. Omi/HtrA2 appears to interact with 
PINK1 and both are components of the same stress-sensing pathway, with Omi/HtrA2 
phosphorylation decreased in brains of patients with PD carrying mutations in PINK1 [367]. 
Recently it has also been shown that HtrA2/Omi accumulates in the neuronal and glial 
inclusions found in brains of patients with alpha-synucleinopathies [368].  
 
1.5.2.8 Candidate gene studies in PD 
A wide range of genes and proteins have been investigated for an association with both sPD 
and fPD. A common theme for many of these studies has been difficulty in replication of 
results, which is most likely to be because of small sample sizes, inappropriate controls and 
flawed statistical analysis [369]. In this section I will outline the evidence for several of the 
candidate genes which have been most recently, and extensively, investigated.  
The NURR1 (NR4A2) gene located on chromosome 2q22-q23 encodes for the transcription 
factor Nurr1, which belongs to the orphan nuclear receptor superfamily. The protein is highly 
expressed in both developing and adult brain dopaminergic neurons, and appears to be critical 
in the development and maintenance of the dopaminergic system, via its regulation of the 
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expression of a number of proteins key to dopamine synthesis and storage [370]. From studies 
performed in Nurr1 knock-out mice, Nurr1 deficiency results in impaired dopaminergic 
function and increased vulnerability of the midbrain dopaminergic neurons that degenerate in 
PD [370]. Heterozygous mutations in the non coding region of exon 1 of NURR1 were found 
in 10 out of 107 fPD patients [231]. However, numerous follow-up studies in larger patient 
populations have not identified NURR1 mutations, and it is now considered unlikely that these 
are a significant contributor to the development of PD [371], [372].  
The Synphilin-1 gene encodes a protein which links α-synuclein, Parkin and other components 
of the ubiquitin-proteasome system. Synphilin-1 has been found in LB, interacts with α-
synuclein and is a substrate for the ubiqutin E3 ligase function of Parkin [373], [374]. 
Furthermore a mutation (R621C) was described in two patients, with in vivo analysis of the 
mutant protein function demonstrating increased susceptibility to cell death [232]. However, a 
recent study of Synphilin-1 mutations in sPD showed no significant association with disease 
[375]. Until more information is available, the significance of this gene in sPD and fPD 
remains unknown. 
MAPT encodes the microtubule-associated protein tau. Meta-analyses have shown that the H1 
haplotype (several MAPT polymorphisms which are in linkage disequilibrium) increases 
susceptibility to PD, with homozygosity for tau H1 giving a 1.57 times increased risk of PD 
[376], [377], [378], [379]. These genetic findings are of particular interest, as MAPT is known 
to co-aggregate with α-synuclein in LB [380], [381].  
Finally, there have been several reports suggesting an association between Gaucher disease, a 
recessively inherited lysosomal storage disorder, resulting from mutations in the 
glucocerebrosidase gene (GBA) on chromosome 1q21, and parkinsonism [382]. An early 
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survey found that 31 out of 99 Asheknazi patients with apparently IPD had one or two mutant 
GBA alleles [383], and a subsequent post-mortem study found that 23% of cases of LB 
dementia had GBA mutations [384]. Thus a possible biochemical interaction between 
glucocerebrosidase and α-synuclein was proposed [385], [384]. Other populations have since 
been screened for GBA mutations and the findings suggest that GBA is a susceptibility gene in 
PD [386], [387], [388], [389], [390]. A recent interesting finding is that four subjects out of a 
study group of 420 demonstrated digenic inheritance of both a GBA mutation and a G2019S 
LRRK2 mutation [388]. In summary, these findings may be of great importance for our 
understanding of the pathogenesis of PD, and point us in the direction of the lysosome, as does 
the recent identification of mutations in the ATP13A2 gene responsible for the PARK9 locus 
[360]. 
 
1.5.2.9 Summary 
As we have discovered more about the fPD genes over the last decade this knowledge has 
provided us with a better understanding of the potential underlying pathogenic mechanisms of 
both sPD and fPD. As outlined above, the known fPD genes have implicated a number of 
potentially pathogenic mechanisms, such as PINK being linked to mitochondrial dysfunction 
and Parkin being linked to dysfunction of the ubiquitin proteasome system. These 
mechanisms are discussed in section 1.5.3. Further expanding our knowledge of the known 
genes, and continuing our efforts to identify new PD genes, may therefore be of crucial 
importance to developing our understanding of the pathogenesis of PD.    
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1.5.3 Potential pathogenic mechanisms in PD  
A number of potential pathogenic mechanisms involved in neurodegeneration in PD have been 
identified, often through in vitro and in vivo studies into the role of individual PD genes. These  
mechanisms include: mitochondrial and ubiquitin-proteasome dysfunction, abnormal protein 
aggregation and phosphorylation, oxidative stress, and inflammation [1], [391], [392], [393], 
[99], [394], [395], [396], [328] (see figure 1.6). There is also evidence that the final steps of 
cell death in PD may occur by apoptosis [397], [398], with several studies demonstrating 
increased expression of cell signals associated with this process, including p53 [397], [398], 
[399]. It has also been demonstrated in model systems that each of the putative pathogenic 
mechanisms in PD covered in this section is able to induce apoptosis [400].  
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Figure 1.6 Putative interacting pathways underlying the pathogenesis of PD. Both mutations in 
fPD genes encoding α-synuclein, parkin, DJ-1, PINK1 and LRRK2, as well as environmental factors, 
are associated with PD pathogenesis, through mitochondrial dysfunction, oxidative damage, abnormal 
protein aggregation and protein phosphorylationl. β-Synuclein is known to prevent α-synuclein 
aggregation through activation of Akt signaling. UPS is ubiquitib-proteasome system; ATP is 
Adenosine-5’-triphosphate; TFAM is mitochondrial transcription factor A; PI3kinase-Akt is 
phosphatidylinositol 3-kinase/Akt; ER is endoplasmic reticulum; mtDNA is mitochondrial DNA. 
Green arrows indicate promoting or activating effects whilst red lines with blunt ends indicate 
inhibitory effects. Taken from Thomas & Beal 2007 [1]. 
1.5.3.1 Oxidative stress and mitochondrial dysfunction  
Pathogenic roles for oxidative stress and mitochondrial dysfunction in PD have long been 
proposed. It has been recognised for many years that nigrostriatal dopaminergic neurons are 
under significant oxidative stress, probably as a result of redox cycling of catechols, leading to 
increased generation of reactive oxygen species (ROS) which are harmful to the cell [1]. 
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Decrements in reduced glutathione levels in SNc of subjects with pre-symptomatic PD suggest 
that oxidative damage occurs earlier than the observed neuronal loss [401]. Recently a 
prominent role for Nrf2/ARE signaling in the pathogenesis of PD has been proposed [402]. 
The leucine-zipper transcription factor Nrf2 regulates the coordinated induction of the 
antioxidant response element (ARE)-driven cascade of cytoprotective genes, which includes 
numerous antioxidant and anti-inflammatory proteins [403]. In Nrf2 knockout mice neuronal 
tissues were shown to be more susceptible to oxidative stress and mitochondrial dysfunction 
[404], [405], [406]. 
The phosphatidylinositol 3-kinase/Akt pathway has also come to prominence as it may be of 
importance for dopaminergic neuronal survival. Recent animal studies have demonstrated that 
overexpression of the oncoprotein Akt protects against 6-hydroxydopamine (6-OHDA)-
induced dopaminergic toxicity and confers neurotrophic effects on dopamine neurons [407]. 
Parkin [408], DJ-1 [409] and PINK1 [227] are also all known to mediate cell survival through 
the Akt pathway. 
Some of the recent evidence of a pathogenic role for mitochondrial dysfunction includes the 
identification of deficits in the subunits and activity of complex I, and a high amount of 
mitochondrial DNA (mtDNA) deletions in the SNc of subjects with PD [410], [411], [412], 
[413]. Animal studies also provide supportive evidence, with a low mitochondrial mass 
observed in mouse SNc [414], and with a targeted deletion of mitochondrial transcription 
factor A in mouse midbrain dopaminergic neurons leading to Parkinsonism [415].  
The evidence for interaction between oxidative stress and mitochondrial dysfunction comes 
from a recent in vitro study which showed an impairment of mitochondrial complex I due to 
chronic depletion of antioxidant glutathione [416]. Furthermore, PPARgamma coactivator 
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1alpha (PGC-1a), which is involved in mitochondrial biogenesis and respiration, is known to 
be a modulator of ROS generation during oxidative stress [417]. Nigrostriatal dopaminergic 
neurons in PGC-1a knockout mice are more vulnerable to MPTP, whilst overexpression of 
PGC-1a protected neural cells from oxidative stress-induced death [418]. 
Several ‘PD genes’ also provide evidence for the link between mitochondria and oxidative 
damage. The α-Synuclein gene appears to link oxidative stress and mitochondrial dysfunction 
to abnormal protein degradation. Mice overexpressing human mutant A53T α-synuclein 
induce mitochondrial damage due to aberrant α-synuclein accumulation [419]. It has also been 
shown that mice lacking α-synuclein are resistant to mitochondrial toxins such as MPTP, 3-
nitropropionic acid and malonate, while overexpression of human α-synuclein in mice 
enhances their vulnerability to MPTP [420], [421].  
The Parkin gene appears to link oxidative stress and mitochondrial dysfunction to the 
ubiquitin proteasome system, with apparently neuroprotective properties demonstrated in 
several model systems [310]. It has been shown to prevent mitochondrial swelling, 
cytochrome c release and caspase activation, whilst these functions are impaired when parkin 
mutations are present [422]. Furthermore Parkin knockouts in mice and Drosophila show 
increased oxidative stress and mitochondrial dysfunction [423], [424]. Oxidative 
modifications of the protein, which impair its ubiquitin E3 ligase activity, have been shown to 
compromise its protective function [425], [426]. Finally, in proliferating cells, Parkin has been 
shown to localise to the mitochondria, associate with mitochondrial transcription factor A 
(TFAM), and enhance mitochondrial biogenesis [427].  
The association between PINK1 and the mitochondrion, as well as the role of the antioxidant 
DJ-1, have already been reviewed (sections 1.5.2.5.2. and 1.5.2.5.3.). It is also of interest that 
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there is recent evidence to suggest that oxidative damage due to dysfunction of PINK1 results 
in recruitment of DJ-1, thus maintaining steady-state levels of PINK1 through a physical 
interaction and overexpression of DJ-1 [332]. Although little is known about the function of 
LRRK2, recent evidence suggests that up to 10% of the protein may be associated with 
mitochondrial membranes [428], [312], [429].  
 
1.5.3.2 Protein aggregation, phosphorylation and the Ubiquitin-proteasome system 
The Lewy body (LB) is one of the neuropathological hallmarks of PD, and therefore it is 
unsurprising that ‘proteolytic stress’ has gained early support as one of the key underlying 
pathogenic mechanisms in PD [394]. There is evidence that LBs might represent aggresome-
like inclusions which form as a protective response to high levels of misfolded/ubiquitylated 
proteins [430]. Another concept which provides support for this theory is that with PD being 
an age-related disorder, there is a good correlation with the aging process itself which is 
associated with a gradual increase in levels of damaged proteins that need to be cleared [431], 
[432], [433]. Furthermore the dopamine neurons in the SNc appear particularly vulnerable in 
PD, with relatively low levels of  proteasomal enzyme activity [434], and a high level of 
dopamine metabolism which leads to the formation of oxidized proteins [435].  
The ubiquitin-proteasome system (UPS) is the mechanism by which eukaryocytic cells 
remove mutant, damaged, misfolded or unwanted intracytoplasmic proteins [9], [436], [437], 
[438], [394], [395]. The proteins which are to be removed are tagged with ubiquitin molecules, 
signaling for their transport to the proteasome, where they are degraded. The peptides and 
amino acids which are generated by this process are then recycled, with the resulting ubiquitin 
monomers also re-used (see figure 1.7).  
 - 51 -
Chapter 1                                                                                                     General Introduction                         
 
 
 
 
 
Figure 1.7 The Ubiquitin-proteasome system (UPS). The steps by which the UPS clears unwanted proteins: 
ATP-dependent activation of ubiquitin monomers; labelling of unwanted/damaged proteins with chains of 
activated ubiquitin molecules by CHIP; transport of ubiquitinated proteins to the proteasome by chaperone 
molecules such as heat shock proteins (HSPs); recognition and unfolding of ubiquitinated proteins by 
proteasome regulators; and ATP-dependent degradation of unwanted proteins by the proteasome. The red 
circles represent ubiquitin. Taken from Goldberg 2003 [9]. 
 
The process of ‘proteolytic stress’ will occur if the capacity of the UPS to degrade unwanted 
protein is exceeded, for example if excess misfolded protein is produced. If this occurs an 
accumulation and aggregation of abnormal proteins will develop, which will have an effect on 
the ability of the cell to perform various cellular functions, including apoptosis [394], [395].  
In fPD mutations in α-synuclein, Parkin, and UCH-L1 have all been linked to proteolytic 
stress. α-Synuclein is a naturally unfolded protein that is prone to misfold and to aggregate; 
this tendency is enhanced when the protein is in a mutant form or present in excess levels, 
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possibly exceeding the capacity of the proteasome to clear them. Indeed, overproduction of α-
synuclein has been shown to lead to neuronal degeneration with aggregate formation [439], 
[440]. Parkin mutations could hinder ubiquitylation, and hence impede the functioning of the 
UPS, leading to cell death. Investigators have demonstrated that in subjects with Parkin 
mutations, excess levels of substrate proteins, in a non-ubiquitiylated state, can be detected 
[441]. UCH-L1 mutations could also disrupt the UPS, and it has now been demonstrated in 
experimental models that treatment with inhibitors of this protein leads to dopamine neuronal 
degeneration with inclusion bodies [442].  
More evidence for the importance of the UPS comes from the observation, in postmortem 
studies, of proteasomal impairment in the SNc of subjects with sPD [434]. Furthermore, in 
model systems proteasome inhibitors can induce selective degeneration of cultured dopamine 
neurons with the formation of LB-like inclusions [442], [443], [444], [445], [446], although it 
is important to point out that these results have not been replicated by several other 
investigators [447], [448], [449]. 
Therefore from the evidence available to date an intervention that prevents or reverses 
proteolytic stress might be neuro-protective in PD [450]. One such strategy is to upregulate 
heat shock proteins (HSPs) and make use their ability to promote protein refolding and 
facilitate the degradation of severely misfolded proteins. In model systems upregulated HSPs 
have been shown to protect dopamine cells from toxicity induced by proteasome inhibition or 
excess levels of misfolded proteins [451], [452] and also to prevent aggregate formation and 
degeneration of dopaminergic neurons induced by over expression of α-synuclein in 
Drosophila [453], [454], [455], [456].  
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The physiological function of LRRK2 is as yet unknown, and hence so are the underlying 
pathogenic mechanisms of LRRK2-related PD. However, its structure suggests that LRRK2 
functions as a kinase, and there is now evidence that its kinase activity is regulated by GTP, 
and that any alterations in the protein which reduce its kinase activity cause a corresponding 
reduction in neuronal toxicity [457]. Therefore it has been proposed that for LRRK2-related 
PD abnormal protein phosphorylation may be the key step in the pathogenic mechanism.  
 
1.5.3.3 Inflammation 
There is a long-standing debate in the literature regarding the role that inflammation may play 
in the pathogenesis of PD. The well documented association between encephalitis and 
parkinsonism has already been mentioned here (see section 1.5.1.2). More recently it has been 
proposed that pathogenic process in PD could be due to activation of microglia and 
upregulation of inflammatory cytokines such as TNF-α  in the striatum of affected subjects 
[458], [392], [459]. Both in vitro and in vivo studies have suggested that inducing cytokine 
formation leads to dopamine neuronal cell death, with anti-inflammatory compounds being 
shown to be attenuate MPTP and 6-OHDA induced toxicity [460] [461], [462], [463].  
The intriguing report of a case of parkinsonism induced by accidental exposure to 
lipopolysaccharide (LPS) from Salmonella minnesota [464] has also provided additional 
support for the role of inflammation in PD. There is evidence that the presence of LPS in the 
basal ganglia can induce microglial activation, increasing cytotoxic molecules and leading to 
dopamine cell death [465], [466], [467], [468], [469], [470], [471], [396].  
 - 54 -
Chapter 1                                                                                                     General Introduction                         
A recent study in which both celecoxib and pioglitazone were demonstrated to reduce 
mitochondrial dysfunction suggests that the mitochondrial impairment seen in PD may be 
caused by inflammation [472]. 
The final piece of evidence to support a major role for inflammation in PD comes from several 
cohort studies in which subjects who took non steroidal anti inflammatory drugs (NSAIDs) 
were found to be less likely to develop PD than were controls, suggesting a possible 
neuroprotective role in PD  [473], [474], [475], [476]. However other more recent studies have 
failed to show a protective effect of NSAIDs for PD [477], [478], [479], [480], [481].  
Whilst a role for inflammation in the pathogenesis of PD appears attractive, there is clearly 
more work to be done in order to determine its true importance in this process.   
 
1.5.3.4 Summary 
The identification of the ‘PD genes’ over the last decade has provided the major impetus for us 
to gain a better understanding of the pathogenic mechanisms involved in PD. Despite this 
progress, none of the mechanisms discussed above has been proven to be the primary cause of 
cell death for either fPD or sPD, although there is now increasing evidence that these various 
mechanisms are in fact interactive, promoting cell death through a complex network (see 
figure 1.5). Other processes not covered here, for which there is little evidence at present in 
PD, such as excitoxicity, may also be important. The discovery of mutations in LRRK2 in both 
fPD and sPD raises hope of further progress in this field. The role of LRRK2 in the 
pathogenesis of PD is still poorly understood and is one of the major questions for ongoing 
research. This project aims to contribute to this area by investigating the contribution of 
LRRK2 to UK fPD and sPD both at the level of genetic variation and functional effect.   
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1.6 Aims of the work presented in this thesis 
The overall aims of this study are: 
1. To recruit a large well characterised cohort of subjects with autosomal dominantly 
inherited PD from around the UK. 
2. To elucidate an accurate diagnosis in various affected members of a UK family with 
an inherited autosomal dominant movement disorder using imaging, molecular genetic 
and pathological techniques. 
3. To perform a comprehensive genetic analysis of the entire coding region of LRRK2 in 
the cohort of familial PD patients. 
4. To perform an analysis of key coding regions within LRRK2 in a large cohort of UK 
sporadic PD patients. 
5. To perform initial functional characterisation of novel LRRK2 mutations identified in 
this study.  
The specific aims of each section of the study are outlined in the introduction to each chapter. 
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2 Materials and Methods 
 
2.1 Subjects 
2.1.1 Familial PD 
Subjects were recruited from around the UK with familial PD (fPD). The majority of these 
subjects had self reported to our group previously, in response to advertisements in the 
national press, or via our website 
(http://medweb.bham.ac.uk/clin_neuro/genetics/Patient_Information.html). Some subjects 
were new referrals from other clinicians around the UK. In addition a small number were 
recruited as part of a study of fPD undertaken in conjunction with colleagues at the Institute of 
Neurology (ION) and the Queen Square Brain Bank for Neurological Diseases in London. 
These subjects were recruited to the study between April 2005 and March 2008. 
For the purpose of this thesis inclusion criteria to the study were: (i) the subject must have 
definite PD, according to UKPDS (United Kingdom Parkinson’s Disease Society) Brain Bank 
clinical diagnostic criteria for PD (table 1.1) [14], family history was not used as an exclusion 
criteria. The diagnosis was determined on clinical examination by myself. (ii) the subject must 
report at least 2 other family members with PD. Where possible other living affected family 
members were examined to confirm the diagnosis, but if the diagnosis in deceased family 
members was by historical family report strenuous effort was made to obtain copies of death 
certificates on these individuals. (iii) segregation of PD in the subject’s family had to be 
consistent with an autosomal dominant pattern, with three or more PD cases in at least two 
consecutive generations (see figure 2.1).  
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 Subject must have definite PD, according to UKPDS (United Kingdom 
Parkinson’s Disease Society) Brain Bank clinical diagnostic criteria for PD.  
 Subject must report at least 2 other family members with PD.  
 Segregation of PD in the subject’s family had to be consistent with an 
autosomal dominant pattern, with three or more PD cases in at least two 
consecutive generations.  
Figure 2.1 Inclusion criteria for entry into the familial PD study.  
 
                           
 
All subjects gave their informed written consent to take part in the study. The study had 
appropriate ethical approval from South Birmingham LREC, Sandwell and West Birmingham 
LREC and London MREC. All data was kept under the provision of the Data Protection Act. 
 
2.1.1.1 Familial PD methods 
A search of the database for patients with Parkinson’s disease and at least 2 other affected 
family members was performed. 190 subjects who had previously expressed an interest in 
taking part in our research and were registered on the database were contacted by letter or 
telephone to determine whether they were still willing or able to take part in the study. In 
addition those subjects who had recently been referred to our group and those subjects who 
had been identified via the ION collaborative study were also contacted by letter or telephone. 
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Subjects who wished to participate in the study were then offered a research appointment in 
clinic or at home. 
At the time of recruitment to the study a full medical history and epidemiological 
questionnaire, based on the PD GEN questionnaire 
(http://www.pdgen.bham.ac.uk/docs/PG%20GEN%20Questionnaire.pdf) (figure A.3), were 
recorded and a neurological examination performed on each subject. The UPDRS III (Unified 
Parkinson’s Disease Rating Scale, Part III) [6] and the Hoehn and Yahr [13] PD rating scales 
were used to obtain a disease severity score in each subject in their ‘on state’ (figure A.1 and 
table 1.2). In addition a Folstein MMSE (Mini Mental State Examination) [19] (figure A.2) 
was performed on each subject as an assessment of their cognitive function. A levodopa 
equivalence dose was calculated for all individuals who were taking anti-parkinsonian 
medication, based on a previously used scale: levodopa 100mg=133mg of controlled release 
levodopa=1mg Pergolide=6.67mg Bromocriptine=1mg Pramipexole=4mg Ropinirole [17]. In 
each case, where the subject gave their permission, a video was taken to visually record the 
clinical features of disease. Olfactory function was also tested in each subject using the 
University of Pennsylvania Smell Identification Test (UPSIT-40, Sensonics, Haddon Heights, 
NJ) and olfaction was categorised as normal or pathologic according to normative data in 
relation to gender and age [482], [483]. Furthermore, with permission of the subject, and 
where possible, I reviewed the medical records of the subject relating to their PD to confirm 
clinical details such as initial presenting symptoms and response to medication.  
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2.1.2 Sporadic PD 
The largest number of subjects with PD came from the Parkinson’s Disease DNA Bank (PD 
GEN study). The aim of this ongoing study is to obtain epidemiological data and DNA 
samples on a large cohort of subjects with PD from around the UK who had entered two other 
studies, a large randomised assessment of the relative cost-effectiveness of classes of drugs for 
Parkinson’s disease (PD MED study) and a large randomised assessment of the relative cost-
effectiveness of surgery for Parkinson’s disease (PD SURG trial). These are pragmatic trials of 
medical and surgical therapy, details of which can be found at www.pdmed.bham.ac.uk; 
www.pdsurg.bham.ac.uk; and www.pdgen.bham.ac.uk. The DNA samples were collected 
between 2002 and 2007.  
The second largest collection of subjects with PD came from an existing local study, the 
Birmingham PD study. The aim of this study was to obtain demographic data and DNA 
samples from subjects with unselected PD. These samples were collected by Dr David 
Nicholl, predominantly from neurology outpatient clinics in the West Midlands between 1994 
and 1998. 
Some subjects with PD came from our local ongoing study entitled the Birmingham 
Neurodegenerative Disorders DNA Bank (NDD). The aim of this study is to obtain 
demographic details and DNA samples on a cohort of subjects with unselected PD from 
neurology outpatient clinics at the University Hospitals Birmingham NHS Trust and Sandwell 
and West Birmingham Hospitals NHS Trust. Samples for this study were collected by myself 
or Dr Nicholl between April 2005 and March 2008. With permission of the participating 
subject, I reviewed the subject’s medical records relating to their PD to confirm clinical details 
such as initial presenting symptoms and response to medication.  
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The final source of subjects with PD came from the PINE study. The aim of this ongoing 
clinic based study is to obtain demographic data and DNA samples on subjects with 
unselected PD from Aberdeen, Scotland. These samples were collected by Dr Carl Counsell 
between 2002 and 2005.  
In each of the four studies covered above there is also a control cohort. This consists of DNA 
samples from the unaffected spouse or carer of a subject with PD who had themselves donated 
a DNA sample to the collection. Demographic details were also obtained from the control 
subject.  
All subjects had given their informed written consent to take part in the studies listed above. 
The studies had appropriate ethical approval from London MREC, South Birmingham LREC, 
West Midlands MREC, and North of Scotland LREC. In addition appropriate ethical approval 
from Coventry LREC was obtained in order to perform molecular genetic analyses on samples 
from the PD GEN collection. All data was kept under the provision of the Data Protection Act. 
 
2.2 Functional neuro-imaging 
In order to evaluate basal ganglia function seven subjects underwent dopamine transporter 
SPECT scanning using [123I]-FP-CIT SPECT (DaTSCAN, Amersham Health) at Sandwell and 
West Birmingham Hospital NHS Trust. This technique enables in vivo demonstration of 
striatal dopamine activity, and has been shown to demonstrate significantly reduced striatal 
uptake in PD [129].  
Six subjects from family 6, the kindred investigated in detail in chapter 4 (subjects III:1-III:5 
and IV:1) and the proband subject from family 12 underwent DaTSCANs. These images were 
reviewed by Dr Alp Nothgi and Dr Edward Rolfe, consultant radiologists at Sandwell and 
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West Birmingham Hospital and University Hospitals Birmingham NHS Trusts, respectively. 
They are experienced in the interpretation of DaTSCANs, and were blinded to the 
demographic and clinical data on these subjects. 
 
2.3 Genomic DNA extraction from Venous blood 
Following informed consent whole venous blood was collected from patient and control 
subjects in ethylenediaminetetraacetic acid (EDTA) vacuette tubes (Griener Bio-One Ltd). 
These samples were stored at 4°C or at -80°C (if extraction was delayed by more than 48 
hours) until DNA extraction was performed using the NucleonTM BACC3 kit (GE Healthcare 
UK Ltd).   
The principle steps of this technique are: cell lysis, followed by deproteinisation, DNA 
extraction, DNA recovery, and the final step of DNA washing. Lysis of red blood cells was 
performed by adding four volumes of lysis solution A (proprietary) to whole blood and mixing 
for 10mins at room temperature. Next, white blood cells were pelleted by centrifugation at 
1600xg for 8 mins and then re-suspended in 2ml of re-suspension solution B (proprietary). 
After vigorous mixing and incubation at 37°C, the samples were deproteinised by adding 
500μl of sodium percholrate.  To extract the DNA 2ml of chloroform (Fisher Scientific) was 
added, followed by 300μl of Nucleon resin (proprietary) and the samples centrifuged at 
1400xg for 4 mins.  Next the upper aqueous layer, which contains the DNA, was harvested 
and 2 volumes of ice cold 100% ethanol (Sigma) added to precipitate the DNA. The 
precipitated DNA was desalted with 70% ethanol, air dried and re-suspended in Tris-EDTA 
(TE) buffer (10mM Tris pH 7.6, 1mM EDTA) (Sigma). Finally, in order to dissolve the DNA, 
the samples were left at room temperature for 24-48hrs on a rotatory mixer. After 24-48 on 
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this mixer the DNA concentration of each sample was measured on a spectrophotometer, 
before being stored at -80°C. These stock DNA samples were diluted to 100ng/μl in TE buffer 
to create the working solutions for PCR, these were also stored at -80°C until needed. 
 
2.4 Polymerase chain reaction (PCR) 
Since its development in the 1980s PCR has revolutionised molecular genetics as a technique 
for rapid analysis of DNA. It permits the exponential amplification of specific regions of 
interest in the DNA, with the use of pre-designed DNA ‘primers’ which flank the target 
sequence, and a heat stable DNA polymerase ‘Taq’ named after the thermophilic Thermus 
aquaticus in which it was discovered. The region of interest is amplified in a series of 
reactions, which are illustrated in figure 2.2.  
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Region of interest
Primers
DNA polymerase
Double stranded DNA
Reaction Mixture (A)
Denaturation
Step 1
Strand Separation
Step 2 Annealing
Primer Annealing
Step 3
Primer Extension
First cycle products
Extension
Second cycle
Second cycle products
Third cycle
Third cycle products
X 25 
cycles
(B)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 The principle of PCR. The reaction mixture contains double stranded 
DNA, Taq DNA polymerase and primers (A). A denaturation step (step 1) separates 
double stranded DNA to allow primers to anneal (step 2). Complimentary strands are 
then produced from the primers by the DNA polymerases (step 3) to result in first 
cycle products. During the second cycle, first strand products and genomic DNA act as 
template for primer annealing and extension (B). During the subsequent cycles the 
amount of DNA doubles, leading to an exponential increase typically over 25 cycles. 
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The reagents and cycling conditions used in a standard PCR reaction to amplify genomic DNA 
for genotyping are given below in table 2.1 and figure 2.3. However, for each PCR primer 
sequence, the annealing temperature, cycling times and component concentrations had to be 
optimized, details of which can be found in appendix C. Each annealing temperature was 
dependent upon the specific primer sequences, with extension times determined by PCR 
product length, with 1min per kb used as a guide. 
  
Reagent 
Stock Final 
concentration concentration 
Water (distilled and autoclaved) N/A N/A 
10x Buffer (Bioline) 10x 1x 
dNTP mix (Fermentas) 2mM 160µM 
MgCl2 (Bioline) 50mM 1.5mM 
Forward primer (AltaBioscience) / (Eurogentec) 10pmole/µl 0.5pmole/µl 
Reverse primer (Altabioscience) / (Eurogentec) 10pmole/µl 0.5pmole/µl 
Taq (Bioline) 5u/µl 0.1u/µl 
DNA 100ng/µl 5ng/µl 
 
Table 2.1 Constituents of a standard polymerase chain reaction (PCR).  
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               95°C  5mins 
               Denaturation: 95°C  30s 
               Annealing:  50-60°C 30s       x30 cycles 
               Extension:  72°C  1mins  
               72°C   7mins  
 
 
Figure 2.3 Standard cycling conditions of a polymerase chain 
reaction (PCR). 
 
 
2.4.1 Primer design 
In order to achieve successful PCR reactions, the specific oligonucleotide primer sequences, 
and annealing temperatures, are crucial. Here I have listed some of the general principles 
which I followed when designing my primers: (i) primers were between 18 and 24bp in 
length; (ii) the melting temperatures of forward and reverse primers were approximately equal, 
and varied between 50-60°C; (iii) the GC content varied between 40-60%; (iv) primers 
contained no more than three consecutive bases of the same type; (v) the sequence of the 
primers were tested using BLAST to ensure that they were unique to the target resgion. 
The primers and temperatures used to study each of the 51 exons and exon-intron boundaries 
of LRRK2 by PCR were those described previously [283], [280]. In addition I designed 
specific primer pairs for the DNA sequence of LRRK2 to screen for variations within exons 
41, 42 and 49, and for the cDNA sequence of the gene in order to investigate the effect of 
novel mutations on RNA expression, all by the use of the Primer3 program 
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(http://fokker.wimit.edu/primer3/input.htm). These primers are all listed, with annealing 
temperatures and MgCl2 concentrations, in appendix C.  
 
2.4.2 PCR troubleshooting 
The various primer pairs used in this study all have different optimal PCR conditions. The 
optimal annealing temperatures were available for the primer pairs used in previous studies, 
but not for the newly designed primer pairs. However, the other reaction conditions were not 
available for any of the primers, hence the standard PCR protocol, as listed above, was used as 
a starting point for optimisation. The different problems encountered during this optimisation 
process, and the methods used to overcome them, are outlined here. 
 
2.4.2.1 Non-specific products 
Non-specific amplification occurs as a result of primers annealing to DNA sequences other 
than that required. When this problem was encountered the annealing temperature of the PCR 
was increased by 2-5°C and/or the MgCl2 concentration decreased from the standard 1.5mM 
to 1mM in order to make the reaction more specific.   
 
2.4.2.2 Low product yield 
If in contrast to non-specific amplification, when there was little or no product formed by the 
PCR, the melting temperature was reduced by 2-5°C and/or the MgCl2 concentration increased 
up to 2.5 or 3mM. This had the effect of making the PCR less stringent. 
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2.4.2.3 Primer dimers 
This occurs when primers interact with each together to form small products called ‘primer 
dimers’, which are seen at the bottom of the agarose gel. This can result in a reduction in 
product yield and may then interfere with genotyping processes such as sequencing. When this 
problem was encountered, several strategies were adopted to increase the likelihood of primers 
annealing to the DNA rather than other primers. These included adding 5-10% 
dimethylsulfoxide (DMSO) (Sigma) to the reaction mix, which can aid strand separation and 
reduce primer interactions, and/or increasing DNA concentrations whilst decreasing primer 
concentrations. If these steps were unsuccessful then the primers were re-designed. 
 
2.5 Gel electrophoresis 
Agarose gel electrophoresis is a standard method by which DNA fragments can be separated 
by size. Different concentrations of agarose were used to give maximal separation of 
differently sized fragments, such that higher concentrations were used for better resolution of 
smaller fragments. Typically a 1% gel was used to visualize PCR products. Agarose gels 
(Bioline) were made up in 1x Tris-Borate-EDTA (TBE) buffer (89mM Tris-borate, 2mM 
EDTA, pH8.3) (Sigma) containing ethidium bromide (Sigma). Ethidium bromide intercalates 
with DNA to allow visualisation with ultra violet (UV) light. During the course of my project 
the ethidium bromide was replaced by the newer and less toxic nucleic acid gel stain 
GelRedTM (Biotium). Before loading onto the gel, PCR products were combined with 1μl of 
loading dye (Invitrogen) which added colour and weight to the sample. A DNA ladder (Helena 
Biosciences) of an appropriate size-range was loaded into one lane of each gel to allow sizing 
of DNA fragments. Then electrophoresis was carried out for 1-2 hours at 120V in horizontal 
 - 68 -
Chapter 2                                                                                                   Materials and Methods                         
gel tanks. Finally DNA bands were visualised on a UV illuminator and pictures were taken 
using Genescan (SynGene) gel documentation system.   
 
2.5.1 Mutation detection by gel electrophoresis 
The principal of a higher percentage agarose giving better resolution was used to screen PCR 
products for a novel five-base deletion, see section 5.3.2.4. Specific primers were designed 
(see appendix C) to generate a small PCR product of 60bp in length, with a 55bp product 
produced if the deletion was present. A 3% high resolution RESponseTM Research agarose 
(Geneflow) gel was used, with a low size-range ladder, HyperladderTM V (Bioline), and 
electrophoresis carried out at 120V for 3 hours in order to resolve this 5bp size difference (see 
figure 5.3).  
 
2.6 Restriction fragment length polymorphism (RFLP) analysis 
RFLP analysis is a commonly used technique for genotyping which exploits the ability of 
restriction endonucleases to recognise specific DNA sequences, and cleave at particular sites 
in this sequence. DNA polymorphisms can change the recognition sequence of a restriction 
endonuclease, altering whether the enzyme will cleave the DNA at this position or not. Hence, 
different DNA banding patterns will be produced on an agarose gel, depending on whether the 
polymorphism is present or not, allowing wild-type to be distinguished from mutant DNA.  
In this study RFLP analysis was used to screen for the G2019S mutation (c.6055G>A) in exon 
41, as described in section 6.3.2.2. A restriction endonuclease which recognised this 
polymorphic site, Sfc I from Streptococcus faecium (New England Biolabs), had been 
described previously in the literature [288], [484]. I used the online NEBcutter program 
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(http://tools.neb.com/NEBcutter2/index.php) to confirm that the different alleles of this 
polymorphism did indeed alter the recognition sequence of the enzyme. I then designed PCR 
primers to amplify this region of interest with the polymorphic site asymmetrically placed 
within it, in order to allow discrimination between homozygous and heterozygous individuals. 
The PCR primers and conditions can be found in appendix C. 
The Sfc I recognition site was confirmed as:  
 5’…. C^TRYAG….3’; where Y= C or T and R= A or G. 
The DNA target sequence in the PCR product is wild type CTACGG and mutant CTACAG. 
The PCR product size is 257bp, hence after restriction digest the products are 239bp and 18bp 
if the homozygous mutation is present, and 257bp, 239bp and 18bp if the heterozygous 
mutation is present. 
Following the manufacturer’s guidelines, the PCR products were incubated with Sfc I at 37°C 
for 2½ hours, 4μl of loading dye was then added and the samples were run on a 2.5% agarose 
gels for 2 hours to ensure clear band separation. The bands were visualised on a UV 
illuminator in order for the genotype to be determined, and pictures were taken using 
Genescan (SynGene) gel documentation system. Using control samples known to either 
heterozygous for the G2019S mutation or wild type, I was able to consistently show a band of 
257bp for wild-type samples with bands of 257bp and 239bp for subjects heterozygous for the 
mutation (see figure 6.3).  
 
2.7 Sequencing 
I used the automated Sanger (dideoxy) DNA sequencing method to determine the nucleotide 
base sequence of my DNA and cDNA samples.  This is a PCR based technique which uses a 
small concentration of fluorescently tagged dideoxynucleotides (ddNTPs) in the reaction mix, 
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along with the standard deoxynucleotides used in normal PCR reactions. The ddNTPs lack 3’ 
hydroxyl groups such that phosphodiester bonds cannot be formed with other nucleotides, and 
hence if incorporated into the sequence will cause abrupt termination of DNA strand 
elongation. The random incorporation of these ddNTPs results in a collection of DNA strands 
of different lengths with tagged ddTNPs at the 3’ end.  Electrophoresis of these tagged 
products on a denaturing polyacrylamide gel separates the strands by size. The four types of 
ddNTPs (adenosine, cytosine, guanine and thymine) have different fluorescent tags, such that 
the 3’ base of each strand can be determined by laser excitation of theses tags, and the 
sequence of the template DNA is obtained by compiling the nucleotide base information from 
the different length strands. 
In preparation for sequencing, 15µl of each PCR product was ‘cleaned-up’ by the addition of 
2µl of antarctic phosphatase (New England Biolabs) to catalyze the removal of 5´ phosphate 
groups, and 2µl of exonuclease 1 (New England Biolabs) to degrade single-stranded primer 
DNA.  These enzymatic mixes were then incubated at 37°C for 15 mins, followed by 15mins 
at 85°C to inactivate the enzymes. The treated PCR product was then diluted with water to an 
appropriate concentration for sequencing, 5-20ng depending upon product length. The next 
step was to prepare these diluted samples for cycle sequencing using the BigDye terminator 
v3.1 kit (Applied Biosystems) as outlined in table 2.2. I prepared 10µl sequencing reactions 
and used the cycling conditions described in figure 2.4.   
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Reagent 
Stock Final 
concentration concentration 
Water (distilled and autoclaved) N/A N/A 
BigDye Buffer (Applied Biosystems) 5x 1x 
N/A (1µl per 
10 µl reaction) 
BigDye (Applied Biosystems) N/A 
Forward or Reverse Primer (AltaBioscience) / 
(Eurogentec) 
10pmole/µl 5pmole/µl 
DNA Variable Variable 
 Table 2.2 Constituents of a standard cycle sequencing reaction. 
 
 
 
   
     96°C  2mins 
     Denaturation:  96°C  20s 
     Annealing:              50°C  15s         x30 cycles 
     Extension:              60°C  4mins  
  
Figure 2.4 Standard cycling conditions of sequencing reaction. 
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The products from the cycle sequencing reaction were then purified using the EDTA/ethanol 
method. First DNA was precipitated by adding 2.5µl of 0.125M EDTA and 35µl of 95% 
ethanol to each sample, and incubating at room temperature for 30mins.  The precipitated 
DNA was then pelleted by centrifugation at 2,250xg for 30mins at 4°C. These pellets were 
then washed twice with 95% ethanol and dried at 65°C for 20mins. Finally, the purified DNA 
pellets were re-suspended in 10µl of HiDi formamide, (Applied Biosystems), incubated at 
95°C for 5mins and then loaded onto capillary sequencer ABI 3700 machines to read the 
sequence. The data obtained from the sequencer was analysed using Chromas version 2.13 
(Technelysium, Australia) and ClustalW (http://www.ebi.ac.uk/Tools/clustalw/). 
When there were only a small number of samples to be sequenced I organised for the process 
to be performed by the Functional Genomics and Proteomics Unit (University of Birmingham) 
‘plasmid to profile’ service. In this instance 200-500ng of PCR product was mixed with 
10pmole of either forward or reverse primer, and the volume made up to 10μl with distilled 
water. These samples were sequenced using a similar protocol to that described above, and 
loaded onto an ABI 3700 capillary sequencer machine. The data was collected via the 
functional genomics website (http://www.genomics.bham.ac.uk/) and analysed using software 
as previously described. 
 
2.8 PCR fragment analysis  
Automated high-resolution PCR fragment analysis allows separation of PCR products 
differing in length by as little as 1 base pair [485]. Either the forward or reverse PCR primer is 
labelled with a fluorescent compound, so that after amplification the labeled PCR products can 
be separated with an automated sequencing system. With the use of a fluorescent-labeled 
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DNA length marker or ‘size standard’ and GeneScan® software (Applied Biosystems), the 
exact size of each peak can be displayed and analysed. This technique can also be used with 
cDNA for a semi-quantitative estimation of the relative abundance of wild-type and aberrant 
transcripts [485], [486], [487]. 
I used this fragment analysis technique to analyse post-PCR products for both DNA (section 
5.3.2.6) and cDNA (section 7.5.2). In the PCR reactions either the forward or reverse primer 
was labeled with 6-Carboxyfluorescein (6-FAM), the primers and reaction conditions can be 
found in the relevant sections. I first prepared a ‘HiDi master mix’ by adding GeneScanTM 500 
LIZ® internal ‘size standard’ (Applied Biosystems), which allows sizing of DNA fragments 
35-550bp long, to HiDi formamide (Applied Biosystems). 4µl of the LIZ® size standard was 
added to every 500µl HiDi used for the reaction and then mixed by vortexing. 10µl of this 
‘HiDi master mix’ was added to 1µl of each PCR product. The PCR products were used neat 
or diluted 1:10 with distilled water, depending on strength of PCR fragments visualised on 
agarose gel electrophoresis.  
The reaction mixture was then incubated at 95°C for 5mins, before being loaded onto a 
capillary sequencer ABI 3700 machine. The data obtained was analysed with the ABI Prism 
Genemapper 3.5TM software (Applied Biosystems). 
  
 
2.9 Denaturing high performance liquid chromatography (DHPLC) 
DHPLC is a well validated high throughput technique used to identify DNA sequence 
variations via the detection of heteroduplexes in PCR products by HPLC [488], [489], [490], 
[491], [492], [493]. Before analysis by DHPLC, the PCR products were denatured and slowly 
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re-annealed to create homo and heteroduplexes (see section 6.1.2 for details) using the 
conditions described below (figure 2.5). 
 
 
               Denaturation:  95°C  6mins 
                           93.5°C  1min 
               Reannealing:             -1.5°C per cycle for 29 cycles 
                           25°C  10mins  
 
Figure 2.5 Standard cycling conditions for ‘Duplexing’ 
reaction  
 
 
The DHPLC reactions were performed using the Transgenomic WAVE® system 
(Transgenomic Ltd).  Column temperatures for analysis of each PCR product were determined 
by examination of PCR product melt profiles generated by WAVE® navigator software to 
cover the entire region (see figure 2.6). All PCR products required two column temperatures, 
some required four (see appendix F). Time shifts were also used for some temperatures to 
ensure that the entire peaks of the chromatogram could be visualised. 5µl of duplexed PCR 
product was loaded onto the DNASep column (Transgenomic Ltd) at the pre-selected analysis 
temperatures and eluted from the column by an acetonitrile gradient (see section 6.1.2 for 
details). Eluted DNA fragments were subsequently detected by UV absorption and 
chromatograms generated by the WAVE® navigator software. Chromatograms were analysed 
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automatically by the ‘mutation detection’ software and also manually to detect mutations or to 
confirm the presence of wild-type sequence. 
Key: 
            59.5° 
            60° 
            61.5° 
 
 
 
 
Figure 2.6 Example of PCR product melt profile created by the Transgenomic NavigatorTM 
software. Base position is plotted against helical fraction and the melt profiles at three different 
temperatures are represented by different colours. Temperatures for analysis were chosen which 
corresponded to a helical fraction of between Melting temperatures are selected by trying to get the 
target sequence between the 0.60 and 0.99 helical fraction range. The helical fraction gives the 
proportion of DNA that is double stranded and therefore allows the DHPLC machine to detect 
homo- and hetero-duplices.  
 
 
2.10 Primary cell lines 
Two subjects carrying novel LRRK2 mutations consented to having both a further blood 
sample taken, for the extraction of lymphocytes, and to having a skin biopsy performed. 
Lymphocytes were extracted from whole blood and transformed with Epstein-Barr Virus 
(EBV) into immortalized lymphoblast cell lines. Fibroblasts obtained from the skin biopsies 
were grown into fibroblast cell lines. Both of these cell lines were kindly generated for us by 
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Professor Malcolm Taylor in the Institute for Cancer Studies, at the University of 
Birmingham. Control lymphoblast and fibroblast cell lines were obtained as gifts from 
Professor Taylor and Dr Andrew Filer in the department of Rheumatology, University of 
Birmingham. 
 
2.10.1 Lymphoblast lines 
The media I used to maintain the lymphoblast cell lines was made up of Roswell Park 
Memorial Institute medium (RPMI) (Invitrogen) supplemented with L-glutamine, 10% bovine 
foetal calf serum (Sigma) and penicillin/streptomycin antibiotics (1000 units/ml penicillin and 
0.1 mg/ml streptomycin) (Sigma). Lymphoblast cultures (10-15ml) were maintained in T75 
flasks, and kept at 37°C in a humidified atmosphere containing 5% CO2. These cells were 
grown in suspension, and were split every 4-5 days by removing 5-6ml of the media 
containing lymphoblasts from the flask. The removed cells were either then discarded or 
further processed, dependent upon the nature of their use in planned experiments, as covered 
in the relevant sections below. Finally, 5-6ml of fresh culture media, pre-warmed to 37°C, was 
added to the flask and the cells placed back into the incubator. 
 
2.10.2 Fibroblast lines 
The media I used to maintain the fibroblast cell lines was made up of Dulbecco’s Modified 
Eagle Medium (D-MEM) (Invitrogen) supplemented with 4500mg glucose/l, L-glutamine, 
NaCO3, 10% bovine foetal calf serum (Sigma) and penicillin/streptomycin antibiotics (1000 
units/ml penicillin and 0.1 mg/ml streptomycin) (Sigma). Fibroblast cultures were maintained 
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in T75 flasks, covered with 10ml of growth media, and kept at 37°C in a humidified 
atmosphere containing 5% CO2.  
The cells were split every 5-7 days when they reached 80-90% confluency. Prior to splitting, 
complete growth media, phosphate buffered saline solution (PBS) (Gibco) and 1x 
trypsin/EDTA solution (0.05% trypsin, 0.02% EDTA) were pre-warmed to 37°C. The media 
was removed from the flask and cells washed twice with PBS, to remove any of the bovine 
foetal calf serum which could have inhibited trypsin activity. 2ml of trypsin/EDTA solution 
was added to each flask and incubated at 37°C for 5 minutes in order to detach cells from the 
flask. Trypsin is a serine protease which cleaves adhesion proteins, whilst EDTA chelates the 
calcium required by some adhesion proteins. 5ml of pre-warmed complete growth media was 
then added to inactivate the trypsin and re-suspend the cells. The cells were transferred to a 
15ml centrifuge tube, and pelleted by centrifugation at 1500rpm at 20°C for 5 minutes. The 
supernatant was then removed, cells were re-suspended in fresh growth media, plated at 20-
25% confluency in T75 flasks and re-incubated. The method by which fibroblasts were 
harvested was dependent upon the nature of their use in planned experiments, as covered in 
the relevant sections below. 
 
2.10.3 Harvesting of cells 
Prior to DNA and RNA isolation, the cell density of lymphocytes was measured using a 
haemocytometer, before they were pelleted by centrifugation at 500 x g at 20°C for 5 minutes, 
and the supernatant removed. For Fibroblasts, after trypsinisation the cell density of the re-
suspended cells was measured, using a haemacytometer. The cells were then re-pelleted by 
centrifugation at 500 x g at 20°C for 5 minutes and the supernatant removed.   
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2.10.3.1 DNA isolation 
DNA was isolated using the DNeasy® blood and tissue kit (Qiagen) according to 
manufacturer’s instructions for cultured cells. All steps of the DNA isolation process were 
carried out a room temperature. Using the maximum number of cells (5 x 106) permitted by 
the protocol, the cell pellet was re-suspended in 200μl PBS and 20μl of proteinase K was 
added to lyse the cells. I then added 200μl of Buffer AL (without added ethanol), the sample 
was mixed by vortexing and then incubated at 56°C for 10 min. Next, 200μl of 100% ethanol 
(Sigma) was added before vortexing again. This mixture was pipetted into a DNeasy® mini 
spin column which was placed in a 2 ml collection tube. This was centrifuged at 8000 rpm for 
1 min. The flow-through and collection tube were discarded and the spin column placed into a 
new 2 ml collection tube. Then 500μl Buffer AW1 was added and the column was again 
centrifuged at 6000 x g for 1 min. The flow-through and collection tube were again discarded 
and the spin column placed into a new 2 ml collection tube. Next 500μl of Buffer AW2 was 
added and the column centrifuged at 20,000 x g for 3 min to dry the DNeasy® membrane. The 
flow-through and collection tube were once again discarded. This centrifugation step ensured 
that no residual ethanol was carried over this can interfere with subsequent reactions. The spin 
column was placed into a clean 2 ml microcentrifuge tube, and 200μl of Buffer AE was 
pipetted directly onto the DNeasy® membrane. After incubation for 1 min the tube was 
centrifuged at 20,000 x g for 1 min to elute. This elution step was repeated once to increase 
DNA yield.  
A sample of the isolated DNA was then assessed in a nanodrop ND-100 spectrophotometer 
(Labtech International) to make ensure a high yield of DNA was obtained with no solvent 
contamination. DNA was stored at -80°C until use in PCR. 
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2.10.3.2 RNA isolation 
RNA was isolated using the RNeasy® mini kit (Qiagen) according to manufacture’s 
instructions for cultured cells. All steps of the RNA isolation process were carried out at room 
temperature, with RNase free reagents, tubes and pipette tips. Before isolating RNA, Buffer 
RPE had to be prepared from concentrate by adding 4 volumes of 100% ethanol (Sigma) to 
obtain a working solution. As the number of pelleted cells used was <5 x 106, the cell pellet 
was dissolved in 350μl Buffer RLT, to disrupt the cells, and the mixture vortexed for 1 min. 
Then 350μl of 70% ethanol (Sigma) (diluted in RNase-free water (Qiagen)) was added and 
mixed well by pipetting. The sample was transferred to an RNeasy® spin column and placed 
in a 2 ml collection tube. This was centrifuged at 8000 x g for 15 seconds and the flow-
through discarded. Next 700μl of Buffer RW1 was added to the spin column, which was 
centrifuged at 8,000 x g for 15 seconds to wash the spin column membrane, and the flow-
through again discarded. 500μl of Buffer RPE was then added to the spin column, which was 
centrifuged at 8,000 x g for 15 seconds to wash the spin column membrane, and the flow-
through discarded. A further 500μl of Buffer RPE was added to the spin column, which was 
centrifuged at 8,000 x g for 2 mins to again wash the spin column membrane, and the flow-
through discarded. The spin column was then placed into a new 2 ml collection tube and 
centrifuged at 8,000 x g for 1 min to eliminate any possible contamination with Buffer RPE. 
Next the spin column was placed into a new 1.5 ml collection tube, 30μl RNase-free water 
(Qiagen) was added to the spin column membrane, which was then centrifuged at 16,000 x g 
for 1 min to elute the RNA. This elution process was then repeated with another 30μl RNase-
free water (Qiagen) to obtain a higher yield of RNA.  
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A sample of the isolated RNA was then assessed in a nanodrop ND-100 spectrophotometer 
(Labtech International) to ensure a high yield of RNA was obtained with no solvent or DNA 
contamination. The RNA was stored at -80°C until further use. 
I used the DNA-freeTM (Applied Biosystems) kit according to manufacture’s instructions to 
remove any contaminating DNA from the RNA samples before cDNA generation. This kit can 
remove trace to moderate amounts of contaminating DNA (up to 50μg DNA/ml RNA) from 
purified RNA. The routine DNase treatment protocol was used, as less than 200μg nucleic 
acid was present per ml of samples used. The manufacture’s recommendations are to use 1μl 
(2U) of the recombinant DNase I (rDNase I) for up to 10μg of RNA, hence all reactions were 
performed with less than 10μg of RNA. The reagents, tubes and pipette tips were RNase free.  
I used 35μl reactions in RNase free microtubes (Applied Biosytems), adding 1μl of rDNase I, 
3.5μl (0.1 volume) of 10X DNase I reaction Buffer, and 2μl of RNase free water (Qiagen) to 
28.5μl of RNA isolate. The reaction contents were mixed gently and then incubated at 37°C 
for 30 minutes. After 30 minutes 3.5μl (0.1 volume) of re-suspended DNase inactivation 
reagent was added, mixed well and then incubated for 2 minutes at room temperature, 
ensuring that the contents of the tube were mixed 3 times during the incubation period to 
redisperse the inactivation reagent. The samples were then centrifuged at 10,000 x g for 11/2 
minutes and then the supernatant, which contains the RNA, was transferred into a fresh RNase 
free microtubes (Applied Biosytems). The RNA was then assessed in a nanodrop ND-100 
spectrophotometer (Labtech International) and stored at -80°C until use in cDNA generation. 
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2.10.3.3 cDNA generation 
cDNA was generated using the High capacity cDNA archive kit (Applied Biosystems) 
according to manufacture’s instructions. Nuclease-free reagents, tubes and pipette tips were 
used. Approximately 0.9-1µg of total RNA was used in each Reverse Transcription (RT) 
reaction. For each reaction I prepared a 20μl master mix (see table 2.3 for constituents) which 
was added to 30μl of the isolated RNA (30ng/μl) and mixed well.  
A negative control without the MultiScribe™ Reverse Transcriptase (Applied Biosystems) 
was also prepared for each reaction. These mixtures were incubated at 25°C for 10 minutes 
and then at 37°C for 120 minutes. The cDNA generated was stored at -20°C. 
 
 
Volume (μl)/ 
Component 
reaction 
10X Reverse Transcription Buffer                 
(Applied Biosystems) 
5μl 
25X dNTPs (Applied Biosystems) 2μl 
10X random primers (Applied Biosystems) 5μl 
MultiScribe™ Reverse Transcriptase 50U/μl 
(Applied Biosystems) 
2.5μl 
Nuclease-free water (Qiagen) 5.5 μl 
 Table 2.3 Constituents of a reverse transcription reaction. 
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2.11 Nonsense-mediated decay (NMD) assay 
NMD is a cellular mechanism which reduces the abundance of potentially deleterious 
transcripts containing a premature termination codon [494], [495], [15], [496]. In order to 
study the effects of NMD in our patient and control fibroblast cell lines, I designed an assay 
using cycloheximide (CHX), a potent inhibitor of NMD [497]. This is a well recognised 
technique that has been used before in fibroblast cell lines, although numerous concentrations 
of CHX, numbers of cells and incubation times have been used [498], [499], [500], [501], 
[502], [503]. The protocol I used was based upon that of Baker et al. (2006) [498] and was 
also recommended by a collaborator at the Institute of Neurology in London, Dr Henry 
Holden.  
Fibroblast cell lines from two subjects with PD and two control subjects were grown to 
confluency in T75 flasks as described previously (section 2.10.2). These cells were split and 
re-plated into T25 flasks, 15 flasks for each of the 4 subjects. These cells were subsequently 
grown to 80-90% confluency. Once confluent, the cells from 3 flasks for each subject were 
harvested for RNA extraction as previously described (section 2.10.3.2). Then 6 of the 
remaining 12 flasks for each subject were incubated with 500µM CHX (Sigma) and 6 without 
CHX. After 2 hours incubation the cells from 3 CHX-treated flasks and 3 untreated flasks for 
each subject were harvested for RNA extraction. This procedure was repeated again after 8 
hours incubation. cDNA was subsequently generated from each RNA sample, as previously 
described (section 2.10.3.3), for further analysis.  
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2.12 Western blotting 
Western blotting is a commonly used technique in which the specificity of antigen-antibody 
recognition is utilised in order to detect, and quantify, a particular protein of interest in various 
samples. In this technique, proteins are first size-fractionated on polyacrylamide gels, by 
electrophoresis. The samples are then transferred or ‘blotted’ onto a nitrocellulose membrane 
again via electrophoresis, and antibodies employed to bind to the protein of interest and allow 
detection. The protocol which I used to perform western blots is outlined below. 
 
2.12.1 Sample preparation 
Samples were prepared differently for the lymphoblast and fibroblast cells, but all protein 
extractions were performed on ice, with a protease inhibitor cocktail (Sigma) and 
CytobusterTM protein extraction reagent (Promega) chilled to 4°C, in order to minimise 
proteolysis.  
Prior to protein isolation, the cell density of lymphocytes was measured using a 
haemocytometer, before they were pelleted by centrifugation at 500 x g at 20°C for 5 minutes, 
and the supernatant removed. The pellet was washed once with sterile PBS pre-warmed to 
37°C to remove all trace of media that might be inhibitory to protein analysis. Pre-chilled 
CytoBusterTM (Promega) (150μl per 106 cells) containing 1:100 dilution of protease inhibitor 
cocktail (Sigma) was then applied. This mixture was incubated on ice for 30 minutes, 
transferred into a fresh 1.5ml eppendorf tube, and then centrifuged at 16,000 x g at 4°C for 5 
minutes. The supernatant containing the cell extract was subsequently removed and transferred 
into a clean tube for further analysis, the pellet was stored at -80°C.  
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In the case of the fibroblast lines, cells were harvested when they had reached 80-90% 
confluency. Cell culture flasks were washed twice with sterile PBS pre-warmed to 37°C to 
remove all trace of media. The relevant volume of pre-chilled CytoBusterTM (Promega) (500μl 
per T25 and 1.5ml per T75 flask) containing 1:100 dilution of protease inhibitor cocktail 
(Sigma) was applied. The flask was then incubated on ice for 30 minutes, before cells were 
detached using a cell scraper, the cell suspension aliquoted into a fresh 1.5ml eppendorf tube, 
and then centrifuged at 16,000 x g at 4°C for 5 minutes. The supernatant containing the cell 
extract was subsequently removed and transferred into a clean tube for further analysis, the 
pellet was stored at -80°C.  
In order to quantify the total protein concentration in each sample, the Biorad DC protein 
assay (Biorad) was used according to manufacture’s instructions for a microplate assay 
protocol. This is a colorimetric assay similar to the Lowry assay [504]: the assay is based on 
the reaction of protein with an alkaline copper tartrate solution, and the subsequent reduction 
of Folin reagent by the copper-treated protein [504]. Proteins cause a reduction of the Folin 
reagent by loss of 1, 2 or 3 oxygen atoms, thereby producing one or more of several possible 
reduced species which have a characteristic blue colour, with a maximum absorbance at 
750nm and minimum absorbance at 405nm [505]. 
Prior to each assay run I prepared an aliquot of ‘working reagent A’ by adding 20 μl of reagent 
S to each ml of reagent A needed for the run. In order to prepare a standard curve I prepared 9 
dilutions of a protein standard, bovine serum albumin (BSA) (Sigma), ranging from 0 to 
1mg/ml of protein. The BSA was diluted in the same buffer as the samples, CytoBusterTM 
(Promega). Then 5 μl of each of the standards and samples were pipetted into separate wells in 
a clean, dry micrplate. I added 25μl of ‘working reagent A', followed by 200μl of reagent B, 
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into each well. The plate was gently agitated for 5 seconds, ensuring that any bubbles were 
popped with a clean, dry pipet tip. After 15 minutes at room temperature and in the dark, 
absorbances were read on a microplate spectrophotometer, VICTOR 3 ™ 1420 multilabel 
counter (PerkinElmer), at 750nm. The absorbance readings of the samples were then 
compared to the standard absorbance curve, to calculate protein concentrations.    
The preparation of the lysate for western blotting was carried out on fresh samples, and was 
not performed on samples which had been pre-frozen. To prepare lysates for western blotting, 
proteins within the samples were denatured by the addition of Novex sodium dodecyl sulphate 
(SDS) sample buffer (Invitrogen) containing 20mM of the reducing agent dithiothreitol (DTT) 
(Sigma) and boiled for 5mins. This was to linearise the proteins, thus allowing them to be 
separated by size as well as ensuring that peptide antigen sequences were available for 
antibody binding.  The sample buffer also contained bromophenol blue, which weighed down 
the samples so that they sank to the bottom of the wells, and allowed them to be visualised.  
 
2.12.2 Polyacrylamide gel preparation 
Polyacrylamide gels were prepared with two different components, an 8% resolving gel for 
separating the protein samples, and a 6% stacking gel containing wells into which protein 
samples were loaded. The constituents of each gel are listed in Table 2.4. This ‘discontinuous’ 
gel system was used to enhance band resolution. It works by creating an ion gradient in the 
stacking gel that causes the proteins to ‘stack’ into a focused band; once the proteins enter the 
separating gel the ion gradient is lost and the proteins are separated according to size.    
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Volume for  
Components 
one gel 
Water 2.8ml 
Protogel (National Diagnostics) 1.6ml 
1.5M Tris/HCl buffer pH 8.8 (Sigma) 1.5ml 
SDS (10%) (Sigma) 60µl 
Resolving gel (8%) 
APS (10%) (Sigma) 21µl 
TeMed (Sigma) 9µl 
Water 1.85ml 
Protogel (National Diagnostics) 0.4ml 
0.5M Tris/HCl buffer pH 6.8 (Sigma) 0.75ml 
10% SDS (Sigma) 30µl 
Stacking gel (6%) 
10% APS (Sigma) 15µl 
TeMed (Sigma) 7.5µl 
 
 
 
 
Table 2.4 Polyacrylamide gel recipe.  Components were mixed in the order listed. 
SDS is sodium dodecyl sulphate. The ammonium persulfate (APS) and N,N,N,N -
tetramethyl-ethylenediamine (TeMed) caused the acrylamide and bisacrylamide 
contained within the Protogel to polymerise, so were added immediately before gel 
pouring. 
  
 
The resolving gel was prepared first and added to pre-made gel casting cassette (Invitrogen) 
using a Pasteur pipette, until it was three quarters full. A layer of 70% ethanol was then 
applied to remove any air bubbles and produce a level surface. This was left to set at room 
temperature for approximately 15mins. After removing the ethanol, the stacking gel layer 
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applied on top. A comb was inserted to create lanes for sample loading, and the gel left to set 
at room temperature for a further 15 minutes. 
 
2.12.3 Gel loading and electrophoresis 
Polyacrylamide gel cassettes were placed into the X-cell surelock mini gel system 
(Invitrogen), clamped tight and Novex tris-glycine running buffer (Invitrogen) (10x stock 
solution diluted 1:10 with distilled water) added to fill the central chamber, before the gel 
combs were removed. In order to allow sizing of protein bands 8μl of HiMarkTM pre-stained 
protein standard (Invitrogen) consisting of 9 pre-stained protein bands in the range of 31-460 
kDa was loaded to at least one lane of every gel. The prepared lysate samples were then 
loaded onto the gel lanes, using the known protein content of each sample to ensure that 
similar quantities of protein were loaded into each lane. Electrophoresis took place at 160V for 
2hrs.    
 
2.12.4 Protein Transfer 
After electrophoresis the polyacrylamide gels were removed from the cassettes and the 
proteins transferred onto hybond nitrocellulose membrane (GE Healthcare UK Ltd) in the 
XCell II blot module (Invitrogen) according to manufacturer’s instructions. Transfer buffer 
was prepared with 20ml Novex transfer buffer (Invitrogen), 100ml of methanol (Fisher 
Scientific) and made up to 500ml with distilled water. All components in the XCell II blot 
module (nitrocellulose transfer membrane, blotting paper and blotting pads) were soaked in 
this buffer prior to stacking, except the gel which was placed in distilled water prior to 
transfer. They were stacked as shown in figure 2.7, inserted into the gel tank and clamped 
tightly together. The transfer module was then topped up with transfer buffer to make sure all 
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the components were bathed in the electrolyte. I performed the protein transfer at 60V for 3 
hrs at room temperature. 
 
 
 
 
 
 
 
 
 
Figure 2.7 Diagrammatical representation of how the different 
components of the transfer module were stacked. Taken from Invitrogen 
website (http://www.invitrogen.com/site/us/en/home/Global/.html) 
 
 
 
 
 
2.12.5 Antibody application 
Once the proteins were transferred onto the nitrocellulose membrane, they were ready to be 
probed with antibodies. In order to prevent non-specific binding of the primary and secondary 
antibodies to background endogenous proteins, the membrane was first ‘blocked’ in 10ml of 
5% non-fat dry milk (Marvel®, International Foods Ltd) diluted in 1x PBS containing 0.1% 
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Tween 20 (Sigma) and left to agitate on a rotatory mixer for 1hr at room temperature.  The 
primary antibody was then applied to the membrane and left to incubate overnight at 4°C with 
agitation. These antibodies were diluted in the 5% Marvel® in PBS/Tween solution, dilution 
factors varied (see section 7.3.9). After primary antibody incubation, the membranes were 
rinsed for approximately 10s, and then washed three times for 10mins each in the PBS Tween 
to remove any of the primary antibody.   
Horseradish peroxidase (HRP)-conjugated secondary antibodies (Dako), specific to the species 
of animal in which the primary antibody was generated, were then diluted in the 5% Marvel® 
in PBS/Tween (see section 7.3.9 for dilution factors).  The membranes were incubated with 
the secondary antibody solution for 1hr at room temperature, on the rotatory mixer.  Finally 
excess secondary antibody was removed by washing in the PBS/Tween solution three times, 
as after the primary antibody incubation. 
 
2.12.6 Signal detection 
I used enhanced chemiluminescent solution plus (ECL plus) western blotting detection 
reagents (GE Healthcare UK Ltd) according to manufacturer’s instructions to detect HRP 
signals on the conjugated secondary antibodies. The ECL system uses the oxidation of 
Lumigen PS-3 Acridan by the HRP enzyme to produce light (figure 2.8).   
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Light
Protein of 
interest 
(LRRK2) Proteins bound to 
the membrane
HRP
HRP conjugated 
secondary antibody
Primary antibody
ECL: Lumigen PS-3 
Acridan
Nitrocellulose 
membrane
 Figure 2.8 Western blot protein detection. Proteins bound to the nitrocellulose 
membrane have been separated by size on a polyacrylamide gel. Primary antibodies 
bind to the protein of interest and HRP-conjgated secondary antibodies bind to the 
primary. The HRP enzyme converts Lumigem PS-3 Acridan to ester intermediates, 
which react with peroxide to produce light that can be detected on X-ray film. 
 
 
 
 
I added 50µl of solution B to 2ml of solution A, mixed well, applied it evenly to the 
nitrocellulose membrane with a Pasteur pipette, and then incubated the membrane for 5 
minutes at room temperature. The membrane was then patted dry, wrapped in cling film and 
exposed to X-ray film (Thermoscientific) prior to development using an automated x-ray film 
processor (Xograph). 
 
 
 
 - 91 -
Chapter 3                                    Clinical Studies of Familial and Sporadic Parkinson’s Disease                         
3 Clinical Studies of Familial and Sporadic Parkinson’s Disease 
 
3.1 Introduction 
The variability of the presenting features and rate of progression of idiopathic Parkinson’s 
disease (IPD) suggests multiple pathogenic mechanisms and thus implying complex gene-
environment interactions. This would appear to suggest that we should regard PD more as a 
syndrome rather than a single disease.  
When studying the role of genetic factors in the pathogenesis of PD it is therefore also crucial 
to consider a number of other potentially important factors such as age, presenting symptoms, 
co-morbid dementia and environmental exposures. Furthermore, when studying genetic 
factors in distinct cohorts of subjects with familial and sporadic PD it is vitally important to 
consider the demographics of the cohorts in order to put this data into the context of IPD in the 
community.  
 
3.1.1 Demographics  
The demographics of a PD cohort may have important implications for such crucial factors as 
disease phenotype and progression. Indeed, there are many important factors to consider, such 
as age, gender, ethnicity, handedness and family history.  
Increasing age has been shown to be the strongest risk factor for PD [210], [211] and has also 
been shown to be associated with an accelerated rate of symptomatic progression [40], [42].  
PD also appears to occur more commonly in men than women; indeed in most clinic based 
studies males outnumber females by approximately 2:1. Furthermore, recent meta-analyses of  
age-adjusted male to female incidence ratios for PD have shown a male to female ratio of 1.46 
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and 1.49 [506], [507]. Some differences in disease phenotype have been noted between the 
genders, but the reasons for this are unclear. It may be that male gender itself is a risk factor, 
or it may be a surrogate for other factors. Another explanation comes from in vitro evidence 
that oestrogen may be neuroprotective [508].  
There is evidence to suggest that incidence of PD may also vary by ethnicity. Prevalence rates 
appear to be lower in Asians than in whites, with lower rates in blacks than those in non-
Hispanic whites [509], [510], [511], [512], [513], [514], [515]. Indeed, in a recent study age- 
and gender-adjusted incidence rates were highest amongst Hispanics, followed by non-
Hispanic whites, Asians and then blacks [515]. These potential ethnic variations may point to 
important differences in genetic factors or may be as a result of different environmental 
exposures.  
Handedness and PD has also been investigated and in a large clinic-based study of patients 
with PD 92% were found to be right handed [516]. This fits  with population figures which 
indicate that 8-15% of people are left-handed [517], [518]. Handedness was found to be 
significantly related to side of asymmetric disease, such that left-handed individuals tended to 
have more severe disease on the left hand side of the body. This may be due to a combination 
of anatomic vulnerability and/or hand usage [516]. 
Family history of neurodegenerative disorders is another potentially important factor and in a 
recent study 25% of PD patients reported a positive family history of neurodegenerative 
disorders [17]. In the DATATOP study of PD 19% of patients reported a positive family 
history of PD [41]. In a population-based study, the reported frequency of a positive family 
history of PD was 10.3% in subjects with PD and 3.5% in age- and sex-matched controls 
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[213]. Furthermore, Bonifati et al. reported that a family history of PD was positive in 24% of 
100 consecutive PD cases and 6% of spouse controls (p<0.001) [214].     
Generally fPD is thought to have a different phenotype to sPD, for example Parkin related PD 
typically presents at a younger age and shows slower disease progression [234], [235], [236]. 
Recently there have been some more comparative studies which have re-investigated this 
proposed difference. Carr et al. compared 26 fPD patients to 52 age-matched sPD patients 
[233]. Baba et al. compared 40 fPD patients to 1277 consecutive PD patients (1087 without a 
family history of PD and 190 with a family history of PD) [519]. Furthermore in a recent 
prospective study by Papapetropoulos et al. 50 fPD patients were compared to 50 age- and 
sex-matched sPD patients [520]. All three studies showed similar demographic and phenotypic 
characteristics between the two groups, suggesting a similar topography of neurodegenerative 
insult and shared aetiological factors between the two groups [233], [519], [520]. 
 
3.1.2 Initial motor symptoms 
There has been relatively little work done into the nature of initial motor symptoms in PD and 
their predictive utility for disease progression. A recent study, however, did investigate the 
pattern and relationship between initial symptoms and clinical examination findings in 840 
patients with PD [17]. The initial motor symptoms were: 49% tremor, 21% bradykinesia, 10% 
gait difficulty, 8% micrographia, 5% rigidity and 7% other. Indeed tremor (59%) and 
bradykinesia (16%) were also the most common initial motor symptoms reported in the 
DATATOP series [41]. In general there appeared to be a consistent relationship between 
initial motor symptoms and symptom rating at first clinic visit.  
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3.1.3 Cognitive dysfunction and PD 
Cognitive changes are common in PD and cause substantial disability [45]. Indeed mild 
cognitive impairment can develop into a sub cortical dementia called PD with dementia 
(PDD).  As outlined in the introduction, the diagnosis of dementia in PD is complicated by the 
other disease entity of dementia with Lewy bodies (DLB). The reported rates of dementia in 
PD are variable, ranging from 3 to 80% [521], [53], [54], [52]. A recent systematic review on 
the prevalence of PDD suggested that 24 to 31% of PD patients have dementia [55]. One of 
the most established risk factors for dementia in PD is advanced age, whilst other factors such 
as disease duration and later onset of PD have not been consistently associated with the 
development of dementia [56], [522], [523], [58], [524]. 
  
3.1.4 Olfaction and PD 
Olfactory dysfunction is found in 70-100% of subjects with PD, making it is as common a 
clinical sign as resting tremor [108], [109], [525], [110]. It is known to be associated with 
neuronal loss and Lewy body deposition in the olfactory pathway [112], [525]. Olfactory 
identification is the most widely used assessment, with the University of Pennsylvania Smell 
Identification Test (UPSIT) validated as a method of quantification [116], [117]. Indeed, 
olfactory dysfunction has been shown to appear prior to the onset of motor symptoms [117]. 
Olfactory testing has also been performed in asymptomatic individuals, and in some studies 
olfactory dysfunction has been shown to be predictive of development of PD [119], [120], 
[121], [122].  
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3.1.5 Environmental exposures and PD 
As outlined in the introduction, a number of environmental risk factors for PD have been 
proposed on the basis of presumed pathogenic mechanisms. However, many of the 
epidemiological studies designed to investigate these factors (such as smoking, toxin exposure 
and infections) were retrospective, with small sample sizes and in some cases used 
inappropriate controls. Furthermore, the time period in which patients are at risk of developing 
PD is unknown and therefore it is not clear whether early, late, cumulative or lifetime 
exposures should be studied. This section will briefly outline evidence for and against a 
pathogenic role in PD for some other environmental exposures, not covered in the 
introduction, which have been recorded on subjects studied in this project. 
There have been numerous studies investigating a link between caffeine consumption and PD. 
An inverse association between PD and coffee consumption [201], [526], [527], [528], [529] 
and between PD and tea consumption has been identified by many of these studies [527], 
[530]. Indeed a meta-analysis of eight case-control and five cohort studies showed a 
significantly decreased PD risk for coffee drinkers (pooled relative risk 0.69) that was 
independent of smoking [203].  
The role of occupation and risk of PD has also been investigated, and certain occupations do 
have an increased risk of exposure to potentially important environmental factors, such as 
head injury, pesticides or toxins. However, interpretation of data from the numerous studies of 
the effects of lifestyle is difficult due to the overlapping nature of the risk factors, and the 
variability of the results. Some studies have shown a positive association between PD and 
farming, rural living and ingestion of well water [531], [532], [533], [534]. This relationship 
could be due to chemical or pesticide exposure. Indeed one study found that associations with 
rural living were a function of exposure to pesticides [535]. Furthermore the association of 
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well water ingestion might be due to leaching of pesticides from soil into ground water [536]. 
Thus rural living and farming might simply be surrogate markers for pesticide exposure, 
which is discussed in the introduction. 
Several recent studies into the long suspected link between head trauma and PD have been 
performed. Bower et al. counted only head traumas that required medical care, and found the 
frequency of head trauma to be higher in  PD cases than controls (OR 4.3, 95% CI=1.2-15.2) 
[537]. In another study involving siblings with PD, history of head trauma was associated with 
a younger onset of PD by a mean of 3.3 years [538]. A case control study of 93 pairs of twins 
discordant for PD also found an association between PD and head trauma (OR= 3.8, 95% 
CI=1.3-11.0) [539]. Most recently the Geoparkinson study found that head injury showed an 
exposure-response relationship with PD (for being knocked unconscious more than once, (OR 
2.56, 95% CI= 1.78-3.69) [153].  
 
3.2 Aims of the chapter 
The three major aims of the work in this chapter were firstly to recruit a large cohort of 
subjects with familial PD (fPD) from around the UK and to collect demographic, phenotypic 
and epidemiological data on this cohort. Secondly to analyse and discuss the demographic, 
phenotypic and epidemiological data collected. Thirdly to analyse and discuss the 
demographic data on several cohorts of patients recruited from around the UK with 
predominantly sporadic PD (sPD).  
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3.3 Subjects and methods 
3.3.1 Familial and sporadic PD 
I recruited subjects with familial PD (fPD) from around the UK between April 2005 and 
March 2008. Proband cases were selected where segregation of PD in their family was 
consistent with an autosomal dominant (AD) pattern, with three or more PD cases in at least 
two consecutive generations, as covered in section 2.1.1.  
Subjects with sporadic PD (sPD) came from four sources, as covered in section 2.1.2. The 
largest number of subjects with sPD came from the Parkinson’s Disease DNA Bank (PD GEN 
study) (www.pdgen.bham.ac.uk), DNA samples were collected between 2002 and 2007. 
Subjects with sPD also came from local studies, the Birmingham PD study in which samples 
were collected between 1994 and 1998 and the Neurodegenerative Disorders DNA Bank in 
which samples were collected between April 2005 and March 2008. The final source of 
subjects with sPD came from the PINE study, samples were collected in Aberdeen between 
2002 and 2005.  
All subjects had given their informed written consent to take part in the studies listed above 
and appropriate ethical approval had been obtained (see sections 2.1.1 and 2.1.2). All data was 
kept under the provision of the Data Protection Act. 
 
3.3.2 Statistical methods 
Statistical analysis was performed using the SPSS for Windows release 15.0 (SPSS Inc, 
Chicago, Ill., USA). Continuous variables were tested for normal distribution using 
Kolmogorov-Smirnov test and homogeneity of variance was tested using the Levene’s statistic 
where appropriate. Categorical variables were compared using χ2 analyses, whilst continuous 
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variables (age at evaluation, and age at disease onset) were investigated using analysis of 
variance (ANOVA), Hochberg’s GT2 Post Hoc analysis and two-tailed independent T-tests. 
GraphPad software (http://graphpad.com/quickcalcs/) was used to compare my data to that 
from previously reported studies, with advice and assistance from a statistician, Dr Peter 
Nightingale, Wellcome Trust Clinical Research Facility, University of Birmingham. A p value 
<0.05 was considered significant. 
 
3.4 Results of the fPD study 
I recruited a total of 46 proband cases from families containing three or more members 
affected by PD, where segregation of PD in the proband’s family was consistent with an AD 
pattern, to the study. From these 46 families seven other members affected by PD, two 
members affected by dopa responsive dystonia (DRD) and 16 unaffected family members 
were also recruited to the study. 
In addition I recruited ten proband cases from families in which, after detailed examination of 
family history, only two affected family members could be confidently identified. From these 
ten families two other members affected by PD, one member affected by Alzheimer’s disease 
and three unaffected family members were also recruited to the study. Data on the 
geographical location, demographic and clinical characteristics and epidemiological survey on 
this cohort is available but is not presented in this thesis.  
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3.4.1 Geographical location of families 
As can be seen in figure 3.1 below 44 of the fPD probands were recruited from throughout 
England, with a bias towards the West Midlands (48%). Two of the fPD probands were 
recruited from Wales. 
 
 
 
North East
North West
Wales
West Midlands
East Midlands
East Anglia
London
South East
South West
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Pie chart representing geographical location of probands with familial PD 
recruited to this study.  
 
3.4.2 Number of affected family members  
As can be seen in figure 3.2, of the 46 families recruited to the study there were 35 families 
(76%) with three members affected by PD, eight families (17%) with four members affected 
by PD and three families (7%) with five members affected by PD. 
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4 Affected
Members
5 Affected
Members
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Pie chart representing number of family members affected by PD for the 46 
proband subjects recruited to this study.   
 
3.4.3 Pedigrees 
Figure 3.3 gives examples of the pedigrees recorded for four of the families with three or more 
affected members, other pedigrees can be found in chapters 4 and 5 and appendix D. 
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3.4.4 Demographics and clinical characteristics 
The demographics and clinical characteristics of the 46 proband cases from families 
containing three or more members affected by PD are listed in tables 3.1 to 3.5, with the 
numbers of individuals affected by PD in each family presented in figure 3.2. The continuous 
variables (age at evaluation, and age at disease onset) were found to be normally distributed. I 
compared my data to that available from previous studies, and where possible performed 
statistical analysis. However, as discussed below, unless stated no statistically significant 
differences were identified, probably due to the small group size of my fPD cohort.  
 
 
10 32 
25
33 
Key:         Proband case Possible 
PD 
Male PD Female Deceased 
Figure 3.3 Example pedigrees of PD families with three or more affected members. 
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3 or more affected 
family members 
 Mean (SD) 
68.0 (11.3) Age at evaluation 
Age range 39-89 
57.9 (12.6) Age at symptom onset 
Age range 30-78 
 Number (%) 
27 (59) Gender                 Male 
                            Female 19 (41) 
45 (98) Ethnicity       Caucasian 
                         Other 1 (2) 
36 (86) Handedness          Right 
                            Left 6 (14) 
14 (30) F/H other                     Y 
neuro.conditions          N 32 (70) 
 
 
 
 
 
3 or more affected 
 family members 
Initial motor 
Number (%) symptom (s) 
Tremor 27 (61) 
Bradykinesia 8 (18) 
Rigidity 9 (20) 
Gait difficulty 3 (7) 
Micrographia 7 (16) 
Other 6 (14) 
Initial motor 
Number (%) 
symptom location 
Right arm 17 (39) 
Left arm 18 (41) 
Both arms 0 (0) 
Right leg 5 (11) 
Left leg 2 (5) 
Both legs 3 (7) 
Table 3.1 Demographics and clinical 
characteristics of fPD proband cases (a). 
Other 8 (18) 
Table 3.2 Demographics and clinical 
characteristics of fPD proband cases (b). 
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3 or more affected 
family members 
 Mean (SD) 
UPDRS III score 31.4 (14.8) 
Hoehn and Yahr stage 2.8 (1.1) 
Hoehn and Yahr stage Number (%) 
Stage 1 3 (7) 
Stage 1.5 1 (2) 
Stage 2 12 (26) 
Stage 2.5 7 (15) 
Stage 3 8 (17) 
Stage 4 5 (11) 
Stage 5 5 (11) 
Missing 5 (11) 
Parkinsonian features 
on examination 
Number (%) 
Bradykinesia 44 (96) 
Rigidity 45 (98) 
Tremor 30 (65) 
Postural instability 39 (85) 
Missing 1 (2) 
3 or more affected 
 
family members 
Other clinical features Number (%) 
41 (89) Response              Yes 
1 (2) to anti-PD             No 
3 (7) therapy           No Rx 
               Not recorded 1 (2) 
Mean L-dopa dose, 
mg/day (SD)
636.8 (382.9) 
34 (74) Levodopa 
Dopamine agonists 22 (48) 
COMT Inhibitor 13 (28) 
16 (35) Other anti-PD Rxs 
26 (57) Dystonia               Yes 
13 (28)                            No 
            Not recorded 7 (15) 
22 (48) Dyskinesias          Yes 
18 (39)                              No 
             Not recorded 6 (13) 
10 (22) Dementia              Yes 
                             No 36 (78) 
Table 3.4 Demographics and clinical 
characteristics of fPD proband cases (d). 
Table 3.3 Demographics and clinical 
characteristics of fPD proband cases (c). 
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3.4.5 Epidemiological survey  
The epidemiological data obtained on the 46 proband cases from families containing three or 
more members affected by PD are listed in tables 3.6 and 3.7. 
 
 3 or more affected 
 family members 
Other clinical features Mean (SD) 
MMSE 28.0 (2.8) 
18.4 (6.8) UPSIT Score 
9-32 Range 
Missing data 20 
15.4 (5.4) Male UPSIT Score 
9-25 Male Range 
Missing data 12 
23.3 (6.0) Female UPSIT Score 
14-32 Female Range 
Missing data 8 
Table 3.5 Demographics and clinical 
characteristics of fPD proband cases (e). 
 - 105 -
Chapter 3                                    Clinical Studies of Familial and Sporadic Parkinson’s Disease                         
 
 
 
 
 
3 or more affected 
family members 
 
 Number (%) 
8 (17) 
31 (67) 
Well water           Yes 
consumption         No 
                 Not recorded 7 (15) 
3 (6) 
38 (83) 
Head injury          Yes 
                            No 
                Not recorded 5 (11) 
0 (0) 
41 (89) 
Meningitis or        Yes    
encephalitis           No 
                Not recorded 5 (11) 
24 (52) 
19 (41) 
Smoking            Never 
                      Yes or Ex 
                Not recorded 3 (7) 
 Mean (SD) 
Pack years (smokers or 
ex smokers) 
16.9 (13.2) 
3 or more affected 
family members 
 
 Number (%) 
11 (24) Toxin                 Yes 
28 (61) exposure            No 
                 Not recorded 7 (15) 
27 (59) Lived most       Town 
10 (22) of life             Country 
5 (11)                      Both 
            Not recorded 4 (9) 
13 (28) Occupation      Manual 
27 (59)                    Non manual 
3 (7)                           Farmer 
                Not recorded 3 (7) 
16 (35) Tea or                  Yes 
1 (2) coffee drinker       No 
               Not recorded 29 (63) 
 Mean (SD) 
Table 3.6 Epidemiological data on fPD 
proband cases (a). 
No. cups per day (tea or 
coffee drinkers) 
4 .9 (1.2) 
Table 3.7 Epidemiological data on fPD 
proband cases (b). 
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3.5 Results of the sPD study 
A total of 697 unselected PD cases from four different collections were available for this part 
of the study. There were 357 subjects from the PD GEN study, 254 subjects from Birmingham 
PD study, 57 subjects from the Neurodegenerative Disorders study, and 29 subjects from the 
PINE study. The demographics of the 697 subjects from are given in table 3.8. Where 
available, data on family history of PD is given, as are the initial presenting symptoms for 
subjects from the PINE study. 
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PD GEN study B’ham PD study NDD study PINE study  
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
72.6 (9.1) 62.7 (11.5) 67.5 (10.3) 73.1 (11.8) Age at evaluation 
Age range 47-102 31-90 45-86 42-95 
67.2 (9.2) 57.2 (13.9) 55.6 (9.7) 71.9 (11.7) Age at symptom onset 
Age range 40-99 18-85 39-72 42-95 
 Number (%) Number (%) Number (%) Number (%) 
236 (66) 151 (59) 34 (60) 15 (52) Gender             Male 
                         Female 121 (34) 103 (41) 23 ( 40) 14 (48) 
346 (97) 251(99) 54 (95) 29 (100) Ethnicity       Caucasian 
                       Other 11 (3) 3 (1) 3 (5) 0 (0) 
52 (15) 79 (31) 13 (23) 7 (24) 
Family                    Yes 
233 (65) 77 (30) 25 (44) 22 (76) history of PD           No 
                Not recorded 0 (0) 72 (20) 98 (39) 19 (33) 
Initial motor symptoms Number (%) Number (%) Number (%) Number (%) 
Tremor 17 (59) 
Bradykinesia 3 (10) 
Rigidity 0 (0) 
Gait difficulty 4(14) 
Micrographia 0 (0) 
 5 (17) Other 
 Table 3.8 Demographic & clinical characteristics of 4 sPD cohorts.  
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The continuous variables (age at evaluation, and age at disease onset) were found to be 
normally distributed and were investigated with ANOVA. This revealed significant 
differences between the four cohorts for both age at evaluation and age of disease onset (F- 
value 47.806, P-value <0.001, 3 degrees freedom and F-value 38.744, P-value <0.001, 3 
degrees of freedom). Subsequent investigation was with Hochberg’s GT2 Post Hoc analysis 
and independent T-tests and this is presented below in tables 3.9 and 3.10. 
 
Cohort PD GEN study B’ham PD study NDD study PINE study 
p<0.0001* p<0.0001* p=0.7814 PD GEN study  
p<0.0001* p=0.0040* p<0.0001* B’ham PD study  
p<0.0001* p=0.0040* P=0.0259* NDD study  
p=0.7814 p<0.0001* P=0.0259* PINE study  
Table 3.9 Statistical analysis (independent T-tests) of the comparison in age at evaluation 
between four sPD cohorts. *= statistically significant difference. 
 
Cohort PD GEN study B’ham PD study NDD study PINE study 
p<0.0001* p<0.0001* P=0.010* PD GEN study  
p<0.0001* p=0.4099 p<0.0001* B’ham PD study  
p<0.0001* p=0.4099 p<0.0001* NDD study  
P=0.010* p<0.0001* p<0.0001* PINE study  
Table 3.10 Statistical analysis (independent T-tests) of the comparison in age at disease 
onset between four sPD cohorts. *= statistically significant difference. 
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χ2 analyses of the categorical variables showed no significant difference between gender or 
ethnicity in any of the four sPD cohorts (Pearson Chi-Square=4.626, p=0.201, 3 degrees of 
freedom and Pearson Chi-Square=4.943, p=0.176, 3 degrees of freedom). However, there was 
a smaller proportion of subjects from the PD GEN cohort (15%) who reported a family history 
of PD, compared to 24% of subjects in the PINE cohort, 31% of subjects in the Birmingham 
PD cohort and 23% of subjects in the NDD cohort. Despite missing data for the PD GEN, 
Birmingham PD and NDD studies (20%, 39% and 33% respctively) χ2 analyses revealed there 
to be a significant difference in family history of PD between the four sPD cohorts (Pearson 
Chi-Square=85.643, p<0.0001, 3 degrees of freedom). Further analysis between individual 
cohorts revealed that the only statistically difference was between the PD GEN and 
Birmingham PD cohorts (Pearson Chi-Square=50.669, p<0.0001, 1 degree of freedom).  
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3.6 Discussion of demographic and clinical characteristics of the fPD cohort 
I will first consider the demographics and clinical characteristics of my cohort of 46 proband 
subjects with fPD.   
 
3.6.1 Demographics 
I recruited 46 proband cases from UK families with three or more members affected by PD, 
with a geographical bias towards the West Midlands (see figure 3.1). This bias was because I 
was based in this region and received a larger number of referrals from colleagues within the 
region. This may be important when considering the generalisability of the results of this study 
to the UK as a whole.  
 
3.6.1.1 Number of affected family members 
With regard to the number of affected family members, there is data available from two 
previous studies of fPD (with AD inheritance) for comparison. In the first study 72% of the 
families had 2-5 known affected individuals, 20% had 6-10 affected individuals and 8% had 
more than 10 affected individuals [293]. In the second study 58 % of the families had 3 or 
more affected members and 42% of the families had 2 individuals with PD [280]. However, 
these data are not directly comparable as one of the original entry criteria to my study was for 
families to have 3 or more affected individuals with PD. The proportion of families with 
different numbers of affected individuals clearly varies between different studies, probably 
reflecting differing recruitment criteria.  
In the majority of the families recruited to my study the proband had self-reported their family 
history of PD. This so called ‘family history method’ is the method used by most studies of 
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fPD. Where possible I examined the reportedly affected relatives of the proband for signs of 
PD, or other neurological disease. However, in most cases the other affected family members 
were deceased at the time of the study, also in some cases it was not possible to contact the 
affected relatives. In addition, copies of death certificates of deceased affected family 
members were obtained in ten cases, to help confirm the diagnosis of PD reported by the 
proband.  
This raises for discussion the accuracy of the family history data which I obtained. Several 
studies have compared the validity of the ‘family history method’ in first-degree relatives to 
the study of each relative, the ‘family study method’. The findings were generally similar, in 
that reliable and accurate family history information on PD in first degree relatives can be 
obtained. However, there was some over-reporting of PD in relatives who were not affected 
and the family history information was more reliable when a more conservative diagnostic 
algorithm was used [540], [541], [542]. Although in some cases in my study, information on 
relatives other than first degree relatives was given, this suggests that the reliability of the data 
I obtained should be good. 
 
3.6.1.2 Age at symptom onset and gender 
The demographics of a PD cohort will depend on a number of factors, but most notably in this 
study on the fact that the subjects were selected for study because of their strong family 
history of PD. This makes direct comparison between demographic data from my cohort and 
demographic data from the clinic-based cohorts listed in the introduction difficult. 
Nevertheless, the basic demographics of this PD cohort appear comparable to those from a 
number of different clinic based populations of PD presented in table 3.11. 
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Author 
Number of 
subjects 
Symptom 
Age (years) % Male 
onset (years) 
Uitti et al. (2005) 840 70.0 61.0 68 
Jankovic et al. (2001) 297 61.6 55.1 61 
Goetz et al. (2000) 100 72.0 58.0 53 
Scigliano et al. (1996) 335 59.2 54.8 52 
Hely et al. (1995) 125 62.6 60.7 55 
Starkstein et al. (1992) 105 66.0 56.3 60 
Diamond et al. (1990) 371 60.5 55.8 67 
Jankovic et al. (1990) 800 61.1 59.0 66 
Current study 46 68.0 57.9 59 
 
 
Table 3.11 Demographics of clinic-based PD populations. Adapted from Uitti et al. 2005 [17] 
 
The data on ages at evaluation and symptom onset, and the slight predominance of males in 
this cohort is all in general agreement with the previously reported data (see table 3.11). The 
age of disease onset in the fPD cohort (57.9) does appear to be younger than that reported in 
the largest population based study (61.0), although this difference is not statistically significant 
(P=0.06). The difference in proportion of males versus females between these two cohorts is 
also not statistically significant (p=0.19). These differences may not have been statistically 
significant because of the small group size of my fPD cohort.  
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The general similarity in the age of symptom onset data from my fPD cohort to the 
population-based studies does suggest that in this aspect at least the cohort is more similar to 
sPD than some forms of fPD (such as Parkin related PD) which tend to have a younger age of 
onset [234], [235], [236]. One reason why fPD cases report an earlier age of disease onset may 
be that they are more aware of the symptoms of the condition, notice them earlier and self-
refer. Interestingly, even though the majority of our fPD subjects self-referred themselves to 
my study, the age of symptom onset is still similar to that reported in sPD.   
A more direct comparison of the demographics of my fPD cohort can perhaps be performed 
with the limited data available from three other recent studies of fPD in which cohorts of 
patients with fPD and apparently AD inheritance (in the case of the first two studies) have 
been recruited [293], [280], [26]. In addition a useful comparison can also be made with data 
from the two studies mentioned in section 3.1.1, which compared cohorts of patients with fPD 
and sPD [233], [520]. This data is presented below in table 3.12. 
.  
Number of Symptom onset Author % Male subjects (years) 
Mata et al. (2005) 100 53.0 65 
Di Fonzo et al. (2005) 60 49.2 Not given 
Nichols et al. (2007) 88 61.2 58 
Carr et al. (2003) 26 60.1 69 
Papapetropoulos et al. (2007) 50 61.1 58 
Current study 46 57.9 59 
 
Table 3.12 Comparative demographics of fPD cohorts.  
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Therefore, the gender distribution of 59% male and mean age of onset of 57.9 (12.6) years for 
my fPD cohort is generally comparable with the figures from previous studies of fPD. Where 
available data permitted comparison, differences were not statistically significant, although 
this may again be due to small group size.  
 
3.6.1.3 Ethnicity 
There was only one non-Caucasian patient recruited to my fPD cohort. Given the increasingly 
diverse ethnicity of the UK, with 7.9% of the population reporting as non-white at the 2001 
census [543] there does appear to be an underrepresentation of non-Caucasians. This perhaps 
can be explained by two factors, first most patients self referred via advertisements in the 
media and internet. There may be a proportion of non-Caucasians whose first language is not 
English, especially amongst the age group associated with PD, and therefore these patients 
would be less likely to respond to advertisements in English. Second, different genetic 
variations and environmental exposures amongst different ethnic populations may give 
different risks of developing PD. Indeed there is evidence of ethnic variations in incidence of 
PD, recently Van Den Eeden et al. found that age and gender-adjusted incidence rates were 
highest amongst Hispanics, followed by non-Hispanic whites, Asians and then blacks [515].  
 
3.6.1.4 Handedness 
The data on handedness from this study shows that 86% of subjects were right handed. This 
fits with the general population figures in which 8-15% of people are found to be left-handed 
[517], [518]. Indeed in a single large study on a clinic-based sample of patients with PD 92% 
were found to be right handed [516].  
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3.6.1.5 Family history of other neurodegenerative diseases 
As outlined in section 3.1.1, up to 25% of PD patients report a family history of 
neurodegenerative disorders [17]. In my study 30% of the patients reported a family history of 
neurodegenerative disorders, apart from PD, ranging from multiple sclerosis to motor neurone 
disease; the largest single condition reported being dementia. Given that all the subjects were 
selected because they had a family history of PD, and extensive family histories were taken, 
this finding is perhaps not surprising. Most of the probands were unable to confirm the type of 
dementia in their families, or describe the clinical features, however one explanation is that 
this dementia was associated with Lewy body pathology and hence this could be important to 
associate with subsequent genetic data from these families. 
 
3.6.2 Clinical characteristics 
A number of different phenotypic characteristics of this cohort of fPD patients have been 
presented in tables 3.2 to 3.5, which are discussed below. 
 
3.6.2.1 Initial motor symptoms 
In my study tremor was the most commonly reported initial motor symptom (61%). This was 
also the most commonly reported initial symptom in previous studies, including in fPD, at 
frequencies of 47%, 54% and 59% respectively [17], [41], [519]. In these studies bradykinesia 
was the next most common initial symptom, in my current study 18% reported their first 
symptom to be bradykinesia with 20% reporting rigidity. Furthermore, the upper extremities 
were the most frequently reported location for initial motor symptoms in my study (80%). 
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This tallies with data from the previous studies which also found upper extremities to be the 
most common site for initial motor symptoms (68% and 89% respectively) [17], [519]. 
It is important to point out that for a number of patients there may have been some recall bias 
as at time of recruitment to the study, as it was a number of years since their symptoms first 
began. This was minimised by referring to medical records to confirm the subject’s reports in 
as many cases as possible. In addition a number of subjects reported more than one initial 
motor symptom and in this study these were all recorded, hence the total percentage is greater 
than 100%. The data from this part of the study provides further support that the PD 
phenotype of subjects in my fPD cohort is generally similar to the that which one would 
expect to find from a clinic based cohort of predominantly sporadic disease.  
 
3.6.2.2 Severity of disease 
In this study, the mean UPDRS III motor score was 31.4 and the mean modified Hoehn and 
Yahr stage was 2.8, on treatment. Although there is missing data on five patients, the data 
suggests that within this cohort there is an equal mixture of early stage (modified Hoehn and 
Yahr stage of 2.5 or less) and more advanced disease. In a recent study with a symptomatic 
disease duration of 7 years, compared to 10 in my study, the UPDRS III score on treatment 
was 30.9 and 73% of patients had a modified Hoehn and Yahr stage, on treatment, of 2.5 or 
less [17]. Furthermore in a study of fPD patients with a mean disease duration of 8.9 years, the 
mean UPDRS III score on treatment was 32.1 (24.0) and the mean modified Hoehn and Yahr 
stage, on treatment, was found to be 2.7 [520]. 
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3.6.2.3 Clinical signs 
The data on clinical features demonstrates that a very high proportion of probands have 
evidence of bradykinesia, rigidity and postural instability, whilst only 65% have tremor. In a 
previous study the proportion of patients with tremor was 66% for fPD patients, with 74% 
having rigidity, and 74% for sPD patients, with 82% having rigidity [520]. In another study 
only 4% of fPD patients had tremor, although in the same study only 8% of the sPD patients 
had tremor [233]. Whilst data on the other features of PD were not given in these two papers, 
there does appear to be a discrepancy between the higher percentage of patients with rigidity 
in my study, and the very small proportion of patients with tremor in the previous study.  
There are several possible explanations for these apparent differences, first both the fPD and 
sPD cohorts in the Carr et al. study had very low frequencies of tremor and therefore it may be 
explained by methodological variations or the different populations from which the two 
studies recruited. The higher proportion of patients with rigidity in my study may be explained 
by the longer disease duration. Another explanation is that because the current study cohort is 
composed solely of patients with autosomal dominantly inherited PD these patients may have 
a different disease phenotype to the previously studied fPD patients.  
 
3.6.2.4 Treatment 
In my study, 89% of probands reported positive response to anti-PD therapy and the average 
daily L-dopa dosage was 636.8mg (SD 382.9). Comparison of this average daily dosage of L-
Dopa to equivalent figures reported in previous studies is difficult as different methods have 
been used to calculate L-Dopa equivalencies. However in a recent study of a large cohort of 
PD patients (fPD and sPD) which used the same L-Dopa equivalency calculation, with an 
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average disease duration of 7 years, the average daily L-Dopa dose was 589.6mg [17]. The 
higher average daily dose seen in my study may be explained by the longer disease duration, 
although variations in prescribing patterns from country to country may also partly explain the 
difference. The relatively long disease duration of the patients in my study is also reflected by 
the data showing the proportions of patients receiving different PD medications, suggesting 
that a number of these patients have complex treatment regimens.  
The proportion of patients in the current study who reported treatment-induced dyskinesias 
(48%) fits with the average daily dose of L-dopa given and the average disease duration of ten 
years. In two other recent studies 27% and 22% of fPD patients, compared to 37% and 24% of 
sPD patients respectivel, reported dyskinesias [233], [520]. The average disease durations in 
these studies were 5.9 years and 8.9 years for fPD and 8.5 years and 7.5 years for sPD 
respectively [233], [520]. Therefore the data on treatment and dyskinesias fits with a cohort of 
patients in which the average disease duration is 10 years and clinical features are typical of 
IPD.  
 
3.6.2.5 Dementia 
In this study 22% of probands were reported to have dementia. The dementia type was 
Parkinson’s disease with dementia (PDD) as the onset in all cases had been more than one 
year after the onset of motor symptoms. The estimates of prevalence of dementia in PD from 
the literature are very variable, but 22% seems comparable to those of 24% to 31% quoted in a 
recent systematic review [55]. The mean MMSE score for proband cases in my study was 
28.0, whilst in a recent study of fPD and sPD mean MMSE scores of 23.6 and 24.0  
respectively were recorded [520]. Whilst the cognitive function of probands in the my study 
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may actually be better than expected, and could be explained by genuine differences in disease 
phenotype, and potentially disease mechanism, there is limited data available on similar 
cohorts of patients and any assumptions must be made with caution.   
 
3.6.2.6 Olfactory dysfunction 
In this study the fPD probands were found to have impaired olfactory function with a mean 
UPSIT-40 score of 18.4 (males 15.4 and females 23.3). These scores were similar to the 
recently reported mean score of 17.1 found in a cohort of British patients with IPD (mean age 
70.6) and contrasts with the mean score of 27.6 found in normal age-matched controls [118]. 
The mean score is lower for the male subjects, which is as expected as normal values are 
known to be lower in men and decrease with age [483]. Wenning et al. also recorded UPSIT 
scores in 118 patients with IPD and 123 healthy control subjects. They found a marked 
impairment in olfactory function the IPD group compared to controls [544]. Some subjects in 
my study had scores within the normal range, this is to be expected as up to 30% of PD 
patients have normal smell despite Lewy body disease [110].  
Numerous other studies of olfactory dysfunction in PD have been performed, including a 
study in which the UPSIT scores of subjects with ‘malignant’ PD were significantly worse 
than those of subjects with ‘benign’ PD  [114]. In another study of fPD, olfactory dysfunction 
was found to be a phenotypic characteristic of familial parkinsonism [545]. In a recent 
comparison of tremor-dominant and standard PD no significant difference in olfactory 
dysfunction was found. However, a subgroup of tremor-dominant PD with a family history of 
tremor had less olfactory dysfunction than those without a family history or those with 
standard PD. The authors proposed that patients with a family history of tremor may represent 
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a different disease process even though, apart from differences in olfaction, they are clinically 
similar to other patients with tremor-dominant parkinsonism [546]. 
In my study there was missing data on 20 subjects (43%). This is mainly because these 
subjects were unable to complete the test. In the majority of cases it was the more severely 
affected subjects who were unable to complete the test and this potential bias needs to be 
considered. However, the olfactory function of the subjects with fPD in this study cohort was 
reduced and is similar to that identified in a cohort with IPD, perhaps indicating similar 
disease mechanisms between the two groups. The individual subject UPSIT-40 scores will be 
useful to correlate with molecular genetic findings later in this study.  
 
3.6.3 Summary of demographic and clinical characteristics of fPD cohort 
Whilst taking into consideration that this was not a population-based study, and that a 
relatively small number of subjects were studied, several important conclusions can be drawn 
from this part of the study. First I successfully recruited a large cohort of fPD patients with 
AD inheritance, along with appropriate demographic and clinical data. Second the 
demographics and clinical characteristics of my cohort appear very similar to those of the fPD 
cohorts which have been previously described in the literature, and indeed to those of the 
much larger cohorts of PD patients recruited as part of population based studies. The data also 
suggests that the typical phenotype of patients within my cohort is more similar to the sPD 
phenotype rather than the typical ‘slowly progressive’ fPD phenotype which has been reported 
with fPD associated with certain genetic variations, such as Parkin, PINK1 and DJ-1 [234], 
[235], [300], [236], [227], [320], [321], [342], [344], [345]. Therefore this cohort of subjects 
with fPD can be used for molecular genetic analyses and data will be generalisable. 
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3.7 Discussion of epidemiological survey of fPD 
I will now consider data on epidemiological factors, which may be important for the aetiology 
of PD, which was collected as part of my study of fPD, these results can be found in tables 3.6 
and 3.7 above. Before discussing the data it is important to point out that unlike the other case-
control epidemiological studies discussed here and in the introduction, my study was designed 
as a clinical and molecular genetic study of fPD, and not as a population-based study of 
epidemiological factors in PD. The epidemiological data was collected primarily for future 
reference to any genetic variations which might be identified in this cohort, and therefore 
discussion of the data in this section can only be observational, looking for potential trends.  
Aside from caffeine consumption, which is covered separately below, up to 15% of data for 
each of the categories is missing or not recorded, in the majority of instances this was because 
the subject was unable to give accurate answers.  
 
3.7.1 Smoking and caffeine consumption 
Smoking is one of the most studied risk factors for PD with an apparent reduced risk of PD 
amongst smokers [200], [201], [202]. However, 41% of the probands in my study were 
smokers or ex-smokers, with an average 16.9 pack years. Data from the 2003 Health Survey 
for England showed that 27% of men and 24% of women were current smokers [547]. Further,  
self-reported cigarette smoking figures may underestimate true smoking prevalence by 
approximately 2.8% [548]. Therefore the percentage of smokers or ex-smokers amongst 
patients with fPD in my study is perhaps higher than would be expected.  
Whilst less well studied than smoking, there is some data suggesting an inverse relationship 
between caffeine consumption and risk of developing PD [201], [526], [527], [528], [529], 
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[530]. One might therefore expect to find a low proportion of tea or coffee drinkers in my 
cohort of fPD patients. Of the available data, virtually all the probands were tea or coffee 
drinkers. This is the opposite of the trend that might be expected from previous studies, but 
given that 63% of the data on caffeine consumption is missing it is impossible to draw any 
firm conclusions. The data is missing as enquiry into caffeine consumption was not added to 
the study protocol until after a number of the subjects had already been recruited.     
 
3.7.2 Occupation  
Occupation can give important information as to which potentially hazardous environmental 
factors a subject may exposed. For example farming may be surrogate marker for pesticide 
exposure and welding may be a surrogate marker for heavy metal exposure.  My data shows 
that 59% of subjects had non-manual occupations (e.g. clerical work, teacher). There were 
only a few subjects who were farmers, or worked on farms. However, there is likely to be a 
bias in this cohort with regard to occupation. This is the result of the bias of recruitment from 
the West Midlands, and also the methods of recruitment, such as via the internet, which might 
significantly influence the socio-economic composition of the group. Some of the individual 
exposures are dealt with separately below, but these data appear to suggest that in my cohort 
of fPD subjects occupational-related environmental exposures could be important aetiological 
factors in about one third of subjects. This may be important when considering the results of 
genetic analyses of these subjects, but it is not really possible to generalise these findings even 
to other similar cohorts of AD fPD subjects.   
.   
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3.7.3 Rural living, farming, well water consumption and toxin exposure 
As outlined in the introduction, there is overlap with these three risk factors, which makes 
individual analysis difficult. There is some evidence in support of an increased risk of PD in 
subjects exposed to pesticides [155], [158]. The evidence in support of an increased risk of PD 
from other environmental toxins is less clear [173], [174]. 
In my fPD cohort, only 22% reported living in the country for most of their lives and 11% 
reported to have lived in both town and country equally. These findings tally with the finding 
that relatively few probands were farmers. Furthermore, only 17% of probands reported 
drinking well water for more than 6 months and only 24% of probands reported toxin 
exposure. Patients were questioned about any exposure that they might regard as potentially 
toxic, but in most cases it was pesticide exposure that was reported. Thus within this cohort 
there was a minority of patients who through rural living, well water consumption, and 
occupation, may have been at exposed to putative toxic compounds.  
Recall bias may be important, particularly with regard to well water consumption and toxin 
exposure. Indeed, the geographical bias towards the West Midlands is also a potentially 
crucial factor in explaining these findings. Once again, however, this data may prove 
important later when putting the findings of genetic analyses into the context of the whole 
disease process.     
 
3.7.4 Head injury and infections 
In my study only 3 (6%) probands reported a head injury that had knocked them unconscious. 
Furthermore there was not a single subject who reported a history of cerebral infection. Thus, 
whilst interpreting the data with caution, head injury and infection do not appear to be 
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important environmental risk factors in the development of PD in this cohort of subjects with 
fPD.  
 
3.7.5 Summary of the epidemiological survey of fPD 
Whilst taking into consideration that this was not a population-based study, the over-
representation of subjects from the West Midlands, and the recall bias which is inherent in this 
type of retrospective study, some conclusions can be drawn from this epidemiological survey. 
First, that head injury and cerebral infection do not appear to be significant risk factors for PD 
in this cohort. Second, similar proportions of subjects reported a history of toxin exposure, 
rural living and well water consumption, ranging from 17-24%. At least in the context of this 
fPD cohort, if these risk factors are important in the aetiology of PD they would only appear to 
be so in up to a quarter of cases.    
 
3.8 Discussion of sPD study 
I will now consider the demographics of four cohorts of patients recruited from around the UK 
with PD, unselected for family history of the condition, and also the clinical characteristics of 
one of these cohorts. The majority of these patients had apparently sPD. 
 
3.8.1 Demographics 
There have been a number of studies of PD in which the basic demographics of large cohorts 
of patients have been discussed. The cohorts of patients discussed in this section are from four 
different studies and the results have been listed separately. As such the data will be 
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considered and put into the context of the literature as four separate collections, but discussed 
together below.   
 
3.8.1.1 Age at evaluation and symptom onset 
The average age at evaluation is 62.6 years for the PD GEN study, 62.7 years for the 
Birmingham PD study, 67.5 years for the NDD study and 73.1 years for the PINE study. The 
average age at symptom onset is 67.2 years for the PD GEN study, 57.2 years for the 
Birmingham PD study, 55.6 years for the NDD study and 71.9 years for the PINE study. There 
were statistically significant differences between the four cohorts for both age at evaluation 
and age of disease onset (see tables 3.9 and 3.10). Whilst the age at symptom onset is 
comparable to those reported in the literature (see table 3.11) for both the Birmingham PD and 
NDD studies, it is 6.2 years older than the next highest figure for the PD GEN collection and 
10.9 years older than the next highest figure for the PINE study [17]. Indeed comparison of the 
age at symptom onset between the PD GEN cohort and that reported in the largest population 
based study (61.0) revealed a statistically significant difference (P<0.0001).  
The subjects in all four studies were not recruited on the basis of age or family history. The 
observed differences in age at symptom onset, and age at evaluation, of these cohorts is likely 
to be due to the nature of the clinics from which the patients are recruited. The subjects in the 
PD GEN study were recruited from general neurology clinics, movement disorder clinics and 
the clinics of elderly care physicians from throughout the UK. So this cohort of subjects 
should be most representative of a community-based sample of PD patients. 
The subjects in the Birmingham PD and NDD studies were for the most part been recruited 
from specialist movement disorder clinics at two major neuroscience centres in the West 
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Midlands and are less representative of a community based sample. It is expected that at least 
some of these subjects may have younger onset of disease and perhaps even atypical, or 
difficult to diagnose disease.  
The PINE cohort was recruited from a single movement disorder clinic at a major 
neuroscience centre in Aberdeen. The relatively late age of symptom onset may be explained 
by the small numbers of patients in this cohort or may be a peculiarity of the demographic 
composition of that single clinic.   
 
3.8.1.2 Gender 
The percentage of male subjects was 66% in the PD GEN study, 59% in the Birmingham PD 
study, 60% in the NDD study and 52% in the PINE study. No statistical difference was 
detected between the four cohorts. These figures are all comparable to those from the literature 
(see table 3.11). Indeed the difference in proportion of males between the PD GEN cohort and 
the largest population based cohort (68%) was not statistically significant (p=0.46). 
The reasons for the apparent predominance of males in these studies are unclear, it may be that 
male gender itself is a risk factor or it may be a surrogate for another risk factor to which men 
might have a greater exposure. Another explanation comes from the in vitro evidence that 
oestrogen may be neuroprotective [508]. Furthermore, the isolation of a PD susceptibility gene 
on the X chromosome could potentially explain the higher risk of PD in men [364]. Finally 
mitochondrial dysfunction has been reported in PD [549], [550], [551], [323] and as the sex 
ratio is similar to that in Leber’s hereditary optic neuropathy, which results from disruption of 
the  mitochondrial electron transport chain, mitochondrial dysfunction might be a possible 
explanation.   
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3.8.1.3 Ethnicity 
Virtually all the subjects were Caucasian, ranging from 95% in the NDD study to 100% in the 
PINE study. No statistical difference was detected between the four cohorts. There is evidence 
that ethnic variations in incidence of PD may exist, with prevalence rates lower in Asians than 
whites (non-hispanic or hispanic) and lower rates in blacks than those in non-hispanic whites 
[509], [510], [511], [512], [513], [514], [515]. Most recently Van Den Eeden et al. found that 
age and gender-adjusted incidence rates were highest amongst Hispanics, followed by non-
Hispanic whites, Asians and then blacks [515]. Given that at the 2001 census 7.9% of the UK 
population, and 11.2% of the West Midlands population, was non-white [543] there may still  
be an underrepresentation of non-Caucasians in these cohorts, which could represent a bias in 
subject recruitment due to language difficulties.  
 
3.8.1.4 Family history of PD 
In the PD GEN study 15% of subjects report a family history of PD, of which 98% have one, 
and 2% have two other affected family members. Of these other affected family members, 
60% are first degree relatives and 40% are other more distant family members. In the PINE 
study 24% of subjects report a family history of PD, of which 57% have one, and 43% have 
two other affected family members. Unfortunately there is some missing data for the 
Birmingham PD and NDD studies. However, 31% of subjects in the Birmingham PD study 
and 23% of subjects in the NDD study report a family history of PD. Indeed there was a 
statistically significant difference detected between the PD GEN and Birmingham PD cohorts 
(p<0.0001). The figures on reported family history of PD in the literature range from 16-19% 
[17], [41]. The higher figures reported particularly in the Birmingham PD study, may reflect in 
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part the recruitment from specialist movement disorder clinics at major neuroscience centres, 
where a higher proportion of patients might be expected to have a positive family history of 
PD.  
 
3.8.1.5 ‘Community-based’ sample? 
When studying sPD one of the major aims is to ensure that the study cohort is as 
representative of a ‘community-based’ IPD cohort as possible. The major reason for this is to 
try to ensure that when genetic analyses are performed any variations which may be identified 
are as relevant as possible to the ‘typical’ IPD seen by general practitioners, physicians and 
neurologists rather than the more ‘atypical’ cases that might be seen in specialist movement 
disorder clinics. 
To this end the PD GEN collection, recruited from many non-specialist clinics throughout the 
UK, may be most appropriate for this type of study. It is interesting that the diagnosis re-
evaluation rate, to date, for subjects in the PD MED study is 2.2% (35 out of 1592 cases) 
[552]. This is much lower than the expected, and widely quoted, 8-10% rate [553], [554], 
suggesting a high diagnostic accuracy rate.  
The demographics of the PD GEN cohort are in general terms similar to those previously 
reported in the literature. Indeed the mean age at evaluation in a recent community-based 
study of PD in London was also 72 years, with a mean age of disease onset of 69.2 years [76]. 
Statistical analysis revealed no significant difference between the ages at evaluation 
(p=0.5488), although I was unable to perform statistical analysis of age at disease onset 
between the PD GEN cohort and this publsihed data. Thus generalisable data can be generated 
from this study of sPD.  
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3.8.2 Clinical characteristics 
Clinical data is available for the PINE study, with initial motor symptoms listed in table 3.8. 
The most common symptom was reported as tremor (59%) followed by other (17%). From the 
literature, tremor has also been reported as the most common initial motor symptom in two 
previous studies (49% and 59% respectively) followed by bradykinesia (21% and 16% 
respectively) [17], [41]. Therefore whilst only relatively few patients are being considered, the 
most common initial motor symptom tallies with that reported in the literature.    
 
3.8.3 Summary for the sPD study 
Taking into consideration the relatively small numbers of subjects in the NDD and PINE 
cohorts, several conclusions can be drawn from this part of the study. First the demographics 
of all four cohorts appear similar to those which have been previously described in the 
literature. Second the 357 subjects from the PD GEN study and are most representative of a 
‘community-based’ sample of IPD with appropriate demographic data available. This cohort 
can be used for molecular genetic analyses of sporadic PD and the data will be generalisable. 
    
3.9 Comparison of PD GEN and fPD cohorts 
A brief comparison of the demographics of the sPD and fPD cohorts to be used in the genetic 
analyses in future chapters may be informative, as presented in table 3.13. 
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PDGEN study fPD study  
 Mean (SD) 
P value 
Mean (SD) 
72.6 (9.1) 68.0 (11.3) =0.006 Age at evaluation 
Age at symptom onset 67.2 (9.2) 57.9 (12.6) <0.0001 
 Number (%) Number (%) P value 
236 (66) 27 (59) Gender            Male 
=0.3276 
Female 121 (34) 19 (41) 
346 (97) 45 (98) Ethicity     Caucasian 
=1.000 
Other 11 (3) 1 (2) 
 
 
Table 3.13 Comparison of the demographics of the PD GEN and the fPD cohorts. 
 
On comparing the data between the PD GEN and fPD cohorts, there is a statistically 
significant difference in both age at evaluation and symptom onset between the two groups, 
with both being younger in the fPD group. The small observed differences in gender and 
ethnicity between the two cohorts are not ststistically significant. 
A useful comparison can be made with data from three studies which compared cohorts of 
patients with fPD and sPD, although in the first two of these studies below the two cohorts 
were age matched (also gender matched in the Papapetropoulos et al. study). Carr et al. (2003) 
found that 69% of their fPD patients were male and the mean age of disease onset was 60.1, 
67% of their sPD patients were male [233]. Papapetropoulos et al. (2007) found that 58% of 
their fPD patients were male and the mean age of symptom onset was 61.1 [520]. Baba et al. 
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(2006) found that 66% of their sPD patients were male, and 65% of their fPD patients (from 
two large fPD kindreds) were male, with a mean age of symptom onset of 56.8 years (range 
25-73) in the first kindred and 52.9 years (range 31-71) in the second kindred [519]. Therefore 
there were also some observed differences between the sPD and fPD cohorts in these studies. 
The compositions of the PD GEN and fPD cohorts, the potential biases involved and the 
methodological considerations, have previously been discussed separately. However it may be 
important to re-consider the differences in demographic characteristics between the two 
cohorts later when discussing data from genetic analyses.    
 
3.10 Conclusions 
The aims of this chapter were to obtain and discuss demographic, phenotypic and 
epidemiological data on a large cohort of subjects with fPD and to discuss demographic data 
on several cohorts of subjects with sPD. Overall the demographics and clinical characteristics 
of the fPD and sPD cohorts collected for this study appear similar to those previously 
described in the literature and thus the results are generalisable.  
I have explained that the fPD cohort is self-referred rather than population based. 
Nevertheless, the cohort provides a valuable resource for phenotype-genotype correlations in 
fPD. The PD GEN cohort appears to be closely representative of a ‘community-based’ PD 
collection and the data presented here justifies the use of this cohort for phenotype-genotype 
correlations in sPD.  
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4 A Novel GTP Cyclohydrolase 1 Mutation in a British Kindred 
with Variable Phenotypes Ranging from Parkinson’s Disease to 
Dopa-Responsive Dystonia 
 
4.1 Introduction 
In chapter 3 data was presented and discussed on 46 families with 3 or more affected 
members, compatible with autosomal dominant (AD) inheritance, that were successfully 
recruited to this study. In this chapter a more detailed study of a single family is presented. In 
this family there is variety and overlap of clinical features, presentations and diagnoses. 
Affected subjects display phenotypes ranging from PD to slowly progressive parkinsonism to 
Dopa responsive dystonia (DRD). The different clinical phenotypes in this family may be due 
to variable expression of a novel missense mutation within the GTP cyclohydrolase 1 gene. 
The first section of the chapter provides some background information on the clinical and 
genetic features of DRD and the role of functional neuro-imaging. As pathological 
gastrointestinal tissue has been examined in two subjects, the pathological changes in the 
enteric nervous system which are associated with PD are also outlined. 
 
4.1.1 Dopa responsive dystonia (DRD) 
The conditions which can mimic IPD have already been outlined in the introduction. One of 
these is the movement disorder of Dopa-responsive dystonia (DRD). Dystonia is condition 
that causes sustained muscle contractions, repetitive twisting movements, and abnormal 
postures of the trunk, neck, face, or arms and legs [555]. Tremor can also be present. Dystonia 
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can be classified in several ways, including on the basis of the genetic factors involved. The 
loci DYT1 to DYT15 have been identified to date [556].  
DRD is an inherited metabolic disorder, now classified as DYT5, which results in dopamine 
deficiency in the basal ganglia. It was first described by Segawa in 1976 as an AD dystonia 
[557] and is also sometimes referred to as hereditary progressive dystonia with marked diurnal 
fluctuation (HPD). The incidence has been estimated to be between 0.5 and 1 per million, 
although this may be an underestimate due to misdiagnosis [558], and it is reported as being 
two to four times more common in females. DRD usually presents in childhood, most 
commonly between the ages of 4-8, although it has also been reported to manifest as late as 
the sixth decade. The typical presentation of DRD is of a lower limb dystonia with diurnal 
variation, although the spectrum of symptoms can be broad, even occurring as a 
predominantly parkinsonian condition [559], [560], [558], [561], [562], [563], [564], [557]. 
Indeed the presentation tends to be less severe with a later age of onset [565]. Interestingly, 
marked intra-familial variability of the clinical manifestations of DRD have also been 
observed [566], [567].  
Most subjects with DRD have an excellent and sustained response to low dose Levodopa (50-
100mg), and this is an important clinical diagnostic test. In comparison to PD there is also a 
very low incidence of dyskinesias and the ‘on-off phenomena’ associated with long-term 
Levodopa therapy [16]. This suggests a functional rather than anatomical lesion [568] and 
indeed post-mortem data on subjects with DRD indicates that there is little morphological 
change in the substantia nigra and striatum [569], [570]. Positron emission tomography (PET) 
studies have also shown minimal abnormalities in pre- and postsynaptic functioning neurons 
[571], [572].  
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Heterozygous mutations in the GTP cyclohydrolase I gene (GCH1) are the most common 
cause of AD DRD [573], [574], [575] and are responsible for approximately 50% of cases. 
GCH1 is located on chromosome 14 (14q22.1-q22.2) and encodes the 32-kDa (250 amino 
acids) guanosine 5'-triphosphate cyclohydrolase 1 (GTPCH1) protein (EC3.5.4.16). This is the 
rate-limiting enzyme in the synthesis of tetrahydrobiopterin (BH4) from GTP [576], see figure 
4.1 below. BH4 is a co-factor for tyrosine hydroxylase (TH), the rate-limiting enzyme in the 
synthesis of dopamine. The resulting deficiency of the BH4 cofactor presumably results in 
decreased phenylalanine hydroxylase activity, although serum phenylalanine levels are not 
usually elevated in DRD [577]. In subjects with DRD an oral phenylalanine-loading study can 
be used as a clinical diagnostic test. It increases the requirement for phenylalanine-
hydroxylase activity, thus unmasking a partial BH4 deficiency and leading to elevated serum 
phenylalanine levels [578], [579]. Homozygous mutations in GCH1 have been recognised for 
some time  [580], [581], [582] and cause a more severe phenotype of a progressive 
neurological condition resembling atypical phenylketonuria [565]. 
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Figure 4.1 Synthesis and catabolism of the neurotransmitters catecholamine and indolamine.  
GTPCH1 is the rate-limiting enzyme in the synthesis of tetrahydrobiopterin (BH4). BH4 has a 
central role as cofactor in metabolic pathways, including the synthesis of dopamine, in the hepatic 
metabolism of phenylalanine to tyrosine, and in the production of the serotonin precursor 5-
hydroxytryptophan (5-HTP). Therefore, the downstream consequences of GTPCH1 deficiency 
include alterations in a number of pathways that are important in biological and neurological 
homeostasis and function. A deficiency of dopamine underlies the movement disorder seen in dopa-
responsive dystonia and can explain the remarkable clinical response to dopamine replacement 
therapy. The multiple metabolic consequences, secondary to GTPCH1 deficiency, may explain the 
more complex phenotype often seen in dopa-responsive dystonia and beyond that explained by 
simple dopamine deficiency. Abbreviations: PTS denotes pyruvoyl-tetrahydropterin synthase, 
GFRP-GTPCH feedback regulatory protein, SPR sepiapterine reductase, DHPR dihydropteridine 
reductase, NOS nitric oxide synthase, qBH2 quinoid dihydropterin, NO nitric oxide, 5-HTP 5-
hydroxytryptophan, PCD pterin, COMT catechol-o-methyltransferase, AADC aromatic L-amino 
acid decarboxylase, B6 pyridoxine, 3-O MD 3-O-methyldopa, 5-HIAA 5-hydroxy-3-indole acetic 
acid, NE norepinephrine, DOPAC dihydroxyphenylacetic acid, HVA homovanillic acid, EPI 
epinephrine, DHPG dihydroxyphenyl glycol, MHPG 3-methoxy,4-hydroxyphenolglycol, and VMA 
vanilmandelic acid.  Taken from Venna et al. 2006 [16]. 
 
There are reports of the nuclear localisation of GCH1 [583], as well as the involvement of 
GCH1 and BH4 in cellular differentiation [584], apoptosis [585] and mRNA stability [586]. 
BH4 also appears to increase the release of dopamine into neuronal synapses at high 
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concentrations [587]. Therefore it is likely that there are still proteins and cellular processes to 
be discovered that depend upon GCH1 and BH4 for activity or that control the sub cellular 
localisation of GCH1 or BH4, or both. 
GCH1 contains six exons, and about 100 different mutations (missense, nonsense and 
frameshift) in the coding region or exon-intron junctions have been identified to date from 
different populations [588], [16], [589], [590]. Some of these mutations are shown below in 
figure 4.2. The overall reported frequency of point mutations varies from 50-60% of cases of 
clinically definite DRD [591], [562], [592], [593], [594]. Of these, approximately half were 
missense mutations, up to 17% were nonsense mutations, and up to 15% were frameshift 
mutations and  [594], [595].   
Many subjects with GCH1 mutations do not have a family history of DRD and there appears 
to be a high new mutation rate [596]. Incomplete penetrance of GCH1 mutations has also been 
identified, with estimates varying from 15% to 38% in men and 45% to 87% in women [597], 
[563], [596]. 
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M211V Q89X Q182X M213T T94K Q182E R214W W96X R184H R216X M102K L185R M221T M102R T186K –22C>T M211V M102X V191X –39C>T K224R G108D V191I –132C>T K224X G108V S196A  F234S Y109X P199L R241W Q110X G201E R249S S114X G203R 
 
ATG 
 
Figure 4.2 Mutations in the GCH1 gene associated with DRD. The genomic organisation and location of 
mutations in the human GCH1 gene on chromosome 14q22.1-q22.2. Red indicates exons. Adapted from 
Venna et al. 2006 [16]. 
 - 138 -
Chapter 4                                                              A Novel GCH1 Mutation in a British Kindred                        
AD GCH1 deficiency has been modeled in the GTP cyclohydrolase deficient hph-1 mouse, 
which shows many similar biochemical features as in human DRD [598], although the mice 
do not demonstrate an overt movement disorder.    
There is an AR form of DRD with several missense mutations described in the gene encoding 
tyrosine hydroxylase (TH), in European subjects. The associated phenotype is generally more 
severe than the AD form, with an earlier age of onset [599]. Interestingly, the phenotype 
associated with the homozygous Leu205Pro mutation in TH was early onset parkinsonism 
[600]. There is also a single report of AD DRD caused by a mutation in the sepiapterine 
reductase gene (SPR) [601]. 
In summary, the nigrostriatal DA neurons appear susceptible to decreases in GCH1 activity, 
BH4 level and TH activity. DRD can therefore be considered as the phenotype resulting from 
dopamine deficiency without neuronal death, in contrast to PD which occurs with neuronal 
cell death [600]. 
 
4.1.2 Dopamine Transporter (DAT) Imaging  
DAT imaging is a demonstration of in vivo striatal dopamine activity and yields results which 
are in keeping with other observations of the dopamine system such as autopsy studies [123], 
[124], [125]. DAT is a sodium chloride-dependent protein on the pre-synaptic dopaminergic 
nerve terminal which controls dopamine levels by active re-uptake of dopamine after its 
interaction with the postsynaptic receptor [127]. The DAT ligands for SPECT, including 
[123I]FP-CIT (DaTSCAN) [128] have all shown significantly reduced striatal uptake in PD 
[129], even in early cases [130]. The abnormal uptake progresses from the putamen to 
caudate, and matches contralaterally to the side of the body more affected clinically. DAT 
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imaging is reproducible with test/retest variability in healthy controls and subjects with PD of 
7% for DaTSCAN [131].  
In some large studies of PD 11-15% of subjects have been found to have normal nigrostriatal 
uptake of presynaptic ligands [132], [133], [134], [135], [136]. In the ELL-DOPA study, 21 
(14.7%) of patients scanned with β-CIT SPECT had normal initial scans. Follow-up scans 
remained normal in patients rescanned after 4 years. [602], [132]. The diagnosis in these 
patients remained unclear, and they have since been referred to as SWEDDs (Scans Without 
Evidence of Dopaminergic Deficit) [137]. 
These observations are important because they stimulated a debate as to whether it is possible 
to have PD with a normal presynaptic PET or SPECT scan, and are also of relevance to my 
data which is discussed later in this chapter. It has been proposed that at least some patients 
with SWEDDs have been misdiagnosed with PD, and may actually have an alternative 
diagnosis, such as essential tremor [137]. It has also been proposed that at least a proportion of 
these patients may have dystonic tremor or tremor associated with dystonia [136]. 
Alternatively these patients may indeed have a form of parkinsonism without true akinesia and 
a normal DaTSCAN. 
As would be expected from its known aetiopathogenesis, studies of DAT imaging in DRD 
have consistently shown normal dopamine transporter density, whilst activity was abnormal in 
PD [603], [604], [605], [606]. Thus it has been proposed that where there is diagnostic 
difficulty, such as a negative family history or atypical presentation of DRD, DAT imaging 
can be a useful diagnostic test.  
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4.1.3 Dopaminergic neuronal loss in the enteric nervous system 
PD has traditionally been regarded as a disease of the dopaminergic neurons in the substantia 
nigra. Gastrointestinal dysfunction, ranging from abnormal salivation to constipation, is a 
prominent non-motor feature of PD. Dysfunctional motility is the likely pathophysiological 
mechanism which underlies at least some of the gastrointestinal symptoms. Control of 
gastrointestinal motility arises from both the local intrinsic enteric nervous system (ENS) and 
central locations. The ENS consists of a deep myenteric plexus (Auerbach’s plexus) and a 
more superficial submucosal plexus (Meissner’s plexus), as depicted in figure 4.3. Central 
control arises from the autonomic inputs into the ENS. Parasympathetic innervation originates 
in the dorsal motor nucleus of the vagus (DMV) in the medulla and generally promotes 
increased motility, sympathetic input originates in paravertebral and sacral ganglia, and 
generally serves to inhibit gastrointestinal motility [607]. 
 
 
 
 
 
 - 141 -
Chapter 4                                                              A Novel GCH1 Mutation in a British Kindred                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Arrangement of the enteric nervous system, depicted here for the 
small intestine. Panel A: appearance in separated layers. The deep myenteric 
plexus (Auerbach’s plexus), which consists of numerous ganglia and connecting 
nerve fibre bundles, lies between the longitudinal and circular muscle layers. A 
second ganglionated plexus is in the submucosa (Meissner’s plexus). These 
plexuses provide nerve fibre plexuses in the muscle, in the mucosa and around 
arterioles. Panel B: The enteric plexuses shown in a cross section of the intestine. 
Taken from Furness 2007 [8]. 
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Pathological analyses of gastrointestinal samples in subjects with PD have revealed neuronal 
loss. Lewy bodies (LBs) and Lewy neurites (LNs) have also been found in both the myenteric 
and submucosal plexuses of the ENS in various portions of the gastrointestinal tract including 
the colon [607], [608], [609], [610], [611], [612], [613], [614], [615]. The majority of 
inclusions were found in cellular processes and cell bodies of vasoactive intestinal polypeptide 
(VIPergic) neurons [610], [616]. Anderson et al. have recently shown that there is also loss of 
enteric dopaminergic neurons, with associated changes in colon motility, in an MPTP mouse 
model of PD [617]. 
The central areas associated with gastrointestinal motility (DMV) have also been implicated 
[607]. One study suggests that the DMV is the earliest central site affected in PD, as α-
synuclein pathology in the DMV was found in human brains without damage to the substantia 
nigra [107]. Braak even raised the intriguing question as to whether an environmental agent 
that induces aggregations could move by retrograde transport from the ENS to the CNS [607].   
 
4.2 Aims 
The aims of this detailed study of one family were firstly to describe the variety and overlap of 
clinical features, presentations and diagnoses within this family and to demonstrate the 
difficulties that can occur in coming to an accurate diagnosis. Secondly to present and discuss 
the results of imaging, molecular genetic and pathological studies that have aided elucidation 
of an accurate diagnosis in the various affected members of this family and to describe how 
this information may further understanding of the conditions involved.  
 
 
 - 143 -
Chapter 4                                                              A Novel GCH1 Mutation in a British Kindred                        
4.3 Subjects and methods 
4.3.1 Subjects 
I identified family 6 for further specific study from a total of 46 families containing three or 
more members affected by PD, where the inheritance in the family appeared to be AD, which 
had been recruited to this study as described in section 2.1.1. 
Nine members of this family were studied. All subjects underwent a clinical assessment, in 
their ‘on state’ if on anti-PD medication, by me to confirm the clinical features. For six 
subjects I assessed olfactory function by use of the University of Pennsylvania Smell 
Identification Test (UPSIT-40) (Sensonics, Haddon Heights, NJ) and olfaction was 
categorised as normal or pathologic according to normative data in relation to gender and age 
[482], [483]. Clinical assessment was performed prior to functional neuro-imaging, molecular 
genetic and pathological studies. 
 
4.3.2 Methods 
4.3.2.1 Functional neuro-imaging 
To evaluate basal ganglia function six subjects from family 6 (III:1-III:5 and IV:1) underwent 
dopamine transporter SPECT scanning using [123I]-FP-CIT SPECT (DaTSCAN, Amersham 
Health) at Sandwell and West Birmingham Hospital NHS Trust. In two of the subjects a 
second DaTSCAN was performed at a period of 18 months after the first scan. These images 
were reviewed by a consultant radiologist, Dr Edward Rolfe, Department of neuro-radiology, 
University Hospital Birmingham, experienced in the interpretation of these images, who was 
blinded to the demographic and clinical data on these subjects.  
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4.3.2.2 Pathological studies 
In two subjects (III:1 and III:4) healthy bowel tissue was available from previous hemi-
colectomies, performed for large bowel malignancies. This enabled examination of neural 
tissue from the mesenteric plexus. The tissue was studied by an experienced neuro-pathologist, 
Dr Martyn Carey, Department of Pathology, University of Birmingham, for the presence of 
neuronal loss and evidence of Lewy bodies. Tissues were prepared using standard protocols, 
and immunohistochemical staining was performed using a monoclonal antibody to alpha-
synuclein (Novocastra) to detect the presence of Lewy bodies. 
  
4.3.2.3 DNA extraction and molecular genetic studies 
I extracted DNA from venous blood samples taken from family members as described in 
section 2.3. The DNA samples were then sent to the laboratory of Dr Vincenzo Bonifati, 
Erasmus MC Rotterdam, The Netherlands, where molecular genetic screening in this family 
was performed by Erik Simonds.  
In six members of the family (III:1-III:5 and IV:1) screening for known and novel mutations 
was performed by PCR and sequencing of the entire coding sequence, and intron-exon 
boundaries, of the genes Alpha-synuclein, Parkin, DJ-1, PINK1, LRRK2 and GCHI. Multiple 
ligation-dependent probe amplification (MLPA) was used to detect the presence or absence of 
copy number variation in these genes, using MLPA kits P051 and P052 (MRC Holland). 
MLPA is a well validated and high resolution method to detect copy number changes of up to 
45 loci in one relatively simple, semi-quantitative PCR-based assay [618], [619], [620]. 
Subsequently, three unaffected family members (IV:2-IV:5) and 159 UK control samples from 
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the PD GEN study were screened by Erik Simonds for the novel GCH1 mutation identified in 
subjects III:1, III:4, III:5 and IV:1. 
 
4.4 Results 
4.4.1 Clinical studies  
Of the nine members of this family who have been studied, two subjects had slowly 
progressive PD, one subject had benign parkinsonism and two subjects had DRD. The four 
remaining members were unaffected. The median age of disease onset was 50 with median 
disease duration of 20 years. All available clinical details on affected and unaffected members 
of these families are given in detail in this section. All the studied members of this family are 
Caucasian. 
The pedigree of this family is shown in figure 4.4 and a summary of the clinical features of the 
nine studied members of this family can be found in table 4.1.  
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Key: 
 PD 
4.4.1.1 Subject III:1 
The proband case III:1 is a right-handed male, he was aged 82 at the time of evaluation and 
had onset of symptoms aged 58. His initial symptom was a resting tremor of the right hand. A 
diagnosis of PD was made and he was started on Levodopa (Sinemet) with significant 
treatment benefit. His symptoms have progressed slowly since diagnosis and his anti-
parkinsonian medication has been increased. 
At the time of evaluation he had had intermittent ‘off-period’ dystonia of the right leg for 
about 5 years and had also had treatment-induced dyskinesias of the right arm, as well as of 
the head and neck, for approximately 10 years. He did not have any significant problem with 
‘off-time’ or fluctuations in his motor symptoms. His past medical history included 
hypertension as well as colon and skin cancer. He was retired and had worked as a chef for 26 
years. He had never smoked and had lived most of his life in the town. 
 Par
D
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 ?P  
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 Male 
 Female 
 Deceased 
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III:1 
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III:2 
80 
III:3 
78 
III:4
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 I:3    I:4 I:1 I:2 
II:1 II:4 II:3 II:2 
III:6 III:7 III:8 
IV:2 IV:3 IV:4 
59 55 44 
   Figure 4.4 Pedigree of family 6. The ages at evaluation of the nine family members studied in detail 
   are given. 
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Neurological examination, on treatment, revealed features typical of PD with mask-like facies, 
asymmetrical rest tremor, bradykinesia and cog wheeling rigidity, all worse on the right side, 
as well as postural instability with retropulsion on the pull test and dyskinesias. His gait was 
slow with reduced arm-swing on the right side. His Hoehn and Yahr stage was 3, with a 
UPDRS III score of 31. The remainder of his neurological examination was normal. There was 
no evidence of significant cognitive deficit with a MMSE score of 27. His anti-parkinsonian 
medication at time of evaluation consisted of Levodopa (Sinemet) at a total daily dose of 
650mg.  
CT scanning of his brain, aged 84, showed cerebral atrophy, commensurate with his age. 
The clinical diagnosis in this subject was a slowly progressive form of PD.  
 
4.4.1.2 Subject III:2 
He is a left-handed male, was aged 80 at the time of evaluation and was asymptomatic. His 
past medical history included hypertension and osteoarthritis. He was retired and had been a 
railway worker for 50 years. He was an ex-smoker with a 5 year pack history and had lived 
most of his life in the town. Neurological examination revealed no features of PD. There was 
no evidence of significant cognitive deficit with a MMSE score of 27.  
 
4.4.1.3 Subject III:3 
He is a right-handed male, was aged 78 at the time of evaluation and had onset of symptoms 
aged 75. His initial symptoms were a resting tremor of the right hand and slow gait. A 
diagnosis of parkinsonism was made, although his symptoms had not worsened since their 
onset and at the time of evaluation he had not received any anti-parkinsonian therapy. He was 
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reported to have had two cerebrovascular accidents (CVAs); the first was at the age of 65 
when he had transient balance problems and the second episode was at the age of 71, when he 
had developed left arm weakness and dysarthria. His past medical history included angina and 
atrial fibrillation. He was retired and had worked as a hairdresser for 50 years. He was an ex-
smoker with a 20 year pack history and had lived most of his life in the town. 
Neurological examination revealed some features of parkinsonism, with an asymmetrical rest 
tremor, bradykinesia and cog wheeling rigidity, all worse on the right side. His gait was slow 
but was within normal limits. His Hoehn and Yahr stage was 1, with a UPDRS III score of 9. 
The remainder of his neurological examination was normal. There was no evidence of 
cognitive deficit with a MMSE score of 30.  
Neither a CT scan of his brain, aged 73, nor an MRI scan of his brain, aged 78, had revealed 
any evidence of a CVA. 
The clinical diagnosis in this subject was parkinsonism as he did not meet the UKPDS brain 
bank diagnostic criteria (see appendix A) for definite PD.   
 
4.4.1.4 Subject III:4 
He is a right-handed male, was aged 68 at the time of evaluation and had onset of symptoms 
aged 50. His initial symptoms were a resting tremor of the left hand and slow gait. A diagnosis 
of PD was made and he was initially commenced on Levodopa (Sinemet) 150mg daily, with 
significant treatment benefit. His symptoms had progressed slowly since diagnosis and were 
well controlled on a small dose of anti-parkinsonian medication. His past medical history 
included angina, hypertension and erectile dysfunction. He was retired and had worked as an 
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exhibition designer for over 30 years. He had never smoked and had lived most of his life in 
the town.  
Neurological examination, on treatment, revealed features suggestive of PD, namely an 
impassive face, asymmetrical rest tremor, bradykinesia and cog wheeling rigidity, all worse on 
the left side. His gait was slow and he had poor arm swing, again worse on the left side.  He 
also had evidence of postural instability with retropulsion on the pull test.  His Hoehn and 
Yahr stage was 2, with a UPDRS III score of 19. The remainder of neurological examination 
was normal. There was no evidence of significant cognitive deficit with a MMSE score of 28. 
His anti-parkinsonian medication at time of evaluation consisted of Levodopa (Sinemet) at a 
total daily dose of 150mg.  
He underwent an MRI scan of his brain, aged 69, which revealed some areas of non-specific 
increased signal in the right lentiform nucleus and around the posterior horns of both lateral 
ventricles, consistent with long-standing hypertension. 
The clinical diagnosis in this subject was of a slowly progressive form of PD. 
 
4.4.1.5 Subject III:5 
He is a right-handed male, was aged 66 at the time of evaluation and had onset of symptoms 
aged 44. His initial symptoms were a shuffling gait, difficulty with gait initiation and tremor 
of both legs. He was initially diagnosed with PD and commenced on a dopamine agonist 
(Bromocriptine) with significant treatment benefit. His symptoms progressed slowly, although 
Levodopa was added to his therapy six years after diagnosis, at the age of 50, to give a total 
daily levodopa equivalent dose of 250mg.  
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At the time of initial evaluation, his symptoms were well controlled on treatment. His past 
medical history included erectile dysfunction but was otherwise unremarkable. He was retired 
and had worked as retail store manger for 30 years. He had never smoked and had lived most 
of his life in the town. His neurological examination at this time, on treatment, appeared to be 
normal with no evidence of the features of PD. There was no evidence of significant cognitive 
deficit with a MMSE score of 28. His anti-parkinsonian medication at time of evaluation 
consisted of dopamine agonist (Bromocriptine) and Levodopa (Sinemet) to give a total daily 
levodopa equivalent dose of 250mg.  
This subject was subsequently re-evaluated by Dr David Nicholl, and given a trial period of 
one week off anti-parkinsonian therapy. During this period his symptoms worsened, he 
developed a feeling of akathisia and a resting tremor of both feet. He also developed some 
dystonic posturing of both feet, worse on the right, which tended to be worse at the end of the 
day. Neurological examination at this time revealed dystonic posturing of the right foot and 
resting tremor of both feet. On restarting anti-parkinsonian medication the symptoms 
improved.  
The clinical diagnosis in this subject was DRD. 
 
4.4.1.6 Subject IV:1 
She is a right-handed female, was aged 26 at the time of evaluation and had onset of 
symptoms aged 6. Her initial symptoms were a clawing of the toes and in-turning of the ankle 
of the right foot. Her symptoms progressed slowly but she subsequently developed similar 
symptoms of the left foot. No specific neurological diagnosis was made. At the age of 24 she 
developed dystonic posturing of the right hand, especially when typing or writing. All of these 
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symptoms were worse in the evening or when stressed.  Her past medical history was 
unremarkable. She was a secretary, had never smoked and had lived most of her life in the 
town.  
Neurological examination at the time of evaluation, off treatment, revealed the presence of a 
dystonic tremor of the right hand with a tendency to claw and she developed dystonic writer’s 
cramp whilst writing. Both feet were dystonic and were inverted. There were no other 
abnormal neurological features in the upper or lower limbs and allowing for the dystonic 
posturing of her feet her gait appeared within normal limits. There was no evidence of 
significant cognitive deficit with a MMSE score of 29.  
She was also assessed by Dr David Nicholl and given a working diagnosis of DRD. MRI 
scanning of her brain revealed an apparent persistence of non-myelinated white fibres around 
the trigones, occipital and frontal horns. She was commenced on Levodopa (Sinemet), with 
significant treatment benefit, and the dose was titrated up to a total daily dose of 300mg.  
The clinical diagnosis in this subject was DRD. 
 
4.4.1.7 Subjects IV:2, IV:3 and IV:4 
All three subjects were asymptomatic and neurological examination revealed no features of 
PD. Their ages at evaluation are listed in figure 4.4. Subject IV:3 has a history of 
hypothyroidism. 
  
4.4.1.8 Olfactory testing 
I performed olfactory testing on the five affected subjects and four unaffected subjects studied. 
The results were compared to the normative values and percentiles for age and gender 
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provided in ‘The Smell Identification Test Administration Manual’ to determine the olfactory 
diagnosis [482]. The UPSIT score was 21 for subject III:1 (Severe Microsmia, 40th percentile), 
31 for subject III:2 (Mild Microsmia, 71st percentile), 21 for subject III:3 (Severe Microsmia, 
23rd percentile), 28 for subject III:4 (Moderate Microsmia, 31st percentile), 26 for subject III:5 
(Moderate Microsmia, 24th percentile) and 37 for subject IV:1 (Normosmia, 40th percentile).  
 
4.4.1.9 Other subjects  
According to family reports other known affected members of the family were: (i) subject II:1. 
He had been observed by the family to have had a shuffling gait and upper limb tremor, which 
started in his 50’s, and was wheelchair bound for the last 6-7 years of his life. A formal 
diagnosis of PD was not made, and although he was treated with levodopa it is unclear 
whether he responded to this therapy. There was no reported significant cognitive deficit. His 
occupation was as a railway worker. He died at the age of 82. (ii) Subject II:2. She had 
developed tremor of both arms in her 70’s and was diagnosed with PD. She had received 
treatment with levodopa to which she responded. Her condition was slowly progressive, but 
she remained independently mobile on treatment. There was no reported significant cognitive 
deficit. She died at the age of 91. She had three children, subjects III:6- III:8, all of whom 
were asymptomatic. (iii) Subject II:3. She was reported to have had Alzheimer’s disease.  
Other family members who were known to be asymptomatic include: (i) the mother of the 
proband, subject II:4, who died at the age of 94. (ii) The maternal grandfather of the proband, 
subject I:1, who died in his 70’s. (iii) The maternal grandmother of the proband, subject I:2, 
who died in her 70’s and was reported to have suffered from epilepsy. (iv) The paternal 
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grandfather of the proband, subject I:3, who died in his early 80’s. (v) The paternal 
grandmother of the proband, subject I:4, who died in her early 50’s. 
 
4.4.2 Functional neuro-imaging 
The DaTSCAN images on five affected subjects (III:1, III:3-III:5 and IV:1) and one 
unaffected subject (III:2) are shown below in figures 4.5-4.12. Subjects III:3 and III:4 had a 
second DaTSCAN performed approximately 18 months after the first scan due to the 
inconclusive result of the first scan and atypical disease phenotype. When detected, reduced 
uptake was regarded as suggestive of reduced basal ganglia function.  
Subject III:1 had an abnormal scan with bilateral reduced uptake, worse on the left side. 
Subject III:2 had a normal scan. Subject III:3 had two scans, the first was found to be 
abnormal with reduced uptake on the right side, whilst the follow-up scan 18 months later was 
found to be normal. Subject III:4 had two scans, both scans were abnormal with bilateral 
reduced uptake, worse on the right side. Subject III:5 and IV:1 had normal scans. These 
findings are summarised in table 4.1. 
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Right     Left 1 2 3
 
 
Figure 4.5 DaTSCAN of subject III:1. An abnormal scan, which shows bilateral reduced striatal uptake of [123I]FP-
CIT, worse on the left side, as demonstrated by the arrow. Images 1-7 represent transverse sections through the brain, 
where 1 is the most superior and 7 the most inferior section.  
 
Figure 4.6 DaTSCAN of subject III:2. A normal scan, showing normal striatal uptake of [123I]FP-CIT bilaterally. Images 1-
7 represent transverse sections through the brain, where 1 is the most superior and 7 the most inferior section.  
Right     Left 
4 5 6 7
1 2 3
4 5  6 7
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Figure 4.7 DaTSCAN 1 of subject III:3. An abnormal scan, showing reduced striatal uptake of [123I]FP-CIT on the 
right side, as demonstrated by the arrow. Images 1-7 represent transverse sections through the brain, where 1 is the most 
superior and 7 the most inferior section.  
Right     Left 1 2 3
 
4 5                                               6                                                 7 
Figure 4.8 DaTSCAN 2 of subject III:3. Follow-up scan 18 months after first scan, a normal scan showing normal 
striatal uptake of [123I]FP-CIT bilaterally. Images 1-7 represent transverse sections through the brain, where 1 is the most 
superior and 7 the most inferior section.  
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Figure 4.9 DaTSCAN 1 for subject III:4. An abnormal scan, showing bilateral reduced striatal uptake of [123I]FP-
CIT, worse on the right side, as demonstrated by the arrow. Images 1-7 represent transverse sections through the brain, 
where 1 is the most superior and 7 the most inferior section.  
Right     Left 1 2 3
  7   
 Figure 4.10 DaTSCAN 2 for subject III:4. Follow-up scan 18 months after first scan, an abnormal scan showing 
bilateral reduced striatal uptake of [123I]FP-CIT, worse on the right side, as demonstrated by the arrow. Images 1-7 
represent transverse sections through the brain, where 1 is the most superior and 7 the most inferior section. 
4 5 6
I
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Figure 4.11 DaTSCAN of subject III:5. A normal scan, showing normal striatal uptake of [123I]FP-CIT bilaterally. 
Images 1-7 represent transverse sections through the brain, where 1 is the most superior and 7 the most inferior section.  
Figure 4.12 DaTSCAN of subject IV:1. A normal scan, showing normal striatal 
uptake of [123I]FP-CIT bilaterally. . Images 1-4 represent transverse sections through 
the brain, where 1 is the most superior and 4 the most inferior section. RT= right, LT= 
left. 
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4.4.3 Molecular genetic studies  
The entire known coding sequences and intron-exon boundaries of Alpha-synuclein, Parkin, 
PINK1, DJ-1 and LRRK2 were sequenced in subjects (III:1-III:5 and IV:1). No novel or 
known mutations were identified in the coding sequences of these genes. 
 
A novel heterozygous missense mutation was identified in the first exon of GCH1, see figure 
4.13, affecting the fifth nucleotide of the open reading frame (c.A5G). This mutation is 
predicted to replace glutamic acid with glycine (p.E2G). As given in table 4.1, the novel 
GCH1 mutation was identified in four of the affected members of the family, but not in 
subject III:3 or the other unaffected subjects III:2 and IV:2-IV:5. This novel GCHI mutation 
was also not identified in 300 UK control chromosomes, from the PD GEN control cohort (see 
appendix B). 
MLPA did not reveal any copy number variation in the PD genes Alpha-synuclein, Parkin, 
PINK1, DJ-1 and LRRK2 or GCH1 
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Wild type 
Mutant 
Figure 4.13 Electropherograms from subjects who are wild–type and heterozygote for the novel 
GCH1 mutation c.A5G. Arrow indicates position of nucleotide variation. 
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4.4.4 Pathological studies      
Histopathological study of the ENS from healthy bowel tissue, performed by Dr Martyn 
Carey, in subjects III:1 and III:4 did not reveal the presence of any neuronal loss, Lewy bodies 
or any other pathology suggestive of PD. 
 
 
 
     Human M E K G P V R A P A E K P R G A R C S N G F P E R D P P R P
* 
     Mouse - - - - - - - - - M E K P R G V R C T N G F S E R E L P R P
    Chicken - - - - - - - - - - - - M A A A R S C N G Y A R R E G P - P
    E.coli - - - - - - M P S L S K E A A L V H D A L V  - - - - - - - - 
Figure 4.14 Human GTPCH1 protein aligned with other orthologs from mouse, chicken, zebrafish and 
E.coli. Amino acid number is based on the human protein. GenBank accession number human P30793, mouse 
Q05915, chicken P50141 and E. coli P27511. * Indicates position of amino acid substitution E2G. Adapted 
from Pelletier et al. 2001 [21]. 
 - 161 -
Chapter 4                                                              A Novel GCH1 Mutation in a British Kindred                        
 
 
 
Subject  
& 
gender 
Age 
at 
eval
Age at 
sympt. 
onset 
Clinical 
Diagnosis 
L-Dopa 
Response 
H&Y 
Stage 
MMSE 
UPSIT score 
(percentile) 
GCH1 
DaT 
Path. mut.  
SCAN 
p.E2G 
21 
III:1 M 82 58 PD Y 3 27 A Y Norm 
(40th) 
31 
III:2 M 80 N/A Unaffected N/A N/A 27 N N N/A 
(71st) 
21         
(23rd) 
1 A 
III:3 M 78 75 Parkinsonism No Rx 1 30 N N/A 
2 N 
Y-low 
dose 
28         
(31st) 
1 A 
III:4 M 68 50 PD 2 29 Y Norm 
2 A 
Y-low 
dose 
26         
(24th) 
III:5 M 66 44 DRD N/A 28 N Y N/A 
Y-low 
dose 
37         
(40th) 
IV:1 F 26 6 DRD N/A 29 N Y N/A 
IV:2 F 59 N/A Unaffected N/A N/A N/A N/A N/A N N/A 
IV:3 F 55 N/A Unaffected N/A N/A N/A N/A N/A N N/A 
IV:4 M 44 N/A Unaffected N/A N/A N/A N/A N/A N N/A 
Table 4.1 Summary of the clinical, functional neuro-imaging, molecular genetic and pathological data 
on nine subjects from family 6. PD denotes Parkinson’s disease; DRD dopa responsive dystonia; N/A not 
done or not appropriate; MMSE mini mental state examination score; UPSIT University of Pennsylvania Smell 
Identification Test; DaTSCAN dopamine transporter imaging. Age and sex corrected percentile values for 
UPSIT scores are presented in brackets. 
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4.5 Discussion  
The results section of this chapter described the clinical characteristics of family 6 as well as 
functional neuro-imaging, molecular genetic and pathological data on affected and unaffected 
family members. A novel missense mutation within the GTP cyclohydrolase 1 gene coding 
sequence was identified in affected subjects only.  
 
4.5.1 Clinical studies 
There was a wide variation of phenotypes within this family, ranging from PD to DRD. Given 
the atypical nature of some of these phenotypes, it is not surprising that accurate diagnosis was 
challenging in several members of the family. I determined the clinical phenotypes before the 
results of functional neuro-imaging, molecular genetic and pathological studies were available. 
The clinical symptoms and signs observed in the proband subject III:1, and subject III:4, 
excluding the positive family history, fitted the UKPDS brain bank diagnostic criteria for 
definite PD (see appendix A). For both subjects their symptoms responded well to Levodopa 
therapy, and subject III:1 also had levodopa-induced dyskinesias. However in both cases their 
conditions were much more slowly progressive than would normally be expected in IPD. The 
reported rates of progression of PD vary greatly even amongst cohorts, but both pre-levodopa 
era studies, and more recent work, have shown similar results. The pre levodopa results 
showed that the proportion of subjects severely disabled (Hoehn and Yahr stage 4 or 5)  or 
dead at 5 years was 28%, with this figure rising to 61% at 5-9 years follow up and 83% at 10-
15 years [13]. More recently the proportion of subjects severely disabled (Hoehn and Yahr 
stage 4 or 5) or dead at 4 years was 22%, with this figure rising to 71% at 10 years follow up. 
Approximately 10% of subjects followed a more benign course  [621]. 
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Subject III:3 had very mild features of parkinsonism which were not disabling and did not 
require treatment, his clinical signs did not reach the UKPDS brain bank diagnostic criteria for 
definite PD. Subjects III:5 and IV:1 exhibited a much different phenotype to the other affected 
family members, with predominantly lower limb symptoms and signs of dystonia, with diurnal 
fluctuation, which responded well to Levodopa therapy and were slowly progressive. The 
clinical diagnosis in both of these subjects was DRD with no parkinsonian features evident. 
The major difference between the two was that the symptoms in subject IV:1 started at a much 
younger age, and were more severe. This could suggest genetic anticipation of an inherited 
mutation, as previously suggested [622]. However, there are a number of reports of a more 
severe phenotype when symptoms begin at an earlier age [623], [574], [565]. Whilst the onset 
of DRD in subject III:5 is much later than the typical childhood onset there are reports of 
subjects presenting as late as the sixth decade, with less severe symptoms [565].  
There are multiple affected members of this family who exhibit various features consistent 
with a movement disorder. Although there is too little clinical information available on 
affected subjects from previous generations, i.e. subjects II:1 and II:2, to make definitive 
conclusions, the reported phenotype of subject II:1, father of the proband, does appear to be 
similar to that of the proband and subject III:4. 
Whilst it was possible that two separate conditions may be inherited within this family, the 
working hypothesis was of a single AD inherited condition that provides the unifying 
diagnosis to explain all the observed phenotypes i.e. a single genetic variation with variable 
expression. Given the pattern of symptoms and signs, and negative clinical investigations such 
as cerebral MRI scans, there were only two realistic differential diagnoses to be considered. 
The first was fPD and the second was DRD.  This is discussed further below in section 4.5.3. 
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There was also another potentially important pattern  noted in the phenotypic presentation in 
this family, which is that the subjects with an older age of onset (III:1, III:3, III:4 and II:1) 
present with predominantly parkinsonian features, whilst the subjects with a younger age of 
onset (III:5 and IV:1) present with features typical for DRD. Assuming that the affected 
subjects in this family all have the same genetic variation, this suggests that either gene-
environment interactions are affecting the presenting phenotype at different ages or that the 
effect of the genetic variation causing the condition is mitigated by a second genetic variation, 
thus affecting the phenotype at different ages.  
 
4.5.1.1 Olfactory testing 
Olfactory dysfunction is found in 70-100% of PD patients [108], [109], [110] and is associated 
with neuronal loss and Lewy body deposition in the olfactory pathway [112]. Furthermore, 
olfactory dysfunction is markedly reduced in PD from the early stages (UPSIT mean scores of 
20-21) [113], [108], [114], [115]. Given that DRD is a result of dopamine deficiency without 
neuronal cell death [600], the UPSIT-40 data would be expected to be normal in patients with 
this condition. 
In my study, the mean UPSIT-40 score for the affected subjects was 26.6 (SD 6.6). In a recent 
study of olfaction in PD, the mean score in 18 British subjects with IPD was 17.1 and in 27 
age-matched controls it was 27.6 [118]. The individual subject scores were compared to the 
normative values and percentiles for age and gender [482]. The individual UPSIT score from 
this study were 21 for subject III:1 (Severe Microsmia, 40th percentile), 31 for subject III:2 
(Mild Microsmia, 71st percentile), 21 for subject III:3 (Severe Microsmia, 23rd percentile), 28 
for subject III:4 (Moderate Microsmia, 31st percentile), 26 for subject III:5 (Moderate 
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Microsmia, 24th percentile) and 37 for subject IV:1 (Normosmia, 40th percentile). Therefore, 
apart from the youngest subject IV:1 all the affected subjects had at least moderately reduced 
olfactory function, but there was no clear correlation of loss of smell to a particular phenotype 
within the family. Indeed, even the score for subject III:1, who was most severely affected by 
parkinsonian symptoms and had a symptom duration of 24 years, was not as low as that of  the 
average score of 17.1 from the previous study of IPD [118]. This data indicates that the 
olfactory pathway is only moderately affected by the underlying condition in this family, 
which is perhaps not surprising given that the symptoms in the affected members of this 
family have been so slowly progressive. However it does suggest that there may be some 
associated PD-type CNS pathology.     
 
4.5.2 Functional neuro-imaging 
DaTSCANs were performed in this study to provide further supportive evidence for the 
clinical diagnoses, particularly given the atypical phenotypic features in this family. Indeed the 
data from these scans supported the clinical diagnoses in most cases.  
The scans for subjects III:1 and III:3 are abnormal as would be expected for subjects with PD 
or parkinsonism [128], [129], [130]. The scans for subjects III:2, III:5 and IV:1 are normal, as 
would be expected for an unaffected subject and for subjects with DRD, in which dopa uptake, 
dopa decarboxylation and dopamine storage in the nigrostriatal dopaminergic terminals should 
be normal [603], [604], [605], [606].  
The DaTSCAN data for subject III:3, who had a three year history of slowly progressive 
parkinsonism, is more difficult to explain. His first scan was abnormal, as would be expected 
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for a subject with parkinsonian. However, the second scan performed 18 months later was 
normal.  
As outlined in the introduction, there is a category of subjects with  parkinsonism who have 
normal DaTSCANs, so called SWEDDs [137]. 11-15% of subjects with PD have been found 
to have normal nigrostriatal uptake of presynaptic ligands [132], [133], [134], [135], [136]. It 
has been proposed that some of  these patients with SWEDDs may have been misdiagnosed 
with PD, and may actually have an alternative diagnosis, such as essential tremor [137] or 
dystonic tremor [136].  
However, this would not explain why for subject III:3 his DaTSCAN had changed from being 
abnormal to normal. There are several possible explanations for this, first that there was a 
technical problem. However, this seems unlikely as both scans were performed using the same 
technique on the same scanner. Second, a change in medication or use of CNS stimulants can 
affect the scan. However there was no change in the subject’s medication and no reported use 
of medications such as CNS stimulants (for example amphetamines or sympathomimetics). 
Perhaps the most likely explanation may be test/rest variability and indeed DaTSCAN 
test/retest variability in healthy controls and PD has been reported as 7% [131]. The use of 
another form of functional neuro-imaging, which has traditionally been regarded as the gold 
standard for assessing the function of the dopaminergic nigrostriatal pathway, 18F-fluorodopa 
PET [624], may be able to clarify whether there is indeed any abnormality within the 
dopaminergic neurons in the basal ganglia of this subject.  
In summary, whilst the DaTSCANs in this family do in general correlate with clinical 
phenotype, what is really intriguing is that both abnormal and normal scans have been found 
in subjects carrying the same GCH1 mutation, as is discussed below.  
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4.5.3 Molecular genetic studies 
4.5.3.1 PD genes 
The coding sequence of the five genes for Mendelian PD for which there is strongest 
evidence: alpha-synuclein, Parkin, PINK1, DJ-1, and LRRK2 were screened for mutations. 
There were no novel or known mutations identified in the coding sequence of alpha-synuclein, 
Parkin, PINK1, DJ-1 or LRRK2. 
Given the phenotypes observed in this family the negative screening is perhaps not surprising, 
as apart from Parkin they differ markedly from the phenotypes associated with mutations in 
the other PD genes. The phenotypes associated with the AD genes alpha-synuclein and 
LRRK2 are very similar to that of IPD, although there is a relative paucity of tremor, younger 
onset, and longer disease course, reported with alpha-synuclein [242], [239], [288], [283], 
[289], [290], [285], [625].  
Of the recessive genes, Parkin-related PD is the most common, with homozygous mutations 
responsible for approximately half of patients with autosomal recessive fPD with disease onset 
before the age of 45 years [304]. The typical associated phenotype shows early onset of 
parkinsonism with slow disease progression, good levodopa response, and levodopa-induced 
dyskinesias. Dystonia at onset is also seen more frequently than in IPD and indeed the 
phenotypical spectrum overlaps with classical PD for late-onset cases, and with DRD [234], 
[235], [300], [236], [626]. Interestingly, pseudodominant inheritance has also been reported 
with Parkin-related PD [301], [627], [628], [629]. This is a description of an inheritance 
pattern where a parent and child are affected by a phenotype that is normally inherited in a 
recessive pattern. This inheritance pattern may occur when a phenotype, which is normally 
inherited in a recessive pattern, does not reduce reproductive fitness and the carrier rate is high 
[630], [631]. PD associated with PINK1 and DJ-1 mutations is much rarer than Parkin related 
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PD but with a similar phenotype to that of  typical Parkin PD [227], [320], [321], [342], [344], 
[345].  
Therefore of all the PD genes, a mutation within Parkin was most likely to explain the wide 
range of phenotypes seen within this family. Although no mutations were identified in the 
coding sequences, it was important to test gene dosage especially for the Parkin gene. This 
data is discussed below in section 4.5.3.2 
 
4.5.3.2 GCH1 
The novel heterozygous missense mutation in the first exon of GCH1 (c.A5G) identified in 
four affected family members is not listed as a known mutation 
(www.biopku.org/dbsearches/BIOMDB_Results.asp), or a polymorphism 
(www.ensembl.org/Homo_sapiens/geneseqview?db=core;gene=ENSG00000131979). It was 
also not detected in 300 UK control chromosomes. This novel GCH1 mutation is predicted to 
replace glutamic acid with glycine (p.E2G) in GTPCH1, a change predicted to alter function in 
the protein as one of the larger hydrophilic amino acids is replaced by a small hydrophobic 
one.  
The first exon of GCH1 is the area of the gene that mutations are most commonly found in 
association with DRD (see figure 4.2). The M1X and E2X mutations are of particular interest 
as they occur so close to the site of our novel mutation. The M1X mutation was identified in a 
36 year old female, and her asymptomatic mother, who had symptoms of gait difficulty and 
limb dystonia since the age of 8. At the age of 20 she began to complain of a postural tremor 
of her hands, her symptoms showed diurnal fluctuation and responded to Levodopa therapy. 
This subject was heterozygous for a base substitution (c.G3C) in the initiation codon, which 
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results in a frameshift and a small 46 amino acid peptide translation product [632]. The E2X 
mutation was identified in two individuals from a family (mother and daughter). They were 
heterozygous for a two base insertion (c.3insGG) which results in a frameshift and production 
of a truncated protein [574]. 
Our novel mutation does not cause a frameshift, but knowledge of the structure and functional 
domains of GTPCH1 may provide clues as to how the mutation could be pathogenic for DRD. 
GTPCH1 is a homodecamer assembled from five dimmers into a ring-like structure that has 
the appearance of two pentamers aligned face to face [633]. Only the GTPCH1 decamer has 
enzyme activity [634]. The C-terminal portion of GTPCH1, which is directly involved in 
catalysis, has evolved conservatively with 55% of the terminal 100 amino acids being identical 
in human and bacterial proteins [635], [636]. However, the N-terminal region of GTPCH1 
shows a high degree of species diversity, with primates having a nine amino acid N-terminal 
extension (see figure 4.14). This suggests that that the N-terminus may be involved in 
functions unrelated to catalysis, such as the binding of accessory proteins [637]. This region 
may also be involved in the interaction with the GTPCH1 feedback regulatory protein 
(GFRP),  by stabilizing the protein-protein complex [637].  It is interesting to note the large 
number of apparently pathogenic mutations identified in this region, indicting that any change 
in the amino acid composition of the N-terminal region could significantly effect the normal 
functioning of the protein.    
 
It has been proposed that most GCH1 mutations exert a dominant negative effect, with the 
mutant polypeptide interacting with the wild-type, to form dysfunctional GTPCH1 
heterodecamers. The activity of GTPCH1 has been shown to be reduced to less than 20% that 
of normal controls in phytohemagglutinin-stimulated lymphocytes [574] and biopterin 
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concentrations in the putamen of two autopsied subjects with DRD were also found to be 
reduced to 16% of that of age-matched control subjects [570]. More recent co-transfection 
experiments with wild-type and mutated GCH1 cDNA also supported this theory [638]. 
However, formation of heterodecamers was not demonstrated for two other DRD missense 
mutations where aberrant subunits were not able to interact with the wild-type subunits [639].  
Whilst these mutations could also exert a dominant-negative effect at the transcriptional level, 
the recent findings of deletions of GCH1 suggests that at least in these cases 
haploinsufficiency of GTPCH1 may be the molecular cause of signs and symptoms of DRD 
[640]. 
Further evidence in support of a pathogenic role of the novel GCH1 mutation identified in the 
current study is provided by the results of the MLPA screening which did not reveal any copy 
number variation in GCH, or in any of the PD genes alpha-synuclein, Parkin, PINK1, DJ-1 
and LRRK2. MLPA is a recently developed technique which has been shown to be as reliable 
and more time- and cost-efficient in detecting copy number variation as quantitative real-time 
PCR [640], [641].  
 
4.5.4 DRD or PD or overlap? 
The identification of a novel missense mutation in GCH1 in four affected subjects suggests 
that the AD inherited movement disorder within this family is indeed a variant of DRD. 
Subjects III:5 and IV:1 displayed a typical DRD phenotype, although an age of onset of 44 for 
subject III:5 was substantially later than the usual childhood or adolescent presentation. 
However, symptoms in subjects III:1 and III:3 started later and they displayed a predominantly 
parkinsonian variant of DRD.  
 - 171 -
Chapter 4                                                              A Novel GCH1 Mutation in a British Kindred                        
Whilst DRD typically manifests as lower limb dystonia with diurnal variation the spectrum of 
symptoms can be broad, even occurring as a predominantly parkinsonian condition [559], 
[560], [623], [558], [561], [642], [562], [563], [564], [557], [643], [16]. Indeed, with a later 
age of onset subjects appear more likely to present with parkinsonian features rather than 
dystonia and diurnal fluctuation [626], [644], [575], [645]. Furthermore, marked intra-familial 
variability of the clinical manifestations between affected members with the same mutation 
has been reported previously [566], [567].  
There are several previous reports in which affected subjects within the same family have 
typical and atypical presentations of DRD, although in most instances molecular genetic 
analyses were not performed. Nygaard et al. described a family in which the proband had 
typical DRD whilst three members over the age of 50 developed a parkinsonian syndrome 
without dystonia. 18F-fluorodopa PET scans performed on the proband and two of the 
subjects with parkinsonian presentations were normal [646]. The investigators proposed that 
the parkinsonism was an expression of the disease and that their findings did not support 
consideration of the DRD gene as a risk factor for PD [646]. Harwood et al. reported a family 
in which some members presented in childhood with a typical dystonia whilst others presented 
as adults with a parkinsonian syndrome [647]. Most recently Grimes et al. reported that a 
female member of large DRD family, with a heterozygous 18 base pair deletion in exon 1 of 
GCH1, presented with parkinsonism in the absence of dystonia at the age of 56 [644]. 
Interestingly, the proband case (III:1) in our study displayed treatment-induced dyskinesias, 
but a low incidence of dyskinesias and the ‘on-off phenomena’ associated with long-term 
Levodopa therapy in PD, have previously been reported in DRD [16]. Indeed this difference 
has been considered to distinguish DRD from fPD, particularly associated with Parkin 
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mutations. The reason for this difference is unknown, but may be due to differences in nerve 
terminal integrity and/or postsynaptic receptor changes. However, there are now several 
reports in which subjects with GCH1 mutations have been shown to display levodopa-induced 
dyskinesias [626], [644], [648], [649], [650]. 
This raises the question as to whether GCH1 mutations may in fact be the cause of some cases 
of fPD and to my knowledge there is only one study in which subjects with PD were screened 
for GCH1 mutations. This study was of 87 Danish subjects with early onset PD, including 
both familial and sporadic disease, no GCH1 mutations were identified [651].  
 
4.5.4.1 Phenocopy or more than one disease? 
The novel GCH1 mutation is not carried by subject III:3 and would not therefore explain his 
symptoms. The simplest and perhaps most likely explanation is that he is a phenocopy and has 
mild form of sporadic PD. Phenocopies in GCH1 mutation positive families have previously 
been reported [644], [652]. Furthermore, this subject had the oldest age of onset of symptoms 
(75) and from previous studies of large families it has been suggested that the  later the disease 
onset the less likely that the individual is truly affected by DRD [644].  
The other more complex explanation is that there is in fact more than one inherited movement 
disorder within family 6. The father of the proband (II:1) was reported to have displayed 
symptoms of a condition which started in his 50’s and appeared to be very similar to the 
condition displayed by subjects III:1 and III:4. Therefore one could hypothesize that he may 
have carried the novel GCH1 mutation which he passed on to his offspring. A maternal aunt of 
the proband (II:2) was reported to have had PD which was diagnosed in her 70’s and indeed 
her symptoms appeared more typical of IPD. Her grandchildren, subjects IV:2-IV:4 who are 
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unaffected, do not carry the GCH1 mutation. Therefore one could speculate that subject II:2 
carried a separate mutation for late onset PD which has as yet not been identified from the 
molecular genetic screening performed on family 6. If this mutation shows incomplete 
penetrance, as has been reported in other forms of AD PD [283], [287], [281], [279], [248], 
[653], it may also have been carried by subject II:4 who passed it onto her offspring. Therefore 
subject III:3 may carry this unknown mutation which has resulted in him developing late onset 
PD. Furthermore, whilst the predominantly parkinsonian variant of DRD displayed by subjects 
III:1 and III:4 could be caused by the novel GCH1 mutation alone, it is possible that they also 
carry this unknown mutation and it is the combination of the two mutations which has resulted 
in their atypical phenotypes. How this interaction would occur to alter the clinical expression 
of the DRD from a dystonia to parkinsonism is unknown. Following this theory through, 
subjects III:5 and IV:1, who displayed the more typical DRD phenotype, may have inherited 
the novel GCH1 mutation alone. The only way to prove this theory would be to identify 
another AD inherited gene mutation within this family.  
 
4.5.4.2 Functional neuro-imaging in DRD 
The theory of two separate AD inherited movement disorders within this family is based on a 
number of assumptions, most notably reduced penetrance of an unknown mutation. The 
abnormal functional neuro-imaging data obtained on subjects III:1 and III:4 might provide 
support for the coexistence of DRD and PD within these two individuals. Indeed, this has been 
investigated in previous studies. Hjermind et al. presented a case report concerning a 38 year 
old subject with a combination of dystonic and parkinsonian signs which began at the age of 
28. He was found to have a point mutation in exon 5 of GCH1, an abnormal DAT scan and 
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treatment induced dyskinesias. Although the subject did not carry a Parkin mutation, the 
authors concluded that he may either have a variant of DRD or alternatively DRD and early 
onset PD [650]. Postuma et al. reported the case of a subject with onset of DRD aged 15 years, 
who presented with a prominent isolated leg tremor and carried a point mutation in exon 5 of 
GCH1. Although her 18F-fluorodopa PET scan showed that uptake on both sides was within 
normal limits, there was some asymmetry noted. However, she was also found to have 
polymorphisms of the Parkin gene in a compound heterozygous state. The authors speculated 
that either of the Parkin polymorphisms could change its in vivo activity and alter the clinical 
expression of her DRD  [654]. 
Kikuchi et al. reported a 54 year old subject with adult onset DRD and parkinsonism (aged 39) 
who carried a point mutation in exon 5 of GCH1, with no mutations detected in the coding 
region of Parkin. Motor fluctuations were noted several years after starting treatment. He was 
also found to have an abnormal 18F-fluorodopa PET scan [648]. Furthermore, Turjanski et al. 
reported abnormal 18F-fluorodopa PET scans on six subjects with adult-onset dystonia-
parkinsonism, which appeared similar to those of 12 age matched subjects with PD [571], 
although these subjects were not analysed genetically.  
Therefore whilst functional neuro-imaging in DRD has previously been reported to be normal 
[603], [604], [605], [606], the data from the last two studies suggests that the DaTSCAN 
abnormalities observed in subjects III:1 and III:4 with atypical DRD could be due to DRD 
alone. 
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4.5.4.3 Variable expression of GCH1 
If the phenotypes in this family are indeed due to the novel GCH1 mutations alone a 
mechanism to explain the variable expression of this mutation is required, particularly the 
association of parkinsonian features with a later age of onset. One proposed mechanism is that 
age-dependent differences in the function of the basal ganglia-thalamocortical motor loop may 
influence the development of parkinsonian features in adult-onset DRD [655]. Another  
possible explanation is that chronically decreased GCH-I activity may result in impaired 
synaptic function in the nigrostriatal pathways [570], [569], [563]. It has also been proposed 
that dopamine transporters are decreased in the putamen, possibly reflecting a regression of 
nerve terminals derived from nigral dopaminergic neurons [570], [569].  
 
4.5.5 Pathological studies 
Study of the ENS in subjects III:1 and III:4 did not reveal the presence of any pathology 
suggestive of PD. Neuronal loss (with LBs and LNs) has previously been identified in the 
ENS in subjects with PD, although no lesions were found to occur in the ENS in the absence 
of immunoreactive inclusions in the lower brainstem [607], [608], [609], [610], [611], [612], 
[613], [614], [615].  
The gastrointestinal specimens investigated in this study were from affected subjects III:1 and 
III:4 who both exhibited the PD phenotype. These findings do not support the hypothesis that 
the movement disorder exhibited by these two subjects is associated with a typical PD-type 
pathology. Therefore given that both of these subjects carry a GCH1 mutation this would 
appear to suggest that their phenotype is caused by a parkinsonian-type variation of DRD. 
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There are a number of possible factors which must be considered which discussing this data. 
Firstly, there was only limited tissue available for study from one section of the 
gastrointestinal tract and had more tissue been available underlying PD-type pathology may 
have been identified. Furthermore, due to sectioning of the tissue PD-type pathology in parts 
of the specimen which were not examined may have been missed. Indeed, in previous studies 
the majority of pathological changes have been observed in the cellular processes and cell 
bodies of a specific neuronal type, the VIPergic neuron [610], [616]. Secondly, fPD can be 
associated with various types of pathology. Indeed in LRRK2-associated PD pathology ranging 
from neurofibrillary tangles to pure nigral degeneration without LBs has been reported [27], 
[271], [279], [656], [284], [657], [658], [659], [625]. Therefore, a pathological process 
specific to the basal ganglia, for example without the presence of LBs, might not be evident on 
examination of the ENS only. Finally, because there are relatively few reports on the 
pathological findings in the ENS in subjects with PD, it is not known how common even 
typical PD-type pathology is in the ENS. Hence, the chance of identifying the presence of PD-
type pathology in an individual subject, or even two subjects, may in fact be very low.  
Therefore, despite study of the gastrointestinal tissue on two affected members of this family it 
is not possible to make definitive conclusions as to the underlying pathological process in this 
family, and to be certain of this post mortem brain tissue is required.  
 
4.5.6 Future work 
There are clinical, functional neuro-imaging and molecular genetic studies that can be done to 
further our knowledge on both this unique family and the implications of this novel GCH1 
mutation for our understanding of DRD. 
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The first is to assess the proband subject (III:1) off his anti-parkinsonian therapy to further 
clarify the phenotypes associated with the novel GCH1 mutation. If other family members 
become affected, assessment of their phenotype would also help with this clarification. The 
second is to screen other unaffected family members for the GCH1 mutation to allow an 
estimate of the penetrance of this mutation. This information will be crucial for future genetic 
counselling of family members. The third is to clarify the apparently contradictory functional 
neuro-imaging results for subject III:3. As discussed in section 4.5.2, this could be done with 
the use of a 18F-fluorodopa PET scan. The fourth is to screen for the novel GCH1 mutation in 
the UK fPD cohort which I have recruited (see chapter 3). Given the phenotype of late onset 
PD in this family, it is important to determine if the novel GCH1 mutation may also be 
important in fPD. The fifth is to determine whether the functional effects of this novel 
mutation are similar to those previously reported in DRD. Bonafe et al. have shown that in 
cytokine-stimulated skin fibroblasts intracellular neopterin and biopterin concentrations were 
low and GTPCH activity was reduced. They concluded that this technique was helpful in 
diagnosing subjects with DRD [660]. In collaboration with  Professor Malcolm Taylor, in the 
Institute for Cancer Studies, University of Birmingham, I have generated fibroblast cultures 
for subjects III:1, III:2, III:4 and III:5, which will allow us to repeat this work in these four 
family members with varying phenotypes. The sixth is to screen for any novel gene mutations 
associated with PD, which may be identified in the future by other investigators, in the five 
affected members of the family. This would allow further clarification as to whether the wide 
range of phenotypes could be due to the subjects carrying mutations in more than one gene 
associated with parkinsonism.  
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4.6 Conclusions 
The aims of this chapter outlined in section 4.2 have largely been met.  The clinical diagnosis 
in affected subjects from this unique family has proven challenging for over 20 years because 
of the atypical nature of the symptoms and signs. However, the identification of a novel 
heterozygote GCH1 missense mutation, in affected subjects, has at last provided an 
explanation for the diverse clinical presentations observed in this family, and will allow more 
accurate genetic counseling. 
The association of this GCH1 mutation with such a wide range of phenotypes also furthers our 
understanding of the way late onset DRD can present. Furthermore, the association of this 
novel GCH1 mutation with a late onset parkinsonian phenotype and abnormal functional 
neuro-imaging, suggests a potential role for the GCH1 gene in PD, which requires further 
investigation.  
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5 Comprehensive Molecular Genetic Analysis of the LRRK2 
Gene in a UK Familial Parkinson’s Disease Cohort 
 
5.1 Introduction 
In chapter 3 demographic and clinical data was presented and discussed on 46 UK families in 
which there were three or more members affected by PD, where segregation in each family 
was consistent with an autosomal dominant (AD) pattern. In this part of the study I screened 
the proband case from each of these families for known and novel coding sequence variations 
in all 51 exons of LRRK2. 
The clinical phenotype associated with LRRK2 mutations in subjects with both familial and 
sporadic PD, in several different populations, closely resembles that of idiopathic PD (IPD) 
[288], [283], [289], [290], [285], [625]. Indeed LRRK2 has emerged as potentially the most 
relevant of the PD genes identified to date for our understanding of IPD.  
 
5.1.1 LRRK2 Background 
As has been outlined in the introduction, LRRK2 is a large gene, located  on chromosome 12 
(12p11.2-q13.1) which contains 51 exons and encodes a protein of 2527 amino acids 
(286kDa) [25], [27]. Sequence analysis indicates that the LRRK2 protein contains several 
discrete domains (see figure 5.1). LRRK2 is predominantly a cytoplasmic protein and is 
associated with cellular membrane structures such as mitochondria, Golgi apparatus, 
endoplasmic reticulum and cytoskeleton [429], [428], [661], [656], [662], [312]. At the protein 
level, LRRK2 expression has been shown in brain and peripheral organs [656], [663]. 
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The presence of the protein-protein interaction domains (ankyrin, LRR and WD40) suggests 
that LRRK2, in addition to protein kinase and GTPase activities, may also serve as a scaffold 
to a multiprotein complex. The physiological function of LRRK2 is not yet established. 
However, there is evidence from in vitro as well as in vivo over-expression and mutagenesis 
experiments to suggest that the protein is likely to regulate neurite maintenance and neuronal 
survival. MacLeod et al. used a rodent model in which they generated a mouse/human 
chimera. Over-expression of PD-associated mutant LRRK2 alleles (G2019S and I2020T) in the 
kinase domain led to reduced neurite complexity, the formation of tau-positive inclusions, 
lysosomal abnormalities and apoptotic cell death [664].  
. 
5.1.2 Molecular genetic studies of LRRK2-related PD 
The past three years has seen an explosion in the number of studies performed on LRRK2 on a 
number of different populations of PD patients throughout the world. Five missense mutations, 
which are believed to be definitely pathogenic, have been identified: R1441C, R1441G, 
Y1669C, G2019S and I2020T [18], [278]. However, a number of other variations have been 
identified, the significance of which are still being evaluated. Overall, LRRK2 mutations 
appear to account for approximately 10% of familial PD (fPD) cases with AD inheritance 
[279], [280], [665], [26], [293], [666]. 
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One of these LRRK2 mutations, G2019S (c.6055G>A) in exon 41, appears to be particularly 
important as it alone accounts for up 5% to 6% of familial and 1% to 2% of sporadic PD (sPD) 
cases [282], [283], [284], [285], [281], [282], [667]. Furthermore, this mutation is found in 
sPD at even higher frequencies in certain populations, including Askenazi Jewish (18%) [668] 
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Figure 5.1 Schematic representation of LRRK2 protein domain structure and LRRK2 coding sequence 
variants identified to date. Panel A= Schematic representation of LRRK2 exons 1-51 with amino acid 
variants described to date. Putatively pathogenic amino acid substitutions are shown above, with those 
segregating with disease in red. Variants believed to be polymorphisms are shown below. Corresponding 
exon numbers are shown in black. Panel B= schematic representation of LRRK2 protein structure from 
residue 1-2527, with estimated domain boundaries indicated by residue numbers beneath. Abbreviations: 
ANK=ankyrin repeat region; COR=C terminal of Ras; Ex=exon; LRR=leucine-rich repeat domain; Roc=Ras 
of complex (GTPase); WD40= domain of 40-60 amino acids which terminate in a Trp-Asp (W-D) dipeptide. 
Adapted from Mata et al. 2006 and Nichols et al. 2007 [18], [26].  
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and North African Arab subjects (41%) [287]. The discovery of the G2019S mutation in 
apparently sPD raises the possibility of a link between fPD and sPD.   
It had been proposed that subjects of European origin, Ashkenazi Jews and North African 
Arabs carrying the G2019S mutation all inherited the mutation from a single common Middle 
Eastern founder [669], [670], [281], [671], [672]. However Zabetian et al. observed two 
distinct haplotypes; haplotype 1 was present in families of Ashkenazi Jewish and European 
ancestry, whereas haplotype 2 occurred in European American families. They estimated that 
the families with haplotype 1 shared a common ancestor 2,250 years ago, whereas those with 
haplotype 2 appeared to share a more recent founder [673]. Two Japanese patients 
heterozygous for the G2019S mutation shared a haplotype distinct from that observed in 
Europeans, thus suggesting that G2019S originated from separate founders in Europe and 
Japan [674], [673].  
 
5.1.3 Clinical studies LRRK2-related PD 
The clinical phenotype of most LRRK2 mutation positive PD patients appears 
indistinguishable from that of typical IPD, including a good response to Levodopa [27], [288], 
[283], [289], [290], [285], [625]. A recent large study reported that the age of onset of LRRK2-
related PD is approximately 60 years [675], although a variable age at onset for subjects 
carrying the G2019S mutation, ranging from 28 to 86 years, has been reported [287], [282], 
[676], [677],  [678], [290], [679], [279], [292], [286], [284], [281], [680], [293], [675]. It is 
interesting that there does not appear to be a gene dose effect associated with the G2019S 
mutation. This has been demonstrated by the finding that subjects with homozygous G2019S 
mutations have an age of onset (30-82 years) almost identical to those of heterozygous 
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G2019S mutation carriers [669], [681]. Furthermore, Ishihara et al. described the phenotypes 
of 26 PD subjects with homozygous G2019S mutations, from an international consortium of 
studies. Their phenotypes were indistinguishable from subjects with heterozygous G2019S 
mutations [681].  
As has been outlined in the introduction, functional imaging with SPECT ligands for the 
dopamine transporter ([123I]FP-CIT, [123I]β-CIT, [123I]IPT, and [99mTc]Trodat) provides a 
marker for presymptomatic neuronal degeneration, and striatal uptake correlates with disease 
severity, in particular bradykinesia and rigidity [126]. There have been some functional 
imaging studies on subjects with LRRK2 mutations, mostly in subjects with fPD, but also 
some in sporadic disease. In general the pattern of nigrostriatal dopaminergic dysfunction seen 
in heterozygous carriers of LRRK2 mutations was similar to that observed in IPD [682], [683], 
[279], [684], [290], [685], [686]. We await functional imaging studies on subjects who are 
homozygous carriers of LRRK2 mutations. 
 
5.1.4 Comprehensive screening for LRRK2 mutations  
Despite the intense research into LRRK2-PD over the last 3 years there are relatively few 
comprehensive screens of the whole coding region of the gene. This is understandable because 
of the large size of the gene, and the complexity and cost involved of screening all 51 exons. 
Therefore most studies have focused on testing for mutations within the known ‘hot-spot’ 
exons, such as exon 41, or even simply looking for known pathogenic mutations. Therefore 
the frequency of LRRK2 mutations may have been underestimated and other potentially 
important variations missed.  
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Including one of the original studies in which LRRK2 was identified as the PARK8 gene, to 
date there are only twelve studies that have performed a comprehensive analysis of the whole 
coding region of the LRRK2 gene in large cohorts of subjects with PD [27], [292], [279], 
[293], [294], [280], [26], [665], [687], [666], [688], [689]. These studies had cohort sizes 
ranging from 23 to 272 subjects. In the most part these subjects had been recruited from 
tertiary referral centres. In another study analysis was limited to 29 exons [690]. In four other 
studies in which a comprehensive analysis of the coding region of the LRRK2 gene was 
carried out, this was only performed on small numbers of families, ranging from 1 to 15 [283], 
[290], [281], [659].  
The overall findings from these studies were that pathogenic LRRK2 mutations were detected 
in 5-12% of subjects where segregation of PD in their families was consistent with an AD 
pattern, the associated disease phenotypes appeared similar to IPD, and the mutations with 
unequivocal disease segregation were clustered in the C-terminal half of the protein [27], 
[292], [279], [293], [280], [26], [665], [687], [666], [688]. 
 
5.1.5 Functional effects of the pathogenic LRRK2 mutations 
There has now been some work performed on the five mutations which are believed to be 
pathogenic on the basis of co-segregation data: R1441C, R1441G, Y1669C, G2019S and 
I2020T [18], [278]. [278]. In vitro expression of several mutant LRRK2 proteins (R1441C, 
Y1669C, G2019S and I2020T) has shown to cause toxicity in cultured cells [661], [457], 
[691], [664], [312]. Biochemical studies on cultured cells transfected to express LRRK2 have 
demonstrated a modest (0.5- to 3-fold) but consistent increase in kinase activity for the 
G2019S mutation [429], [661], [691], [692]. The effect of the other LRRK2 mutations on 
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kinase activity is more controversial. The functional effects of LRRK2 mutations identified in 
this thesis are covered in more detail in chapter 7.  
 
5.2 Aims of the chapter 
The first aim of the work in this chapter was to screen all 51 exons of LRRK2 for known and 
novel mutations in proband subjects from 46 UK families with three or more affected 
members, where segregation of PD in the family was consistent with an AD pattern.  
The second aim of this chapter was to screen for any novel potentially pathogenic variations 
detected in the coding sequence of LRRK2 in other affected and unaffected members of the 
relevant proband’s family, and within cohorts of subjects with sPD and controls. This was to 
determine whether any novel variations segregate with the disease and to assess their possible 
role in sPD.  
 
5.3 Subjects and methods 
5.3.1 Subjects 
The first part of this chapter involved the study of subjects with familial PD (fPD) from 
around the UK. I recruited a total of 46 proband cases from families where segregation of PD 
was consistent with an autosomal dominant pattern, with three or more PD cases in at least 
two consecutive generations, between April 2005 and March 2008, as covered in section 2.1.1. 
In addition, from these 46 families there were seven other members affected by PD and 16 
unaffected family members who I also recruited to the study.  
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I assessed olfactory function in all subjects by use of the University of Pennsylvania Smell 
Identification Test (UPSIT-40) (Sensonics, Haddon Heights, NJ). Olfaction was categorised as 
normal or pathologic according to normative data in relation to gender and age [482], [483]. 
The second part of this chapter involved the screening of other cohorts of familial and 
sporadic PD for novel LRRK2 variations I had detected. The following cohorts of PD patients 
and controls were used:  (i) PD GEN cohort of PD patients (see section 3.5); (ii) NDD cohort 
of PD patients (see section 3.5); (iii) PINE cohort of PD patients (see section 3.5);  (iv) Queen 
Square PD patient and control collection (see appendix B)  (iv) PD GEN control cohort (see 
appendix B); (v) PINE cohort of controls (see appendix B); (vi) NDD cohort of controls (see 
appendix B); (vii) Birmingham MND control collection (see appendix B). 
 
5.3.2 Methods 
I screened all 51 exons of LRRK2 by PCR and sequencing for known and novel mutations in 
the 46 proband subjects. In addition, where pathogenic mutations or novel coding sequence 
variations were identified in proband subjects, and other affected or unaffected family 
members had been recruited to the study, I also screened for these specific variations by PCR 
and sequencing of the relevant exon. Subsequently, I designed specific assays to screen for 
novel LRRK2 coding sequence variations detected in this study in cohorts of patients with 
sporadic and familial PD, and controls.  
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5.3.2.1 DNA extraction 
I extracted DNA from venous blood as described in section 2.3. DNA was also extracted from 
flash frozen brain tissue by Cathy Woodward, according to standard protocols, in the 
laboratory of a collaborator Professor Nicholas Wood, Institute of Neurology, London.   
 
5.3.2.2 PCR and sequencing 
I studied the whole coding sequence and exon-intron boundaries of the LRRK2 gene by PCR 
using primers and PCR temperatures as described in previous studies  [283], [280]. Primers 
and reaction conditions are detailed in appendix C, each PCR was optimized as described in 
section 2.4.  
In addition, I designed specific primers for screening for novel LRRK2 variations detected 
within exons 42 and 49 by using the Primer3 program 
(http://fokker.wimit.edu/primer3/input.htm). Primers selected and reaction conditions are 
detailed in appendix C. Each PCR was optimized as described in section 2.4. 
I performed all sequencing using the dideoxy DNA sequencing method as described in section 
2.7. The consequences of mutations on the amino acid sequence were predicted according to 
LRRK2 cDNA sequence deposited in Genbank (accession number AY792511). The effects on 
protein structure and function were predicted using the Protein Sequence Analysis Launcher 
(ProSAL)- (http://xray.bmc.uu.se/subnet/prosal.html), the Oriel Gene Mining Tools- 
(http://bioinfo.itb.cnr.it/oriel/spilce-view.html) and the Exonic splicing enhancers finder 
(ESEfinder)- (http://rulai.cshl.edu/tools/ESE2).  
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5.3.2.3 Restriction fragment length polymorphism (RFLP) analysis 
I used RFLP, as described in sections 2.6, to screen for the G2019S mutation within exon 41 
of LRRK2, in the Birmingham PD study and PINE study patient and control collections. The 
PCR primers selected and reaction conditions can be found in appendix C, the PCR was 
optimised as described in section 2.4. 
 
5.3.2.4 Agarose gel electrophoresis 
I used gel electrophoresis with a 3% high resolution RESponseTM Research agarose 
(Geneflow) gel, as described in section 2.5.1, to screen for the novel LRRK2 variation in exon 
42, identified in this study, in the NDD cohort of PD patients and controls, the PINE cohort of 
PD patients and controls, the Queen Square PD patient and control collection and the 
Birmingham MND control collection. The PCR primers selected and reaction conditions are 
detailed in appendix C, the PCR was optimised as described in section 2.4. 
 
5.3.2.5 Denaturing High Performance Liquid Chromatography (DHPLC) 
I used DHPLC, as described in sections 2.9 and 6.3.2.3, to screen for LRRK2 variations in six 
exons (31, 32, 38, 40, 41 and 42) in the PD GEN patient and control collections. This was 
performed using the Transgenomic WAVE system (Transgenomic Ltd).  
 
5.3.2.6 PCR fragment analysis 
I used PCR fragment analysis, as described in section 2.8, to screen for the novel LRRK2 
variation in exon 49, identified in this study, in the PD GEN cohort of PD patients and 
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controls, the NDD cohort of PD patients and controls and the PINE cohort of PD patients and 
controls.  
 
5.3.2.7 Functional neuro-imaging 
To evaluate basal ganglia function the proband subject from family 12 underwent a  dopamine 
transporter SPECT scan using [123I]-FP-CIT SPECT (DaTSCAN, Amersham Health) at 
Sandwell and West Birmingham Hospital NHS Trust. This scan was reviewed by a consultant 
radiologist, Dr Alp Notghi, Department of Radiology, Sandwell and West Birmingham 
Hospital NHS Trust, experienced in the interpretation of these images, who was blinded to the 
demographic and clinical data on this subject.  
 
5.3.2.8 Statistical analysis 
I performed statistical analysis using the SPSS for Windows release 15.0 (SPSS Inc, Chicago, 
Ill., USA). Observed genotypes were compared with the Fisher’s exact test (two-tailed) and 
interpreted as significant if the distribution differed by p<0.05. However, as multiple 
hypothesis testing was performed on the subject and control data, the Bonferroni correction (or 
adjustment) for multiple comparisons was used, to safeguard against these multiple tests of 
statistical significance falsely giving the appearance of significance. The correction was 
calculated using the website: (http://www.quantitativeskills.com/sisa/calculations/bonfer.htm), 
giving an adjusted p value of <0.002. Power calculations were made using a program 
developed by Heather Cordell in Microsoft Excel [693], [694], and with the advice of a 
statistician, Dr Sayeed Haque, Department of Psychiatry, University of Birmingham. 
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Where control data on LRRK2 variations was not available from my study, the recently 
published control data from a North American cohort of 275 unrelated neurologically normal 
individuals was used [666]. This is stated in the text and the demographics of this cohort can 
be found in appendix E. 
 
5.4 Results  
5.4.1 Comprehensive screening of LRRK2 in familial PD 
5.4.1.1 Genetic studies of 46 proband cases 
By using sequence analysis, I identified 61 LRRK2 sequence variations in this study, 15 of 
which had not previously been reported. These 61 variations are all listed, with frequencies, in 
tables 5.1-5.4.  
Of the LRRK2 variations identified, 25 were in protein coding regions. Sixteen of these coding 
sequence variations are predicated to lead to non synonymous amino acid substitutions (see 
table 5.1). Three of these heterozygous variations which had not previously been described 
are: (i) c.4364delAT in exon 31 which results in a substitution of glycine for aspartic acid at 
position 1455 (p.D1455G); (ii) c.6187delCTCTA (p.L2063STOP) in exon 42; and (iii) 
c.7187insGT (p.T2397STOP) in exon 49. These three variations were identified in one 
proband case each, from families 48, 12 and 38 respectively. All three variations cause a shift 
in the reading frame and are predicted to lead to the introduction of a premature termination 
codon, with production of a truncated protein. The chromatograms for these changes are 
shown below in figure 5.2. Cross species alignment of D1455, L2063 and T2397 reveals that 
these regions are generally conserved (see figure 5.4). 
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Of the previously described LRRK2 mutations for which there is data to suggest pathogenicity, 
including segregation with disease, three probands were found to be heterozygous carriers of 
the c.6055G>A (G2019S) mutation in exon 41 (families 10, 32 and 33). In addition, one 
proband was found to be a heterozygous carrier of the c.4321C>T (R1441C) mutation in exon 
31 (family 20). The chromatograms for these changes are shown below in figure 5.3. 
Of the previously reported putatively pathogenic LRRK2 mutations, for which disease 
segregation data is not available, one proband was found to be a heterozygous carrier of the 
c.3683G>C (S1228T) mutation in exon 27 (family 1) and one proband was found to be a 
heterozygous carrier of the c.5606T>C (M1869T) mutation in exon 38 (family 3). 
Nine of the coding sequence variations were synonymous, of which one heterozygous 
variation was novel: c.5412A>G (p.G1804G) in exon 37, listed below in table 5.2. This novel 
variation and was identified in one proband case only. 
The remaining 36 LRRK2 variations identified were non-coding (intronic) variations, of which 
13 have not previously been described, these changes are listed below in tables 5.3 and 5.4. 
There were 23 LRRK2 variations detected with a minor allele frequency (MAF) of 3% or 
higher, for which control data was available. The genotype frequencies did not deviate from 
those predicted by Hardy-Weinberg equilibrium (HWE). The genotype and allelic frequency 
of these variations was tested against control data for evidence of association with disease. 
Control data was available from my study for the LRRK2 variation c.4624C>T, one of the 
coding sequence variations which leads to a non synonymous amino acid substitution (control 
data contained in work outlined in chapter 6). The remaining control data was taken from the 
recently published study by Paisan-Ruiz et al. [666]. A similar genotype and allelic frequency 
was observed in patients and controls for all of these variations, and statistical analysis failed 
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to provide evidence of an association with disease for any of the variations (see tables E.2-
E.4). However, this was not designed as an association study and the analysis must be 
interpreted with caution given the relatively small number of cases used, and the low minor 
allele frequency for the majority of variations investigated. For one of the more common 
variations, with a minor allele frequency of 0.4, this study had 73% power to detect a 
difference with an odds ratio of 1.8. For one of the rarer variations, with a minor allele 
frequency of 0.08, this study only had 29% power to detect a difference with an odds ratio of 
1.8.   
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Figure 5.2 Mutant and wild-type chromatograms for three novel LRRK2 variations 
identified in this study. Panels Ai and Aii- mutant and wild-type chromatograms for the 
c.4364delAT (D1355G) mutation in exon 31. Panels Bi and Bii- mutant and wild-type 
chromatograms for the c.6187delCTCTA (L2063STOP) mutation in exon 42. Panels Ci and 
Cii- mutant and wild-type chromatograms for the c.7187insGT (T2397STOP) mutation in 
exon 49. Arrows indicate position of nucleotide variations. 
Ci 
Bii 
Cii 
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Figure 5.3 Mutant and wild-type chromatograms for pathogenic LRRK2 
mutations. Panels Ai and Aii- mutant and wild-type chromatograms for the 
c.6055G>A (G2019S) mutation in exon 41. Panels Bi and Bii- mutant and wild-type 
chromatograms for the c.4321C>T (R1441C) mutation in exon 31. Arrows indicate 
position of nucleotide variations. 
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 hs G T H L D V S D E K .  F G L L L Y D I L T .  L R E V M V K E N K  
mm G T H L D V S D E K .  F G L L L H D I W T .  L K E V M V K L N K  
 rn G T H L D V S D E K .  F G L L L H D I W T .  L K E V M V K I N K  
 gg G T H L D V S D E K .  F G L H Q F K K N S .  - - - - - - - - - -  
 tn G T H T D V S N E L .  F G L L L Y D L L T .  I R - - - - R D S G  
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Figure 5.4 Schematic representation of LRRK2 protein domain structure, three novel LRRK2 coding sequence 
variants identified in this study, and the cross species protein alignment of these variants. Panel A= Schematic 
representation of LRRK2 exons 1-51 with three novel amino acid variants described in this study. Corresponding exon 
numbers are shown in black. Panel B= Schematic representation of LRRK2 protein structure from residue 1-2527. 
Abbreviations: ANK=ankyrin repeat region; COR=C terminal of Ras; Ex=exon; LRR=leucine-rich repeat domain; 
Roc=Ras of complex (GTPase); WD40= domain of 40-60 amino acids which terminate in a Trp-Asp (W-D) dipeptide. 
Panel C= Cross species alignment of LRRK2. Human (Homo sapiens, hs) LRRK2 protein AAV63975.1 aligned with 
other orthologs from Mouse (Mus musculus, mm) NP_080006; Rat (Rattus norvegicus, rn) XP_235581; Chicken (Gallus 
gallus, gg) XP_425418.1; and Tetraodon (Tetraodon nigrovirdis, tn) CAG05593.1. * Represents amino acid of interest 
mutated in these three novel variants. X Represents conserved amino acid across species. Adapted from Zimprich et al. 
2004, Mata et al. 2006 and Nichols et al. 2007 [27], [18], [26].  
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Nucleotide change 
LRRK2 
exon 
Genbank 
reference 
number 
Predicted 
protein 
change 
Number of 
LRRK2 probands in 
domain which change 
identified 
c.149G>A 1 rs2256408 p.R50H  46/46 
c.356T>C 4 rs3399546 p.L119P  1/46 
c.1653C>G 14 rs7308720 p.N551K  2/46 
c.2167A>G 18 rs1087830 p.I723V ANK 4/46 
c.3683G>C 27 N/A p.S1228T LRR 1/46 
c.4193G>A 30 rs7133914 p.R1398H ROC 3/46 
c.4321C>T 31 rs3393992 p.R1441C ROC 1/46 
c.4364delAT 31 N/A p.D1455G ROC 1/46 
c.4624C>T 32 rs3395890 p.P1542S COR 3/46 
c.4541G>A 32 rs3550703 p.R1514Q COR 1/46 
c.4934T>A 34 rs1156414 p.S1647T COR 29/46 
c.5606T>C 38 rs3560279 COR p.M1869T 1/46 
c.6055G>A 41 rs3463758 p.G2019S Kinase 3/46 
c.6187delCTCTA 42 N/A p.L2063STOP Kinase 1/46 
c.7187insGT 49 N/A p.T2397STOP WD40 1/46 
c.7190C>T 49 rs3761863 p.T2397M WD40 22/46 
 
 
 
Table 5.1 Sixteen LRRK2 coding sequence variations which lead to non synonymous 
amino acid substitutions identified in this study. Variants not previously described in the 
literature are shown in bold, pathogenic mutations are shown in red, other variants are known 
single nucleotide polymorphisms (SNPs).  
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Nucleotide 
change 
LRRK2 
exon 
Genbank 
reference 
number 
Predicted 
protein 
change 
LRR Number of probands 
K2do in which change 
main identified 
 c.578C>T 5 rs10878245 p.L153L 25/46 
c.2857T>C 22 rs7966550 p.L953L  10/46 
c.4269G>A 30 rs11175964 p.K1423K ROC 3/46 
c.4872A>C 34 rs1427263 p.G1624G COR 21/46 
c.4911G>A 34 rs11176013 p.K1637K COR 30/46 
c.5412A>G 37 N/A p.G1804G COR 1/44 
c.5457C>T 37 rs10878371 p.G1819G COR 28/44 
c.6324G>A 43 rs10878405 p.E2108E Kinase 29/46 
c.7155A>G 48 rs33962975 p.G2385G WD40 13/46 
Table 5.2 Nine synonymous LRRK2 coding sequence variations identified in this 
study. Novel variant shown in bold, other variants are known single nucleotide 
polymorphisms (SNPs).    
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Nucleotide 
change 
LRRK2 
intron 
Genbank Number of 
reference probands in which 
number change identified 
IVS5+33T>C 5 N/A 1/46 
IVS16+39C>T 16 N/A 1/46 
IVS17-114T>C 16 N/A 1/46 
IVS19-9insT 18 N/A 2/46 
IVS20-11insT 19 N/A 36/46 
IVS20+21insA 20 N/A 2/46 
IVS26-8delT 26 N/A 3/46 
IVS30+28G>A 30 N/A 17/46 
IVS34+67T>A 34 N/A 45/46 
IVS36+59A>C 36 N/A 2/46 
IVS36+68delA 36 N/A 44/46 
IVS43+133C>A 43 N/A 1/46 
IVS49+33T>G 49 N/A 1/46 
Table 5.3 Thirteen non-coding (intronic) LRRK2 variants 
identified in this study which have not previously been 
described in the literature.  
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Nucleotide 
change 
LRRK2 
intron 
Genbank Number of 
reference probands in which 
number change identified 
IVS2-56G>A 1 rs2723273 46/46 
IVS3+45T>C 3 rs1352879 46/46 
IVS4+38A>T 4 rs2131088 7/46 
IVS5-44T>G 4 rs2723270 1/46 
IVS6-125T>C 5 rs6581622 5/46 
IVS8-160C>T 7 rs732374 33/46 
IVS10-10C>A 9 rs7955902 34/46 
IVS11+130G>A 11 rs7969677 11/46 
IVS13+104G>A 13 rs28903073 1/46 
IVS14+68G>C 14 rs10784462 33/46 
IVS30-137C>T 29 rs11175963 1/46 
IVS30-62A>T 29 rs7305344 40/46 
IVS30+52insGT 30 rs10650388 35/46 
IVS34-31T>C 33 rs1896252 36/46 
IVS34+32A>G 34 rs11564205 16/46 
IVS35-51A>T 34 rs10878368 38/46 
IVS35+23T>A 35 rs70307276 38/46 
IVS36+36T>C 36 rs7137665 22/46 
IVS38+35G>A 38 rs17484342 2/46 
IVS40+48C>T 40 rs2404834 9/46 
IVS43+53G>A 43 rs11176143 11/46 
IVS45+ 101G>A 45 rs890575 33/46 
IVS47-9delT 46 rs11317573 39/46 
Table 5.4 Twenty-three previously described non-coding 
(intronic) LRRK2 single nucleotide polymorphisms (SNPs) 
identified in this study.  
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5.4.1.2 Screening for novel LRRK2 variations 
Three novel non synonymous LRRK2 exonic variations: c.4364delAT (D1455G), 
c.6187delCTCTA (p.L2063 STOP), and c.7187insTG (p.T2397STOP) were identified in the 
fPD cohort. I then screened for these variants in large cohorts of subjects with sporadic PD 
and controls, the demographics of these cohorts can be found in chapter 3 and appendix B. 
Screening was performed by agarose gel electrophoresis, denaturing high performance liquid 
chromatography (DHPLC), or PCR fragment analysis (examples of raw data from are shown 
below in figures 5.5-5.7). 
The novel variations were not identified in any subjects from either the patient or control 
cohorts, the results are given below in table 5.5.  
I also screened for the c.4364delAT (D1455G) variation in the affected brother of the proband 
case who carried the mutation (subject II:2, see section 5.4.2.1 and figure 5.8). He was found 
to be wild-type at this position.  
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Number of subjects carrying LRRK2 variations (%) in each cohort tested 
LRRK2 
variants 
PD  
GEN 
Pts 
NDD 
Pts 
PINE 
Pts 
B’HM 
PD Pts 
QSPD  
Pts 
PD 
Total NDD PINE QSPD MND Total 
GEN 
Pts 
Cont 
Cont Cont Cont Cont Cont 
L2063 
STOP 
(Exon 42) 
0/35
0 (0) 
0/50 
(0) 
0/32   
(0) 
0/227   
(0) 
0/776 
(0) 
0/1435  
(0) 
0/221 
(0) 
0/47 
(0) 
0/53   
(0) 
0/31  
(0) 
0/136   
(0) 
0/488  
(0) 
T2397 
STOP 
(Exon 49) 
0/32
9     
(0) 
0/54  
(0) 
0/31   
(0) 
N/A N/A 
0/414   0/258   
(0) 
0/45  
(0) 
0/53   
(0) 
0/356  
N/A N/A 
(0) (0) 
D1455G 
(Exon31) 
0/34
9 
 (0) 
0/55 
(0) 
0/32 
(0) 
N/A N/A 
0/436 
(0) 
0/143 
(0) 
0/46 
(0) 
0/53 
(0) 
N/A N/A 
0/242
(0) 
 
 
 
Table 5.5 Summary of screening results for three novel non synonymous LRRK2 exonic variations: 
D1455G, L2063STOP, and T2397STOP in cohorts of subjects with sporadic PD and controls. Screening 
was performed in a patient cohort from the Birmingham PD study, patient and control cohorts from the PD GEN 
study, NDD study, PINE study, and Queen Square (QSPD) DNA collection, and a control cohort from the 
Birmingham MND DNA collection. Abbreviations: Pts= patients; Cont= controls; B’HM= Birmingham. 
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Figure 5.5 Screening for novel LRRK2 variant L2063STOP by agarose gel electrophoresis of 
PCR products. PCR reaction was performed as described in section 5.3.2.4. The PCR products 
were then run on a 3% high resolution RESponseTM Research agarose (Geneflow) gel at 120V for 3 
hours. The sizing ladder run on the gel was HyperladderTM V (Bioline). The PCR product was 60 
base pairs in length in wild-type and 55 base pairs if the variant was present, as indicated by arrows. 
Lanes 1-17 represent wild-type PCR products from wild-type subjects and lane 18 a PCR product 
from a subject heterozygous for the L2063STOP variant (proband subject II:1 from family 12). 
Abbreviations: bp= base pairs. 
 
 
 
 
 
 
 
 
 
  
    Base pairs   Base pairs 
Figure 5.6 Screening for LRRK2 variant c.7187insGT (T2397STOP) by fragment 
analysis of PCR products using Genescan®. Panels A and B show electrophoretograms 
of amplified fluorescent-labeled PCR products from DNA template for the c.7187insGT 
variation. Panel A represents DNA from subject carrying the variation and panel B 
represents DNA from a control subject. The wild-type PCR product is 332 base pairs and 
the mutant PCR product is 334 base pairs in size. Mutant PCR product is absent in the 
control subject. The y-axis represents the intensity of fluorescence, expressed as relative 
fluorescence units (RFU).  
    332                       334 332                        
RFU 
   329         331         333          335         337      329         331         333          335         337    
B A 
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DHPLC Chromatograms LRRK2 variant DHPLC column 
 
 
 
 
 
 
 
 
 
and Exon Wild Type Variant temperatures 
54.7°C 
55.9°C 
L2063STOP 
56.9°C 
Exon 42 
58.0°C 
59.5°C 
60°C 
D1455G        
Exon 31 
61.5°C 
  
Figure 5.7 Screening for LRRK2 variants identified in this study, L2063STOP and 
D1455G, by denaturing high performance liquid chromatography (DHPLC). PCR 
reactions were performed as described in section 6.3.2.4 and then DHPLC used to screen for 
variants. The figure demonstrates DHPLC chromatograms, at different column temperatures, 
for the two LRRK2 variants from subjects who were known to be wild-type or heterozygous 
carriers (proband subjects II:1 from family 12 and II:1 from family 48) of the variants. The 
chromatograms clearly show one peak for the subjects who were wild-type, representing 
homoduplexes only, and two peaks for the subjects carrying the variants, representing a 
mixture of homoduplexes and heteroduplexes. This technique allows discrimination between 
wild-type and mutants for these variations, and is described in more detail in chapter 6. 
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5.4.2 Clinical studies 
The clinical features and pedigrees of proband cases carrying the three novel exonic variations 
identified in this study: (i) c.4364delAT (D1455G) in exon 31, (ii) c.6187delCTCTA (p.L2063 
STOP) in exon 42; and (iii) c.7187insGT (p.T2397STOP) in exon 49 are presented below. The 
clinical features and pedigrees of proband cases carrying the pathogenic (G2019S and 
R1441C) and the two putatively pathogenic mutations (S1228T and M1869T) are presented in 
appendix D. This data is summarised in table 5.6 below. All studied family members are 
Caucasian. 
 
5.4.2.1 Family 48 
One affected member of this family (II:1) was studied, although extensive clinical information 
is also available on his brother (II:2). 
  
 
  
  Key:
 
 
 
 
 
 
The proband case, II:1, carries the heterozygous D1455G mutation. He is right-handed, was 
aged 71 at the time of evaluation, and had onset of symptoms aged 60. His initial symptom 
was tremor of his left arm. His symptoms responded well to Levodopa therapy. He had 
Figure 5.8 Pedigree for family 48 
 
            Proband case 
            Male 
I:1             Female 
            Deceased 
            PD 
II:2 II:3 II:1 II:4 
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reported dystonia in the lower limbs for one year and on-state dyskinesias for two years before 
the date of evaluation. He had also reported increasingly unpredictable on/off phenomena, 
with on periods only lasting for approximately two hours. His anti-parkinsonian medication at 
time of evaluation consisted of Levodopa and Amantadine (levodopa equivalent dose of 
450mg daily).  
Neurological examination revealed features typical of IPD, with mask-like facies, and 
asymmetrical tremor, rigidity and bradykinesia as well as postural instability. His Hoehn and 
Yahr stage was 4, with a UPDRS III score of 44. He did complain of some cognitive deficit, 
with a MMSE score of 20.  
There were four other affected members of the family. The first is subject II:2, a brother of the 
proband. He had a definite diagnosis of PD in life and his brain was donated to Queen Square 
Brain Bank post mortem. He was right handed and had onset of symptoms aged 63. His initial 
symptom was clumsiness of the left hand. He had asymmetrical rigidity, bradykinesia and 
tremor. He responded well to Levodopa and developed on state dyskinesias three years after 
diagnosis. His final recorded anti-parkinsonian medication was Levodopa and dopamine-
agonist (Pergolide) (levodopa equivalent dose of 700mg daily). He died aged 70. Pathological 
examination of his brain showed features typical of IPD- alpha-synuclein immunoreactive 
neurites and Lewy bodies (LBs) in the substantia nigra. LBs were either uniformly positive or 
showed a strongly positive halo with weaker or absent staining of the central core. 
From family report the other affected family members were: (i) the father of the proband, 
subject I:1, he was diagnosed with ‘mild’ PD. (ii) Two sisters of the proband, subjects II:3 and 
II:4 had definite PD.  
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5.4.2.2 Family 12 
One affected member of this family was studied (II:1). 
 
 
 
 
 
 
 
 
 
The proband case, II:1, carries the heterozygous L2063STOP mutation. He is right-handed, 
was aged 63 at the time of evaluation and had onset of symptoms aged 56. His initial symptom 
was tremor of his left arm. His symptoms responded well to dopamine agonist therapy 
(Pramipexole). His anti-parkinsonian medication at time of evaluation was a combination of 
Levodopa and a dopamine agonist (Pramipexole) (levodopa equivalent dose of 1400mg daily).  
Neurological examination revealed features typical of IPD, with mask-like facies, and 
asymmetrical tremor and rigidity as well as postural instability. He was also mildly dyskinetic. 
His Hoehn and Yahr stage was 1, with a UPDRS III score of 11. He did not complain of any 
cognitive deficit and his MMSE score was 30. 
From family report there were two other affected members of the family: (i) the mother of the 
proband, subject I:1. She was diagnosed with PD at the age of 75, responded well to Levodopa 
therapy and died at the age of 88.  (ii) A maternal uncle, subject I:2. He was diagnosed with 
PD in his early 60’s and died in his late 60’s.  
Figure 5.9 Pedigree for family 12 
    Key: 
            Proband  
            Male               Deceased 
            Female            PD 
             
I:1 I:2 
II:1 
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A DaTSCAN was performed on the proband, which revealed reduced uptake in the putamen 
bilaterally, consistent with parkinsonism (see figure 5.10).  
 
1   2 3 
4 5 6 
 
 
 
Figure 5.10 DaTSCAN for proband subject from family 12. An abnormal scan, showing 
bilateral reduced striatal uptake of [123I]FP-CIT, as demonstrated by the arrows. Images 1-6 
represent transverse sections through the brain, where 1 is the most superior and 7 the most 
inferior section. RT= right, LT= left. 
Olfactory testing was performed on subject 12:1; the UPSIT score was 15. 
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5.4.2.3 Family 38 
One affected member of this family was studied (III:1). 
 
 
 
 
 
 
 
 
 
The proband case, III:1, carries the heterozygous T2397STOP mutation. He is left-handed, 
was aged 82 at the time of evaluation and had onset of symptoms aged 78. His initial symptom 
was tremor of his left arm. His symptoms responded well to Levodopa therapy. His anti-
parkinsonian medication at time of evaluation consisted of Levodopa at a dose of 300mg 
daily.   
Neurological examination revealed features typical of IPD, with mask-like facies, and 
asymmetrical tremor, rigidity and bradykinesia as well as postural instability. His Hoehn and 
Yahr stage was 3, with a UPDRS III score of 26. Although he did not complain of any 
cognitive deficit, his MMSE score was 27. 
According to family report there were two other affected members: (i) the father of the 
proband, subject II:1. He was diagnosed with PD at his late 70’s. He had tremor, gait difficulty 
and some cognitive dysfunction, he died at the age of 86. (ii) The paternal grandmother of the 
proband, subject I:1. She developed a tremor and gait difficulty in her late 70’s, although a 
Figure 5.11 Pedigree for family 38 
  Key: 
            Proband case 
            Male 
            Female 
            Deceased 
            PD 
 
I:1 
II:1 
III:1 
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formal diagnosis of PD was not made. She died at the age of 80. Olfactory testing was 
performed on subject III:1; the UPSIT score was 12.  
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Family L-dopa LRRK2 Age at Age at Initial Hoehn & UPDRS L-Dopa &  
Proband 
gender 
eval. onset symptoms Yahr stage III score response dose mutation (mg/day) (Het) 
Unilateral arm 
tremor 
48 M 71 60 4 44 Good 450 D1455G 
Unilateral arm 
tremor 
12 M 63 56 1 11 Good 1400 L2063STOP 
Unilateral arm 
tremor 
38 M 83 78 3 26 Good 300 T2397STOP 
Unilateral arm 
tremor, 
bradykinesia 
10 M 71 54 2 17 Good 550 G2019S 
Unilateral 
bradykinesia, 32 F 70 59 2 29 Possible Nil G2019S 
micrographia 
Unilateral 
rigidity 
33 F 61 49 2 23 Good 800 G2019S 
No 
treatment 
20 F 72 71 Gait difficulty 2 15 Nil R1441C 
Neck rigidity, 
unilateral arm 
tremor 
1 F 75 65 3 28 Good 525 S1228T 
Unilateral arm 
tremor, 
bradykinesia, 
micrographia 
3 M 67 64 1 12 
No 
treatment 
Nil M1869T 
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Table 5.6 Summary of clinical data on proband cases carrying novel exonic LRRK2 frameshift 
mutations identified in this study, as well as proband cases carrying previously described pathogenic 
and putatively pathogenic LRRK2 mutations. Abbreviations: M= male; F= female; eval= evaluation; L-
Dopa= levodopa; Het= heterozygous. 
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5.5 Discussion 
In this chapter the coding sequence of LRRK2 was screened for both known mutations and for 
variations which had previously not been described, in 46 proband cases from the UK fPD 
cohort described in chapter 3. Sixteen coding sequence variations in LRRK2, which lead to 
non synonymous amino acid substitutions, were identified. Of these three were novel 
heterozygous variations c.4364delAT (D1455G), c.6187delCTCTA (p.L2063STOP), and 
c.7187insGT (p.T2397STOP). These three novel variations were found in one proband case 
each and all result in a shift in the reading frame, with the introduction of a premature 
termination codon. 
Furthermore, previously reported pathogenic LRRK2 mutations, that have been shown to 
segregate with disease, were identified in four probands, three were heterozygous carriers of 
the G2019S mutation and one was a heterozygous carrier of the R1441C mutation. Taken 
together, the data suggests that previously reported pathogenic LRRK2 mutations are 
associated with 8.7% of PD cases in this cohort. Of the previously reported putatively 
pathogenic LRRK2 mutations, for which disease segregation data is not available, one proband 
was a heterozygous carrier of the S1228T mutation and one proband was a heterozygous 
carrier of the M1869T mutation. All of these LRRK2 coding sequence variations are shown 
below in figure 5.12.    
One novel synonymous coding sequence variation was identified, c.5412A>G (p.G1804G) in 
exon 37, in one proband case. Thirteen novel non-coding sequence (intronic) variations were 
also identified. 
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The different categories of LRRK2 mutations identified are discussed below individually in 
terms of phenotype-genotype correlation and importance for understanding of LRRK2-related 
PD. One factor which must be considered is that is possible that some of the proband cases do 
in fact carry LRRK2 mutations in regions of the gene which were not analysed in my study, 
 
 
  
  
 
 
          B
 
2527 
ANK LRR ROC COR Kinase WD40 
690 860 
984 1278 
1335 1510
1511 1878
1879 2138 
2142 2498 
Ex14 
N551K 
Ex18 
I723V Ex30 
R1398H 
K1423K 
Ex34 
G1624G 
K1637K  S1647T 
Ex49 
T2397M 
Ex38 Ex42 
Ex31 L2063STOPM1869T 
R1441C Ex49 Ex27 Ex41 D1455G T2397STOP S1228T G2019S          A 
Ex 1 
R50H 
1 
Ex32  Ex37 Ex5 Ex22 Ex43 Ex48 Ex 51 R1514Q G1804G 
P1542SEx4 
L153L L953L E2108E G2385G 
G1819G 
L119P 
Figure 5.12 Schematic representation of LRRK2 protein domain structure and LRRK2 coding 
sequence variants identified in this study. Panel A= Schematic representation of LRRK2 exons 1-51 with 
amino acid variants described in this study. Putatively pathogenic amino acid substitutions are shown above, 
with those segregating with disease in red and the novel changes identified in this study in blue. Variants 
believed to be polymorphisms are shown below. Corresponding exon numbers are shown in black. Panel B= 
schematic representation of LRRK2 protein structure from residue 1-2527, with estimated domain 
boundaries indicated by residue numbers beneath. Abbreviations: ANK=ankyrin repeat region; COR=C 
terminal of Ras; Ex=exon; LRR=leucine-rich repeat domain; Roc=Ras of complex (GTPase); WD40= 
domain of 40-60 amino acids which terminate in a Trp-Asp (W-D) dipeptide. Adapted from Mata et al. 2006 
and Nichols et al. 2007 [18], [26].  
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such as the 5’or 3’ untranslated or promoter regions. Furthermore, they may have a type of 
mutation that will not be detected by sequencing, such as copy number variation. This is 
considered again later.   
In comparison to data generated from other comprehensive analyses of LRRK2 from different 
populations around the world (Europe, Russia, Asia, North America and UK) the findings of 
this study appear quite similar. Pathogenic mutations have previously been identified in 5-12% 
of subjects from families with AD inheritance, mutations with unequivocal disease segregation 
have been noted to cluster in the C-terminal half of the protein and subjects carrying the 
mutations appeared to have typical late-onset PD [27], [292], [279], [293], [280], [26], [294], 
[665], [687], [689], [688], [666].  
Three of these studies deserve further mention, the first because it was the largest cohort of 
subjects and controls. Paisan-Ruiz et al. screened 272 North American subjects with PD, 64 of 
whom had a positive family history of the condition, and 275 neurologically normal controls.  
In total the authors identified 90 variants (exonic and intronic) within LRRK2 [666]. Four PD 
cases carried the G2019S mutation, and six novel LRRK2 nonsynonymous disease specific 
variants (M712V, R1728L, R1728H, T2141M, R2143H, and L2466H) were also identified in 
six unrelated PD cases, and not found in 275 controls [666].  
The study of Nichols et al. is noteworthy because of the unique approach taken to the selection 
of subjects. These authors screened one subject from each of 88 families who had the highest 
family-specific multipoint LOD score at the LRRK2 locus from a cohort of 430 North 
American PD families without the G2019S mutation. They identified twelve coding sequence 
variants which lead to nonsynonymous amino acid substitutions, of which five had not 
previously been described (E10K, E334K, Q1111H, I1192V and L1795F) and seven 
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previously reported. Again the clinical features of subjects carrying the LRRK2 mutations 
appeared typical for PD with an age at onset range of 57-75 [26].  
The study by Khan et al. is important as it was the only other comprehensive screen of a large 
cohort of UK subjects with fPD. This group screened 117 subjects with PD (60 with a family 
history consistent with AD inheritance and 57 sibling-pairs). The G2019S mutation was 
identified in three subjects, with the R1941H and T2356I mutations each being identified in 
one subject. The clinical features were again those of typical IPD [279]. 
 
5.5.1 Novel Frameshift mutations 
5.5.1.1 The D1455G mutation 
The c.4364delAT (D1455G) mutation in exon 31 was identified in the proband case from 
family 48 and was absent in 484 UK Caucasian control chromosomes, supporting its case as a 
pathogenic change. I predict this heterozygous mutation to cause a shift in the reading frame, 
to result in a premature termination codon at position 1457, corresponding to a truncated 
protein of 1456 amino acids. Truncation of the protein at this position removes the kinase 
domain and would be likely to severely affect the function of the GTPase domain. The aspartic 
acid at position 1455 is highly conserved across species (figure 5.4) suggesting the importance 
of this region for proper function of LRRK2.  
The phenotype of the proband appeared typical for IPD with onset of symptoms aged 60, good 
response to Levodopa therapy and treatment-induced dyskinesias (section 5.4.2.1 and table 
5.6).  
To ascertain segregation of this mutation in the family I was fortunate to be able to obtain 
DNA from this proband’s deceased brother (individual II:2, figure 5.8) as described in 
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sections 5.3.2.1 and 5.4.2.1. However, on screening for the novel variation he was found to be 
wild type at this position. The phenotype of this subject appeared typical for IPD with good 
response to Levodopa, indeed very similar to that of the proband. Neuro-pathology was also 
typical for IPD. Although in the majority of the patients with LRRK2 mutations Lewy body 
pathology typical of PD has been reported [27], [271], [279], [656], [284], [657], [658], [659], 
[625], this subject appears to be a phenocopy and his disease is likely to have been IPD. 
Phenocopies have been reported previously in LRRK2-related PD families [294], [290], [279], 
[282]. Another explanation for this finding could be a technical error, in that a sample mix up 
could have occurred. This could be investigated with DNA fingerprinting analysis to ascertain 
if they shared common parents. 
Although the absence of the novel mutation in this subject does not appear to support a 
pathogenic role for the mutation, the predicted effect of the mutation is so dramatic that this 
should still be considered. Unfortunately other family members are unavailable for DNA 
studies, but functional evidence of the effect of the mutation would lend further support to this 
argument, as discussed in chapter 7. 
 
5.5.1.2 The L2063STOP mutation 
The c.6187delCTCTA (p.L2063STOP) mutation in exon 42 was identified in the proband case 
from family 12 and was absent in 976 UK Caucasian control chromosomes, suggesting that it 
is a pathogenic change. I predict this heterozygous mutation to cause a shift in the reading 
frame to result in a premature termination codon at position 2063, corresponding to a 
truncated protein of 2062 amino acids. This mutation is within the centre of the kinase domain 
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and again is predicted to severely affect protein function. The leucine at position 2063 is 
conserved across species, except chicken (see figure 5.4).  
The phenotype of the proband appeared typical for IPD with onset of symptoms aged 56, good 
response to anti-parkinsonian therapy and treatment-induced dyskinesias (section 5.4.2.2 and 
table 5.6). Furthermore a DaTSCAN was performed which revealed reduced uptake in the 
putamen bilaterally, consistent with parkinsonism. There are previous reports of functional 
imaging studies on subjects with LRRK2 mutations, mostly in subjects with fPD, but also 
some in sporadic disease. Isaias et al. used SPECT scanning and reported that in subjects with 
PD who carried the G2019S mutation, the pattern of reduced striatal uptake of [123I]FP-CIT 
was similar to that observed in IPD [682]. Other brain imaging studies have involved the use 
of [18F]fluorodopa positron emission tomography (PET) scans. The pattern of dopamine 
deficiency seen in PD subjects who carried LRRK2 mutations appeared similar to that 
observed in IPD [683], [279], [684], [290], [685], [686]. Also of interest is that in some 
asymptomatic carriers of LRRK2 mutations PET scans suggested early nerve terminal loss, 
whilst dopa uptake, decarboxylation and storage of dopamine were maintained and therefore 
prevented onset of symptoms [685], [686]. This may provide a unique opportunity to study the 
presymptomatic phase of PD.   
 
5.5.1.3 The T2397STOP mutation 
The c.7187insGT (p.T2397STOP) mutation in exon 49 was identified in the proband case 
from family 38 and was absent in 712 UK Caucasian control chromosomes, suggesting that it 
is a pathogenic change. I predict this heterozygous mutation to cause a shift in the reading 
frame to result in a premature termination codon at position 2397, corresponding to a 
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truncated protein of 2397 amino acids. The variation is within the WD40 domain. This domain 
can be involved in a variety of processes such as signal transduction, pre-mRNA processing 
and cytoskeleton assembly, but lacks enzymatic activity and regulatory function [277]. 
Therefore, by causing a truncation of the protein at this position this novel variation may alter 
the ability of LRRK2 to accurately coordinate protein-protein interactions, such as those that 
may exist between its substrates, or for LRRK2 dimerisation. A LRRK2 variant (Gly2385Arg) 
in the WD40 coding domain has been observed in several Asian populations, and is 
significantly more common in patients than controls. The associated disease phenotype is 
indistinguishable from IPD and it has been proposed as a common risk allele for PD in those 
populations [293], [294], [279], [280], [695], [696], [697], [698], [699], [700], [701], [702]. 
Indeed in vitro studies have shown that both wild type and the Gly2385Arg variant LRRK2 
protein localise to the cytoplasm and form toxic and aggregates and when put under oxidative 
stress, the Gly2385Arg variant was more toxic and associated with a higher rate of apoptosis 
[696].  
Against a pathogenic role for the T2397STOP mutation is the finding that the methionine at 
position 2397 is only conserved across human, mouse and rat (figure 5.4). Furthermore, there 
is a common single nucleotide polymorphism (SNP) at c.7190T>C (39/45 fPD cases), carried 
in homozygous form by the proband from family 38, which results in the amino acid 
substitution p.T2397M. Thus the amino acid at position 2937 appears less critical for proper 
function of LRRK2.  
The phenotype of the proband carrying the T2397STOP mutation appeared typical for IPD, 
with onset of symptoms later than the other two novel frameshift mutations, at 78 years, and 
he had good response to Levodopa therapy (section 5.4.2.3 and table 5.6).  
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5.5.1.4 Summary 
This is the first time that frameshift mutations in the coding sequence of LRRK2 have been 
described. The phenotype observed in all three novel variations described here appears to be 
typical for IPD, as has been observed in previous studies of LRRK2 positive PD patients [27], 
[288], [283], [289], [290], [285], [625]. 
The are only three other reports of nonsense mutations. Recently a 4 base pair deletion in the 
splice donor site of exon 19 (IVS20+4delGTAA) was reported [665]. The affected subject had 
fPD (father and possibly mother also affected) and although his phenotype appeared quite 
typical for IPD, he did have onset of symptoms at 38 [665]. Two point mutations, the first one 
a known SNP, that are predicted to result in truncated proteins have also been described 
c.5175C>T (p.R1725STOP) in exon 36 and c.5620G>T (p.E1874STOP) in exon 38, but no 
clinical details are available on these subjects [293], [666]. 
The three novel mutations identified in this study appear to be rare familial mutations as they 
have not been found in 872, 1392 and 828 sPD chromosomes respectively. Indeed the 
p.L2063STOP mutation in exon 42 was not found in 160 chromosomes from the Queen 
Square Brain Bank fPD cohort. The pathogenicity of these variants is not yet certain, with 
other affected family members needed to confirm co-segregation with disease. 
Most LRRK2 mutations described to date are missense mutations and the working hypothesis 
of the mechanism of pathogenicity has been through a gain of function effect. The 
identification of these three novel frameshift mutations suggests that at least for these 
variations pathogenicity may be through a novel mechanism for LRRK2-related PD- loss of 
functional LRRK2 via haploinsufficiency, although a toxic gain of function from a mutant 
protein species also remains a possibility. These putative pathogenic mechanisms are 
discussed in more detail in chapter 7.  
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5.5.2 Previously described pathogenic mutations 
In this study three probands were found to be heterozygous carriers of the G2109S mutation 
and one proband was found to be a carrier of the R1441C mutation. Therefore previously 
described likely pathogenic LRRK2 mutations have been found in 8.7% of this cohort. These 
two mutations were not found in 180 and 242 age-matched UK controls respectively (table 
6.3). The pathogenic roles of G2019S and R1441C have been established on the basis of 
absence in large number of control chromosomes, co-segregation with disease in several large 
pedigrees, cross species conservation of the relevant amino acids and predicted structural 
importance of the amino acids involved [27], [283], [290], [281], [289], [703], [292]. 
 
5.5.2.1 The G2019S mutation 
The probands carrying the G2019S mutation from families 10 and 33 had typical clinical 
features of IPD and responded well to levodopa therapy. Indeed, the sister of the proband from 
family 10 (subject III:2) was also affected and carried the same mutation. She was aged 60 at 
disease onset and again had typical clinical features of IPD, although she was unable to 
tolerate anti-parkinsonian medication (see sections D.1 and D.3 and table 5.6). However, the 
proband carrying the G2019S mutation from family 32 had more atypical disease. Her 
symptoms began at the age of 59, however they were very slowly progressive and she had 
been unable to tolerate Levodopa. Twelve years after the onset of disease she remained mildly 
affected, without any treatment, and she had a Hoehn and Yahr stage of 2 (see section D.2 and 
table 5.6).  
The mean age of onset of symptoms of the subjects carrying the G2019S mutation was 55.5 
(SD 5.1), with a range of 49-60, and apart from the proband case in family 32 the associated 
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phenotype was typical for IPD. This is in general agreement with previously reported findings 
from studies in large cohorts of subjects with fPD [27], [292], [279], [293], [294], [280], [26], 
[665], [687], [666], [688], [689]. 
From the demographic, clinical and epidemiological data available on the subjects carrying the 
G2019S mutation, there is no clear explanation as to why the proband from family 32 
appeared to have an atypical form of PD and subject III:2 from family 10 had an apparently 
poor response to Levodopa therapy. The previously reported clinical phenotype associated 
with the G2019S mutation has in most cases been very similar to IPD, although with a wide 
range of age at onset [282], [677], [704], [678], [705], [682], [706]. However, there are reports 
of the mutation being associated with slowed disease progression [282], [667] and recently a 
heterozygous carrier of the G2019S mutation was reported who had a more atypical 
phenotype. She had onset of symptoms aged 39, with hypokinesia only at the onset of disease, 
although she developed more typical features later [688].  
Given that the pathology associated with G2019S mutations ranges from typical Lewy body 
pathology to neurofibrillary tangles through to nigral degeneration without Lewy bodies [656],  
[284], [657], [658], [707], [708] one might expect a wider range of associated phenotypes. 
Several studies have not identified G2019S mutations in other neurodegenerative conditions 
such as Alzheimer's disease, progressive supranuclear palsy (PSP), and multiple system 
atrophy (MSA) [709], [710], [711], [712], [713], [714], [657], [715]. However, there are two 
recent reports in which G2019S mutations have been associated with frontotemporal dementia 
and corticobasal degeneration [716], [717]. Therefore the finding of the G2019S mutation 
associated with a more atypical form of PD is interesting and warrants further clinical 
investigation as discussed below in section 5.6. 
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5.5.2.2 The R1441C mutation 
The proband carrying the R1441C mutation had onset of disease aged 71, and had typical 
clinical features of PD. This has been reported previously, although a slower progression of 
the parkinsonism has also been noted [27], [703], [293], [280], [718], [666]. Recent studies 
have identified two major haplotypes for R1441C carriers, indicating a minimum of two 
independent founders [718], [280], [719].  
The p.R1441 amino acid residue is the second most common location of pathogenic 
substitutions, after p.G2019S, indeed  the p.R1441 residue appears to be prone to mutagenesis 
as the two pathogenic substitutions (p.R1441C; c.4321C>T and p.R1441G; c.4321C>G) and 
one putatively pathogenic substitution (p.R1441H, c.4322G>A) affect the same residue. This 
residue is highly conserved across species and even between the ancestral LRK1 within 
invertebrates and LRRK1 and LRRK2 in vertebrate radiations [18].  
From the few reports of pathological findings in carriers of R1441C mutations, a broad 
spectrum ranging from Lewy body pathology to tau pathology was noted [27], [271]. Once 
again several studies have not identified R1441C mutations in other neurodegenerative 
conditions [711], [712], [713], [715], although there is a single PD patient with a R1441H 
mutation whose disease subsequently evolved into PSP [720]. 
 
5.5.2.3 Summary 
In this study of UK fPD pathogenic LRRK2 mutations were identified in 8.7% of probands. 
The mean age of onset of symptoms of the subjects carrying the pathogenic LRRK2 mutations 
was 58.6 (SD 8.2), with a range of 49-71, and apart from the proband case in family 32, the 
associated phenotype was typical for IPD.  
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These findings raise the question as to whether screening for the pathogenic mutations 
(G2019S and R1441C) in fPD cases is something that should be considered in routine clinical 
practice. At the current time there is no therapy which prevents or slows neurodegeneration in 
the condition. Incomplete penetrance has also been reported in LRRK2-positive families [283], 
[287], [281], [279]. The relatively high frequency of the G2019S mutation has allowed some 
estimates of penetrance to be made, namely 15-17% at age 50, increasing to more than 50% by 
age 80, depending on cohort [281], [287], [721], [675]. The oldest clinically unaffected 
heterozygote reported is aged 89 years [722]. Furthermore, although the G2019S mutation 
shows clear familial segregation, rare phenocopies have been reported [282], [287], [290], 
[294]. Estimates of penetrance for the R1441C mutation suggest that less than 20% of carriers 
show PD symptoms before the age of 50, whilst at 75 years more than 90% of carriers show 
symptoms [718].  
At the current time screening for LRRK2 mutations in both affected and unaffected subjects 
remains a research rather than diagnostic tool. Much more data, and I believe a clear set of 
guidelines for testing and counseling, is required before it should come into routine clinical 
practice.  
The known functional effect of these pathogenic LRRK2 mutations is covered in more detail in 
chapter 7.  
 
5.5.3 Non synonymous coding sequence variants 
In this study I identified one heterozygous carrier for each of the putatively pathogenic 
missense mutations S1228T (c.3683G>C in exon 27) and M1869T (c.5606T>C in exon 38). 
Whilst the S1228T mutation was not identified in 68 age-matched UK controls, but was in her 
 - 223 -
Chapter 5                                           Molecular Genetic Analysis of LRRK2 in UK Familial PD                        
unaffected sibling, one out of 75 age-matched UK controls was found to be a heterozygous 
carrier of the M1869T mutation (table 6.3). 
 
5.5.3.1 The S1228T mutation 
The proband carrying the S1228T mutation is from family 1 (subject III;1), her phenotype 
appeared typical of IPD and her symptoms responded well to Levodopa therapy. Her 
monozygotic twin sister (subject III:2) also carried the same mutation but was unaffected (see 
section D.5 and table 5.6).  
There has only been one previous report of this mutation, in a sibling pair from a family in 
which segregation was consistent with an AD pattern. The phenotype in these subjects appears 
similar to that of the proband from our study. Both subjects from the previous study had onset 
of disease aged 49, one with tremor and the other with tremor and bradykinesia. The disease 
phenotype appeared typical for IPD with good response to Levodopa [294]. The authors did 
not find any carriers of this mutation in a screen of 337 IPD subjects and 1200 controls. 
The c.3683G>C S1228T mutation is located in the LRR domain of LRRK2, one of the 
protein-protein interaction domains [274]. Therefore a mutation within this region could 
prevent accurate coordination of protein-protein interactions, such as those that may exist 
between its substrates, or for LRRK2 dimerisation.  
From the demographic, clinical and epidemiological data available on these two subjects there 
is no clear explanation as to why the proband case should have developed PD whilst her twin 
sister did not. The two possible explanations for this finding are, first that this mutation has 
reduced penetrance. This would be in keeping with the reduced penetrance observed in other 
LRRK2 mutations [283], [287], [281], [279], [281], [287], [721]. Second, the S1228T mutation 
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may not be pathogenic, or it may represent a risk factor for PD. To be certain of the true 
pathogenicity of this mutation co-segregation and/or functional evidence of a pathogenic 
effect of this mutation are required. The unaffected sister of the proband subject could of 
course be in the pre-symptomatic phase of PD, and performing DaTSCANs on both 
individuals could provide evidence of this, and thus provide further support for a pathogenic 
role for this mutation. 
 
5.5.3.2 The M1869T mutation 
The proband carrying the M1869T mutation is from family 3 (subject II:1). His phenotype 
generally appeared typical of IPD. His unaffected sister (subject II:2) did not carry the 
mutation (see section D.6 and table 5.6).  
There have only been two previous reports of this mutation. One was in an affected member of 
a family in which disease segregation was consistent with an AD pattern. Similar to the 
proband from my study, the phenotype of this subject appeared typical for IPD, with disease 
onset aged 70. An affected sibling did not carry this mutation [293]. The second was of an 
apparently sporadic case of PD with onset aged 62. Her phenotype appeared to be typical of 
IPD, with good response to Levodopa [289]. The mutation was not found in 1000 and 278 
controls in each of these studies [293], [289].   
The c.5606T>C M1869T mutation is located in the COR domain of LRRK2. The R1441C 
mutation in the ROC domain has been reported to decrease GTP hydrolysis activity [663], 
[723] or increase GTP binding [691]. Furthermore, the Y1699C mutation in the COR domain 
also appears to increase GTP binding [691]. Therefore, a predicted consequence of the 
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mutations in this region of LRRK2 has been to increase the downstream kinase activity 
through perturbation of the GTPase domain. 
In my study I also identified the M1869T mutation in an unaffected control subject. This 
individual is female, was 46 at the time of entry to the study and had no family history of PD. 
The findings of an affected sibling who did not carry the mutation and an unaffected control 
with the mutation argues against the M1869T mutation being pathogenic. However, as 
discussed before, phenocopies have been reported in LRRK2-related PD families [294], [290], 
[279], [282]. Furthermore, the unaffected individual was only aged 46 and may be at risk of 
developing PD later, this would be in keeping with the reduced penetrance observed in other 
LRRK2 mutations [283], [287], [281], [279], [281], [287], [721]. 
To be certain of the true pathogenicity of this mutation co-segregation and/or functional 
evidence of a pathogenic effect of this mutation are required. 
 
5.5.3.3 Other nonsynonymous coding sequence variants 
There were nine other previously described nonsynonymous variants identified in this study 
(table 5.1), six of which reside in functional domains: I723V maps to the ANK domain; 
R1398H maps to the ROC domain; R1514Q, P1542S and S1647T map to the COR domain; 
and T2397M maps to the WD40 domain. For varying reasons, which are discussed below, 
these variations are not believed to be pathogenic. The homozygous variation 149G>A 
(p.R50H) was found in all probands, as in previous studies [293], [280], suggesting an error 
within the consensus genomic sequence. The heterozygous variation 356T>C (p.L119P) was 
found in one proband. This variation has been identified in patients at similar frequencies in 
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previous studies. Although it was not found in controls, there is no evidence to date for 
segregation with disease [27], [280], [666]. 
The variation 1653C>G (p.N551K) was found in 2 probands, the variation 2167A>G 
(p.I723V) in 4 probands, the variation 4193G>A (p.R1398H) in 3 probands, the variation 
4934T>A (p.S1647T) in 29 probands, and the variation7190C>T (p.T2397M) in 22 probands. 
These variations have been identified previously in patients [293], [280], [26] and controls 
[666] at similar frequencies. There was no significant difference between genotype or allele 
frequencies in patients from our study and controls from the study by Paisan-Ruiz et al. (see 
appendix E). 
The heterozygous variation 4541G>A (p.R1514Q) was found in one proband and three 
controls, and the heterozygous variation 4624C>T (p.P1542S) was found in three probands 
and four controls. These variations have been identified previously in patients [293], [280], 
[26] and controls [27], [280], [666] at similar frequencies. Again there was no significant 
difference between genotype or allele frequencies in patients from our study and controls from 
the study by Paisan-Ruiz et al. for the 4624C>T variation (see appendix E). 
These variations are felt to be a neutral, disease unrelated changes. 
 
5.5.4 Synonymous coding sequence variations 
Nine synonymous coding sequence variations were identified in this study, including one 
variation not previously described 5412A>G (G1804G), found in one proband. His initial 
symptoms were micrographia and shuffling gait, which began at the age of 70 and he had 
good treatment response to Levodopa. However, he had had a rapid progression of his disease 
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and when assessed for this study, eight years after onset of disease, he had developed a severe 
dementia and was bed bound (Hoehn and Yahr stage 5).  
The 5412A>G (G1804G) variation is in the COR domain, but is not predicated to affect 
function of the mature protein, or to affect splicing of LRRK2 messenger RNA because it is 
not near the end of the exon, or likely to result in creation of a cryptic splice/donor site. I did 
not screen controls for this variation, and genetic material was not available on other family 
members to assess for segregation with disease.  
Although six of the other synonymous variants are found in LRRK2 functional domains (table 
5.2), it is unlikely that any of the nine variants are pathogenic because they are not predicted to 
affect function of the mature protein. Furthermore, eight of these variations have been 
identified previously in patients [293], [724] and controls [280], [666] at similar frequencies. 
There was no significant difference detected between the genotype or allele frequencies for 
any of these eight variants in patients from our study and controls from the study by Paisan-
Ruiz et al. (see appendix E).  
 
5.5.5 Intronic variations 
Thirty-six intronic sequence variations were identified in this study, including thirteen novel 
variations (tables 5.3 and 5.4). The aim of the work in this chapter was to screen the coding 
sequence of LRRK2, the identification of intronic changes was as a consequence of the 
location of the primers in the intronic sequence. Therefore I did not generate control data for 
the novel changes and genetic material was not available to assess for segregation with 
disease. However, in silico analysis (http://bioinfo.itb.cnr.it/oriel/spilce-view.html) showed 
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that none of the novel intronic variations appear to significantly modify intron/exon splice 
sites. 
The 23 intronic variations which have previously been described were identified previously in 
patients and controls [280], [666] at similar frequencies. The homozygous variations IVS2-
56G>A and IVS3+45T>C were found in all probands, as previously reported [280], 
suggesting an error within the consensus genomic sequence. There were nine intronic 
variantions detected with a MAF of 3% or higher, for which control data was available, and 
statistical analysis failed to provide evidence of an association with disease (see appendix E).  
Although the 36 intronic variations are likely to be neutral, disease unrelated changes, control 
data for both the novel variations, and for those previously described variations for which 
control data was not available for analysis in this study, would be helpful to assess whether 
they associate with disease. 
 
5.5.6 Olfaction 
As a further aid to the clinical assessment, I performed olfactory testing on the proband cases. 
Olfactory dysfunction is found in 70-100% of PD patients [108], [109], [110] and is associated 
with neuronal loss and Lewy body deposition in the olfactory pathway [112]. Furthermore, 
olfactory dysfunction is markedly reduced in PD from the early stages (UPSIT mean scores of 
20-21) [113], [108], [114], [115]. The data on the four subjects carrying the G2019S mutation, 
one subject carrying the R1441C mutation, one subject carrying the L2063STOP mutation and 
one subject carrying the T2397STOP mutation are discussed here.  
The mean UPSIT-40 score for all seven subjects was 20.1 (SD 6.5). The mean score for the 
subjects with the G2019S mutation was as 24.8 (SD 4.1), whilst the scores for the subjects 
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with the R1441C, the L2063STOP and the T2397STOP mutations were 15, 15 and 12 
respectively. The mean score is similar to a recent study of olfaction in PD in which the mean 
score in 18 UK subjects with IPD was 17.1, whilst in 27 age-matched controls the mean score 
was 27.6 [118]. 
The individual subject scores in this study can be compared to the normative values and 
percentiles for age and gender [482]. The individual UPSIT scores for the subjects with 
G2019S mutations ranged from 20-30 and were all either in the moderate or severe microsmia 
category. The individual scores for the subjects with the R1441C, L2063STOP and 
T2397STOP mutations were all within the anosmia category. Therefore all the subjects 
carrying these LRRK2 mutations had at least moderately reduced olfactory function. The 
olfactory function in the two subjects with the novel frameshift mutations was more severely 
affected than the subjects with the G2019S mutation. 
This data shows that the olfactory function is severely affected in subjects with PD who carry 
these LRRK2 mutations and that the associated pathology appears to affect both the basal 
ganglia and olfactory pathway. The previous studies in which olfaction was assessed in 
subjects carrying LRRK2 mutations demonstrated that most subjects exhibited moderate to 
severe loss of olfactory function, similar or slightly less than that seen in IPD [294], [279], 
[687], [725], [726], [667], [727], [728]. The postmortem data available on some of these 
subjects confimed Lewy body pathology in the olfactory pathways [726].   
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5.6 Future work 
There are several further molecular genetic and functional studies that can be done to further 
both our knowledge on the novel frameshift mutations identified in this study and our 
understanding of the importance of LRRK2 in fPD. 
First, for the novel frameshift mutations, the identification and screening of other affected and 
unaffected family members will be crucial to clarify whether these mutations are indeed 
pathogenic. The further molecular genetic studies which can be used to determine the 
functional effects of these novel mutations, and our current knowledge of the functional 
effects of the G2019S and R1441C mutations, are covered in more detail in chapter 7. 
Although the L2063STOP mutation was screened for in the QSBB fPD cohort, it will also be 
important to screen for the two other novel mutations in this cohort. It would also be valuable 
to screen for all three novel mutations in other fPD cohorts to determine whether they are 
present in different fPD populations.  
Second, given that distinct haplotypes for patients who carry the G2019S and R1441C 
mutations have been identified [673], [718] it would be valuable to assess the haplotype of 
these mutation carriers identified in my study. 
Third, given the atypical clinical phenotype of the proband from family 32, further clinical 
investigations are warranted. A DaTSCAN could be performed in order to provide further 
supportive evidence for the clinical diagnoses, which should be abnormal in a subject with PD 
or parkinsonism [128], [129], [130]. 
Fourth, control samples could be evaluated for the novel synonymous coding sequence 
variation (G1804G) and the thirteen novel intronic sequence variations identified in this study, 
in order to determine whether they associate with disease.   
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Fifth, for the S1228T and M1869T mutations the identification and screening of other affected 
and unaffected family members will be crucial to determine whether these mutations are 
pathogenic. Performing DaTSCANs on both the proband who carries the S1228T mutation, 
and her unaffected sister who also carries the mutation, could provide further support for a 
pathogenic role for this mutation, as discussed in section 5.5.3.1 
Sixth, analysis of copy number variation of LRRK2. As well as missense mutations, copy 
number variations in both Alpha-synuclein and Parkin have been shown to cause PD [251], 
[306], [307]. Copy number variation in LRRK2 has only been studied twice,  and no whole-
gene deletions or duplications were detected [293], [666]. Multiple ligation-dependent probe 
amplification (MLPA) could be used to detect the presence or absence of copy number 
variation in LRRK2 in my cohort of 46 fPD cases, to ensure that this is not another mechanism 
by which LRRK2 could cause fPD. As discussed in section 4.3.2.3, MLPA is a well validated 
and high resolution method to detect copy number changes of up to 45 loci in one relatively 
simple, semi-quantitative PCR-based assay [618], [619], [620].  
Seventh, recently the concept of digenic parkinsonism has been proposed. Dachsel et al. 
identified three patients simultaneously carrying mutations in Parkin and LRRK2 [729]. 
Although compared to patients with a single LRRK2 or Parkin mutations these patients did not 
present with earlier disease onset, or faster disease progression, and direct interaction of the 
two proteins was not observed in co-immunoprecipitation experiments, the authors proposed 
that potential genetic interactions could be concealed by the modulating effects of other genes 
[729]. Lesage et al. found the PD phenotype to be no more severe in two North African Arab 
patients who had both a heterozygous G2019S mutation and one or two Parkin mutations 
[669]. More recently Bras et al. identified a subject with a G2019S mutation and a 
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heterozygous duplication of Parkin exon 9, the subject had early onset of disease but no 
family history of PD [689].  
Therefore it would be valuable to screen our fPD cohort for mutations within the other four 
genes for Mendelian PD for which there is strongest evidence: Alpha-synuclein, Parkin, 
PINK1, and DJ-1. It is most important to do this in the subjects who carry the pathogenic and 
novel LRRK2 mutations in order to test the proposed link between mutations in LRRK2 and 
other PD genes. 
 
5.7 Conclusions 
This is only the second comprehensive screen of LRRK2 in a large cohort of UK fPD subjects. 
I detected three novel frameshift mutations in one proband subject each, which were 
associated with typical late-onset Levodopa responsive PD. This is the first report of 
frameshift mutations in the coding sequence of LRRK2 and may indicate a novel pathogenic 
mechanism for LRRK2-related PD. The previously described pathogenic LRRK2 mutations 
(G2019S and R1441C) were detected in 4 out of the 46 proband subjects screened (8.7%), the 
associated phenotype was in the most part typical of IPD, although one subject had a much 
more slowly progressive condition. This confirms the importance of these mutations in UK 
fPD and suggests an extended disease phenotype associated with the G2019S mutation. Taken 
together, my data suggests that LRRK2 mutations are associated with 15% of fPD cases in this 
UK cohort. 
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6 Molecular Genetic Analysis of Eight Exons of the LRRK2 
Gene in a UK Sporadic PD Cohort 
 
6.1 Introduction 
The identification of the PARK8 gene LRRK2 [25], [27] has led to renewed interest in the role 
that genetic factors may play in apparently sporadic PD (sPD). This is because the phenotype 
associated with LRRK2 mutations resembles that of IPD and through the identification of 
LRRK2 mutations in sPD. Indeed one mutation alone, G2019S in exon 41, is found in 1% to 
2% of sPD cases [282], [283], [284], [285], [281], [282], [679], [730], [731], [675] and can be 
found at even higher frequencies in some populations, including Portuguese (6%) [286], 
Askenazi Jewish (13%) [670], and North African Arabs (41%) [669]. European and North 
American subjects appear to have two distinct haplotypes, suggesting two founders [669], 
[670], [281], [671], [672], [673].  
There have been numerous studies of LRRK2 in sPD over the last four years. However, in 
most studies the strategy has been to screen for the common known LRRK2 mutations, and in 
some instances identified variants have not been screened for in a corresponding control 
cohort. This has led to a need for accurate data on the true frequency of LRRK2 variations in 
sPD and controls, which will be addressed by work presented in this chapter.     
 
6.1.1 LRRK2 variations in sporadic PD  
In previous studies of LRRK2 in sPD most investigators have screened for one or more of the 
five pathogenic mutations that have been shown to segregate with disease: R1441C, R1441G, 
Y1669C, G2019S and I2020T [18], [278], or focused on the exons in which these mutations 
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can be found. In some populations other variations have been found to be common, such as the 
G2385R mutation in the Asian population, which is found in up to 9% of patients surveyed 
[699], [697].  
Screening for the G2019S mutation in different sPD populations has been the focus of much 
work since it was identified in 2005 [282], [283], [284], [285], [281]. The I2020T variant is 
also in exon 41 and some investigators have focused on screening for variations within this 
exon. Furthermore, as the R1441C and R1441G mutations are both found in exon 31, another 
strategy has been to just screen for mutations within these two ‘hot spot’ exons. 
Although the results of different studies are not easily comparable, because of methodological 
considerations such as sample population, definition of fPD and sPD, and different genotyping 
techniques, I have outlined the findings of several of the more extensive screens of LRRK2 
performed in large cohorts of sPD in table 6.1. 
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Authors 
Number Number Number Study LRRK2 
population exons 
screened 
of 
subjects 
of Results 
controls 
No pathogenic 
mutations identified Grimes et al. [732]. Canadian 7 230 129 
(i) G2019S mutation 
in 4 PD subjects only 
Paisan-Ruiz et al. 
[666] 
North 
American 51 272 275 
(ii) 6 novel 
nonsynonymous 
variants in PD 
subjects only 
Skipper et al. [690]. 
 Singapore 29 160* 630 
Two potentially 
pathogenic variants in 
PD subjects only    : 
(i) R1067Q          
(ii) IVS33+6T>A** 
 
Table 6.1 Summary of findings from three studies of LRRK2 performed in sPD cohorts. The 
authors screened for both previously described and for novel variations in the relevant exons. *These 
subjects had a positive family history of PD, which was not compatible with AD inheritance, and had 
previously screened negative for the G2019S mutation. LRRK2 variants identified in this initial screen 
were then screened for in 470 sPD patients. **Intronic variant IVS33+6T>A, decreases the consensus 
donor splice site sequence 
 
 
The clinical phenotype of most LRRK2 positive PD patients appears indistinguishable from 
that of typical IPD [27], [288], [283], [289], [290], [285], [625]. However, the age at onset is 
variable, ranging from 28 to 86 years in subjects with the G2019S mutation [285], [287], 
[288], [676], [282], [677], [289], [678], [290], [679], [279], [292], [286], [284], [281], [680], 
[293].  
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6.1.2 Denaturing high performance liquid chromatography (DHPLC) 
There are several techniques which have been developed for mutation screening, in addition to 
sequencing, and these include single-strand conformation polymorphism (SSCP), denaturing 
gradient gel electrophoresis (DGGE) and denaturing high performance liquid chromatography 
(DHPLC). 
DHPLC was developed in 1995 as a high throughput method for detecting known and novel 
point mutations, deletions and insertions in PCR products [733], [734]. DNA sequence 
variations are detected on the basis of base pair mismatches between chromosomal fragments 
amplified by PCR. The PCR products are denatured and slowly re-annealed before analysis by 
DHPLC. This process results in the formation of homoduplexes and heteroduplexes, between 
the sense and antisense strands of either homoduplex, if a mutation is present (see figure 6.1). 
The heteroduplexes are thermally less stable than their corresponding homoduplexes. 
Once re-annealed, the samples are loaded onto an alkylated stationary phase (DNA SepTM 
Column) which is neutral and hydrophobic. A binding molecule triethylammonium acetate 
(TEAA) is used at this stage as the negatively charged DNA cannot bind by itself [493]. The 
DNA molecules are partially denatured on the column by elevated temperatures, typically 50-
70°ْC, and an increasing gradient of the organic solvent acetonitrile. The duplexes are eluted 
from the column according to the degree of denaturation, the presence of base mismatches in 
the heteroduplexes causes them to denature more extensively than the corresponding 
homoduplexes. Therefore heteroduplexes are eluted first and are seen as one or more 
additional peaks in front of the homoduplexes, both of these fragments are detected by UV 
absorption and visualized as peaks on chromatograms (figure 6.1) [493].  
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DHPLC is a highly sensitive and specific technique, and over 100 genes have now been 
analysed using this method [488], [489], [490], [491], [492], [493]. 
 
6.1.3 Strategy for screening eight exons of LRRK2 
The eight exons of LRRK2 (24, 25, 31, 32, 38, 40, 41 and 42) which were screened in this part 
of the study on sPD were chosen for several reasons. First, mutations in seven of these exons 
have previously been described, suggesting that these may be mutational ‘hot spots’. Second, 
Denature 
Reanneal 
G T A C 
Heteroduplexes Homoduplexes 
A 
G C G C A  A T G C 
Heat 50-70°C 
Wild type: Homoduplex 
Mutant: Homoduplex & heteroduplex 
mV 
mV 
Retention time
Retention time
B 
C 
A T 
Flow 
A T A T A C G C G C G T G TA C 
Figure 6.1 The principle of DHPLC. Panel A= PCR products denatured at high temperatures, 
slowly cooled to form homoduplexes and, if a mutation is present, heteroduplexes. Panel B= Samples 
loaded onto the column and flow through at preset temperature. Panel C= Chromatograms for wild 
type (homoduplex) and mutation containing (homoduplexes and heteroduplexes) samples.  
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all eight exons are located within functional domains of LRRK2, suggesting that mutations 
within these regions may have important implications for the normal function of LRRK2. 
Third, mutations were identified in five of the eight exons in the fPD part of my study, 
suggesting that coding variation within these exons may be important in UK fPD, and hence 
may also be important in UK sPD (see figure 6.2).  
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Figure 6.2 Schematic representation of LRRK2 protein domain structure and coding 
sequence variants identified in eight exons of LRRK2. Panel A= Schematic representation of 
LRRK2 exons 1-51 with amino acid variants described to date. Putatively pathogenic amino acid 
substitutions are shown above, with those segregating with disease in red. Variants identified in my 
familial PD study are shown in bold with the novel variants in blue. Those variants believed to be 
polymorphisms are shown below. Corresponding exon numbers are shown in black. Corresponding 
exon numbers are shown in black. Panel B= schematic representation of LRRK2 protein structure 
from residue 1-2527, with estimated domain boundaries indicated by residue numbers beneath. 
Abbreviations: ANK=ankyrin repeat region; COR=C terminal of Ras; Ex=exon; LRR=leucine-rich 
repeat domain; Roc=Ras of complex (GTPase); WD40= domain of 40-60 amino acids which 
terminate in a Trp-Asp (W-D) dipeptide. Adapted from Mata et al. 2006 and Nichols et al. 2007 
[18], [26]. 
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6.2 Aims of the chapter 
The major aim of the work in this chapter was to screen for known and novel variation in eight 
exons of LRRK2 in a large cohort of UK subjects with sPD and also in controls. The secondary 
aim was to evaluate the use of DHPLC as a high throughput screening tool for detecting 
LRRK2 mutations.  
 
6.3 Subjects and methods 
6.3.1 Subjects 
This chapter involved the screening of cohorts of sPD patients and controls for known and 
novel LRRK2 variations in eight ‘hot spot’ exons selected as described above (section 6.1.3). 
The following cohorts of PD patients and controls were used: (i) PD GEN cohort of PD 
patients and controls; (ii) NDD cohort of PD patients and controls; (iii) PINE cohort of PD 
patients and controls; and (iv) Birmingham PD cohort of PD patients. These subjects had been 
recruited as described in section 2.1.2, the demographics of the patient cohorts can be found in 
section 3.5 and the demographics of the control cohorts can be found in appendix B.  
  
6.3.2 Methods 
6.3.2.1 DNA extraction and PCR 
DNA was extracted from venous blood as described in section 2.3. Seven exons (including 
exon-intron boundaries) of the LRRK2 gene (24, 25, 31, 32, 38, 40, and 42) were studied by 
PCR using primers and PCR temperatures as described in previous studies [283], [280]. 
Primers and reaction conditions are detailed in appendix C, each PCR was optimised as 
described in section 2.4.  
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In addition, specific primers were designed for screening for LRRK2 variations within exon 41 
by restriction fragment length polymorphism (RFLP) analysis or DHPLC as described below 
by using the Primer3 program (http://fokker.wimit.edu/primer3/input.htm). Primers selected 
and reaction conditions are detailed in appendix C. Each PCR was optimised as described in 
section 2.4.  
 
6.3.2.2 Restriction fragment length polymorphism (RFLP) analysis 
RFLP analysis was used to screen for the G2019S mutation (c.6055G>A) in 110 patient 
samples from the Birmingham PD, NDD and PINE studies, as well as in 30 control samples 
from the PINE study. A restriction endonuclease Sfc I was used as described in section 2.6, 
the assay conditions can be found in appendix C. 
  
6.3.2.3 Denaturing High Performance Liquid Chromatography (DHPLC) 
DHPLC, as described in section 2.9, was used to screen for known and novel LRRK2 
variations in eight exons of LRRK2, in 357 patient and 90-180 control samples from the PD 
GEN study. In addition 80 patient and 60 control samples from the NDD and PINE studies 
were screened for mutations in exon 31. In order to detect homozygous mutations in exon 41 
(see section 6.5.1.1) PCR products for exon 41 were mixed in a 1:1 ratio with known wild-
type PCR products at the stage of ‘duplexing’, in order to generate homo and heteroduplexes. 
This work was all performed using the Transgenomic WAVE® system (Transgenomic Ltd.); 
column temperatures for analysis were determined by examination of PCR product melt 
profiles generated by WAVE navigator software. 
Technical assistance for the work presented in this chapter was provided by Fenella Marley.  
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6.3.2.4 Sequencing  
Direct sequencing was performed on any samples showing abnormalities on restriction digest 
or DHPLC. All sequencing was carried out using the dideoxy DNA sequencing method as 
described in section 2.7. The consequences of mutations on the amino acid sequence were 
predicted according to LRRK2 cDNA sequence deposited in Genbank (accession number 
AY792511). The effects on protein structure and function were predicted using the Protein 
Sequence Analysis Launcher (ProSAL)- (http://xray.bmc.uu.se/subnet/prosal.html), the Oriel 
Gene Mining Tools- (http://bioinfo.itb.cnr.it/oriel/spilce-view.html) and the Exonic splicing 
enhancers finder (ESEfinder)- (http://rulai.cshl.edu/tools/ESE2).  
 
 
6.3.2.5 Statistical analysis 
I performed statistical analysis using the SPSS for Windows release 15.0 (SPSS Inc, Chicago, 
Ill., USA). Observed genotypes were compared with the Fisher’s exact test (two-tailed) and 
interpreted as significant if the distribution differed by p<0.05. Power calculations were made 
using a program developed by Heather Cordell in Microsoft Excel, and with the advice of a 
statistician, Dr Sayeed Haque, Department of Psychiatry, University of Birmingham. 
 
 
6.4 Results 
6.4.1 Genetic studies 
In total I identified 15 heterozygous LRRK2 sequence variations in this study, five novel 
variations and ten variations previously described in other studies. Seven variations were in 
the coding sequence, which lead to nonsynonymous amino acid substitutions, and eight were 
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intronic variations. The genotype frequencies did not deviate from those predicted by Hardy-
Weinberg equilibrium (HWE) in either PD subjects or controls.  
Of the known pathogenic LRRK2 mutations, one heterozygous carrier of the exon 41 mutation 
G2019S was identified from the Birmingham PD study by RFLP, and two heterozygous 
carriers of the mutation were identified by DHPLC from the PD GEN collection (figures 6.3 
and 6.4). One heterozygous carrier of the exon 31 mutation R1441C was identified by DHPLC 
from the PD GEN collection (table 6.2.and figure 6.4). Furthermore, five novel LRRK2 
variations were identified by DHPLC in samples from the PD GEN collection, of which one 
was a coding sequence variation, p.P2093P, which is predicted to alter the amino acid 
sequence of LRRK2 downstream of the Proline at 2093. Cross species alignment of P2093 
reveals that this region is generally conserved (see figure 6.5). In addition, one intronic 
variation, IVS40+48C>T, was also found in the homozygous state. These results are 
summarised in tables 6.3-6.4. DHPLC chromatograms for all eight exons can be found in 
appendix F. 
There were 2 LRRK2 variantions detected with a minor allele frequency (MAF) of 3% or 
higher, c.4624C>T and IVS40+48C>T. The genotype frequencies did not deviate from those 
predicted by Hardy-Weinberg equilibrium (HWE). The genotype and allele frequency of these 
variations was tested against control data for evidence of association with disease. A similar 
genotype and allele frequency was observed in patients and controls for both of these 
variations, and statistical analysis failed to provide evidence of an association with disease (p-
values of 0.624 and 0.327 respectively). However, this was not designed as an association 
study and the analysis must be interpreted with caution, given the relatively small number of 
cases and controls used, and the low minor allele frequencies of 0.03 and 0.125 for these 
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variations. With a minor allele frequency of 0.03, this study only had 35% power to detect a 
difference with an odds ratio of 1.8, whilst for a minor allele frequency of 0.125 the study had 
75% power to detect a difference with an odds ratio of 1.8.   
 
. 
 
 
 
  1        2         3         4        5         6         7           8        9 Base  
pairs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Agarose gel electrophoresis of exon 41 PCR products digested with 
Sfc I enzyme. The PCR products were digested with SfcI as described in section 
2.6 and then run on a 2.5% agarose gel at 120V for 2 hours to ensure clear band 
separation. The digested PCR product was 257 base pairs in length in wild-type 
and 239 base pairs if the variant was present, as indicated by arrows. Lane 1 
represents the sizing ladder run on the gel, a low molecular weight DNA ladder 
(New England Biolabs). Lane 2 represents a digested PCR product from a positive 
control for the heterozygous G2019S mutation. Lanes 3-8 represent digested PCR 
products from wild-type subjects and lane 9 represents a digested PCR product 
from a subject newly identified as a heterozygous carrier of the G2019S. 
Abbreviations: bp= base pairs. 
 257bp  350    - 
  300    - 
  
  250    - 
  200    - 
  150    - 
 239bp  75      - 
 50      - 
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DHPLC Chromatograms 
Exon 
DHPLC 
column 
temperatures Wild Type 
Nucleotide 
change & 
predicated Variant protein change 
c.4321C>T 
59.5°C 
R1441C  
60.0°C 
c.4321C>T 
R1441C 
31 
 
c.4321C>T 
61.5°C 
R1441C 
 
 
 
 
 
 
 
 
 
Table 6.2 Screening for LRRK2 variants in exon 31 by denaturing high performance liquid 
chromatography (DHPLC). PCR reactions were performed for eight LRRK2 exons as described in 
section 6.3.2.1 and then DHPLC used to screen for variants. This table demonstrates DHPLC 
chromatograms for exon 31, at three different column temperatures, for the LRRK2 mutation R1441C from 
subjects who were known to be wild-type or heterozygous carriers of this mutation. The chromatograms 
for 60.0°C and 61.5°C show one peak for the subjects who were wild-type, representing homoduplexes 
only, and two peaks for the subjects carrying the variants, representing a mixture of homoduplexes and 
heteroduplexes. This technique allows discrimination between wild-type and mutants for this variation. 
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 Ai Aii 
Bii Bi 
Cii Ci 
Figure 6.4 Mutant and wild-type chromatograms for pathogenic LRRK2 
mutations and novel non-synonymous LRRK2 variant. Panels Ai and Aii- mutant 
and wild-type chromatograms for the c.6055G>A (G2019S) mutation in exon 41. 
Panels Bi and Bii- mutant and wild-type chromatograms for the c.4321C>T (R1441C) 
mutation in exon 31. Panels Ci and Cii- mutant and wild-type chromatograms for the 
c.6279delT (P2093P) variation in exon 42.  Arrows indicate position of nucleotide 
variations. 
 - 246 -
Chapter 6                                          Molecular Genetic Analysis of LRRK2 in UK Sporadic PD                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     hs I Q G K L P D P V K E 
     mm I Q G K L P D P V K E 
     rn I Q G K L P D P V K E 
     gg - - - - - - - - - - - 
     tn V Q R K L P D P V K H 
 
  
 
 
 
 
 
2527
Ex 51 
LRR ROC COR Kinase WD40 
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Figure 6.5  Schematic representation of LRRK2 protein domain structure, a novel LRRK2 coding 
sequence variants identified in this study, and the cross species protein alignment of this variant. 
Panel A= Schematic representation of LRRK2 exons 1-51 with three novel amino acid variant described 
in this study. Corresponding exon number is shown in black. Panel B= Schematic representation of 
LRRK2 protein structure from residue 1-2527. Abbreviations: ANK=ankyrin repeat region; COR=C 
terminal of Ras; Ex=exon; LRR=leucine-rich repeat domain; Roc=Ras of complex (GTPase); WD40= 
domain of 40-60 amino acids which terminate in a Trp-Asp (W-D) dipeptide. Panel C= Cross species 
alignment of LRRK2. Human (Homo sapiens, hs) LRRK2 protein AAV63975.1 aligned with other 
orthologs from Mouse (Mus musculus, mm) NP_080006; Rat (Rattus norvegicus, rn) XP_235581; 
Chicken (Gallus gallus, gg) XP_425418.1; and Tetraodon (Tetraodon nigrovirdis, tn) CAG05593.1. * 
Represents amino acid of interest in this novel variant. X Represents conserved amino acid across 
species. Adapted from Zimprich et al. 2004, Mata et al. 2006 and Nichols et al. 2007 [27], [18], [26].  
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Nucleotide 
Change Exon 
Genbank 
reference 
number 
Predicted 
protein 
change 
LRRK2 
Domain 
Number of Number of 
sPD patients  controls in 
in which which 
change change 
identified identified 
(%) (%) 
c.4321C>T 31 rs33939927 p.R1441C ROC 1/436 (0.2) 0/242 (0) 
c.4624C>T 32 rs33958906 p.P1542S COR 22/350 (6.3) 4/89 (4.5) 
c.4541G>A 32 rs35507033 p.R1514Q COR 8/350 (2.3) 3/89 (3.4) 
c.5606T>C 38 rs35602796 p.M1869T COR 0/314 (0) 1/75(1.3) 
c.6055G>A 41 rs34637584 p.G2019S Kinase 3/463 (0.6) 0/180 (0) 
c.6241A>G 42 rs33995883 p.N2081D Kinase 10/350 (2.9) 5/221 (2.3) 
c.6279delT 42 N/A p.P2093P Kinase 0/350 (0) 1/221 (0.5) 
 
 
 
 
 
Table 6.3 Seven LRRK2 coding sequence variations which lead to non synonymous 
amino acid substitutions identified in this study of sPD with control data. Variant not 
previously described in the literature is shown in bold, pathogenic mutations are shown in 
red, other variants are known single nucleotide polymorphisms (SNPs).  
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 Number of Number of  sPD patients  Genbank controls in  Nucleotide in which Intron  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.4.2  Clinical studies-subjects with known pathogenic and novel LRRK2 mutations 
The clinical features of the four subjects who were identified as heterozygous carriers of 
pathogenic LRRK2 mutations, which have previously been shown to segregate with disease, 
are given in detail in appendix D and summarised in table 6.5. In addition the demographics of 
the two controls, who were found to be heterozygous carriers of the putatively pathogenic 
M1869T mutation, and the novel p.P2093P variation, respectively, are also given.  
 
Change reference which change change number identified identified (%) (%) 
IVS24+31T>C 24 N/A 1/352 (0.3) 0/90 (0) 
IVS24+46G>T 24 N/A 1/352 (0.3) 0/90 (0) 
IVS38-9A>G 37 rs4128646 2/314 (0.6) 0/75 (0) 
IVS38+35G>A 38 rs1748434 15/314 (4.5) 0/75 (0) 
IVS38+54T>C 38 N/A 1/314 (0.3) 1/75 (1.3) 
IVS38+80A> 38 N/A 1/314 (0.3) 0/75 (0) 
IVS40+34T>C 40 rs1744415 7/348 (2.0) 3/89 (3.4) 
IVS40+48C>T 40 rs2404834 86/348 (24.7) 17/89 (19.1) 
Table 6.4 Eight LRRK2 intronic sequence variations identified in 
this study of sPD with control data. Novel variations are shown in 
bold, other variants are known single nucleotide polymorphisms 
(SNPs).  
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Age at  LRRK2 ID &  Age at F/H  Initial H&Y L-Dopa 
Gender evaluation disease MMSE onset PD symptoms stage response mutation 
PD237 
M 
71 70 No 
Unilateral 
tremor, 
bradykinesia 
N/A N/A Good G2019S 
PP0293 
F 
78 76 No N/A 2.5 30 Good G2019S 
PP0360 
M 
61 60 No N/A 1 28 Good G2019S 
PP0071 
F 
71 61 No N/A 3 29 Good R1441C 
PC109 46 N/A No N/A N/A N/A N/A M1869T 
F 
PC157 49 N/A No N/A N/A N/A N/A P2093P 
F 
 
 
 
 
 
Table 6.5 Demographics and clinical features of the subjects and controls carrying pathogenic 
LRRK2 mutations, and a novel LRRK2 variation. Abbreviations: M= male; F= female; FH= family 
history; L-Dopa= levodopa; H&Y stage= Hoehn and Yahr stage; MMSE= mini mental state 
examination score. 
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6.5 Discussion 
In this chapter eight ‘hot spot’ exons of LRRK2 was screened for known and novel mutations 
in a large cohort of UK subjects with predominantly sPD. In total 15 heterozygous LRRK2 
sequence variations were identified. Of the known pathogenic LRRK2 mutations, which have 
been shown to segregate with disease, three subjects were heterozygous carriers of the 
G2019S mutation (0.6%) and one subject was a heterozygous carrier of the R1441C mutation. 
Of the previously reported putatively pathogenic LRRK2 mutations, for which disease 
segregation data is not available, one unaffected control individual was found to be a 
heterozygous carrier of the M1869T mutation. Furthermore, five LRRK2 variations were 
identified which have not previously been described, one of which was a coding sequence 
variation (p.P2093P) identified in a control individual, which is predicted to alter the amino 
acid sequence of LRRK2 downstream of the Proline at 2093. All of these LRRK2 variations 
are shown below in figure 6.6.  
There have been very few previous studies in which extensive screens of LRRK2 for known 
and novel mutations have been performed in large cohorts of subjects with sPD. The most 
comparable is by Grimes et al. who screened seven exons (19, 24, 25, 31, 35, 38 and 41) also 
by DHPLC for known and novel variations in 230 unselected Canadian PD patients and 129 
controls [732]. In their cohort 63% of subjects were men, compared to 66% in the PD GEN 
cohort; 34% had a positive family history of PD compared to 15% in the PD GEN cohort and 
the average age of disease onset was 57.7 compared to 67.2 in the PD GEN cohort. They did 
not identify any of the known pathogenic mutations, but did find five novel and two known 
intronic sequence variants [732]. The only LRRK2 variation identified in both studies, the 
intronic change IVS38+35G>A (rs17484342), was found at a minor allele frequency of 0.02 in 
both studies. 
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Paisan-Ruiz et al. screened the whole coding region of LRRK2 in 272 subjects with PD from 
the USA, 24% of whom had a positive family history of the condition, and 275 neurologically 
normal controls. The authors identified 90 LRRK2 variants (exonic and intronic). Four subjects 
with PD carried the G2019S mutation (1.5%), and six novel LRRK2 nonsynonymous disease 
specific variants were also identified [666].  
Skipper et al. performed a screen of 29 LRRK2 exons (23-51) in 160 subjects with PD from 
Singapore. These subjects had a positive family history of PD, but it was not compatible with 
AD inheritance, and they had previously screened negative for the G2019S mutation. Any 
putative LRRK2 variants identified in this initial screen were then screened for in 470 sPD 
patients. They found two potentially pathogenic variants, R1067Q and an intronic variant 
IVS33+6T>A, which decreases the consensus donor splice site sequence. Screening for these 
variants in the 470 sPD cases and 630 controls also from Singapore revealed no more R1067Q 
variants, but there were three PD subjects heterozygous for the IVS33+6T>A variant [690]. 
There is only one previous study in which a large cohort of UK subjects with sPD was 
screened for LRRK2 mutations. This study only screened for mutations in exon 41 and found 
the heterozygous G2019S mutation in 1.6% of their cohort of 482 subjects [284]. 
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Ex41   R1441C M1869T      A G2019S
 
  
 
 
The different categories of LRRK2 variations identified in our study are discussed below 
individually in terms of phenotype-genotype correlation, and for our understanding of the 
importance of genetic factors in apparently sPD. Unfortunately limited clinical data was 
available on subjects from the PD GEN study. 
 
 
 
 
 
 
  
 
 
 
 
 
    B 
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Figure 6.6 Schematic representation of LRRK2 domain structure and LRRK2 sequence variants 
identified in this study of sPD. Panel A= Schematic representation of LRRK2 exons 1-51 with 
sequence variants identified in this study. Putatively pathogenic amino acid substitutions are shown 
above, with those segregating with disease in red. Novel changes identified in this study are shown in 
blue. Variants believed to be polymorphisms are shown below. Corresponding exon numbers are 
shown in black. Panel B= schematic representation of LRRK2 protein structure from residue 1-2527, 
with estimated domain boundaries indicated by residue numbers beneath Abbreviations: ANK=ankyrin 
repeat region; COR=C terminal of Ras; Ex=exon; LRR=leucine-rich repeat domain; Roc=Ras of 
complex (GTPase); WD40= domain of 40-60 amino acids which terminate in a Trp-Asp (W-D) 
dipeptide. Adapted from Mata et al. 2006 and Nichols et al. 2007 [18], [26].
Ex 1 
1 
Ex32 
R1514Q 
P1542S
 
Ex 51 
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6.5.1 Previously described pathogenic mutations- G2019S and R1441C 
The pathogenic roles of G2019S and R1441C have been established on the basis of absence in 
large number of control chromosomes, co-segregation with disease, cross species conservation 
and predicted crucial structural position of the amino acids involved [27], [283], [290], [281], 
[289], [703], [292]. Further evidence of support of a pathogenic role for these mutations 
comes from in vitro expression studies of several mutant LRRK2 proteins, including G2019S 
and R1441C, which have demonstrated toxicity in cultured cells [661], [457], [691], [664], 
[312]. Biochemical studies on cultured cells transfected to express LRRK2 have also 
demonstrated a modest (0.5- to 3-fold) but consistent increase in kinase activity for the 
G2019S mutation [429], [661], [691], [692]. The functional effects of LRRK2 mutations are 
covered in more detail in chapter 7.  
 
6.5.1.1 The G2019S mutation 
The mean age at presentation of subjects carrying the G2019S mutation was 68.7 years (SD 
8.1), with a range of 60-76. All three subjects had good response to Levodopa therapy, there 
was no evidence of major cognitive deficits and where information is available the phenotype 
appeared typical for IPD. This is in general agreement with previously reported findings, 
although in some studies a wider age of disease onset and more benign disease course has 
been reported [282], [284], [283], [677], [704], [678], [705], [682], [706], [675].  
Interestingly the mean age of disease onset in our fPD subjects carrying the G2910S mutation 
was younger (54) than for our sPD subjects (68.7), although this difference was not 
statistically significant (p=0.06) and is probably due to small group sizes. The phenotype of all 
these subjects was for the most part typical of IPD. The reason for the younger age of onset is 
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unclear, although reporting bias must be considered as subjects with a strong family history of 
PD may recognise and report symptoms earlier in the disease course. 
Subjects with fPD who are homozygous for the G2019S mutations have been reported 
previously [681], as outlined in section 5.1.3. Unlike in a previous study of LRRK2 in sPD 
which used DHPLC as a screening technique [732] I specifically looked for this homozygous 
change. I achieved this by mixing PCR products for exon 41, of unknown genotype, with 
known wild-type PCR products for exon 41 in a 1:1 ratio at the stage of ‘duplexing’, in order 
to generate homo and heteroduplexes, as described in section 6.3.2.3. I did not detect the 
homozygous G2019S mutation in any of the subjects, confirming its rarity and suggesting that 
the homozygous mutation may only be of relevance in fPD.    
The high prevalence of the G2019S mutation in sPD in many different populations, and its 
occasional occurrence in controls, is probably explained by its reduced penetrance, with 
estimates ranging from 15-17% at age 50, increasing to more than 50% by age 80, depending 
on cohort [669], [704], [721], [281], [675].  
The majority of samples were screened for the G2019S mutation by DHPLC, as discussed 
below. However, data has also been included on some samples from the Birmingham PD, 
NDD and PINE studies which were screened by RFLP analysis as detailed in section 6.3.2.2. 
This was from preliminary screening work which I performed before I had access to the 
DHPLC machine.  
 
6.5.1.2 The R1441C mutation  
The subject carrying the R1441C mutation had onset of disease aged 61, with good Levodopa 
response and no evidence of major cognitive deficit, again in general agreement with previous 
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findings [27], [703] [293], [280], [718], [666]. The fPD subject from our study who carried the 
R1441C mutation had onset of disease aged 71 and her phenotype was again typical for IPD. 
As discussed in section 5.5.2.2, the p.R1441 amino acid residue is the second most common 
location of pathogenic substitutions, although the majority of previously reported R1441C 
mutation carriers had fPD. Our study is the first reported identification of this mutation in a 
UK sPD cohort, confirming its importance in this population. 
 
6.5.1.3 Summary 
In my study of UK sPD, pathogenic LRRK2 mutations were identified in 4 out of 467 (0.9%) 
subjects screened. The mean age of onset of symptoms of the subjects carrying the pathogenic 
LRRK2 mutations was 66.8 (SD 7.6), with a range of 60-76, and the phenotype appeared 
typical for IPD. Our findings confirm the importance of LRRK2 mutations in this population 
and raise the question as to whether screening for these pathogenic mutations in sPD should be 
considered in routine clinical practice. However, as discussed in section 5.5.2.3, there is as yet 
no therapy which is proven to be preventative or to alter the course of PD, and incomplete 
penetrance and phenocopies have also been reported in several LRRK2-positive families [283], 
[287], [281], [279], [282], [290], [294]. Therefore I believe that until a clear set of guidelines 
for testing and counselling has been established, screening for LRRK2 mutations in sPD 
should remain a research tool.  
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6.5.2 Non synonymous coding sequence variations 
6.5.2.1 The M1869T mutation 
In this study one heterozygous carrier of the putatively pathogenic missense mutation, 
M1869T (c.5606T>C in exon 38), was identified in a control subject. This individual was 46 
at the time of entry to the study and did not have a family history of PD (see table 6.5). As 
previously discussed in section 5.5.3.2, the M1869T mutation is located in the COR domain of 
LRRK2 and the predicted consequence of mutations in this region has been to influence the 
downstream kinase activity through perturbation of the GTPase domain [663], [723], [691]. 
As discussed in section 5.5.3.2 the M1869T mutation was identified in one proband subject 
from my fPD study. There are two previous reports of this mutation, one in fPD and one in 
sPD [293], [289]. The M1869T mutation has not previously been reported in an unaffected 
subject, indeed in the previous studies the variation was not found in 1000 and 278 controls 
respectively [293], [289]. The finding of the M1869T mutation in a control subject goes 
against a proposed pathogenic role for this mutation, as does a previous report that the proband 
case who carried the mutation had an affected sibling who did not carry the mutation [293]. 
However, the unaffected individual in my study who carried the mutation was only aged 46 
and she may be at risk of developing PD later, in keeping with the age-related penetrance 
observed in other LRRK2 mutations [283], [287], [281], [279], [281], [287], [721].  
Therefore, the M1869T mutation may not be pathogenic, or it may represent a risk factor for 
PD. To be certain of the true pathogenicity of this mutation co-segregation with disease in a 
large pedigree and/or functional evidence of a pathogenic effect of the mutation are required. 
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6.5.2.2 The P2093P variation 
One novel non-synonymous coding sequence variation was identified in this study, 
c.6279delT (p.P2093P) in exon 42, which was found in a single control subject. This 
individual was 49 at the time of entry to the study and did not have a family history of PD (see 
table 6.5). 
The c.6279delT (p.P2093P) variation results in a shift in the reading frame, with a predicted 
alteration of the amino acid sequence subsequent to the Proline at position 2093 (which 
remains unaltered). The leucine at position 2093 is conserved across species (see figure 6.5) 
suggesting the importance of this region for proper function of LRRK2. Furthermore, this 
variation lies within the centre of the coding region for the kinase domain of LRRK2, and the 
alteration of the amino acid sequence in this location would be expected to affect protein 
function. Interestingly this novel variation is within the same exon as the novel 
c.6187delCTCTA (p.L2063STOP) mutation which I detected in my fPD cohort. There is 
evidence from biochemical studies on cultured cells transfected to express LRRK2 that the 
G2019S mutation, within exon 41 and hence also in the coding sequence for the kinase 
domain, causes a modest (0.5- to 3-fold) but consistent increase in kinase activity [429], [661], 
[691], [692]. However, the I2020T mutation, also within exon 41, has been shown to either 
modestly increase [428], [691], or decrease kinase activity [692].  
The finding of the P2093P variation in a control subject only goes against a pathogenic role 
for this variation. This variation was also not found in a screen of exon 42 in my fPD cohort 
and has not been described before in fPD, although it would be valuable to screen for this 
variation in a larger cohort of subjects with sPD, such as I performed for the novel 
c.6187delCTCTA (p.L2063 STOP) variation identified in the fPD cohort (see section 5.4.1.2). 
However, the unaffected individual in my study who carried the mutation was only aged 49 
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and, as for the unaffected subject carrying the M1869T mutation discussed above, may be at 
risk of developing PD later, in keeping with the age-related penetrance observed in other 
LRRK2 mutations [283], [287], [281], [279], [281], [287], [721].  
Therefore, to determine whether the P2093P variation may be pathogenic, or even a risk factor 
for PD, co-segregation with disease in a large pedigree and subsequent functional evidence of 
a pathogenic effect for the variation are required. 
 
6.5.2.3 Other nonsynonymous variants 
There were three other known nonsynonymous variants identified in this study (table 6.3), all 
of which reside in functional domains but are not believed to be pathogenic. The heterozygous 
variants c.4541G>A (p.R1514Q), c.4624C>T (p.P1542S) and c.6241A>G (p.N2081D) were 
found at the same, or similar, frequencies in patients and controls. The R1514Q and P1542S 
variations were identified at the same frequencies in patients in both the sPD and fPD cohorts. 
Furthermore all three variations have previously been identified in patients [27], [293], [280], 
[26] and controls [665], [666] at similar frequencies.  
 
6.5.3 Intronic variations 
Eight intronic sequence variations were identified in this study, including four novel variations 
(see table 6.4). The aim of the work in this chapter was to screen the coding sequence of 
LRRK2, the identification of intronic changes was as a consequence of the location of the 
primers in the intronic sequence.  
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Two of the four known intronic variations (IVS38+35G>A and IVS40+48C>T) were also 
identified in our fPD cohort at the same and similar minor allele frequencies of 0.02 and 0.1 
respectively. Indeed they have also previously been identified in a fPD cohort [280]. 
Although the intronic variations IVS38-9A>G and IVS38+35G>A were identified in patients 
only in my study, they have been identified previously in sPD patients and controls at similar 
frequencies [732], [666]. Intronic variations IVS40+34T>C and IVS40+48C>T were 
identified in both patients and controls at similar frequencies in the two groups. Indeed 
statistical analysis of the IVS40+48C>T variation failed to provide evidence of an association 
with disease (p-value of 0.327).  
Each of the four novel variants IVS24+31T>C, IVS24+46G>T, IVS38+54T>C, and 
IVS38+80A>G were identified in one subject only, although only IVS38+54T>C was detected 
in the control cohort. In silico analysis (http://bioinfo.itb.cnr.it/oriel/spilce-view.html) of the 
novel intronic variations suggests that none of them appear to significantly modify intron/exon 
splice sites.  
Therefore the eight intronic variations identified in this study are likely to be neutral, disease 
unrelated changes. 
 
6.5.4 DHPLC as a method for mutation screening 
The secondary aim of the work in this chapter was to evaluate the use of DHPLC as a high 
throughput screening tool for detecting LRRK2 mutations. The analysis temperatures for each 
of the exons were determined through the use of the WAVE navigator software, and the 
availability of positive control samples from our fPD study for six of the exons. The two 
smaller exons (24 and 25) only required the use of two analysis temperatures, whilst the other 
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exons required three to four temperatures in order to ensure that the whole of the exon was 
screened by the technique (see appendix F). The chromatograms obtained from the mutant 
samples were easily distinguished from wild type profiles with both the ‘by-eye’ analysis (see 
appendix F) and the use of the Transgenomic ‘mutation detection’ software. Whilst the 
availability of positive controls is important in the optimization of DHPLC, I clearly 
demonstrated the ability of the technique to detect both variations for which I did not have 
positive controls (e.g. p.N2081D) and novel changes (e.g. IVS24+31T>C). The sensitivity of 
the technique is also demonstrated by its ability to detect intronic variations (see table 6.4) for 
which it was not specifically optimised. Furthermore the technique appeared highly specific, 
with only 12 DHPLC reactions demonstrating abnormal chromatograms, suggestive of a 
mutation, which were subsequently shown to be wild-type on sequencing.   
There are several methods which I could have used in this part of the study, for example direct 
sequencing, single-strand conformation polymorphism (SSCP) and denaturing gradient gel 
electrophoresis (DGGE). Whilst direct sequencing is considered the gold standard in its ability 
to detect known and novel sequence variations, DHPLC does have several advantages, 
namely: high sample throughput, increased speed of analysis, reproducibility and cost 
effectiveness [493]. Whilst it is argued that DHPLC could miss some variations in comparison 
to sequencing, high levels of sensitivity ranging from 92-100% have been reported for 
fragments that are 198-732 base pairs long [488], [489], [492]. The exons analysed in this part 
of the study fell within this range. Further validation of DHPLC for this work comes from my 
fPD study in which I sequenced the eight exons studied here by DHPLC. I did not detect any 
LRRK2 variations by sequencing which were not detected by DHPLC. Our group has a similar 
experience from studies of other genes with these techniques. Furthermore, even sequencing 
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will miss some types of mutations such as copy number variation, or mutations in the 5’or 3’ 
untranslated or promoter regions if appropriate primer sets are not used. Therefore in such a 
large scale screening project as was undertaken in this chapter, the most sensitive but also 
practical and cost effective technique available must be used.   
SSCP is based on the principle that changes in nucleic acid composition affect the secondary 
structure of single stranded DNA, therefore mutations which affect the mobility of the 
fragment can be detected by running products on polyacrylamide gels under non-denaturing 
conditions [735], [492]. Much like DHPLC this technique also requires optimisation, but the 
fragment size should ideally be small (150-200bp) and even at optimal sensitivity it can only 
detect 80-90% of base changes [736]. A form of SSCP has also now been developed for 
automated capillary electrophoresis, using fluorescence as the method of detection (F-SSCP), 
although this does require access to more expensive equipment [492].  
In DGGE double stranded DNA fragments are separated according to the melting behaviour of 
the sequence. The PCR products are formed into heteroduplexes as in DHPLC and are then 
electrophoresed through a polyacrylamide gel containing a gradient of denaturant. The mutant 
or wild-type homoduplex and heteroduplex molecules are separated according to their 
different melting behaviours caused by differences in their sequence, or by mismatches 
present in the area of mutation. The homo and heteroduplexes denature at different times, 
which leads to separation on the gel and the formation of a unique banding pattern [737], 
[736]. Fragment size can be up to 1000bp and the addition of GC clamps to amplification 
primers can increase the sensitivity of this technique to approximately 95% [738], [736].  
Therefore in comparison to these gel based methods DHPLC is highly automated and 
efficient, making it much less labour intensive and more suitable for large scale screening 
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projects, such as that undertaken here [491]. Furthermore the sensitivity of DHPLC is also 
more comparable to that of sequencing with a reported specificity of 100% [490], [493], [492]. 
One criticism of DHPLC is that it can miss homozygote changes. However of the known 
pathogenic mutations, homozygote changes have only been reported for the G2019S mutation 
[669], [681]. Therefore I screened for this homozygous change by ‘spiking’ all my PCR 
reactions for exon 41 with known ‘wild-type’ PCR product in order to generate homo and 
heteroduplexes. This is a well recognised technique to enable DHPLC to detect such changes 
[739], [493]. However as this is more time consuming, and homozygous mutations have not 
been described in other exons, I did not ‘spike’ my PCR products with ‘wild-type’ PCR 
product for the other exons.  
Another potential limitation of the use of DHPLC in screening for LRRK2 mutations is the 
high frequency of common polymorphisms in some exons, such as p.S1647T in exon 34 and 
p.T2397M in exon 49, and the finding of several different polymorphisms in the same 
amplicon, as identified in the fPD part of this study (see tables 5.1-5.4). This means that for 
some exons DHPLC would not be cost effective as too many samples would still need to be 
sequenced to confirm the presence of heterozygote variations identified on DHPLC. However 
for the majority of the remaining LRRK2 exons this technique would clearly be suitable and 
indeed has been used in some previous studies of the gene [740], [671], [732].  
 
6.6 Future work 
There are several further molecular genetic and functional studies that can be done to further 
our understanding of the importance of LRRK2 in sPD. 
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First, it would be valuable to extend my screen of LRRK2 in sPD to include all 51 exons. I 
have demonstrated the effectiveness of DHPLC as a mutation screening technique, and 
screening the whole LRRK2 coding sequence using this method would permit a complete 
comparison between the LRRK2 variation frequency in UK fPD and sPD. However, some 
exons may not be suitable for DHPLC, as discussed above, and may need to be screened by 
direct sequencing. The remaining exons could be screened by DHPLC, although as I do not 
have access to positive controls for all the exons I would need to generate these in order to 
optimise the DHPLC reactions. One way to generate mutations would be via site directed 
mutagenesis, a technique which has been used successfully in DHPLC method validation in 
the past [741].      
Second, as discussed in section 5.6, analysis of copy number variation of LRRK2. Copy 
number variation in LRRK2 has only been studied once in sPD, and no whole-gene deletions 
or duplications were detected [666]. Multiple ligation-dependent probe amplification (MLPA) 
could be used to detect the presence or absence of copy number variation in LRRK2 in my sPD 
cases, to ensure that this is not another mechanism by which LRRK2 could cause sPD. As 
discussed in section 4.3.2.3, MLPA is a well validated and high resolution method to detect 
copy number changes of up to 45 loci in one relatively simple, semi-quantitative PCR-based 
assay [618], [619], [620].  
Third, in order to confirm the findings of my extensive study of LRRK2 in sPD, and those of 
the previous two similar studies in North American cohorts [732], [666] it would be valuable 
to repeat this work on other sPD cohorts around the world. This would for two reasons: (i) to 
determine whether the novel c.6279delT (p.P2093P) variation described in this study is found 
in subjects with sPD in other populations. (ii) It would enable us to determine whether there 
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are any other LRRK2 variations in sPD, not present in the existing study cohorts, which may 
be important in different populations.  
Fourth, as discussed in section 5.6, given that distinct haplotypes for patients who carry the 
G2019S and R1441C mutations have been identified [673], [718], [280], [719] it would be 
valuable to assess the haplotype of these mutation carriers identified in our study.  
Fifth, further molecular genetic studies are needed to better understand the functional effects 
of both the pathogenic LRRK2 mutations and the novel coding sequence variation identified in 
this study. Our current knowledge of the functional effects of the G2019S and R1441C 
mutations, and the further molecular genetic studies which can be used to determine the 
functional effects of these mutations, and the novel LRRK2 mutations which I detected in my 
study of fPD, are covered in more detail in chapter 7.  
Sixth, as discussed in section 5.6, the concept of digenic parkinsonism has recently been 
proposed. Several authors have identified subjects with LRRK2 and Parkin mutations. 
Although associated phenotypes have not been more severe, there may be potential genetic 
interactions [729], [669], [689]. Therefore it would be valuable to screen the sPD subjects 
found to have pathogenic LRRK2 mutations for mutations within the other four genes for 
Mendelian PD for which there is strongest evidence: Alpha-synuclein, Parkin, PINK1, and DJ-
1. 
 
6.7 Conclusions 
This is the most extensive screen for known and novel LRRK2 mutations performed in a large 
cohort of UK subjects with sPD and is the first use of the PD GEN cohort. Four subjects 
(0.9%) were found to carry known pathogenic mutations, all of whom had late-onset 
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Levodopa responsive PD. Otherwise, screening of the other ‘hot spot’ exons failed to reveal 
any of the other known pathogenic or novel coding sequence variations within this patient 
cohort. I also demonstrated that DHPLC is an effective method for high throughput mutation 
detection in the LRRK2 gene.  
The work presented here confirms the importance of the G2019S and R1441C mutations in 
UK sPD, and suggests that in the future screening for these mutations may become indicated 
in the clinical setting, with appropriate pre-test genetic counselling. 
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7 Functional Analyses of Two Novel LRRK2 Mutations 
 
7.1 Introduction 
In chapter 5 data was presented from my comprehensive molecular genetic analysis of the 
coding sequence of LRRK2 in proband cases from 46 families with three or more members 
affected by PD, compatible with AD inheritance. The most striking finding from this study 
was the identification of three novel coding sequence variations which are predicted to result 
in premature termination codons: D1455G in exon 31, L2063STOP in exon 42 and 
T2397STOP in exon 49.  
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Figure 7.1 Schematic representation of LRRK2 domain structure and three novel 
frameshift mutations identified in familial PD study. Panel A= Schematic representation of 
LRRK2 exons 1-51, with location of the three novel mutations indicated, along with 
corresponding exon numbers above. Panel B= Schematic representation of LRRK2 protein 
structure, from residue 1 to 2527, the estimated domain boundaries are indicated by residue 
numbers beneath. Abbreviations: Ex=exon; Roc=Ras of complex (GTPase); COR=C terminal of 
Ras; WD40= cytoskeleton assembly domain. Adapted from Mata et al. 2006 and Nichols et al. 
2007 [18], [26]. 
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To my knowledge, these are the first LRRK2 frameshift mutations to have been described. The 
introduction to this chapter gives an overview of some of the functional research that has been 
performed on LRRK2 to date, focusing on the current understanding of how pathogenic 
LRRK2 mutations are believed to lead to the development of PD. The results of the functional 
analyses performed on two of these novel LRRK2 mutations are then presented and discussed 
in the context of existing data. 
 
7.1.1 Structure and function of LRRK2  
Initial reports using RT-PCR and Northern blot analysis showed that LRRK2 mRNA is 
expressed in various regions of the neuroaxis, including whole brain, spinal cord, substantia 
nigra and striatum [27], [25]. Subsequent studies have confirmed that LRRK2 mRNA is 
localised to a variety of neuronal populations in human and rodent brains [662], [742], [743], 
[744], [23], [745], [746], [747]. Furthermore all published studies have shown that LRRK2 
protein is highly expressed in the areas of the CNS receiving a dopaminergic input, such as 
caudate-putamen and frontal cortex [662], [742], [743], [744], [746], [656], [663]. 
More recent reports of LRRK2 mRNA expression in the SN of both rodents and humans have 
revealed contradictory results. Investigators used a variety of in situ hybridization and RT-
PCR techniques, with some studies showing low levels or even absence [743], [744], [746], 
whilst others have shown clearly detectable levels [745], [747], [742]. The different results 
obtained may be as a result of biological variability or be due to methodological 
considerations. Furthermore, some recent immunofluorescence analyses have revealed 
LRRK2 protein in dopaminergic neurons of the SN [662], [743], [23].  
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LRRK2 is predominantly a cytoplasmic protein and is associated with cellular membrane 
structures such as mitochondria, Golgi apparatus, endoplasmic reticulum and cytoskeleton 
[429], [428], [661], [656], [662], [312]. Data from cultured mouse primary neurons, suggests 
that both wild-type and mutant LRRK2 associates with lipid rafts [748]. This may be 
important as lipid rafts are known to play important roles in cellular functions such as signal 
transduction, membrane trafficking and cytoskeletal organization [749]. Intriguingly, both 
Parkin and α-synuclein have also been shown to associate with lipid rafts [750], [751], [752]. 
A recent report has also suggested a regulatory role for LRRK2 in synaptic vesicle endocytosis 
[753]. 
LRRK2 acts as a serine/threonine kinase that can undergo autophosphorylation [429], [457], 
[691]. In vitro studies have shown that LRRK2 can phosphorylate the generic kinase substrate 
myelin basic protein  [429]. Recently, other likely more physiological substrates such as ezrin, 
radixin and moesin (the ERM protein family) have been identified [692]. These closely related 
proteins are crucial components that provide a regulated linkage between membrane proteins 
and the cortical cytoskeleton, just below the plasma membrane, and also participate in signal-
transduction pathways [754]. Collapsin response mediator protein (CRMP-2) has also been 
identified as a potential LRRK2 substrate [692]. CRMP-2 is of interest because it is involved 
in regulation of growth cones and microtubule dynamics [755] and it has been shown to 
interact with Numb, an endocytosis-related protein that controls cell number in neurogenesis 
[756], [755]. Furthermore CRMP-2 is expressed in areas active in neurogenesis such as the 
olfactory bulb [757], [758] and phosphorylated CRMP-2 has also been found in neurofibrillary 
tangles in Alzheimer’s disease [759], [760]. 
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Several studies have now shown that through its ROC domain LRRK2 can bind GTP [663], 
[457], [691], [723], [761] although the evidence in support of the ability of LRRK2 to 
hydrolyse GTP is more mixed. Studies using cultured cells have shown a low level, or even an 
absence, of GTPase activity [663], [723], [761]. However, epitope-tagged LRRK2 which was 
produced and purified from transgenic mouse brain expressing human LRRK2, demonstrated 
robust GTPase activity compared to Rac1 [663]. These observations may be due to 
methodological differences between the studies and/or the presence of an LRRK2-specific 
GTPase-activating protein in mouse brains. GTP binding certainly stimulates LRRK2 kinase 
activity and GTP/GDP binding appears to be required for this activity as specific artificial 
mutations that disrupt the GTP/GDP binding site abolish the kinase activity [457], [691], 
[761]. The presence of the protein-protein interaction domains (ankyrin, LRR and WD40) 
suggests that LRRK2, in addition to protein kinase and GTPase activities, may also serve as a 
scaffold to a multiprotein complex. 
The physiological function of LRRK2 is not yet established. However, there is evidence from 
in vitro as well as in vivo over-expression and mutagenesis experiments to suggest that the 
protein is likely to regulate neurite maintenance and neuronal survival. MacLeod et al. used a 
rodent model in which they generated a mouse/human chimera. Over-expression of PD-
associated mutant LRRK2 alleles (G2019S and I2020T) in the kinase domain led to reduced 
neurite complexity, the formation of tau-positive inclusions, lysosomal abnormalities and 
apoptotic cell death [664].  
More recently a Drosophila model for LRRK2-PD was described, in which the investigators 
generated transgenic Drosophila expressing either wild-type human LRRK2 or LRRK2-
G2019S [762]. Expression of wild-type LRRK2 or LRRK2-G2019S in neurons produced 
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adult-onset selective loss of dopaminergic neurons, locomotor dysfunction, and early 
mortality. The expression of mutant LRRK2-G2019S was reported to cause a more severe 
phenotype than expression of equivalent levels of wild-type LRRK2 [762]. We await reports 
on the phenotype and pathology associated with knockout of LRRK2 in rodent models, which 
may provide us with important clues as its function.  
 
7.1.2 Effects of the known pathogenic LRRK2 mutations 
There have been previous studies of the five mutations which are believed to be definitely 
pathogenic: R1441C, R1441G, Y1669C, G2019S and I2020T [18], [278]. In vitro expression 
of several mutant LRRK2 proteins (R1441C, Y1669C, G2019S and I2020T) causes toxicity in 
cultured cells [661], [457], [691], [664], [312]. Some of the LRRK2 protein variants result in 
the formation of aggregates within cultured COS7 cells (transformed African Green Monkey 
kidney fibroblast cells) [661], suggesting that perhaps these mutations can cause misfolding of 
LRRK2. An active kinase domain was also shown to be required for the toxic effect of mutant 
LRRK2 expressed in these cells. This was demonstrated by mutating three residues within the 
kinase domain to create a ‘Kinase-dead’ construct, COS-7 cells were then transfected with 
either full length LRRK2 harboring separate pathogenic mutations, or the ‘kinase dead’ 
protein containing the same mutations. There were fewer aggregates noted within the cells 
transfected with the ‘kinase dead’ version of the protein [661]. 
Biochemical studies on cultured cells transfected to express LRRK2 show a modest (0.5- to 3-
fold) but consistent increase in kinase activity for the G2019S mutation [429], [661], [691], 
[692]. Given the location of residue G2019 within the conserved Mg2+-binding motif of the 
kinase domain it is not surprising that this mutation has an effect on kinase activity. However, 
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since the residue is universally conserved in kinases one might expect the opposite effect i.e. 
the mutation to impair kinase activity.  
The effect of the other LRRK2 mutations on kinase activity is more controversial. Some 
studies have shown the R1441C mutation to increase kinase activity [429] [691], whilst others 
have reported no significant change [661], [692]. The I2020T mutation has been shown to 
either modestly increase [428], [691] or decrease kinase activity [692]. The Y1699C mutation 
has been shown to have either no effect [661], [692], or to cause an increase in kinase activity 
[691]. A modest increase in kinase activity was reported for the R1441G mutant [691], but this 
was not observed in another study [692]. The putatively pathogenic mutations G2385R and 
I1371V do not appear to affect kinase activity [691], whilst the I2012T variant appears to 
decrease kinase activity [691], [692].  
One of the main reasons for these apparently conflicting reports may be due to variation in 
methodological or analytical techniques between the different studies. For example, use of 
autophosphorylation rather than phosphorylation of myelin basic protein or moesin as the 
kinase substrate, how the kinase was expressed or purified with different tags, or whether full-
length or truncated protein was expressed may all contribute to some of the conflicting results. 
It is also possible that changes in kinase activity alone may not be the only, nor even the key, 
noxious effect of LRRK2 mutations.  
The R1441C and R1441G mutations in the ROC domain have been reported to decrease GTP 
hydrolysis activity [663],[723] or increase GTP binding [691]. Furthermore, the I1371V and 
Y1699C mutations located outside the ROC domain, also seem to increase GTP binding [691]. 
Therefore, a predicted consequence of mutations in this region of LRRK2 would be that they 
influence the downstream kinase activity through perturbation of the GTPase domain. Indeed 
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recent information on the crystal structure of the Roc domain confirms that LRRK2 acts as a 
dimmer, with R1441 and I1371 involved in stabilising dimer formation, hence mutations at 
this position could result in decreased GTPase activity [763], [764].  
 
7.1.3 Nonsense LRRK2 mutations 
The importance of the three novel mutations identified in my study is further highlighted by 
the fact that there are only three previous reports of nonsense mutations in LRRK2. None of 
these mutations were reported with any associated functional data. Two point mutations, the 
first one a known SNP, that are predicted to result in truncated proteins have also been 
described c.5175C>T (p.R1725STOP) in exon 36 [293] and c.5620G>T (p.E1874STOP) in 
exon 38 [695]. Both truncated proteins would lack the entire kinase and WD40 domains. No 
clinical details are available for the first of these variations, but the second was identified in a 
Taiwanese subject with sPD. The authors speculated that it could be a disease-causing do novo 
mutation or an inherited mutation displaying reduced penetrance [695]. No relatives were 
available for clinical assessment or genotyping. 
Recently a 4 base pair deletion in the splice donor site of exon 19 (IVS20+4delGTAA) was 
reported in a subject with fPD [665]. Assuming all other LRRK2 exons splice at full length in 
vivo, this deletion would shift the reading frame and correspond to a resultant tuncated protein 
of 771 amino acids. The authors speculated that the mutant mRNA is likely to be degraded by 
a process known as nonsense-mediated decay (NMD) [665].  
NMD is a normal cellular mechanism highly conserved across all eukaryotes examined to 
date. It reduces the abundance of transcripts containing a premature termination codon (PTC) 
to approximately 5-25% of the normal (PTC-free) level. If translated these mRNAs would 
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produce truncated proteins, possibly with dominant-negative or deleterious gain-of-function 
activities [494], [495], [15], [496]. In general only PTCs located more than 50-55 nucleotides 
upstream of a splicing-generated exon-exon junction within mRNA elicit NMD [765], see 
figure 7.2.  
The core NMD machinery is comprised of several factors within a large complex of proteins 
that is deposited on mRNAs at exon-exon junctions during RNA splicing in the nucleus, the so 
called exon-junction complex (EJC). This consists of three trans-acting factors called up-
frameshift (UPF) proteins. One of these proteins, UPF1, is a group I helicase family member 
recruited to mRNAs upon recognition of stop codons by the translation apparatus. Rapid decay 
of PTC-bearing mRNAs is triggered when UPF1 is allowed to interact with the two other UPF 
proteins, UPF2 and UPF3. Other components of the EJC include those in its tetramer core 
(eIF4AIII, MLN51, and the Y14/MAGOH heterodimer), which also participate in NMD. In 
addition, NMD requires factors that regulate UPF1 phosphorylation. The Suppressor with 
Morphogenetic effect on Genitalia-1 (SMG-1) protein phosphorylates UPF1, whereas SMG-5, 
SMG-6, and SMG-7 promote UPF1 dephosphorylation. The requirement for all four of these 
SMG factors implies that a cycle of UPF1 phosphorylation and dephosphorylation drives 
NMD [15], [496]. 
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Figure 7.2 The NMD rule. Nonsense codons located more than 50–55-nucleotides (nts) upstream 
of a splicing generated exon–exon junction within mRNA generally elicit NMD. Removal of introns 
and ligation of resulting exons (Ex) by splicing results in the deposition of an exon junction complex 
(EJC) approx. 20–25-nucleotides upstream of each exon–exon junction. Many mRNAs undergo the 
first (‘pioneer’) round of translation during the process of export, but can be translated by 
cytoplasmic ribosomes (light grey subunits). The SURF complex interacts with EJC and triggers 
NMD. NMD involves mRNA decay from one or both of the 5’ and 3’ ends (dark grey pacmen 
symbolize degradative activities). If PTCs reside less than 50–55 nucleotides upstream of the final 
exon–exon junction or downstream of this junction), then NMD will not occur, and the mRNA is 
remodeled to the steady-state translation initiation complex. Taken from Kuzmiak & Maquat 2006 
[15]. 
Providing evidence of this process in LRRK2-PD would be important and clearly distinct  
from the kinase over-activity models proposed to date for mutant LRRK2. 
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7.2 Aims of the chapter 
The first aim of the work in this chapter was to generate primary lymphoblast and fibroblast 
cell lines from subjects carrying two novel LRRK2 frameshift mutations, L2063STOP and 
T2397STOP, identified in this study. 
The second aim of the work in this chapter was to investigate the effect of these two novel 
LRRK2 frameshift mutations on RNA expression. 
The third aim of the work in this chapter was to assess and optimize three commercially 
available LRRK2 antibodies, and subsequently use these antibodies to investigate the effects 
of the two novel LRRK2 frameshift mutations on protein expression.  
 
7.3 Methods 
The three proband subjects carrying the novel frameshift LRRK2 mutations were asked if they 
were willing to donate blood and skin samples for further research analyses. Only the proband 
subjects from families 12 and 38, who carried the L2063STOP and T2397STOP respectively, 
were willing to participate in these further studies.   
Technical assistance for the work presented in this chapter was provided by Dr Thomas 
Lambert.  
 
7.3.1 Primary cell lines 
The primary lymphoblast and fibroblast cell lines were kindly generated by Professor 
Malcolm Taylor in the Institute for Cancer Studies, at the University of Birmingham. Control 
lymphoblast and fibroblast cell lines were obtained as gifts from Dr Andrew Filer in the 
department of Rheumatology, University of Birmingham. Control fibroblast line 1 (CF1) was 
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from a female subject aged 62, with a 20 year history of sero-positive Rheumatoid arthritis. 
Control fibroblast line 2 (CF2) was from a female subject aged 59 also with a 20 year history 
of sero-positive Rheumatoid arthritis. Control lymphoblast line 1 (CL1) was from a male 
subject aged 30 with no significant past medical history. Control lymphoblast 2 (CL2) was 
from a male subject aged 32 with no significant past medical history. These cell lines were 
subsequently cultured as described in section 2.10. 
 
7.3.2 DNA extraction 
DNA was extracted from fibroblast and lymphocyte cell lines by the use of the DNeasy® kit 
(Qiagen) as described in section 2.10.3.1 
 
7.3.3 RNA extraction and generation of cDNA 
RNA was extracted from fibroblast and lymphocyte cell lines by the use of the RNeasy® mini 
kit (Qiagen) and treated to remove any contaminant DNA with the DNA-freeTM kit (Applied 
Biosystems) as described in section 2.10.3.2. The cDNA was subsequently generated from 
RNA with the High capacity cDNA archive kit, using MultiScribe™ Reverse Transcriptase 
(Applied Biosystems) and an RT-PCR reaction as described in section 2.10.3.3. 
 
7.3.4 PCR fragment analysis and NMD assay 
I designed two primer pairs specific for the cDNA sequence of LRRK2 in order to investigate 
the effect of the L2063STOP and T2397STOP mutations on RNA expression, and to sequence 
the cDNA in this region. They were designed by using the Primer3 program 
(http://fokker.wimit.edu/primer3/input.htm) and spanned at least one non-coding region of 
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LRRK2, to ensure that cDNA rather than any contaminant DNA was amplified. Each PCR was 
optimised as described in section 2.4. The primers selected and reaction conditions are listed 
in appendix C.  
I performed semi-quantitative PCR fragment analysis on these products using a fluorescent-
labeled DNA length marker and GeneScan® software (Applied Biosystems), as described in 
section 2.8, This can be used to assess the relative proportion of wild-type and mutant mRNA 
[485], [486], [487]. The PCR has three phases- exponential, linear and plateau (figure 7.3). In 
the exponential phase the amount of amplified product increases exponentially as reagents are 
not limited. The linear phase is characterised by a linear increase in product as PCR reagents 
become limited and the PCR eventually reaches the plateau phase when the amount of product 
will not change because some reagents become depleted [7]. To ensure that PCR product 
abundance lay within the linear phase of PCR amplification, when the ratio of allele-specific 
products still accurately reflects the relative abundance of target molecules, I selected a PCR 
cycle length of 25 for both reactions. This was on the basis of PCRs I carried out for both 
mutations at cycle lengths of 20, 25 and 31 in order to quantify PCR products by gel 
electrophoresis. This data suggested that at 25 cycles both PCRs are within their linear phases.   
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Figure 7.3 Theoretical plot of PCR cycle number against PCR product amount.  
Panel A: Three phases can be observed for PCRs: exponential phase, linear phase and plateau phase. 
Panel B: Theoretical plot of PCR cycle number against logarithm PCR product amount. Taken from 
Yuan et al. 2006 [7]. 
 
The NMD assay is described in section 2.11. Fibroblast cell lines from subjects carrying the 
L2063STOP and T2397STOP mutations, and two control cell lines (CF1 and CF2), were 
incubated in triplicate with and without 500µM cycloheximide (CHX) (Sigma), a potent 
inhibitor of NMD. All 4 cell lines were at passage number 8. At baseline, 2 and 8 hours cells 
from 3 CHX-treated flasks and 3 untreated flasks for each subject were harvested for RNA 
extraction. cDNA was subsequently generated from each RNA sample (section 2.10.3.3) for 
analysis of the relative proportions of wild-type and mutant mRNA before and after this 
exposure.  
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7.3.5 Sequencing  
All sequencing of DNA and cDNA was carried out using the automated Sanger (dideoxy) 
DNA sequencing sequencing method as described in section 2.7.  
 
7.3.6 Protein extraction 
For the purpose of protein extraction, lymphoblast and fibroblast cells were harvested using 
CytobusterTM protein extraction reagent (Promega) with a protease inhibitor cocktail (Sigma), 
chilled to 4°C. The total protein concentration in each sample was quantified using the Biorad 
DC protein assay (Biorad) according to the manufacturer’s instructions. In order to prepare 
lysates for western blotting, proteins within the samples were denatured by the addition of 
Novex sodium dodecyl sulphate (SDS) sample buffer (Invitrogen) containing 20mM of the 
reducing agent dithiothreitol (DTT) (Sigma) and boiled for 5 minutes (section 2.12.1).  
 
7.3.7 Western blotting 
I prepared polyacrylamide gels with an 8% resolving gel for separating the protein samples, 
gel electrophoresis and transfer (sections 2.12.2-2.12.4). Membranes were incubated with one 
of three primary LRRK2 antibodies NB300-267, NB300-268 or NB110-58771 (Novus 
Biologicals). All three are rabbit polyclonal antibodies, and the secondary antibody used was a 
goat anti-rabbit HRP-conjugated antibody (Dako). 
In order to quantify the amount of LRRK2 protein detected in patient and control samples, the 
membranes were subsequently stripped of the LRRK2 probes using RestoreTM Plus western 
blot stripping buffer (Thermo Scientific), according to the manufacturer’s instructions. Briefly, 
the blot was washed three times for 10 minutes each in PBS-tween, then stripping buffer was 
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added to cover the blot. This was incubated at room temperature for 15 minutes, then removed 
and the membrane washed three times for 10 minutes each in PBS-tween. The membrane was 
then ‘blocked’ as previously described for 1hr at room temperature, prior to being re-probed 
for a 106kDa loading control protein, Nucleolin. This was detected using a mouse monoclonal 
antibody to Nucleolin (abcam) and a goat anti-mouse secondary antibody (Dako). The 
antibody dilution factors are listed below in table 7.1. Antibody application and signal 
detection are described in sections 2.12.5-2.12.6.  
In order to quantify the amount of LRRK2 protein detected in patient and control samples 
band strength estimation, with comparison to the Nucleolin loading control, was performed 
with reflectance densitometry, using the Genescan (SynGene) gel documentation system and 
Genetools software (SynGene).  
 
 
 
 
 
 
 
 
 
 
 
 
 - 281 -
Chapter 7                                                  Functional Analyses of Two Novel LRRK2 Mutations                     
Dilution factor (in 5% dried 
Primary antibodies 
milk powder/PBS-tween) 
LRRK2 (NB267)-rabbit (Novus Biologicals) 1:100 
LRRK2 (NB268)-rabbit (Novus Biologicals) 1:500 
LRRK2 (NB58771)-rabbit (Novus Biologicals) 1:500 
Nucleolin (4E2)- mouse (abcam) 1:5000 
Dilution factor (in 5% dried 
Secondary antibodies 
milk powder/PBS-tween) 
Goat anti-rabbit (Dako) 1:2000 
Goat anti-mouse (Dako) 1:5000 
 
Table 7.1 Antibody dilutions used in western blots.  
 
 
 
 
 
 
 
 
 
 
 
7.3.8 Statistical analysis 
 LRRK2 
Figure 7.4 Example of immunoblotting of human lymphoblast lysates with commercially 
available LRRK2 antibodies. Panel A= Blotting with NB58771 at dilution factor 1:10000, Panel 
B=Blotting with NB267 at dilution factor 1:500, and Panel C=Blotting with NB268 at dilution factor 
1:500. Lanes 1, 2 and 3 were loaded with decreasing amounts of protein: 50µg, 25µg and 12.5µg, from 
human lymphoblast lysates from a single control subject. All recognized a major 286 kDa LRRK2 
human protein band, as indicated by the arrows. Additional bands were detected, the larger bands were 
thought to represent LRRK2 dimers, as indicated by the arrow, whilst those at 100, 170 and 200 kDa 
were thought to be N-terminal cleaved isoforms. Taken from Melrose et al. 2007 [23]. 
     A                                            B                                             C 
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7.3.8 Statistical analysis 
I performed statistical analysis using SPSS for Windows release 15.0 (SPSS Inc, Chicago, Ill., 
USA). Continuous variables were first tested for normal distribution using Kolmogorov-
Smirnov test, and homogeneity of variance was tested using the Levene’s statistic. As they 
showed departures from normality, they were subsequently investigated using a Mann 
Whitney U Test. A p value <0.05 was considered significant. 
 
7.4 Results 
7.4.1 Cell lines and DNA sequencing 
Lymphoblast and fibroblast cell lines were successfully generated from the proband subject 
from family 12 who carried the L2063STOP variation. A fibroblast cell line was successfully 
generated from the proband subject from family 38 who carried the T2397STOP variation, but 
we were unable to successfully grow the lymphoblast cell line.  
DNA was extracted from cultures of the lymphoblast and fibroblast cell lines. Direct 
sequencing of exons 42 and 49 of LRRK2 confirmed the presence of the c.6187delCTCTA 
(p.L2063STOP) and c.7187insGT (p.T2397STOP) variations in the proband subject from 
family 12 and in the proband subject from family 38 respectively. Sequencing results from 
control cell lines revealed wild-type sequence only.  
 
7.4.2 Fragment analysis, sequencing and NMD assay 
The cDNA samples were generated using mRNA extracted from the lymphoblast and 
fibroblast cell lines from the proband subject carrying the c.6187delCTCTA (p.L2063STOP) 
variation, the fibroblast cell line from the proband subject carrying the c.7187insGT 
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(p.T2397STOP) variation and both fibroblast and lymphoblast cell lines from control subjects. 
Sequencing of the cDNA confirmed the presence of the c.6187delCTCTA and c.7187insGT 
variations in the proband subjects and wild-type sequence in the control subjects. Fragment 
analysis using Genescan ®, indicated that in cell lines from the two proband subjects wild-
type mRNA was clearly present whilst the mutant mRNA was present at a much lower level 
(figure 7.5). In the control cell lines only wild-type mRNA was detected. The area under each 
peak represents the amount of either wild-type or mutant mRNA, which was calculated 
automatically by Genemapper 3.5TM software (Applied Biosystems). 
In the NMD assay the fibroblast cell lines from the proband subjects carrying the 
c.6187delCTCTA and c.7187insGT variations, and control cell lines, were incubated with 
500µM CHX. There was a selective and significant increase noted in the level of mutant 
mRNA for both variants (P=0.05), at both 2 and 8 hours incubation, compared to the fibroblast 
cell lines from these proband subjects which had been incubated without CHX (figures 7.6 and 
7.7 and table 7.2). There appeared to be no effect from incubation with CHX on the level of 
wild-type mRNA in the control subjects. 
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Figure 7.5 Fragment analysis of PCR products using Genescan®, electrophoretograms showing 
relative wild-type and mutant mRNA levels in fibroblast cell lines from proband and control 
subjects. Panels A and B show electrophoretograms of amplified fluorescent-labeled PCR products 
from cDNA template for the c.6187delCTCTA variation. Panel A represents cDNA from subject 
carrying the variation and panel B represents cDNA from a control subject. The wild-type PCR 
product is 224 base pairs and the mutant PCR product is 219 base pairs in size. Mutant mRNA is 
present at a lower level than wild-type in proband subject and absent in the control subject. Panels C 
and D show electrophoretograms of amplified fluorescent-labeled PCR products from cDNA template 
for the c.7187insGT variation. Panel C represents cDNA from subject carrying the variation and panel 
D represents cDNA from a control subject. The wild-type PCR product is 332 base pairs and the 
mutant PCR product is 334 base pairs in size. Mutant mRNA is present at a lower level than wild-type 
in proband subject and absent in the control subject. The y-axis represents the intensity of 
fluorescence, expressed as relative fluorescence units (RFU).  
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Figure 7.6 Fragment analysis of PCR products using Genescan®, electrophoretograms showing effect 
on mutant mRNA expression for the c.6187delCTCTA variation after incubation with cycloheximide 
(CHX). Panels A to E show electrophoretograms of amplified fluorescent-labelled PCR products from cDNA 
template for proband subject carrying the c.6187delCTCTA variation. The panels depict mRNA levels from 
baseline to 8 hrs of incubation with or without CHX. Panels F to J show electrophoretograms of amplified 
fluorescent-labelled PCR products from cDNA template for a control subject. The panels depict mRNA levels 
from baseline to 8 hrs of incubation with or without CHX. The wild-type PCR product is 224 base pairs and 
the mutant PCR product is 219 base pairs in size. At baseline the mutant mRNA is present at a lower level than 
wild-type in proband subject and absent in the control subject. Incubation with CHX for 2 and 8 hours both 
result in a selective increase in the level of mutant mRNA in the proband subject compared to incubation 
without CHX. Incubation with CHX appears to have no effect on level of wild-type mRNA in the control 
subject. The y-axis represents the intensity of fluorescence, expressed as relative fluorescence units (RFU).  
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Figure 7.7 Fragment analysis of PCR products using Genescan®, electrophoretograms showing 
effect on mutant mRNA expression for the c.7187insGT variation after incubation with 
cycloheximide (CHX). Panels A to E show electrophoretograms of amplified fluorescent-labelled PCR 
products from cDNA template for proband subject carrying the c.7187insGT variation. The panels 
depict mRNA levels from baseline to 8 hrs of incubation with or without CHX. Panels F to J show 
electrophoretograms of amplified fluorescent-labelled PCR products from cDNA template for a control 
subject. The panels depict mRNA levels from baseline to 8 hrs of incubation with or without CHX. The 
wild-type PCR product is 332 base pairs and the mutant PCR product is 334 base pairs in size. At 
baseline the mutant mRNA is present at a lower level than wild-type in proband subject and absent in the 
control subject. Incubation with CHX for 2 and 8 hours both result in a selective increase in the level of 
mutant mRNA in the proband subject compared to incubation without CHX. Incubation with CHX 
appears to have no effect on level of wild-type mRNA in the control subject. The y-axis represents the 
intensity of fluorescence, expressed as relative fluorescence units (RFU).
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Mutant mRNA peak as % of wild-type mRNA peak 
L2063STOP mutation T2397STOP mutation 
Time after 
treatment with 
CHX CHX                    No CHX CHX                    No CHX 
24.3 21.1 
31.7 18.5 0 hours   
26.1 23.6 
52.5 23.1 47.2 24.8 
50.1 27.4 41.8 26.1 2 hours 
36.5 28.9 37.3 20.5 
48.4 17.1 47.9 22.1 
53.0 24.6 51.7 19.4 8 hours 
45.4 21.8 46.8 23.1 
Table 7.2 Summary of NMD assay in fibroblast cell lines from two subjects with 
LRRK2 mutations. The mutant mRNA peak is expressed as percentage of wild-type 
mRNA peak.  Percentages are given for the assay in which cells were incubated for up to 
8 hours with  cycloheximide (CHX) and without cycloheximide (No CHX). 
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7.4.3 Optimisation of LRRK2 antibodies and western blotting 
I was unable to produce consistently reliable results on western blotting with protein samples 
from either lymphoblast or fibroblast cell lines, with the three commercially available LRRK2 
antibodies used. This was despite using similar protein concentrations and conditions as 
described in the literature for these antibodies [23], [766]. Some of the problems encountered 
in using these LRRK2 antibodies included: detection of small bands only with antibodies 
NB267 and NB268 (figure 7.8), and high background signal due to non-specific antibody 
binding for NB268 (figure 7.9). Larger bands were also detected with the NB268 antibody 
(figure 7.9), which may represent LRRK2 dimers. 
The data which was obtained from the lymphoblast line for the subject carrying the 
 
c.6187delCTCTA (p.L2063STOP) variation with all three antibodies suggests that the full size 
protein (286kDa) is produced in this subject (figures 7.8-7.10). Furthermore, there was no 
evidence of a smaller mutant protein, which I would predict to be 240kDa (figures 7.8-7.10). 
Using Nucleolin as a protein loading control, comparison of the amount of LRRK2 detected in 
proband and control lymphoblast lysates was made. The results in figure 7.10 appear to 
suggest that there is more LRRK2 detected in proband than control lysates, but this was not a 
consistent finding, and provisional densitometry data suggests that the relative amount of full 
size LRRK2 detected is similar between the patient and control lines. 
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Figure 7.9 Immunoblotting with commercial LRRK2 antibodies of human lymphoblast lysates from 
th
N
e proband subject carrying the c.6187delCTCTA variation and controls (b). Panel A= antibody 
B267. Lanes 1 a 2 were loaded with 20µ nd 10µg of protein from the proband subject. A band of the 
rrect predicted size of 286kDa for LRRK2 was detected, as indicated by the arrow, with no smaller bands. 
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Panel B= antibody NB58771, lanes 1 and 2 were loaded with 20µg and 10µg of protein from the proband 
subject. A band of the correct predicted size of 286kDa for LRRK2 was detected, as indicated by the arrow, 
with no smaller bands. Panel C= antibody NB268, lanes 1, 4 and 5 were loaded with 5µg, 10µg and 20µg of 
protein from the proband subject and lanes 2 and 3 were loaded with 10µg and 20µg of protein from the 
control subject. A band of the correct predicted size of 286kDa for LRRK2 was detected, as indicated by the 
arrow. A larger band, possibly representing LRRK2 dimers, as indicated by the arrow, was also noted for the 
proband samples but not the controls. High background as a result of non-specific antibody binding, and 
smaller bands, which may represent cleaved isoforms or degradation products of LRRK2, are also noted. A 
ladder of known molecular mass markers for each blot is represented on the side of each panel. 
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less LRRK2 detected in the control lanes than the proband. Panel Bi= antibody NB58771. Lanes 1 and 2 
were loaded with 10µg and 20µg of protein from the proband subject. Lanes 3 and 4 were loaded with 
10µg and 20µg of protein from a control subject. A band of the correct predicted size of 286kDa for 
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re-probed with Nucleolin antibody. A band of the correct predicted size of 106kDa for Nucleolin was 
detected, as indicated by the arrow, and the band strengths appear consistent with amount of protein 
loaded. Using the Nucleolin bands as protein loading controls, there appears to be less LRRK2 detected in 
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7.5 Discussion 
.5.1 Cell lines 
te fibroblast cell lines for both patients, we were unable to 
s ate a lymphoblast cell line from the proband subject of family 38 who 
he major finding from the PCR fragment analysis studies performed on cDNA samples,  was 
clearly present in the cell lines, whilst the 
ours. The use of 
CHX treatment to inhibit NMD is a well recognized technique and has been used in several 
7
Whilst we were able to genera
succes fully gener
carried the T2397STOP variation. There are several possible reasons for this. First, the blood 
sample from which lymphocytes were extracted was taken approximately 18 hours before 
extraction and second, the relatively older age of this subject. Over many years of experience 
of creating lymphoblast cell lines, Professor Taylor has noted a clear trend that lines are more 
successfully generated in younger patients, and when the lymphocytes are extracted as soon as 
possible after the blood sample has been taken (Malcolm Taylor, personal communication). 
Alternatively this may simply represent a failure of the technique in this individual case.    
 
7.5.2 PCR fragment analysis and NMD assay 
T
that for both variations wild-type mRNA was 
mutant mRNA was present at a much lower level compared to wild type- 26% for the 
L2063STOP mutation, and 21% for the T2397STOP mutation (figure 7.5 and table 7.2). The 
PCR fragment analysis technique used is semi-quantitative, permitting intra-sample 
comparison of amounts of wild-type and mutant mRNA. These techniques are valid for this 
type of study and have been used before in similar work [498], [499], [502].  
I proposed that the mutant mRNA may be degraded by NMD, and in order to confirm this, 
patient and control fibroblast cell lines were incubated with CHX for up to 8 h
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different types of cultured cell lines such as fibroblasts and lymphoblasts [498], [499], [500], 
[501], [502], [503]. Numerous protocols have been detailed, with varying concentrations of 
cycloheximide, types and numbers of cells, as well as incubation times ranging from 4 to 48 
hours [498], [499], [500], [501], [502], [503]. The protocol I used was based upon that used by 
Baker et al. (2006) and also recommended by a collaborator Dr Henry Holden.  
My data showed a selective and significant increase in the level of mutant mRNA for both 
variations after incubation with CHX, compared to the patient cell lines which had been 
incubated without CHX (figures 7.6 and 7.7 and table 7.2). Control cell lines were also 
 (PTC-free) level, and thus reduces synthesis of the encoded truncated protein [494], 
incubated with CHX, which appeared not to have any effect on wild-type mRNA levels. 
However, the Genescan® fragment analysis technique is only semi-quantitative, and to be able 
to fully quantify the effects on mRNA expression a qRT-PCR (real time PCR) technique needs 
to be used, as discussed later. This data provides the first evidence that NMD may indeed be 
an important mechanism in LRRK2 PD. There is only one previous report of a LRRK2 
variation in which the authors speculated that mutant mRNA is likely to undergo NMD [665]. 
The process has been demonstrated previously in PINK-related PD using a similar technique 
[499]. 
NMD is a normal cellular mechanism which reduces the abundance of potentially deleterious 
transcripts containing a premature termination codon (PTC) to approximately 5-25% of the 
normal
[495], [15], [496]. In general only PTCs located more than 50-55 nucleotides upstream of a 
splicing-generated exon-exon junction within mRNA elicit NMD [765], see figure 7.2. Both 
of the novel frameshift LRRK2 mutations which I have studied introduce PTCs which fit these 
criteria.  
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I hypothesise that these two newly identified LRRK2 frameshift mutations cause disease by 
creating functional null alleles, with the mutant mRNAs being degraded by NMD. The overall 
result is a loss of functional LRRK2 due to haploinsufficiency. Although the degradation of 
ed to express LRRK2 show up to a 3-
 different studies. However, my findings for the two novel frameshift mutations, 
the mutant allele is not 100% complete, and it cannot be excluded that low amounts of 
truncated protein lead to a dominant-negative or gain-of-function mechanism, this is an 
apparently novel pathogenic mechanism in LRRK2 PD.  
The mechanism that has previously been proposed for pathogenic LRRK2 mutations is kinase 
over-activity, particularly the G2019S and R1441C mutations for which there is most 
evidence. Biochemical studies on cultured cells transfect
fold increase in kinase activity for the G2019S mutation [429], [661], [691], [692]. The 
R1441C mutation in the ROC domain has been reported to affect GTP hydrolysis and binding 
[663], [723], [691]. A predicted consequence of mutations in this region would be that they 
influence the downstream kinase activity through perturbation of the GTPase domain.  
However the putatively pathogenic mutations G2385R and I1371V do not appear to affect 
kinase activity [691], whilst the I2012T variant appears to decrease kinase activity [691], 
[692].  
Some of the previously conflicting data on the effect of pathogenic LRRK2 mutations on 
kinase activity may be explained by variations in methodological or analytical techniques 
between
which suggest a possible loss of functional LRRK2 due to haploinsufficiency, provide further 
evidence that kinase over-activity alone may not be the only pathological effect of LRRK2 
mutations.  
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7.5.3 Optimisation of LRRK2 antibodies and western blotting 
Due to the lack of replicable data I am cautious in making definitive conclusions about the 
ork performed in this section of the study. However my data supports the findings from my 
A (p.L2063STOP) variation 
 I did not detect a smaller toxic protein in my studies, it may indeed 
lable antibodies. Just over half detected over-expressed human LRRK2 
frozen brain tissue, post mortem delay of only a few hours rendered the technique 
w
mRNA studies, in that for the subject carrying the c.6187delCTCT
a smaller mutant protein does not appear to be produced. These findings may be explained by 
the process of NMD of the mutant mRNA, as I have already proposed, or may be a result of 
degradation of an unstable small mutant protein. Either of these explanations would support 
my theory of haploinsufficiency rather than toxic gain of function as a pathogenic mechanism 
for LRRK2–related PD.  
There are two important caveats to this conclusion. First, my own data also suggests that the 
amount of full size LRRK2 protein appears consistent between both the patient and control 
cell lines. Second, whilst
be present in vivo and my experimental technique was not sensitive enough to detect it. This 
was despite me using LRRK2 antibodies and protocols which had previously been used 
successfully in published studies and recommended personally by other researchers [766], 
[23], (Vincenzo Bonifati, personal communication), (Heather Melrose, personal 
communication).  
The complexity of performing work on the LRRK2 protein, and in particular optimising 
LRRK2 antibodies, is highlighted by two recent studies. Biskup et al. evaluated 21 
commercially avai
protein in cell lines, and only four (including NB267 and NB268) had sufficient specificity to 
detect endogenous LRRK2 in human brain lysate samples [766]. The authors also commented 
that whilst they were successful in visualizing LRRK2 protein by western blotting in fresh 
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unsuccessful in most cases. They speculated that this may be due to a high rate of degradation 
or processes that otherwise render LRRK2 inaccessible to detection by immunoblotting. They 
did not however observe significant decay in LRRK2 protein within protein lysate when 
stored at -20 or -80°C, or dramatic loss of LRRK2 due to freeze/thaw cycles [766].  
Melrose et al. compared immunohistochemical findings for six LRRK2 antibodies (two ‘in 
house’ and four commercially available), including NB267, NB268 and NB58771 used in my 
study. Antibody NB58771 was originally developed by Melrose et al. as one of their ‘in 
house’ antibodies [23]. As in my study, the investigators used human lymphoblast lysates and 
found that all the antibodies recognized a major 286 kDa LRRK2 human protein band (figure 
7.4). They also detected additional protein bands with several antibodies. The larger bands 
were thought to represent LRRK2 dimers [23], as previously reported [428]. The smaller 
bands were thought to represent truncated LRRK2 proteins [23]. At least three N-terminal 
cleaved isoforms of LRRK2 (100, 170 and 200 kDa) have previously been identified by 
immunoprecipitation and mass spectrometry [767]. Indeed, the manufacturer (Novus 
Biologicals) claims that many of these additional bands can be blocked by using the control 
pepitde appropriate for each LRRK2 antibody, suggesting that they are indeed degradation 
products (http://novusbio.com/data_sheet/index/NB300-268). Some of these additional bands 
may also represent non-specific cross-reactivity with other proteins. As in my study, Melrose 
et al. also found that the NB267 and NB268 antibodies displayed the greatest number of 
additional bands, whereas their in-house antibodies, including NB58771 which I also used, 
displayed the least number of additional bands [23].  
The western blots of lymphoblast lysates from the subject carrying the c.6187delCTCTA 
(p.L2063STOP) variation for the three LRRK2 antibodies used in the current study (figures 
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7.8-7.10) closely resemble those published by Melrose et al. (figure 7.4). The clearest band for 
LRRK2, from both my work and that from Melrose et al., can be seen using NB58771. This 
e 
egradation. In addition, there may have been inconsistencies between different batches of 
was also confirmed directly to me by the investigators (Heather Melrose, personal 
communication). However, as the recognition sites of the NB58771 and NB268 antibodies are 
located between amino acids 2500-2527 (figure 7.11), I was reliant on NB267 to detect any 
truncated protein produced in association with the c.6187delCTCTA (p.L2063STOP) 
variation.   
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Figure 7.11 Schematic of the LRRK2 protein structure, from residue 900 to 25
se et al. 20
27, 
and three commercial antibody recognition sites. Adapt lro 07 
[23]. 
ed from Me
The lack of consistent data with the three antibodies used in my study may be for several 
rg
as LRRK2 is technically challenging in many aspects, especially in preventing protein 
reasons. Firstly, as outlined in both of the studies discussed above, working with such a la
rotein p
d
antibodies used in my study and those in previously published work. With particular regard to 
determining whether a truncated protein is produced with the c.6187delCTCTA 
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(p.L2063STOP) variation, I was hindered in not being able to use the most reliable antibody 
available.   
 
7.6 Future work 
There are several further molecular genetic and functional studies that could be performed to 
further both our knowledge on the effects of the three novel frameshift mutations and our 
nderstanding of LRRK2 PD in general.   
,  proband subject from family 38, who carried the T2397STOP variation, 
e fragment analysis, sequencing and NMD assay 
, [770]. Therefore, re-bleeding both subjects carrying 
the fact that the 
quantity of PCR products in exponential phase is in proportion to the quantity of initial 
u
First  re-bleeding the
would allow us another attempt to grow a lymphoblast line from this subject. Having 
lymphoblast cell lines on both of the subjects carrying the novel LRRK2 variations would 
allow me to confirm the findings of th
obtained from the fibroblast cell lines. 
Second, for the NMD assay, it can be argued that RNA obtained from cultured cells does not 
represent a true baseline level. It has been shown that RNA expression levels can be affected 
by lymphoblastic differentiation (for example the somatostatin receptor expression has been 
demonstrated to increase) [768], [769]
the novel LRRK2 variations, and extracting RNA from lymphocytes before they are 
immortalized, would allow me to confirm the baseline findings for this assay.  
Third, in order to fully quantify the amount of mRNA between samples a qRT-PCR (real time 
PCR) technique, with use of an internal standard, is required. This has been used before in 
some previous similar studies of NMD [771], [498], [772]. Real-time PCR detects the 
accumulation of products during the reaction, and is accurately able to exploit 
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template [773], [774]. I was unable to set up this technique due to time constraints, but its use 
would also allow confirmation of the findings from my PCR fragment analysis studies. 
Fourth, in order to confirm my findings from the mRNA studies at the protein level further 
work needs to be performed. The experimental design of the protein studies with the three 
previously used antibodies could be re-optimised in order to produce more consistent and 
reliable data. This could be achieved using epitope-V5 tagged LRRK2 transfected into 
HEK293T cells as positive controls, such as used in a previous study [23]. Furthermore, 
. This is within a protein interaction domain, 
fibroblast cell lysates could be used in addition to the lymphoblast cell lysates in order to 
confirm the results in a second cell line. In addition other commercial LRRK2 antibodies 
could be investigated and optimised within the experimental system in order to determine if 
they produce more consistent and reliable data.  
The development of novel LRRK2 antibodies using other potential antigenic sites within the 
protein would be another strategy. I have in fact already tried this in conjunction with a 
collaborator, Dr David Ramsden, Department of Medicine, University of Birmingham. We 
synthesised a peptide corresponding to amino acids 329 to 349 of LRRK2, as this region 
appeared most promising in terms of antigenicity
armadillo repeats (residues 180-660), named after the β-catenin-like Armadillo protein of 
Drosophila [18]. However, the antigenic response of sheep to our LRRK2 peptide was poor, 
despite re-immunisation. As well as trying other peptide sequences a variant of this peptide 
could be synthesized in which random amino acids are inserted near the N-terminus in order to 
increase its antigenicity.  
Fifth, in order to further explore the effect of the novel variations on LRRK2 function, it 
would be extremely valuable to investigate how they influence the kinase activity of LRRK2. 
 - 300 -
Chapter 7                                                  Functional Analyses of Two Novel LRRK2 Mutations                     
 - 301 -
most notably kinase assays, but the effects on cell toxicity, 
nsider other disease-
ausing mechanisms aside from the ‘kinase over-activity’ paradigm that has been previously 
o
 
 
Using similar approaches to those described in the introduction in vitro expression models of 
these mutant LRRK2 proteins could be generated. These models would allow me to perform a 
number of assessments, 
aggregation, neurite outgrowth and branching could also be determined. 
 
7.7 Conclusions 
In this chapter I investigated the effects of two novel LRRK2 frameshift mutations on RNA 
and protein expression, and the data presented here provides the first evidence that NMD is 
occurring in LRRK2 PD. I thus suggest that in LRRK2 PD one must co
c
prop sed by others. 
 
 
 
 
 
 
 
Chapter 8                                                                                                         General Discussion                        
8 General Discussion 
8.1 Introduction 
The broad aims of this project were to recruit a large well characterised cohort of subjects with 
autosomal dominantly inherited Parkinson’s disease (PD) from around the United Kingdom 
(UK); to assess the contribution of coding sequence variations within the LRRK2 gene in these 
subjects with familial PD (fPD) and also in large cohort of UK subjects with sporadic PD 
(sPD); and to provide initial functional characterisation of any novel mutations identified.  
Proband subjects were successfully recruited from families with three or more members 
affected by PD and known pathogenic LRRK2 mutations were identified in both the familial 
and sporadic groups at frequencies predicated from previous work. In addition, three novel 
coding sequence variations were identified in the fPD group, all of which are predicted to 
cause a shift in the reading frame, and result in premature termination codons. For two of these 
variations my functional data suggests that nonsense mediated decay (NMD) of the truncated 
transcript has occurred, perhaps leading to haploinsufficiency, a novel pathogenic mechanism 
for LRRK2-related PD.  
As part of this project I also performed a clinical and molecular genetic study of a unique 
kindred in which affected members display a variety of phenotypes, ranging from PD to Dopa-
responsive dystonia (DRD). I predict that variable expression of a novel missense mutation 
identified within the GCH1 gene may result in this wide range of observed phenotypes. 
In this chapter I will discuss these findings particularly with regard to our understanding of 
LRRK2-related PD and Dopa-responsive dystonia (DRD), but also with regard to some of the 
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broader concepts in this field  r onment interactions and the 
ent of neuro-protective therapies.  
 
issed 
in screening of the entire predicted coding region of LRRK2 I identified 61 sequence 
 of esearch, such as gene-envir
developm
8.2 Familial PD 
As discussed in chapter 3, a cohort of 46 UK subjects with PD from families in which there 
were three or more members affected by PD and where segregation of disease in the family 
appeared to follow an autosomal dominant pattern were recruited. Importantly the similarity of 
the demographic and clinical characteristics of this cohort to those of fPD cohorts previously 
described in the literature (section 3.6 and table 3.12) makes the results of my molecular 
genetic studies generalisable. Whilst taking into consideration that this was not a population-
based study designed specifically to investigate environmental influences in PD, the data from 
my epidemiological survey indicates: head injury and cerebral infection do not appear to be 
significant risk factors for PD in this cohort; a history of toxin exposure, rural living and well 
water consumption was demonstrated in around 20% of all participants, suggesting that if 
these risk factors are important in the aetiology of PD they would only appear to be so in up to 
a quarter of cases.  
 
8.2.1 LRRK2 in UK familial PD 
One of the major criticisms of previous molecular genetic studies into LRRK2 has been that 
they have not examined the whole coding sequence of the gene, and hence may have m
important sequence variations. Indeed only one previous comprehensive screen of LRRK2 in a 
large cohort of UK subjects with fPD has been performed [279]. As discussed in section 5.5, 
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variations, of which 16 were in protein coding regions and are predicted to lead to 
nonsynonymous amino acid substitutions (see table 5.1). Four probands (8.7%) were found to 
e heterozygous carriers of one of the previously described LRRK2 mutations for which there 
pathogenicity, a figure which corresponds to those quoted in previous 
f developing fPD. This is in contrast to two variations found in Asian 
opulations which appear to be true risk variants for sporadic PD, the first G2385R has been 
associated with a two-fold risk increase in Taiwanese [293], [695], [697], [698], Japanese 
b
is data to suggest 
reports [279], [280], [293], [665], [26], [775]. Three of these probands carried the G2019S 
mutation and one carried the R1441C mutation. The mean age of onset of symptoms of these 
probands was 58.6 (SD 8.2), with a range of 49-71. Three probands displayed phenotypes 
typical for IPD, whilst one proband carrying a G2019S mutation had a more slowly 
progressive disease. This atypical phenotype is unusual in association with the G2019S 
mutation, although there are some reports in the literature of younger disease onset and slower 
disease progression [282], [776], [667]. On olfactory testing all four of these subjects also 
displayed microsmia, or anosmia, which again fits with data from previous reports [294], [279, 
777], [667]. Therefore the findings from my study confirm the importance of these two 
pathogenic mutations in UK fPD. 
Another important observation is that in this study I found no LRRK2 variations which 
increased the risk o
p
[699], and Chinese [700], [701], [702] populations [778]. This variation does however appear 
to be restricted to certain Asian populations only, and has not been found in other Caucasian 
populations tested to date [779], [294], [279], [280]. The R1628P variation has also recently 
been identified as a risk allele [780], [781] within Asian PD populations and was not identified 
in my study.     
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8.2.2 Novel LRRK2 mutations 
Three novel heterozygous variations c.4364delAT (D1455G), c.6187delCTCTA 
(p.L2063STOP), and c.7187insGT (p.T2397STOP) were identified in one proband case each. 
This highlights the importance of performing a comprehensive screen of the whole coding 
sequence of the gene when studying fPD. All three variations result in a shift in the reading 
frame, with the introduction of a premature termination codon. As discussed in section 5.5.1 
this is the first time that frameshift mutations in the coding sequence of LRRK2 have been 
described. The phenotype observed in all three novel variations described here appears to be 
typical for IPD, as has been observed in previous studies of LRRK2 positive PD patients [27], 
[288], [283], [289], [290], [285], [625]. These three novel mutations appear to be rare familial 
mutations, as I did not find them in an extensive screen of sPD chromosomes.  
Most LRRK2 mutations described to date are missense mutations and the working hypothesis 
of the mechanism of pathogenicity has been through a dominant negative effect. The 
identification of these three novel frameshift mutations suggests that at least for these 
 
variations pathogenicity may be through a novel mechanism for LRRK2, of 
haploinsufficiency. Indeed, as discussed in section 7.5.2, the results from my nonsense 
mediated decay (NMD) assay suggest that the c.6187delCTCTA (p.L2063STOP) and 
c.7187insGT (p.T2397STOP) frameshift mutations may cause disease by creating functional 
null alleles, with the mutant mRNAs being degraded by NMD, which results in loss of 
functional LRRK2 (haploinsufficiency). This is an apparently novel pathogenic mechanism in 
LRRK2 PD and is in contrast to the previously proposed kinase over-activity theory for the 
pathogenic LRRK2 mutations [429], [661], [691], [692].  
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8.3 Sporadic PD 
This part of the project involved the study of four cohorts of patients from around the UK, the 
majority of whom had apparently sporadic PD (sPD). When studying sPD one of the major 
aims is to ensure that the study cohort is as representative of a ‘community-based’ IPD cohort 
as possible. This is in order to ensure that when genetic analyses are performed, any variations 
which may be identified are as relevant as possible to the ‘typical’ IPD seen by general 
practitioners, physicians and neurologists rather than the more ‘atypical’ cases that might be 
seen in specialist movement disorder clinics. The demographics of the 357 subjects from the 
PD GEN cohort were the most representative of a ‘community-based’ sample of IPD, and this 
cohort was therefore used for molecular genetic analyses of sPD providing us with 
generalisable data. 
 
8.3.1 LRRK2 in UK sporadic PD 
Eight ‘hot spot’ exons of LRRK2 were screened for known and novel mutations in subjects 
from the PD GEN cohort by denaturing high performance liquid chromatography (DHPLC) 
and at total of 15 heterozygous sequence variations were identified (see figure 6.6). Four 
subjects (0.9%) were found to be heterozygous carriers of known pathogenic mutations, 
previously shown to segregate with disease, of which three carried the G2019S mutation and 
one the R1441C mutation. This corresponds to figures previously reported in the literature 
[282], [283], [284], [285], [281], [282]. All four of these subjects had typical late-onset 
levodopa-responsive PD, again corresponding to  previous reports [288], [283], [289], [290], 
[285], [681], [667]. There were no novel sequence variations identified in protein coding 
gions that are predicted to lead to nonsynonymous amino acid substitutions.  re
 - 306 -
Chapter 8                                                                                                         General Discussion                        
This s the most exte i nsive screen for known and novel LRRK2 mutations performed in a large 
. Furthermore, olfaction was moderately impaired in affected subjects, but 
ith no clear correlation with phenotype. My identification of a novel heterozygote GCH1 
), in affected subjects only, has at last provided an 
cohort of UK subjects with sPD and is the first use of the PD GEN cohort. Furthermore this 
project also demonstrated that DHPLC is an effective method for high throughput mutation 
detection in the LRRK2 gene, and could be used to complete further screening of this gene. My 
data confirms both the importance of the G2019S and R1441C mutations in UK sPD, as well 
as the proposed aetiological link between the fPD and sPD. 
 
8.4 Kindred with variable phenotypes and a novel GCH1 mutation  
The clinical diagnosis in affected subjects from this unique family with phenotypes ranging 
from PD to DRD was challenging for over 20 years because of the atypical nature of the 
symptoms and signs
w
missense mutation, c.A5G (p.E2G
explanation for the diverse clinical presentations observed in this family. The association of 
this novel GCH1 mutation with such a wide range of phenotypes has also furthered our 
understanding of the way late onset DRD can present. Intriguingly, in this family both normal 
and abnormal functional neuro-imaging was noted in association with the same GCH1 
mutation.  
As well as the considerations for DRD, the association of this novel GCH1 mutation with a 
form of late onset familial parkinsonian is perhaps of even greater interest as it suggests a 
potential role for the GCH1 gene in the much more prevalent condition of PD. I will consider 
this subject again in section 8.6 below.  
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8.5 Implications for pathogenesis of PD and neuro-protection 
Since the c.6055G>A (G2019S) mutation in exon 41 was first identified in 2005 in both fPD 
and sPD [281], [282], [283], [284], [285] elucidating the function of the LRRK2 protein, and 
how its dysfunction leads to neurodegeneration, has been the focus of much work. Indeed 
given the location of this mutation within the kinase domain most investigators have focused 
on the effects of on kinase function. As discussed within section 7.1 there is now some 
vidence for a modest increase in kinase activity for the G2019S mutation [429], [661], [691], 
controversial [429], 
bout this theory of toxic gain of function related to kinase activity. The evidence 
er with the previous reports, that some pathogenic 
RRK2 mutations may not increase kinase activity [661], [692], I am cautious about focusing 
solely on kinase over-activity as the pathogenic mechanism. There are also two important 
e
[692], [782], although the effect of the other pathogenic mutations is more 
[691], [661], [692]. Another of the ‘PD genes’ PINK1 also has serine/threonine kinase 
activity, with evidence that loss of function leads to a complex cellular phenotype including 
defects in mitochondrial morphology, increased sensitivity to cellular stressors and reduction 
in subsets of dopaminergic neurons [227], [329], [330], [331], [332], [333], [334], [335], 
[336]. Hence we continue to investigate the role of the kinases in the pathogenesis of fPD, and 
ask whether kinase inhibitors could be therapeutic options for the future.  
We should, however, be cautious in our interpretation of previous results as the true substrates 
for LRRK2 remain to be determined, and hence the model systems used may be inappropriate. 
The identification of the three novel LRRK2 mutations in my study also raises some important 
questions a
from my in vitro studies of the c.7187insGT (p.T2397STOP) and c.6187delCTCTA 
(p.L2063STOP) mutations suggests that they may act by creating functional null alleles, 
resulting in loss of LRRK2 function. Clearly further investigation of the mechanism of these 
mutations is required, but taken togeth
L
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reports that describe abolishing LRRK2 kinase function, with the finding that the toxicity of 
all LRRK2 mutants was diminshed, even those that did not show evidence of kinase over-
activity [661], [457]. It may be that at least some pathogenic mutations cause cell death by 
altering some other feature of LRRK2 biology, but still require intact (basal) kinase function. 
A unifying explanation may be that LRRK2 is a signaling molecule, with kinase activity as a 
key part of the signaling process, such that when the kinase activity is affected (increased or 
decreased) the molecule is unable to function correctly [783], [784], [782].   
As outlined in the Introduction, PD is a complex condition and despite the identification of a 
number of ‘PD genes’ it is still believed that exposure to environmental toxins may play a role 
in the pathogenesis of the condition. Even in the case of LRRK2-related PD the finding of an 
age-dependent penetrance for the G2019S mutation [281], [287], [721] and the identification 
of the G2385R and R1628P risk alleles within several Asian populations [293], [695], [697], 
[698], [699], [700], [701], [702], [778], [780], [781] raises the age-old question as to whether 
there may be a potentially important role for environmental factors.  
Determining what is environmental, what is genetic and the interaction between the two has 
always been difficult to prove. Many observed interactions have proved difficult to reproduce, 
not just in PD, but for many human diseases [785]. Whilst further studies are clearly required 
to investigate this issue, previous attempts including the Geoparkinson study and a Drosophila 
parkinsonian model have not as yet yielded much useful information [153], [786]. One way in 
which this may be overcome is to ensure that prospective studies of disease include a sample 
biobank (usually a DNA collection) and good quality environmental exposure data on both 
subjects and controls. The PD GEN study is a good example of this (www.pdgen.bham.ac.uk). 
DNA samples from this study were used here, and I have also been involved in recruitment to 
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the study. In the case of LRRK2-PD it will also be crucial to identify physiological substrates 
for the protein, which may then give us clues as to which environmental toxins to investigate.    
 
8.6 Future directions and experimental studies 
I have already outlined the future experimental work required to expand upon the data 
generated by this study in the discussion to each of chapters 4 to 7. It is also important to 
consider future studies in general terms, in order to develop a better und
    
erstanding of the 
 mutations it will be vital 
direction in which research into the genetics of PD will move over the next few years. 
With regard to LRRK2-related PD, it is clear from the work presented in this thesis that in 
future a comprehensive screen of the whole coding sequence of the gene in every fPD cohort 
studied will be crucial in order not to miss potentially important variations. Furthermore, it 
will be extremely valuable to determine whether the three novel missense mutations identified 
in this study are found in other fPD, and indeed sPD, cohorts from various populations around 
the world. In order to further elucidate the functional effects of these
to show whether there is any expression of the truncated proteins. Developing in vitro 
expression models of these mutant LRRK2 proteins, alongside wild-type protein, will be 
important in order to better predict their downstream effects. This will specifically allow us to 
use GTPase and Kinase activity assays, as well as permitting us to model other potentially 
pathogenic mechanisms for LRRK2, such as apoptosis. In order for us to understand how 
dysfunction of LRRK2 causes PD it will also be crucial for us to develop a much better 
understanding of the normal function and physiological substrates for LRRK2. Finally, I 
believe that it will also be important for us to assess copy number variation in LRRK2, for both 
fPD and sPD, as it has previously been shown to cause PD in Alpha-synuclein and Parkin-
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related disease [251], [306], [307]. To date it has only been studied twice in LRRK2, and 
although no whole-gene deletions or duplications were detected [293], [666] it may still be 
another mechanism by which LRRK2 could cause PD.    
roduction, we are increasingly aware of 
port of 
As outlined in sections 1.5.2 and 1.5.3 of the Int
interactions between the ‘PD genes’ which may be important within the already complex 
pathogenic process of PD (see figure 1.6). Indeed, the concept of digenic parkinsonism has 
been gaining increasing support, with several recent reports of subjects simultaneously 
harboring mutations in Parkin and LRRK2 [729], [669], [689]. There is also a re
digenism of SCA2 and LRRK2 mutations, with earlier disease onset [787]. Given that identical 
LRRK2 mutations in the same kindred can result in different pathological findings, a 
modulating effect by other genetic variations is an interesting concept [788]. Furthermore, 
there are an increasing number of novel interactions being proposed, such as the observed 
interaction of the Roc domain of LRRK2 with microtubules [789]. This is especially 
interesting given the potentially important role for microtubule-associated protein tau (MAPT) 
in the pathogenesis of PD (outlined in section 1.5.2.8 of the Introduction).  
My own data may also be of importance in relation to investigation of these potential 
interactions, with the discovery of a putative role for GCH1 in PD. This still needs further 
investigation. In the first instance we need to screen for GCH1 mutations in cohorts of subjects 
with fPD and also sPD to confirm if there is an association with PD. As discussed in section 
4.5.6, an assessment of the functional effects of the mutation will also be important to give us 
information regarding the pathogenic mechanisms involved.   
Re-evaluating the pathogenic process in PD in terms of metabolic pathways involved may also 
give us clues as to how and which genes may be interacting. For example, as discussed in 
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section 1.5 of the Introduction, there is now increasing evidence that defects in the breakdown 
of glucosecerebroside to ceramide and glucose may be linked to PD, with mutations in alpha-
synuclein, GBA, ATP13A2 and possibly even LRRK2 implicated in this process [790]. 
ping technologies. 
tion studies, well recognised in 
Metabolomic profiling of plasma, Cerebrospinal fluid (CSF), or urine from subjects with PD 
may give insight into this currently under researched area.  
I believe that the concept of digenic parkinsonism may be potentially crucial, and hence an 
area to focus on over the next few years. In addition to screening for variations in multiple 
genes, it will be necessary to develop both in vitro and in vivo models of potential interactions 
between the various proteins and pathways involved. 
Finally, whilst I have used a candidate gene approach in this study, it is important to highlight 
that another increasingly popular method by which we can investigate genetic factors not just 
in PD, but also for a number of other complex diseases, is through genome wide association 
studies [297]. The idea behind the strategy is to comprehensively test common variations for 
association to disease [791]. Such studies have become feasible through the availability of 
large marker panels, as well as cost-effective and high through-put genoty
Importantly such studies are also able to detect interactions between genetic loci, as well as 
assessing whether small individual effects might contribute more substantially to disease risk 
through nonadditive interactions among loci (known as epistasis). This is all dependent upon 
having access to good quality statistical analytical strategies or programs, which are now 
readily available [791], [792]. Interestingly, there is also now some data from such studies to 
suggest that the poor reproducibility of many genetic associa
many fields of genetic research, may not only be due to statistical fluctuations, but could also 
reflect the role of gene-gene interactions, with these effects varying across different 
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populations tested and re-tested [791], [792]. Genome wide analysis also requires DNA to be 
available on a well phenotyped cohort of subjects, and hence the fPD and PD GEN cohorts 
used in this thesis are ideal for this type of study. Therefore, in collaboration with colleagues 
in Wales (Morris et al.), we are participating in a genome-wide association study (GWAS) of 
young onset PD, and plan to use these samples again in future similar projects. Of course the 
WAS approaches.      
genome wide association studies to date have been based on the common disease, common 
variant hypothesis. The single-nucleotide polymorphisms (SNPs) tested in this screening 
process are all fairly common. If PD genetic susceptibility is due to a series of rare genetic 
variants, these will not be detected using the current G
 
8.7 Implications for clinical practice 
Whilst most of the work presented in this thesis has important implications for research, there 
are some findings that that may influence our clinical practice. Our study of the kindred with 
variable phenotypes and a novel GCH1 mutation reinforces the view that DRD can have a 
very wide range of clinical presentations, and that we should consider the diagnosis even in 
the most atypical cases. The functional neuro-imaging data also serves to remind us of its 
value in difficult diagnostic cases, but also that test/re-test variability can occur with any of 
our imaging modalities.       
The finding that may have most influence on our current clinical practice is the confirmation 
of the importance of the G2019S mutation in UK sPD. My use of the PD GEN cohort for this 
study also adds further generalisability to this finding. There are now several diagnostic 
laboratories which offer testing for the G2019S mutation, and it is something which we can 
order from clinic. This raises the issue as to whether we should screen for this mutation in 
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patients with apparently idiopathic PD. My view is that at present we should probably not 
offer screening for the G2019S mutation to all sPD individuals. The clinical features and 
response to treatment of patients with PD who carry the G2019S mutation are 
indistinguishable from those of subjects with idiopathic PD. A positive test result would not 
alter the way that we manage their disease. A positive test may result in requests from 
unaffected relatives to be tested, and at the current time there is no therapy which is proven to 
be preventative or to alter the course of the condition. In addition, the mutation is known to 
demonstrate incomplete penetrance [283], [287], [281], [279], [721], leading to major 
difficulties in defining clinical prognosis. Caution must be taken when screening for LRRK2 
utations in a clinical setting in both affected and unaffected subjects, and I suggest that a 
 testing and counselling is required before it should 
on 1.6 of the introduction have been met. 
m
clear set of guidelines and framework for
come into routine clinical practice. 
 
8.8 Summary and Conclusions 
In this thesis I have presented the data from a molecular genetic study of the ‘PD gene’ 
LRRK2 in fPD and sPD in the UK, and also from a clinical, imaging and molecular genetic 
study of an individual kindred with variable phenotypes and a novel GCH1 mutation. The 
broad aims presented in secti
The similarity of LRRK2-related PD to idiopathic PD, and the identification of pathogenic 
mutations in both fPD and sPD, has stimulated much research effort since 2004, including this 
project. However, progress has been hampered by few comprehensive screens of the gene, 
particularly in UK populations, and a limited understanding of the effect of the pathogenic 
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e of molecular genetic study, with similar demographics to 
reviously used cohorts, hence providing data which is generalisable. Furthermore, this part of 
 of LRRK2 mutations in subjects with sPD from the UK, 
after 20 years provided 
mutations, although a mechanism of kinase over-activity has been proposed [429], [661], 
[691], [692], [782].  
The work on fPD presented in this thesis confirms the importance of LRRK2 mutations in UK 
subjects. Through a comprehensive screen of the gene in fPD I also identified three novel 
heterozygous frameshift mutations. For two of these mutations, c.6187delCTCTA 
(p.L2063STOP) and c.7187insGT (p.T2397STOP), my data suggests a novel pathogenic 
mechanism in LRRK2-PD, nonsense mediated decay, possibly leading to haploinsufficiency. 
Whilst requiring further investigation, these findings may be of crucial importance for our 
understanding of how LRRK2 dysfunction can result in the development of PD, and also for 
future development of neuro-protective therapies.  
The work on sPD presented in this thesis demonstrated that the PD GEN collection is a 
valuable resource for use in this typ
p
the study confirmed the importance
which may have implications for our clinical practice. I was also able to confirm that DHPLC 
is a valuable high-throughput screening method to detect LRRK2 mutations. 
The clinical, imaging and molecular genetic study of an individual kindred with variable 
phenotypes and a novel GCH1 mutation, presented in this thesis, has 
an explanation for the diverse clinical presentations observed in this family. The association of 
this GCH1 mutation with a wide range of phenotypes furthers both our understanding of late 
onset DRD, and suggests a potential role for the GCH1 gene in the pathogenesis of PD. 
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The information which I have provided in this appendix relates to the clinical assessment of 
subjects who participated in the familial Parkinson’s disease (fPD) study as detailed in section 
2.1. I have provided a copy of the UPDRS III (Unified Parkinson’s Disease Rating Scale, Part 
III) [6] which I used to obtain a disease severity score in each PD subject in their ‘on state’ 
(figure A.1). In addition I have provided copies of the epidemiological questionnaire, based on 
the PD GEN questionnaire 
(http://www.pdgen.bham.ac.uk/docs/PG%20GEN%20Questionnaire.pdf), and the Folstein 
MMSE (Mini Mental State Examination) [19] which I completed for each PD subject as an 
 
 
 
assessment of environmental exposures and  cognitive function (figures A.2 and A.3).    
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The Unified Parkinso ating Scale, Part III          
(Motor examination) 
 
resent with action. 
 = Moderate in amplitude, present with action. 
te in amplitude with posture holding as well as action. 
 = Marked in amplitude; interferes with feeding. 
ction or Postural Tremor of hands 
udged on passive movement of major joints with subject relaxed in sitting position. 
ogwheeling to be ignored) 
 = Absent. 
 = Slight or detectable only when activated by mirror or other movements. 
 = Mild to moderate. 
 = Marked, but full range of motion easily achieved. 
 = Severe, range of motion achieved with difficulty. 
igidity 
atient taps thumb with index finger in rapid succession) 
 = Normal. 
 = Mild slowing and/or reduction in amplitude. 
 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in 
ovement. 
 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing 
ovement. 
 = Can barely perform the task. 
 
n’s Disease R
Speech 
0 = Normal. 
1 = Slight loss of expression, diction and/or volume. 
2 = Monotone, slurred but understandable; moderately impaired. 
3 = Marked impairment, difficult to understand. 
4 = Unintelligible. 
 
Facial Expression 
0 = Normal. 
1 = Minimal hypomimia, could be normal "Poker Face". 
2 = Slight but definitely abnormal diminution of facial expression 
3 = Moderate hypomimia; lips parted some of the time. 
4 = Masked or fixed facies with severe or complete loss of facial expression; lips parted 1/4 
inch or more. 
 
Tremor at rest 
0 = Absent. 
1 = Slight; p
2
3 = Modera
4
 
A
(J
C
0
1
2
3
4
 
R
(P
0
1
2
m
3
m
4
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Finger T
(Patient 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude
derately impaired. Definite and early fatiguing. May have occasional arrests in 
ating movements or arrests in ongoing 
and Movements 
n movements of hands, vertically and horizontally, 
an amplitude as possible, both hands simultaneously) 
ng. May have occasional arrests in 
impaired. Frequent hesitation in initiating movements or arrests in ongoing 
ovement. 
erform the task. 
 of Hands 
on picking up entire leg. Amplitude should be 
 = Mild slowing and/or reduction in amplitude. 
nd early fatiguing. May have occasional arrests in 
quent hesitation in initiating movements or arrests in ongoing 
ith arms folded across chest) 
 = Normal. 
 or may need more than one attempt. 
fall back and may have to try more than one time, but can get up without help. 
 Chair 
e erect, slightly stooped posture; could be normal for older person. 
al; can be slightly leaning to one side. 
 = Severely stooped posture with kyphosis; can be moderately leaning to one side. 
 = Marked flexion with extreme abnormality of posture. 
aps 
opens and closes hands in rapid succesion.) 
. 
2 = Mo
movement. 
3 = Severely impaired. Frequent hesitation in initi
movement. 
4 = Can barely perform the task. 
 
H
(Pronation-supinatio
with as large 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatigui
movement. 
3 = Severely 
m
4 = Can barely p
 
Rapid Alternating Movements
(Patient taps heel on the ground in rapid successi
at least 3 inches) 
0 = Normal. 
1
2 = Moderately impaired. Definite a
movement. 
3 = Severely impaired. Fre
movement. 
4 = Can barely perform the task. 
 
Leg Agility 
(Patient attempts to rise from a straight-backed chair, w
0
1 = Slow;
2 = Pushes self up from arms of seat. 
3 = Tends to 
4 = Unable to arise without help. 
 
Arising from
0 = Normal erect. 
1 = Not quit
2 = Moderately stooped posture, definitely abnorm
3
4
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Posture 
0 = Normal. 
1 = Walks slowly, may shuffle with short steps, but no festination (hastening steps) or 
pulsion. 
alk at all, even with assistance. 
ait 
 (hastening steps) or 
th difficulty, but requires little or no assistance; may have some festination, short 
alk at all, even with assistance. 
sterior displacement produced by pull on shoulders while 
atient erect with eyes open and feet slightly apart. Patient is prepared) 
stural response; would fall if not caught by examiner. 
able, tends to lose balance spontaneously. 
kinesia and Hypokinesia 
ovement in general) 
 = Minimal slowness, giving movement a deliberate character; could be normal for some 
ibly reduced 
gree of slowness and poverty of movement which is definitely abnormal. 
mall amplitude of movement. 
propulsion. 
2 = Walks with difficulty, but requires little or no assistance; may have some festination, short 
steps, or pro
3 = Severe disturbance of gait, requiring assistance. 
4 = Cannot w
 
G
0 = Normal. 
1 = Walks slowly, may shuffle with short steps, but no festination
propulsion. 
2 = Walks wi
steps, or propulsion. 
3 = Severe disturbance of gait, requiring assistance. 
4 = Cannot w
 
Postural Stability 
(Response to sudden, strong po
p
0 = Normal. 
1 = Retropulsion, but recovers unaided. 
2 = Absence of po
3 = Very unst
4 = Unable to stand without assistance. 
 
Body Brady
(Combining slowness, hesitancy, decreased armswing, small amplitude, and 
poverty of m
0 = None. 
1
persons. Poss
amplitude. 
2 = Mild de
Alternatively, some reduced 
amplitude. 
3 = Moderate slowness, poverty or small amplitude of movement. 
4 = Marked slowness, poverty or s
 
 
 
 
 
 
Figure A.1 The UPDRS III (Unified Parkinson’s Disease Rating Scale, Part III).  
Adapted from http://www.mdvu.org/library/ratingscales/pd/updrs.pdf and Fahn & Elton 
1987 [6]. 
 - 319 -
                                                                                                                                    Appendix A                        
 - 320 -
The Mini-Mental State Examination 
tation 
 (   )   What is the (year) (season) (date) (day) (month)? 
id them. Give 1 point for each 
em until he/she learns all 3. 
Trials ___________ 
 “world” backward. 
e. Give 1 point for each correct 
ollowing “No ifs, ands, or buts” 
CLOSE YOUR EYES 
 
 
 
Subject:___________________________Examiner:________________________ 
Date:____________ 
 
Maximum Score 
 
Orien
       5   
       5      (   )  Where are we (state) (country) (town) (hospital) (floor)? 
 
Registration 
       3    (   )  Name 3 objects: 1 second to say each. Then ask the patient 
to name all 3 after you have sa
peat thcorrect answer. Then re
Count number of trials and record. 
 
Attention and Calculation 
  (   )  Serial 7’s. 1 point for each correct answer. Stop after 5 answers.        5   
Alternatively spell
 
Recall 
cts repeated abov       3     (   )  Ask for the 3 obje
                                  answer.   
 
Language 
cil and watch.        2     (   )  Name a pen
  (   )  Repeat the f       1   
       3     (   )  Follow a 3-stage command: 
‘Take a paper in your hand, fold it in half, and put it on the floor.’ 
  (   )  Read and obey the following:        1   
       1     (   )  Write a sentence. 
       1     (   )  Copy the design shown. 
 _____ Total Score 
 
 
 Figure A.2 Mini-Mental State Examination (MMSE). Adapted from Try This:® The 
Hartford Institute for Geriatric Nursing, Division of Nursing, New York University 
HUwww.hartfordign.orgUH. and Folstein et al. 1975 [19]. 
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Familial PD Epidemiology Questionnaire 
                                         
     
 
 
Subject:                 Examiner:                                
 
ate:                                                             D
 
 
Ethnic origin 
ian o gin) 
her) in) 
 hite       Other 
 count re
 
 
Employment
 
Asian (Ind rigin)   Asian (Pakistani origin)    Asian (Chinese ori
sian (Ot   Black (Caribbean origin)    Black (African origA
Black (Other)   W
 
In which ry we  they born?  
 
type of employment if retired) 
er job  
 intoxication by chemical compounds? Yes / 
at w
(e.g. paints, dry cleaning 
 Yes /
hat w
sticides or insecticides? Yes / No 
what was the name of the chemical
 
How long did they work with hydrocarbons/pesticides?         years 
 
 
 
 
Present employment (or last 
How long have they been in this job? years & months 
What oth s have they had? List the main six (with dates) 
(1)       (2) 
(3)       (4) 
(5)       (6) 
 
ave they ever been admitted to hospital due toH
No 
hIf YES, w as the name of the chemical? 
 
Hydrocarbons Have they worked in their employment with: 
industry)?  No 
If YES, w as the name of the chemical? 
 
Have they worked in their employment with: Pe
If YES, ? 
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Environment 
ave they lived most of their life in:  countryside?      town/city?        mixture of the two? 
ts 
clud
nt) on average do they smoke daily? 
.g. per day Cigarettes per day 
 in the past? Yes / No 
top smoking? 
they smoke daily? 
 
H
 
ave they drunk water from a well for more than 6 months of their life at any time?    Yes / H
No 
lease specify P
 
 
moking HabiS
 
Do they smoke NOW (i es all forms of tobacco)? Yes / No n
If YES, in what year did they start smoking? 
 
 
ow many cigarettes (or the equivaleH
e
 
 NO, have they smokedIf
 
hey sIn what year did they start smoking? In what year did t
 
 
How many cigarettes (or the equivalent) on average did 
e.g. per day Cigarettes per day 
 
Coffee/Tea Consumption 
 
How many cups of coffee on average have they drunk each day over the last 10 years? 
 
None         One          Two         Three          F
 
ou  Fiv   Six or more
? 
u  Fiv   Six or more
r        e         
How many cups of tea on average have they drunk each day over the last 10 years
 
None         One          Two         Three          Fo r        e        
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iseaseParkinson’s D  
 Yes, please list their names and relationship (e.g. brother, mother, etc): 
e     Relationship 
lzheimer’s Disease
 
Is there, or has there been, anyone in their family with Parkinson’s disease? Yes / No 
If
 
Nam
 
 
 
 
A  
h memory loss, such as Alzheimer's disease? Yes 
No 
 Yes, please list their names and relationship (e.g. brother, mother, etc): 
elationship 
ther Neurological Conditions
 
Has anyone in their family had a problem wit
/ 
If
 
Name     R
 
 
 
 
 
O  
ad injury that put them in a coma? Yes / No 
ave they ever had meningitis (i.e. infection of the lining of the brain)? Yes / No 
severe infection of the brain tissue) Yes / No 
 
Have they ever had a serious he
H
Have they ever had encephalitis (i.e. 
 
 
 
 
 
 
 
 
 
 
Figure A.3 Familial PD Epidemiology Questionnaire. Based on the PD
uestionnaire (http://www.pdgen.bham.ac.uk/docs/PG%20GEN%20Questionnaire.p
 GEN 
df). q
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e Queen Square PD 
ed in the molecular genetic 
udies performed in chapters 5 and 6 (sections 5.3.1 and 6.3.1).  
ples and 31 control samples from the QSPD collection in screening for 
ritance in the family 
) where onset of disease was before the age 
f 45 years, but there was no family history of PD; sPD; and samples from the Queen Square 
rain Bank for Neurological Diseases with pathologically proven PD (no family history of 
ich I used in the 
oject. These 
mples were from the PD GEN cohort, Birmingham MND collection, Birmingham 
eurodegenerative Disorders DNA Bank (NDD) and PINE cohort. All were predominantly 
aucasian (95%-100%).  
 
 
 
he information which I have provided in this appendix relates to thT
(QSPD) patient and control collection and the control cohorts us
st
I used 776 patient sam
the c.6187delCTCTA (p.L2063 STOP) variation in exon 42 of LRRK2 (table 5.5). As listed in 
table B.1 the 776 patient samples are made up of a mixture of fPD (inhe
followed an AD pattern); young onset PD (YOPD
o
B
PD).  
In table B.2 I have listed the demographics of the control samples wh
molecular genetic studies performed on fPD and sPD in chapters 5 and 6 of this pr
sa
N
C
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QSPD DNA collection 
 fPD 
(AD) 
YOPD 
(sporadic) 
sPD 
Brain 
Bank 
Total  
number 
patients 
Controls 
Number of 
samples 
screened 
80 84 293 319 776 31 
        Table B.1 PD Patient and control samples from the QSPD collection used in 
        screening for the c.6187delCTCTA (p.L2063 STOP) variation in exon 42 of  
        LRRK2. The 776 patient samples are made up of a mixture of fPD samples 
        (inheritance in the family followed an AD pattern); young onset PD (YOPD) where 
        onset of disease was before the age of 45 years, but there was no family history of 
        PD; sPD; and samples from the Queen Square Brain Bank for Neurological Diseases 
        With pathologically proven PD (no family history of PD).  
 
 
 
 
Control 
collection 
Male (%) Female (%)
Mean age 
(range) 
PD GEN 56 (25) 165 (75) 64.8 (32-86) 
MND 47 (35) 57 (65) 57.0 (20-89) 
NDD 17 (36) 30 (64) 69.2 (55-85) 
PINE 33 (62) 20 (38) 77.4 (56-93) 
                Table B.2 Demographics of control samples used in molecular 
              genetic studies of fPD and sPD in chapters 5 and 6. Control cohorts: 
              PD GEN cohort, Birmingham MND collection, Birmingham 
              Neurodegenerative Disorders DNA Bank (NDD), and PINE cohort. 
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Ap
 
The inform tion whi ave  in t pend tes o etic 
analyses (PCRs and on ngth polymorp RF ses) I performed 
in chapters 5, 6 and 7 of this project.  
Each PCR was optimised as cover n sectio ents e stand eaction 
mixture were as listed in table 2.1 and the standard cycling conditions were as provided in 
 
 MgCl2 
cated 
ed 
sing Accuzyme PCR reagents (Bioline) as described below. 
C.1 Comprehensive screen  in
In my study of fPD the whole coding sequence and exon-intron boundaries of the LRRK2 gene 
were studied (chapter 5) using primers and PCR temperatures as described in previous studies 
[283], [280]. These primers, along with annealing temperatures and MgCl2 concentrations are 
listed below in table C.1 
 
 
pendix C 
a ch I h
restricti
provided
 fragment le
his ap ix rela
hism (
 to the m
LP) analy
lecular gen
ed i n 2.4, the constitu  of th ard r
figure 2.3. In the tables below I have listed the PCR primer sequences, annealing temperatures
and magnesium chloride (MgCl2) concentrations used. In some instances the
concentration was adjusted from the constituents listed in table 2.1, and this is indi
below. The PCRs for the DHPLC study in sPD (results presented in chapter 6) were perform
u
 
 of LRRK2  familial PD 
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Exon 
Annealing 
Primer Sequences MgCl2 Concentration 
Temperatures (mM) 
1F 5’-CCCCTGCCGGTTCCCTGAG-3’ 60°C 1mM 1R 5’-GGACAAAATTTGCAAATGTAAGG-3’ 
2F 5’-AGAATTTCAGGAAGGTCTTCAC-3’ 
2R 58°C 1.5mM 5’-AACATTGCCAGTAAAACGTCTCC-3’ 
3F 5’-AAGTGAGATAAGCATCTATTCC-3’ 
AGTG-3’ 58°C 2mM 3R 5’-GCCTTGGATTGCAAACAC
4F 5’-CAGGGAATTAAATACAATGAGAG-3’ 
4R 58°C 1.5mM 5’-GCTACCCTAATCCTGATCTTC-3’ 
5F 5’-CAAACCATTCACAGTCTTCATG-3’ 
5R 5’-TGACAGACAACTCCCACTTC-3’ 58°C 1.5mM 
6F 5’-AATCTCCGTAGCTTGTTTTCTC-3’ 
6R 58°C 1.5mM 5’-TTCAGTATAATGTCAGTGAATG-3’ 
7F 5’-TTATGCTGCCATCTATTTACAG-3’ 58°C 1.5mM 7R 5’-TCAAAGTATGTCAATATGCTAC-3’ 
8F 5’-TTGCTCAATCACTTCCATTGTC-3’ 
8R 58°C 1.5mM 5’-CATTGAATGCTTCCATCTGTAC-3’ 
9-10F 5’-GACTTAGAGTTGGTCAAACTG-3’ 
9-10R 5’-ACAATAAAAGTTACGGTTAAGG-3’ 58°C 1.5mM 
11F 5’-CTCTTGTAAGTGGAGGTGGC-3’ 
11R 58°C 1.5mM 5’-AGTTTACACATAGAAGTCCGG -3’ 
12F 5’-ATGCTTTCCTGTAAATTTGGAC-3’ 
12R 5’-GAAATATTGATATTCTACCTGG-3’ 56°C 2.5mM 
13F 5’-ATATTGGTTCTGCCCTCCTG-3’ 
13R 58°C 2mM 5’-AATCTAAGTGACTCTTCTGCATC-3’ 
14F 5’-GACAATTTCTAGAAAGTAACAG-3’ 
14R 5’-TGTCTCTAACCACATGACTTCC-3’ 58°C 1.5mM 
15F 5’-TACAATGCCTGGCACAGAAC-3’ 
15R 58°C 1.5mM 5’-AAAGACATCCAGTCACCAGC-3’ 
16F 5’-GTATCCAGATGACCAAGGTC-3’ 
16R 5’-GTGGGAATTACACAAACTGC-3’ 58°C 2mM 
17F 5’-TAAATACTTTAAAGCACCAACCC-3’ 
17R 58°C 1mM 5’-CAAAACACTTGCAACAGAGG-3’ 
18F 5’-AAAAGGATCAACAGGTACAGTG-3’ 60°C 1.5mM 18R 5’-AGATACACAATGGCAGGGCTC-3’ 
19F 5’-GTTTGATTTGCCAGTCTCC-3’ 
19R 58°C 1.5mM 5’-TCAAACTGGCATGAATAACCAC-3’ 
20F 5’-CAATACGTAAGAACTTTGGTCC-3’ 
TTGTCTTGGG-3’ 58°C 2.5mM 20R 5’-GGTCAGGTTT
21F 5’-AAAGTGAAAAACCAACATGGC-3’ 
21R 58°C 1.5mM 5’-TTTCATACATCAGGGAAATCC-3’ 
22F 5’-ATTTGAGCACTGAACTGGAG-3’ 
22R 5’-GGAAATTCAACCAAACACTGC-3’ 58°C 2mM 
23F 5’-GCCTGATTGCTAGGAGGTGC-3’ 
23R 58°C 1.5mM 5’-GGGGACTTATCACCCAGTG -3’ 
24F 5’-GTGTGTAAGGCAGAAATATTAG-3’ 
24R 5’-CTCATTGCTATAAAAATGTCAGC -3’ 58°C 1.5mM 
25F 5’-CCTCTTTGATGCTGTTCTTTG-3’ 
25R 58°C 1.5mM 5’-TAAAGGGTCCATATATGACTC-3’ 
26F 5’-TGGAAGTATTAAGGCTATTACC -3’ 
26R 5’-TATATGACTAAATCGAAATCATG -3’ 58°C 2.5mM 
27F 5’-ATGCTAGTTTTGACGTTACAC-3’ 58°C 1.5mM 
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Exon 
Annealing 
Primer Sequences MgCl2 
Temperatures Concentration (mM) 
27R 5’-GCTTCTAGTTTCATGAAATTGG-3’ 58°C 1  .5mM
28F 5’-CTGTTGAAAGGTTGTGCAAGC-3’ 
 58°C 2.5mM 28R 5’-AATAGTAACAATATATGTCCATC-3’
29F 5’-GTGTGACATGTAAAAGAACTC-3’ 
29R 58°C 2mM 5’-AATTCCATACAGTCTACCAGG-3’ 
30F 5’-CCTAGTAAAAACCCAGAATAG-3’ 58°C 1.5mM 30R 5’-AGACTGAAGCAATTGTTTGCC-3’ 
31F 5’-TCTGAAGTCTGCTAGTTTCTC-3’ 
31R 58°C 2.5mM 5’-TCTGACATTTCTAGGCAGTTG-3’ 
32F 5’-AACTGTTAGCACTGAATTTGC-3’ 58°C 2.5mM 32R 5’-AGTGGCCTATTAAAGAACCG-3’ 
33F 5’-AAAATGAGGAAGTTGGACTAG-3’ 
33R 58°C 1.5mM 5’-TGCTCTGGGCGCCATCTG -3’ 
34F 5’-TTCTGACTACTTTCACTGAGC-3’ 
’ 58°C 2mM 34R 5’-AATACATCTATTATAGACTACAG-3
35F 5’-ACCTTCATTGACTTTAAGCAG-3’ 
35R 58°C 2.5mM 5’-GCCATCTCCCTAATTTCTCT-3’ 
36F 5’-GACTCATATCAGTAACAACCC-3’ 58°C 1.5mM 36R 5’-TCAACACCTTGTCTAAACCTC -3’ 
37F 5’-TTGTAGAAAAGGTAAGGAAATC-3’ 
37R 56°C 2mM 5’-ATTTTTCAACTCATCCCTTATGG-3’ 
38F 5’-CCAAGTAGATAGATACTAAGTG-3’ 
3’ 58°C 2mM 38R 5’-CATCCTCATCTTGATCCTAGTC-
39F 5’-CAATGAAACAAGTAGGTCAGG-3’ 
39R 58°C 1.5mM 5’-GTATGCAAAATAAGAGTTCCAG-3’ 
40F 5’-CCATGTTCAGCCTGTTGATGC-3’ 58°C 1.5mM 40R 5’-CACAGTGTTACTGGGAAGTG-3’ 
41F 5’-TTTAAGGGACAAAGTGAGCAC-3’ 
41R 58°C 2.5mM 5’-ACTCTGTTTTCCTTTTGACTC-3’ 
42F 5’-ACAGCCTGGTTTAGAACATC-3’ 58°C 2mM 42R 5’-AAGGAATTAAGCATACAACTAC-5’ 
43F 5’-TTCTTTGCAATGTCTGGACC-3’ 
43R 58°C 2mM 5’-GAGCATGTGAGGTTTTGGC-3’ 
44F 5’-CAGAGCTATAACACTTCAGTC-3’ 
44R 5’-GTTCTAACAGAAGGCTAATTG-3’ 58°C 1.5mM 
45F 5’-GAAAGCAAAAAGAGTTATGTTG-3’ 
45R 58°C 2mM 5’-TATGCAAACCAATGAAAATAGG-3’ 
46F 5’-AATTTATAGTTGAGAAGTCTATC-3’ 58°C 2.5mM 46R 5’-GCTCTCAGGGAGTTTATAATC-3’ 
47F 5’-TAATCATTTAAGATGGAAAGTAG-3’ 
47R 58°C 2.5mM 5’-CTTCCTTATGAATTATCAACAG-3’ 
48F 5’-TATAAGGTTGTATTACACGTAG-3’ 
5’ 58°C 2mM 48R 5’-AAAATTCTCTATTCAGAGGCAG-
49F 5’-CATAATGGTGGTGGTGTCATG-3’ 
49R 58°C 1.5mM 5’-CTGTGTGACCCTCCAAGACC-3’ 
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Exon 
Annealing 
Primer Sequences MgCl2 
Temperatures Concentration (mM)
50F 5’-CCAAGGTATTTGTGTCTTAAAC-3’ 58°C 2mM 50R 5’-AAAATTCCTGATTATACCATATG-3’ 
51F 5’-TAAAAATACATGAGCCAAACTG-3’ 
51R 58°C 1.5mM 5’-AAAAATGTGAGTACCCTTTCC-3’ 
T C. g tempera 2 concentration for 
am ica ied the wh ding sequence and exon-intron 
b rie ohort by PCR (see chapter 5) using primers and 
PCR tem studies [283], [280]. Abbreviations: F= forward 
pr ; R m chloride.
 
 
 
 
 
 
 
C ree  DHPLC
In 6) the PCRs for exons 24, 25, 31, 32, 38, 40, 
4  42 y analysed by DHPLC, were performed using 
Accuzym as because th lity Taq 
po era action constituents required for loading onto 
d rin atography (D ) columns. The  primers, 
re n s are listed below. The same concentration of 
M (1 ere used to amplify all eight exons of LRRK2 
in pa  C.1).  
 
 
 
 
 
 
 
 
able 1 PCR primer sequences, annealin
tion of LRRK2 exons 1-51. I stud
tures and MgCl
plif ole co
s of the LRRK2 gene in the fPD co aund
peratures as described in previous 
= reverse primer; MgCl2= magnesiu  imer
ning for LRRK2 variants in sPD by.2 Sc  
 my study of sPD (results presented in chapter 
 of LRRK2, which were subsequentl1 and
e PCR reagents (Bioline). This w e Accuzyme high fide
lym se can utilise the detergent-free re
HPLC  PCRenatu g high performance liquid chrom
actio constituents and cycling condition
.5mM ) and PCR cycling conditions wgCl2 
 this rt of the study (table C.2-C.3 and figure
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Primers Annealing Temperature 
24DF  5’-GTGTGTAAGGCAGAAATATTAG-3’ 
24 5’- C -3’ 58°C DR  CTCATTGCTATAAAAATGTCAG
25 5’-
25 5’- ’ 58°C 
DF  CCTCTTTGATGCTGTTCTTTG-3’ 
DR  TAAAGGGTCCATATATGACTC-3
31DF  5’-TCTGAAGTCTGCTAGTTTCTC-3’ 
31DR  5’-TCTGACATTTCTAGGCAGTTG-3’ 58°C 
32DF  5’-AACTGTTAGCACTGAATTTGC-3’ 
32DR  5’-AGTGGCCTATTAAAGAACCG-3’ 58°C 
38DF  5’-CCAAGTAGATAGATACTAAGTG-3’ 
38DR  5’-CATCCTCATCTTGATCCTAGTC-3’ 58°C 
40DF  5’-CCATGTTCAGCCTGTTGATGC-3’ 
0DR  5’-CACAGTGTTACTGGGAAGTG-3’ 58°C 4
41DF  5’-AGGGACAAAGTGAGCACAGAA-3’ 
1DR  5’-GAGGTCAGTGGTTATCCATCCT -3’ 58°C 4
42DF  5’-ACAGCCTGGTTTAGAACATC-3’ 
2DR  5’-AAGGAATTAAGCATACAACTAC-5’ 58°C 4
Table C.2 Primer sequences and annealing temperatures for amplification of eight 
exons of LRRK2 by PCR. I studied eight exons (24,25,31,32,38,40,41 and 42) of the 
 
 
 
LRRK2 gene in the sPD cohort by PCR and subsequent DHPLC analysis (see chapter 6). 
Accuzyme PCR reagents (Bioline Ltd) were used which are detergent free, making them 
ideal for DHPLC analysis. Abbreviations: F= forward primer; R= reverse primer. 
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Reagent 
Stock Final 
concentration concentration 
Water (distilled and autoclaved) N/A N/A 
10x Buffer (Bioline) 10x 1x 
dNTP mix (Fermentas) 2mM 0µM 12
MgCl2 (Bioline) 50mM 5mM 1.
Forward primer (AltaBioscience) / (Eurogentec) 10pmole/µl ole/µl 0.5pm
Reverse primer (Altabioscience) / (Eurogentec) 10pmole/µl ole/µl 0.5pm
Accuzyme Taq (Bioline) 2.5u/µl 0.05u/µl 
DNA 100ng/µl 5ng/µl 
 
 
Table C.3 Constituents of a PCR master mix for exons 24, 25, 31, 32, 38, 40, 41 and 42. 
 
 
 
                          95°C  5mins 
             Denaturation: 95°C  30s 
             Annealing:  58°C             30s       x30 cycles 
             Extension:  72°C  1min  
              72°C   7mins  
  
  
  
 
 
      Figure C.1 PCR cycling conditions for exons 24, 25, 31, 32, 38, 40, 
    41 and 42.   
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C.3 Screening for LRRK2 variations within exon 41 by restriction fragme
polymorphism (RFLP) analysis.   
Specific P creening for LRR riations wit on 41 by 
RFLP analysis. These primers, along with annealing temperatures and MgCl2 concentrations, 
are listed below in table C.4. Each PCR was optimised as covered in section 2.4, the 
constituents of the reaction mixture were as listed in table 2.1 and the standard cycling 
conditions were as provided in figure 2.3.  
 
 
nt length 
K2 vaCR primers were designed for s hin ex
Primers Annealing MgCl2 Temperature Concentration 
41PF  5’- GAGCACAGAATTTTTGATGCTTG -3’ 55°C 2mM 
41PR 5’- TTTTATCCCCATTCCACAGCAGTAC-3’ 
Table C.4 PCR primer sequences, annealing temperature and MgCl2 concentration for 
mplification of LRRK2 exon 41, for subsequent RFLP analysis. Abbreviations: F= 
rward primer; R= reverse primer; MgCl2= magnesium chloride. 
r xon 42 by agarose gel electrophoresis.   
K
utation by gel electrophoresis with a 3% 
RESponse
ns, are listed below 
ach PCR was optimised as covered in section 2.4, the constituents of the 
action mixture were as listed in table 2.1 and the standard cycling conditions were as 
rovided in figure 2.3. 
a
fo
  
C.4 Screening for novel LRRK2 va iation within e
Specific PCR primers were designed to screen for the novel c.6187delCTCTA (p.L2063 
STOP) mutation in exon 42 of LRR 2, which was identified during my fPD study (see section 
5.3.2.4). The PCR products were screened for the m
high resolution TM Research agarose (Geneflow) gel, as described in section 2.5.1. 
These primers, along with annealing temperatures and MgCl2 concentratio
in table C.5. E
re
p
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Primers Annealing MgCl2 Temperature Concentration 
42GF  5’- CCAACAGGCTGATGTTTATTCA -3’ 58°C 2mM 
42GR  5’- CCTCCAGTTGTCAAAATGTCA -3’ 
Table C.5 PCR primer sequences, annealing temperature and MgCl2 concentration 
Abbreviations: F= forward primer; R= reverse primer; MgCl2= magnesium chloride. 
for amplification of LRRK2 exon 42, for subsequent agarose gel electrophoresis. 
 
 
tions within LRRK2 DNA and cDNA by PCR fragment analysis.   
Specific PCR primers were designed to screen for the novel LRRK2 mutation c.7187insGT 
(p.T2397STOP) in DNA, which was identified during my fPD study, by PCR fragment 
ere scree or the mutation by PCR 
re also designed in order to 
estigate the effect of the L2063STOP and T2397STOP mutations on RNA expression, by 
annealing temperatures and MgCl concentrations are listed below in tables C.6-C.7. Each 
PCR was optimised as covered in section 2.4, and the constituents of the reaction mixture 
(figure 2.3), but to ensure that PCR product abundance lay within the linear phase of PCR 
amplification, I used a PCR cycle length of 25 for both reactions with cDNA (see section 
called 6-Carboxyfluorescein (6FAM), so that after amplification the labelled PCR products 
tomated sequencing system. The labelled primers were produced 
C.5 Screening for varia
analysis (see section 5.3.2.6). The PCR products w ned f
fragment analysis, as described in section 2.8.  
PCR primer pairs specific for the cDNA sequence of LRRK2 we
inv
PCR fragment analysis, and to sequence the cDNA in this region. These primers, along with 
2 
were as listed in table 2.1. The standard cycling conditions were used for the PCRs on DNA 
7.3.4). Either the forward or reverse PCR primer was labelled with a fluorescent compound 
could be separated with an au
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y Sigma-Genosys. The same primer pairs were used for sequencing of the cDNA, but both 
the forward and reve  were unlabelled. 
b
rse primers
 
Primers Annealing Temperature 
MgCl2 
Concentration 
49DGF  5’-CATAATGGTGGTGGTGTCATG-3’ (6FAM) 
49DGR  5’-GCCTCCTCCAGTTCCTATCC-3’ 
.5mM 58°C 1
Table C.6 PCR primer sequences, annealing temperature and MgCl2 concentration for 
mplification of LRRK2 exon 49 in DNA, for subsequent PCR fragment analysis. 
Abbreviations: F= forward primer; R= reverse primer; MgCl2= magnesium chloride. 
 
a
 
 
Primers Annealing Temperature 
MgCl2 
Concentration 
42CGF  5'- AAAACATCAGAGGGCACACC-3' (6FAM) 
42CGR  5’-ATGGGGCACAACCATATTCT -3’ 58°C 1.5mM 
49CGF  5’-CAAAATAGCCCTGTTGTGGAA -3’ 
49CGR  5'- TTCCGGTTGTAGCCCAATAC -3' (6FAM) 58°C 1.5mM 
Table C.7 PCR primer sequences, annealing temperature and MgCl2 concentration for 
2
amplification of LRRK2 cDNA, for subsequent PCR fragment analysis. The primer pairs 
are specific for the cDNA sequence of LRRK2 to investigate the effect of the L2063STOP and 
T2397STOP mutations on RNA expression, by PCR fragment analysis, and to sequence the 
cDNA in this region. Abbreviations: F= forward primer; R= reverse primer; MgCl = 
magnesium chloride. 
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Appendix D 
The information which I have provided in this appendix relates to section 5.4.2 of the fPD 
study and section 6.4.2 of the sPD study. 
 
2019S and R1441C) and the two putatively pathogenic LRRK2 mutations (S1228T and 
1869T).  
 
 
The proband case III:1 is a right-handed male, was aged 71 at the time of evaluation and had 
onset of symptoms aged 54. His initial symptoms were tremor of the right hand, dragging of 
D.1 fPD study 
I have provided the clinical features and pedigrees of proband cases carrying the pathogenic 
(G
M
D.1.1 Family 10 
Two affected members of this family, III:1 and III:2 were studied, both carry the heterozygous 
G2019S mutation.  
 
 
 
 
 
 
 
III:1 III:2 
II:2 II:1 
Figure D.1 Pedigree for family 10 
Key: 
            Proband case 
            Male 
            Female 
            Deceased 
            PD 
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his right foot and ‘slowing down’. He also had dystonia of the right foot since early in the 
at the time of evaluation had been present 
ars.  
Neurological examination revealed features typical of IPD with mask-like facies, 
asymmetrical bradykinesia and rigidity as well as postural instability and dyskinesias. His 
as a combination of Levodopa and dopamine agonist (Ropinirole) (Levodopa 
quivalent dose of 550mg daily). 
ight-handed, was aged 66 at the time of evaluation, and had onset of 
sequently has tried dopamine agonists (Cabergoline, Ropinirole and 
ramipexole), Amantadine and Selegiline (MAOBI), but could not tolerate these medications.  
eurological examination revealed features al of IPD with mask-like facies, 
symmetrical resting tremor, bradykinesia and rigidity and postural instability. Her Hoehn and 
ahr stage was 3, with a UPD II sco 33. There was no e gnitive deficit 
ith a MMSE score of 30.  
ccording to family reports the other affected members of the family were: (i) a maternal 
unt, subject II:1, who was diagnosed with PD at the age of 55. She was not reported to have 
ad any tremor bu s’. She was said to have had significant 
disease course. His symptoms had responded well to treatment with Levodopa (Sinemet Plus). 
He also had treatment-induced dyskinesias which 
for three ye
Hoehn and Yahr stage was 2, with a UPDRS III score of 17. There was no evidence of 
cognitive deficit with a MMSE score of 30. Anti-parkinsonian medication at time of 
evaluation w
e
Subject III:2 is r
symptoms aged 60. Her initial symptom was gait difficulty. She was initially commenced on 
Levodopa and sub
P
N  typic
a
Y RS I re of vidence of co
w
A
a
h t had ‘general slowing down and fall
treatment benefit from Levodopa and there were no reported cognitive problems. She died at 
the age of 80, PD was listed in part II of the death certificate. (ii) A great uncle on the maternal 
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side of the family, subject I:1, who was said to have had tremor but was not definitely 
diagnosed with PD.  
The mother of the proband (II:2) was unaffected by PD and died at the age of 90, the 
proband’s maternal grandfather (I:2) was also said to be unaffected by PD.  
One affected member (II:1) and one unaffected member (II:2) of this family were studied.  
 
 
The proband case II:1 carries the heterozygous G2019S mutation, whilst the unaffected 
member (II:2) does not. The proband is a right-handed female, was aged 70 at the time of 
evaluation and had onset of symptoms aged 59. Her initial symptoms were right-sided 
bradykinesia and micrographia, and she had dystonia of the left foot which began five years 
after onset of the disease. She was unable to tolerate Levodopa therapy. More recently she 
complained of tremor on the right arm and leg and dragging of the right foot. 
Olfactory testing yielded UPSIT scores of 25 for subject III:1 and 30 for subject III:2.  
 
D.1.2 Family 32 
 
 
 
 
 
 
II:1 II:2 
I:1 I:2 I:3 I:4 I:5 
 
Key: 
            Proband 
            Female 
            PD 
            Possible PD 
case 
            Deceased 
            Male 
Figure D.2 Pedigree for family 32 
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Past medical history included temporal arteritis, gastric ulcer, irritable bowel syndrome and 
macular holes. 
Neurological examination revealed mask-like facies, symmetrical rigidity, asymmetrical 
bradykinesia and postural instability. Her Hoehn and Yahr stage was 2, with a UPDRS III 
was not 
king any anti-parkinsonian medication at time of evaluation. 
er brain from 2005 revealed extensive patchy multi-focal high signal on T2 
weighted scans, suggesting chronic small vessel disease. 
Subject II:2 was unaffected by PD. She is left-handed and was aged 56 at the time of 
evaluation. Her past medical history included depression and irritable bowel syndrome. 
Neurological examination was norma here  no enc  co ive
MMSE score of 30. 
According to family reports the other affected members of the family were: (i  of 
the proband, subject I:1, who was diagnosed with PD at the age of 59. She was said to have 
had tremor, worse on the left than the right, mask-like facies, ‘general slowing down’, 
f freezing. She had treatment benefit with Levodopa and 
Amantadine and had cognitive problems. She died at the age of 76. (ii) A maternal aunt, 
subject I:2, was diagnosed with PD in her mid fifties. She had tremor, rigidity and falls and 
was reported to have had treatment benefit from levodopa. She may also have undergone a 
neurosurgical procedure for her PD. (iii) Three other family members, all maternal uncles, 
subjects I:3, I:4 and I:5 were reported to have had possible PD, although the details available 
are limited. Subject I:3 had walking difficulties, subject I:4 had problems with speech and was 
given a diagnosis of PD. He did not apparently receive any treatment and died at the age of 88.  
score of 29. There was no evidence of cognitive deficit with a MMSE score of 30. She 
ta
An MRI scan of h
l. T was evid e of gnit  deficit with a 
) the mother
shuffling gait, falls, and episodes o
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Olfactory testing yielded UPSIT scores of 24 for subject II:1 and 26 for subject II:2.  
 
D.1.3 Family 33 
asymmetrical tremor, bradykinesia and rigidity as well as postural instability. Her Hoehn and 
One affected member (II:1) and four unaffected members (II:2, II:3, II:4 and III:1) of this 
family was studied.  
 
 
 
 
 
 
 
 
 
 
The proband case, II:1, carries the heterozygous G2019S mutation, the unaffected members do 
not carry this mutation. The proband is a right-handed female, was aged 60 at the time of 
evaluation and had onset of symptoms aged 48. Her initial symptoms were left-sided rigidity 
and dystonia of the left foot. She had treatment benefit with Levodopa. She also had treatment 
induced dyskinesias and complained of wearing off phenomena and freezing. Her past medical 
history included ankylosing spondylitis. 
Neurological examination revealed features typical of IPD, with mask-like facies, and 
     Key: 
             Proband   
  case 
 
             Male 
             Female 
             Deceased 
             PD
 II:1  II:2 II:2 
II:4 
I:1 I:2 I:3 
III:1 
I:4 
Figure D.3 Pedigree for family 33 
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Yahr stage was 3, with a UPDRS III score of 23. She complained of some memory problems 
nd hallucinations, which had been present for approximately a year before the date of 
evaluation, but her MMSE score was 30 
Her anti-parkinsonian medication at time of evaluation was a combination of Levodopa, 
affected family members studied were: (i) subject II:2, she was aged 66 a  
ination was normal. There was no evi
 Subject II:3, he was aged 54 at th
history included subarachnoid haemorrhage and 
es. Neurological examination was normal. There was no evidence of cognitive deficit 
it  score of 30. ( ubject II:4, she was aged 66 at the time aluation. Her 
edical history included hypertension and hypothyroidism. Neurological examination 
al and there was no evidence of cognitive deficit with a MMSE score of 30. (iv) 
e of evaluation. Her past medical history included 
ase. Neurological examination was normal and there was no evidence of cognitive 
inesia and rigidity, but no tremor. She had good 
a
Entacapone (COMT inhibitor) and a dopamine agonist (Ropinirole) (Levodopa equivalent 
dose of 800mg daily).  
The four un t the time
of evaluation and her neurological exam dence of 
cognitive deficit with a MMSE score of 30. (ii) e time of 
evaluation. His past medical nocturnal 
seizur
w h a MMSE iii) S of ev
past m
was norm
Subject III:1, she was aged 42 at the tim
coeliac dise
deficit with a MMSE score of 30.  
According to family reports the other affected members of the family were: (i) the mother of 
the proband, subject I:1. She was diagnosed with PD at the age of 75 and had asymmetrical 
tremor and rigidity. She had good treatment benefit with Levodopa. She died at the age of 95. 
(ii) A maternal aunt of the proband, subject I:2. She was diagnosed with PD at the age of 61 
and had mask-like facies, asymmetrical bradyk
treatment benefit with Levodopa, and developed dyskinesias. She died at the age of 71. (iii) A 
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maternal aunt of the proband, subject I:3. She had received treatment for PD. She died at the 
age of 79. (iv) A maternal aunt of the proband, subject I:4, she has PD and was still alive at the 
time of the study. 
Olfactory testing yielded UPSIT scores of 20 for subject II:1, 31 for subject II:2, 39 for subject 
II:3, 29 for subject II:4, and 30 for subject III:1.  
 
D.1.4 Family 20 
Figure D.4 Pedigree for family 20 
One affected member of this family was studied (II:1). 
 
 
The proband case, II:1, carries the heterozygous R1441C mutation. She is right-handed, was 
aged 72 at the time of evaluation and had onset of symptoms aged 71. Her initial symptoms 
were rigidity and gait difficulty, but also more recently unilateral tremor. She had not been 
commenced on treatment. Her past medical history included Polio at the age of three and a 
myocardial infarction. 
Neurological examination revealed features typical of IPD, with mask-like facies, and 
asymmetrical bradykinesia and rigidity as well as postural instability. Her Hoehn and Yahr 
 
 
 
 
 
 
 
     Key: 
  case
             Fem
             PD 
             Proband   
 
ale 
             Deceased 
             Male 
I:1 
II:1      II:2 
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stage was 2, with a UPDRS III score of 15. She did not complain of any cognitive deficit and 
her MMSE score was 28. 
According to family reports the other members of the family who had a definite diagnosis of 
lfactory testing yielded a UPSIT score of 15 for subject II:1.  
ne affected member (II:1) and one unaffected member (III:2) of this family were studied.  
 
 
The proband case, III:1, carries the heterozygous S1228T mutation, the unaffected family 
member (III:2) also carries the same mutation. The proband is a right-handed female, was 
aged 75 at the time of evaluation and had onset of symptoms aged 65. Her initial symptoms 
were neck rigidity and tremor of his left arm. She was first commenced on Bromocriptine 
therapy with good response. Her anti-parkinsonian medication at time of evaluation consisted 
of a combination of dopamine agonist (Cabergoline) and Levodopa (Levodopa equivalent 
dose of 525mg daily). Her past medical history included two transient ischaemic attacks. 
PD were a maternal aunt, subject I:1, and a maternal cousin, subject II:2, who had  symptoms 
of tremor, bradykinesia and dystonia.  
O
 
D.1.5 Family 1 
O
 
I:1
III:3 III:1  III:2 
II:1 II:2 
Figure D.5 Pedigree for family 1 
     Key: 
             Proband   
  case 
d 
             Essential 
             tremor 
             Possible 
            PD
             Male 
             Female 
ecease
II:3 
             D
             PD 
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Neurological examination revealed features typical of IPD, with mask-like facies, and 
asymmetrical resting tremor, rigidity and bradykinesia. as well as postural instability. Her 
e proband, is right-handed and was aged 75 at the time 
 neurological examination was 
ormal. She did not complain of any cognitive deficit and her MMSE score was 29.  
mily reports there were several other members affected by PD and some 
affected by other neurological conditions: (i) The mother of the proband, subject II:1,  had a 
definite diagnosis of PD. She was diagnosed at the age of 65 and died at the age of 72. She 
was also reported to have had dementia. (ii) A maternal aunt, sub t II:2,  was said 
 p
, p
One affected member (II:1) and one unaffected member (II:2) of this family were studied. 
 
 
 
 
 Figure D.6 Pedigree for family 3 
Hoehn and Yahr stage was 3, with a UPDRS III score of 28. She did not complain of any 
cognitive deficit and her MMSE score was 30. 
Subject III:2, identical twin sister of th
of evaluation. Her past medical history was unremarkable and
n
According to fa
jec to have 
roband, had PD, although she died at the age of 47. (iii) The maternal grandmother of the
subject I:1, had PD and also died at the age of 47. (iv) A maternal uncle, subject II:3
had PD. (v) A sister of the proband, 3, had a diagn of essential tremor.  
 
ossibly 
 subject III: osis 
D.1.6 Family 3 
 
     Key: 
  case
             Fem
             PD 
             Proband   
 
ale 
             Deceased 
II:1 II:2
    I:1   I:2 I:6 I:5    I:3         I:4              Male 
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The proband case II:1 carries the heterozygous M1869T mutation, subject II:2 does not. The 
proband is a right-handed male, was aged 67 at the time of evaluation and had onset of 
symptoms aged 64. His initial symptoms were right-sided bradykinesia, tremor and 
micrographia. He had not been commenced on any anti-parkinsonian medication. His past 
e facies, 
ject I:2, 
ad PD, she received Levodopa therapy and died at the age of 82 (iii) A paternal uncle, subject 
 received Levodopa therapy, he died at the age of 83. (iv) Another paternal 
uncle, subject I:4, had PD. He received Levodopa therapy and died at the age of 87. (v) The 
father of the proband, subject I:5, had tremor but was never formally diagnosed with PD. He 
died at the age of 65 (vi) A paternal aunt, subject I:6, possibly had PD. She died a
80.  
 
 
 
medical history included myocardial infarction, cerebrovascular attack, asthma and 
hypertension. 
Neurological examination revealed findings typical of IPD, with mask-lik
asymmetrical tremor, bradykinesia and rigidity. His Hoehn and Yahr stage was 1, with a 
UPDRS III score of 12. There was no evidence of cognitive deficit with a MMSE score of 30.  
Subject II:2 is right-handed and was aged 63 at the time of evaluation. Her past medical 
history was unremarkable and neurological examination was normal. There was no evidence 
of cognitive deficit with a MMSE score of 30.  
According to family reports other affected members were: (i) A paternal aunt, subject I:1, who 
had PD, she was diagnosed aged 38 and died aged 73. (ii) Another paternal aunt, sub
h
I:3, had PD and
t the age of 
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D.2 sPD study 
I have provided the clinical features of the four subjects who were identified as carriers of 
pathogenic (G2019S and R1441C) LRRK2 mutations. In addition the demographics of the two 
controls, who were found to be heterozygous carriers of the putatively pathogenic M1869T 
mutation, and the novel p.P2093P variation, respectively, are also given.  
All six individuals are Caucasian, PD237 is from the Birmingham PD study and the other 
D.2.1 Subject PD237 
tation. He was aged 71 at the time of initial 
 dysfunction.  His final recorded anti-parkinsonian medication consisted of a 
bination of Levodopa, Selegeline (MAOBI) and Entacapone (COMTI) (Levodopa 
the age of 83 of a myocardial infarction.   
 
three subjects and two controls (PP0293, PP0360, PP0071, PC109 and PC157) are from the 
PD GEN study.  
 
This subject carries the heterozygous G2019S mu
evaluation and had onset of symptoms aged 70. His initial symptoms were unilateral tremor, 
‘slowing down’, reduced turning in bed and quiet speech. He was commenced on Levodopa 
therapy with good treatment effect. Examination revealed features typical of IPD, with mask-
like facies, bilateral tremor, rigidity and bradykinesia which was worse on the right. There was 
no known family history of PD.  
The subject was followed up for eleven years in clinic and was noted to have developed 
dystonia and treatment induced dyskinesias eight years after diagnosis. There was no evidence 
of cognitive
com
equivalent dose of 800mg daily). He died at 
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D.2.2 Subject PP0293 
as no known family 
ed any treatment induced dyskinesias, motor fluctuations or cognitive 
ysfunction. Her latest recorded anti-parkinsonian medication consisted of Ropinirole at a 
 
 
o known family history of PD.  
dose of 
50mg per day.  
This subject carries the heterozygous G2019S mutation. She was aged 78 at the time of entry 
to the PD MED/PD GEN study and had been diagnosed with PD at the age of 76. Her Hoehn 
and Yahr stage was 2.5 and she had a MMSE score of 30. She was commenced on treatment 
with a dopamine agonist (Ropinirole) with good treatment effect. There w
history of PD.  
After two years of follow-up, her Hoehn and Yahr stage remained at 2.5 and she was not noted 
to have develop
d
dose of 25mg per day. 
D.2.3 Subject PP0360 
This subject carries the heterozygous G2019S mutation. He was aged 61 at the time of entry to 
the PD MED/PD GEN study and had been diagnosed with PD at the age of 60. His Hoehn and 
Yahr stage was 1 and he had a MMSE score of 28. He was commenced on treatment with 
Selegeline (MAOBI). There was n
After four years of follow-up his Hoehn and Yahr stage progressed to 2.5, he was not noted to 
have developed any treatment induced dyskinesias or motor fluctuations. His anti-
parkinsonian medication was changed from Selegeline, he was first tried on two dopamine 
agonists sequentially (Pergolide and Ropinirole) both of which were stopped due to side 
effects. His latest recorded anti-parkinsonian medication consisted of Levodopa at a 
4
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evodopa, at the time of entry to the study, but was withdrawn after eight 
, her Hoehn and Yahr stage was recorded as 5, but she was not noted 
 have developed any cognitive dysfunction, with a MMSE score of 30. At this assessment 
edication was Levodopa at a daily dose of 900mg.  
 
erozygous P2093P variation 
 
 
 
D.2.4 Subject PP0071 
This subject carries the heterozygous R1441C mutation. She was aged 71 at the time of entry 
to the PD MED/PD GEN study and had been diagnosed with PD at the age of 61. Her Hoehn 
and Yahr stage was 3 and she had a MMSE score of 29. She had initially been treated with 
Levodopa from the time of diagnosis. A dopamine agonist had been added to treatment 
alongside the L
months because of confusion. There was no known family history of PD. 
The subject was followed up for six years as part of the study and died aged 77. At the age of 
73 her Hoehn and Yahr stage had progressed to 5 and she had been institutionalized. At her 
final assessment aged 76
to
her anti-parkinsonian m
D.2.5 Controls PC109 and PC157  
Individual PC109 carries the heterozygous M1869T mutation and was aged 46 at the time of 
entry to the PD GEN study. Individual PC157 carries the novel het
and was aged 49 at the time of entry to the PD GEN. Both individuals are female, are the 
spouses of subjects who had entered the study, were unaffected by PD and had no known 
family history of PD. 
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Appendix E 
ere volunteers. None 
 
The information which I have provided in this appendix relates to the fPD study in chapter 5. 
Where control data on LRRK2 variations identified in my study was not available in order to 
perform statistical analyses, I used the published control data from a North American cohort of 
275 unrelated neurologically normal Caucasian individuals. Of this cohort 127 were 
ascertained as spouses of an individual affected with PD, the remainder w
of the controls had any first degree relative with a known primary neurological disorder [666]. 
The demographics of this control cohort are listed below in table E.1.  
 
Number of 
Male (%) Female (%) Mean age (range) 
controls 
275 133 (48) 142 (52) 
68 
(55-88) 
          Table E.1 Demographics of control cohort used for statistical 
              analysis in my study of LRRK2 variations in fPD. Control cohort data 
              obtained from study by Paisan-Ruiz al. 2008 [666].  
 
 
The minor allele frequencies of previously described non-synonymous and synonymous 
oding sequence variations, and non-coding (intronic) sequence variations, in patients from 
y study is compared to control data in tables E.2-E.4 below. 
c
m
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 coding sequence 
ns, identified in this 
study with control data. Control data from Paisan-Ruiz et al. 2008 [666]. 
 
 
 
Genbamk Predicated Minor Minor LRRK2 Nucleotide P 
Table E.2 Minor allele frequencies of six previously described LRRK2
variations, which lead to non synonymous amino acid substiutio
 
Nucleotide 
Change 
LRRK2 
exon 
Genbank 
reference 
number 
Predicated 
protein 
change 
Minor 
allele Freq. 
in patients 
Minor 
allele Freq. 
in Controls 
P 
value 
c.578C>T 5 rs10878245 p.L153L 0.34 0.41 0.185 
c.2857T>C 22 rs7966550 p.L953L 0.12 0.15 0.474 
c.4269G>A 30 rs11175964 p.K1423K 0.04 0.07 0.233 
c.4872A>C 34 rs1427263 p.G1624G 0.29 0.37 0.034 
c.4911G>A 34 rs11176013 p.K1637K 0.41 0.47 0.213 
c.5457C>T 37 rs10878371 p.G1819G 0.41 0.47 0.144 
c.6324G>A 43 rs10878405 p.E2108E 0.33 0.30 0.151 
c.7155A>G 48 rs33962975 p.G2385G 0.14 0.13 0.583 
Table E.3 Minor allele frequencies of 
c
eight previously described synonymous LRRK2 
oding sequence variations identified in this study with control data. Control data from 
aisan-Ruiz et al. 2008 [666]. P
 
Change exon reference number 
protein 
change 
allele Freq. allele Freq. value in patients in Controls 
c.1653C>G 14 rs7308720 p.N551K 0.03 0.07 0.090 
c.2167A>G 18 rs10878307 p.I723V 0.04 0.07 0.478 
c.4193G>A 30 rs7133914 p.R1398H 0.04 0.07 0.166 
c.4624C>T 32 rs33958906 p.P1542S 0.03 0.02 0.690 
c.4934T>A 34 rs11564148 p.S1647T 0.34 0.29 0.111 
c.7190C>T 49 rs3761863 p.T2397M 0.30 0.39 0.104 
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    Table E.4 Minor allele fr f nin  des RRK2 ing 
 sin eoti phi d s ient
    rol d ontro  Paisa  al. 2
 
 
 
 
 
 
 
  
Genbank Minor Minor LRRK2 Nucleotide 
equency o
de polymor
l data from
e previously
sms (SNPs) i
n-Ruiz et
cribed L
entified in thi
008 [666]. 
 non-cod
 study in pat   (intronic) 
with cont
gle nucl
ata. C
s   
change intron reference number 
allele Freq. 
in patients 
allele Freq. P value 
in Controls 
IVS4+38A> 131 0.09 0.08 0.826 T 4 rs2 088 
IVS10-10C 95 0.41 0.38 0.100 >A 9 rs7 5902 
IVS11+130G  96 0.12 0.20 0.132 >A 11 rs7 9677 
IVS14+68G 78 0.46 0.56 0.238 >C 14 rs10 4462 
IVS30+52ins  06 0.55 0.62 0.068 GT 30 rs1 50388 
IVS34-31T>C 33 rs1896252 0.57 0.52 0.843 
IVS34+32A>G 34 rs11564205 0.18 0.14 0.286 
IVS36+36T>C 36 rs7137665 0.34 0.38 0.051 
IVS43+53G>A 43 rs11176143 0.12 0.11 0.697 
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The inf  I hav v is ap elates ork carried out in 
chapter 6 eening K2  sP
and 4 g high rform  chro raphy (D ). Tabl elow 
demonstrates DHPLC chro atogra erent ts in all
column temperatures, for subjects known to be wild-type or heterozygous carriers of these 
vari ts, fo amp
detec ases, re pr  as an ation of t hnique.
The ogram ow the su s who we d-type, nting 
homoduplexes only, and two peaks for the subjects carrying the variants, representing a 
 
ere required to cover the entire region, and in most cases there is an optimal column 
m erature for each variant to allow discrimination between wild-type and mutant.  
 
 
 
 
 
 
 
ormation which
, the scr
e pro
for LRR
ided in th pendix r
D in eight exons: 24, 25, 31, 32, 38, 40, 41 
to the w
variants in
2 by denaturin  pe ance liquid matog HPLC e F.1 b
m ms for diff varian  eight exons, at different 
ants. Some varian r ex le 6187delCTCTA (p.L2063 STOP) in exon 42, were not 
ted in the sPD c but a ovided here illustr he tec   
DHPLC chromat s sh  one peak for bject re wil represe
mixture of homoduplexes and heteroduplexes. This technique allows discrimination between 
wild-type and mutants for these variants. For each variant at least two column temperatures
w
te p
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DHPLC Chromatograms 
LRRK2 
Exon 
DHPLC 
column 
temperatures Wild type 
Nucleotide 
change & 
predicated Variant protein change 
 
IVS24+31T>C 55.0°C 
 
  
IVS24+31T>C 57.3°C 
55.0°C 
  
IVS24+46G>T 
24 
IVS24+46G>T 57.3°C 
  
 
54.1°C N/A 
 
56.8°C N/A 25 
57.6°C 
 
N/A 
  
c.4321C>T 
R1441C 
31 59.5°C 
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DHPLC Chromatograms LRRK2 
Exon 
DHPLC 
column 
temperatures Wild type 
Nucleotide 
change & 
predicated 
Variant protein change 
 
c.4321C>T 
R1441C 
60.0°C 
  
c.4321C>T 
R1441C 
61.5°C 
 
c.4364delAT 
59.5°C 
D1455G 
60.0°C 
 
c.4364delAT 
D1455G 
31 
61.5°C 
 
c.4364delAT 
D1455G 
 
c.4624C>T 
P1542S 
 
54.6°C 
 
c.4624C>T 
P1542S 
57.0°C 
54.6°C 
c.4541G>A 
R1514Q 
 
32 
57.0°C 
c.4541G>A 
R1514Q 
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DHPLC Chromatograms LRRK2 
Exon 
DHPLC 
column 
temperatures Wild Type 
Nucleotide 
change & 
predicated 
Variant protein change 
  
c.5606T>C 
51.0°C 
M1869T 
 
c.5606T>C 
52.2°C 
M1869T 
 
  
c.5606T>C 
M1869T 
55.0°C 
  
c.5606T>C 
57.5°C 
M1869T 
51.0°C 
  
IVS38-9A>G 
52.2°C 
  
IVS38-9A>G 
55.0°C IVS38-9A>G 
38 
57.5°C 
  
IVS38-9A>G 
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DHPLC Chromatograms 
LRRK2 
Exon 
DHPLC 
column 
temperatures Wild Type 
Nucleotide 
change & 
predicated 
Variant protein change 
51.0°C IVS38+35G>A 
 
52.2°C IVS38+35G>A 
55.0°C IVS38+35G>A 
57.5°C IVS38+35G>A 
 
51.0°C IVS38+54T>C 38 
 
IVS38+54T>C 52.2°C 
IVS38+54T>C 55.0°C 
IVS38+54T>C 57.5°C 
 
IVS38+80A>G 51.0°C 
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DHPLC Chromatograms 
LRRK2 
Exon 
DHPLC 
column 
temperatures Wild Type 
Nucleotide 
change & 
predicated 
Variant protein change 
IVS38+80A>G 52.2°C 
55.0°C IVS38+80A>G 38 
IVS38+80A>G 57.5°C 
 
58.8°C IVS40+34T>C 
61.3°C IVS40+34T>C 
58.8°C IVS40+48C>T 
61.3°C 
 
IVS40+48C>T 
 
 
 
40 
IVS40+34T>C & 
IVS40+48C>T 
58.8°C 
 
IVS40+34T>C & 
IVS40+48C>T 
61.3°C 
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DHPLC Chromatograms 
LRRK2 
Exon 
DHPLC 
column 
temperatures Wild Type 
Nucleotide 
change & 
predicated Variant 
protein change 
C.6055G>A 
53.8°C 
G2019S 
C.6055G>A 
57.8°C 
G2019S 
59.2°C 
C.6055G>A 
G2019S 
41 
6
C.6055G>A 
0.0°C 
G2019S 
C.6241A>G 
54.7°C 
N2081D 
55.9°C 
C.6241A>G 
N2081D 
 
C.6241A>G 
56.9°C 
N2081D 
58.0°C 
C.6241A>G 
N2081D 
4
5
2 
c.6187delCTCTA
L2063STOP 
4.7°C 
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DHPLC Chromatograms 
LRRK2 
Exon 
DHPLC 
column 
tem es peratur Wild Type 
Nucleotide 
change & 
predicated 
Variant protein change 
55.9°C 
 
c.6187delCTCTA
L2063STOP 
56.9°C 
c.6187delCTCTA
L2063STOP 
 
c.6187delCTCTA
L2063STO
58.0°C 
P 
 
54.7°C 
c.6279delT 
P2093P 
55.9°C 
 
c.6279delT 
P2093P 
56.9°C 
 
c.6279delT 
P2093P 
42 
 
58.0°C 
c.6279delT 
P2093P 
Table F.1 Screening for LRRK2 variants in eight exons: 24, 25, 31, 32, 38, 40, 41 and 42 by 
denaturing high performance liquid chromatography (DHPLC). PC  reacti ormed 
as described in section 6.3.2.4 and then DHPLC used to screen for variants. Thi strates 
DHPLC chro s, at different column temperatures, for the eight exons. At the optimal 
temperature for each variant the chromatograms show one peak for the subjects who were wild-type, 
representing homoduplexes only, and two peaks for the subjects carrying the variants, representing a 
mixture of homoduplexes and heteroduplexes. This technique allows discrim ild-
type and mutants for these variants. Pathogenic LRRK2 mutations are shown in red, with variants 
described for the first time in this study (fPD or sPD) in bold, the other variants listed here were 
identified in this study but have been described previously. 
R ons were perf
s table demon
matogram
ination between w
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Appendix G 
The information which I have provided in this appendix relates to the presentation of data 
from this thes
 
G.1 Association of British Neurologists 
I presented data in poster format at the Association of British Neurologists (AB
meeting in April 2006, in Brighton. This poster was accepted for presentation a
of an abstract, which were subsequently published: Identification of LRRK2 
Parkinson’s disease. AJ Lewthwaite, DJ Nicholl & KE Morrison. JNNP 2006; 7
figure G.1). 
 
G.2 Movement Disorders Society 
I also presented data at the International Congress of The Movement Disorder Society (MDS), 
Istanbul in June 2007. These posters were accepted for presentation after submission of 
abstracts, which were subsequently published: 
(i) Screening K2 mutations in familial Parkinson’s disease. AJ Lewthwaite, TD 
Lambert, NW Wood, DJ Nicholl & KE Morrison. Movement Disorders 2007; 22 Supl 16: 
 
is.  
N) scientific 
fter submission 
mutations in 
7: 1397 (see 
 for LRR
S102-S103 (see figure G.2) 
(ii) Clinical and imaging characteristics of a dominant kindred with benign parkinsonism and 
dopa-responsive dystonia. AJ Lewthwaite, TD Lambert, V Bonifati, DJ Nicholl & KE 
Morrison. Movement Disorders 2007; 22 Supl 16: S266-S267 (see figure G.3). 
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RRK2 mutations in Parkinson’s disease. AJ Lewthwaite, 
Morrison. JNNP 2006; 77: 1397. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 Figure G.1 Abstract submitted to the Association of British 
                 Neurologists (ABN) for scientific meeting in April 2006. This data 
                 was presented as a poster and the abstract subsequently published: 
                 Identification of L
                 DJ Nicholl & KE 
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        Figure G.2 Abstract submitted to the Movement Disorder Society (MDS) for 
      International Congress in June 2007. This data was presented as a poster and the 
      abstract was subsequently published: Screening for LRRK2 mutations in familial 
      Parkinson’s disease. AJ Lewthwaite, TD Lambert, NW Wood, DJ Nicholl 
orrison. Movement Disorders 2007; 22 Supl 16: S102-S103. 
  
  
  
        & KE M
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tional 
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 V Bonifati, 
66-S267.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         Figure G.3 Abstract submitted to Movement Disorder Society (MDS) Interna
         Congress in June 2007. This data was presented as a poster and the abstract subseq
         published: Clinical and imaging characteristics of a dominant kindred with benig
         parkinsonism and dopa-responsive dystonia. AJ Lewthwaite, TD Lambert,
         DJ Nicholl & KE Morrison. Movement Disorders 2007; 22 Supl 16: S2
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